

```
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match      3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACCTCTTCTCTTTATCTTATTATAFAAAAATGTTGGTCTCCACCACTG 2180
    ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2653 CCTTTCTCTCCCATCTCTGTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAACATA 2712

Qy 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 356
ACA96945
ID ACA96945 standard; cDNA; 2846 BP.
XX
AC ACA96945;
XX
DT 24-JUL-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW Human; secreted and transmembrane protein: PRO; cytostatic; gene therapy;
KW tumour; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003032123-A1.
XX
PD 13-FEB-2003.
XX
PF 25-JUN-2002; 2002US-00180555.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
```

PR	06-OCT-1998;	98US-0103258P.																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																										</
----	--------------	----------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	----

PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 04-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.

PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.

```
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match      3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAAAATGTTGGTCTCCCACTG 2180
    ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2653 CCTTTTCTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAAC TA 2712

Qy 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

Qy 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 358
ACA70723
ID ACA70723 standard; cDNA; 2846 BP.
XX
AC ACA70723;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003032111-A1.
XX
PD 13-FEB-2003.
XX
PF 20-JUN-2002; 2002US-00176493.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0064103P.
PR 31-OCT-1997; 97US-0065311P.
PR 13-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066772P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.

31-MAR-1998; 98US-0080107P.
31-MAR-1998; 98US-0080194P.
01-APR-1998; 98US-0080327P.
01-APR-1998; 98US-0080333P.
08-APR-1998; 98US-0081049P.
08-APR-1998; 98US-0081070P.
09-APR-1998; 98US-0081195P.
15-APR-1998; 98US-0081838P.
21-APR-1998; 98US-0082568P.
21-APR-1998; 98US-0082569P.
22-APR-1998; 98US-0082704P.
22-APR-1998; 98US-0082797P.
28-APR-1998; 98US-0083322P.
29-APR-1998; 98US-0083495P.
29-APR-1998; 98US-0083496P.
29-APR-1998; 98US-0083499P.
29-APR-1998; 98US-0083559P.
05-MAY-1998; 98US-0084366P.
06-MAY-1998; 98US-0084414P.
07-MAY-1998; 98US-0084639P.
07-MAY-1998; 98US-0084640P.
07-MAY-1998; 98US-0084643P.
15-MAY-1998; 98US-0085579P.
15-MAY-1998; 98US-0085580P.
15-MAY-1998; 98US-0085582P.
15-MAY-1998; 98US-0085700P.
18-MAY-1998; 98US-0086023P.
22-MAY-1998; 98US-0086392P.
22-MAY-1998; 98US-0086486P.
28-MAY-1998; 98US-0087098P.
28-MAY-1998; 98US-0087208P.
02-JUN-1998; 98US-0087609P.
02-JUN-1998; 98US-0087759P.
03-JUN-1998; 98US-0087827P.
04-JUN-1998; 98US-0088025P.
04-JUN-1998; 98US-0088028P.
04-JUN-1998; 98US-0088029P.
04-JUN-1998; 98US-0088033P.
04-JUN-1998; 98US-0088326P.
05-JUN-1998; 98US-0088167P.
05-JUN-1998; 98US-0088202P.
05-JUN-1998; 98US-0088212P.
05-JUN-1998; 98US-0088217P.
09-JUN-1998; 98US-0088655P.
10-JUN-1998; 98US-0088722P.
10-JUN-1998; 98US-0088738P.
10-JUN-1998; 98US-0088740P.
10-JUN-1998; 98US-0088811P.
10-JUN-1998; 98US-0088824P.
10-JUN-1998; 98US-0088825P.
10-JUN-1998; 98US-0088826P.
11-JUN-1998; 98US-0088861P.
11-JUN-1998; 98US-0088863P.
11-JUN-1998; 98US-0088876P.
12-JUN-1998; 98US-0089090P.
12-JUN-1998; 98US-0089105P.
16-JUN-1998; 98US-0089512P.
16-JUN-1998; 98US-0089514P.
17-JUN-1998; 98US-0089538P.
17-JUN-1998; 98US-0089598P.
17-JUN-1998; 98US-0089653P.
18-JUN-1998; 98US-0089908P.
19-JUN-1998; 98US-0089952P.
22-JUN-1998; 98US-0090246P.
22-JUN-1998; 98US-0090252P.
22-JUN-1998; 98US-0090254P.
24-JUN-1998; 98US-0090429P.
24-JUN-1998; 98US-0090435P.
24-JUN-1998; 98US-0090444P.
24-JUN-1998; 98US-0090461P.
24-JUN-1998; 98US-0090535P.
24-JUN-1998; 98US-0090540P.
25-JUN-1998; 98US-0090676P.
```


PR	17-JUN-1998;	98US-0089532P.
PR	17-JUN-1998;	98US-0089538P.
PR	17-JUN-1998;	98US-0089598P.
PR	17-JUN-1998;	98US-0089599P.
PR	17-JUN-1998;	98US-0089600P.
PR	17-JUN-1998;	98US-0089653P.
PR	18-JUN-1998;	98US-0089801P.
PR	18-JUN-1998;	98US-0089907P.
PR	18-JUN-1998;	98US-0089908P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98WO-US019437.
PR	07-OCT-1998;	98WO-US021141.
PR	01-DEC-1998;	98WO-US025108.
PR	05-JAN-1999;	99WO-US000106.
PR	08-MAR-1999;	99WO-US005028.
PR	02-JUN-1999;	99WO-US012252.
PR	15-SEP-1999;	99WO-US021090.
PR	15-SEP-1999;	99WO-US021547.
PR	30-NOV-1999;	99WO-US028313.
PR	01-DEC-1999;	99WO-US028301.
PR	01-DEC-1999;	99WO-US028634.
PR	16-DEC-1999;	99WO-US030095.
PR	20-DEC-1999;	99WO-US030911.
PR	06-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004914.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006319.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	30-MAR-2000;	2000WO-US008439.
PR	15-MAY-2000;	2000WO-US013358.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	28-JUL-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US022031.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	01-DEC-2000;	2000WO-US032678.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-JUN-2001;	2001WO-US017800.
PR	20-JUN-2001;	2001WO-US019692.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	28-AUG-2001;	2001US-00941992.
XX		
PA	(GETH) GENENTECH INC.	
XX		
PI	Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;	
PI	Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;	
PI	Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;	
PI	Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;	
PI	Zhang Z;	
XX		
DR	WPI; 2003-340824/32.	
DR	P-PSDB; ABO25955.	
XX		
PT	Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346	
PT	and PRO1375, which stimulate proliferation of stimulated T-lymphocytes	
PT	and are therapeutically useful for enhancing immune responses.	
XX		
PS	Claim 2; Fig 158; 661pp; English.	
XX		
CC	The present invention relates to the isolation of novel human PRO	
CC	polypeptides, and the polynucleotide sequences encoding them. The PRO	
CC	polypeptides are secreted and transmembrane proteins. The PRO	

CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for for
CC identifying agonists or antagonists. The polynucleotide sequences
CC encoding PRO polypeptides are useful as hybridisation probes, in
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,
CC in the preparation of PRO polypeptides, for generating transgenic animals
CC or knockout animals, to construct hybridisation probes for mapping the
CC gene which encodes the PRO polypeptide, and for the genetic analysis of
CC individuals with genetic disorders, in gene therapy, for chromosome
CC identification, as chromosome markers, and for generating probes for PCR,
CC Northern analysis, Southern analysis and Western analysis. The present
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent was obtained in electronic format directly
CC from the USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACACTCTTTCCCTTTATCTTATTATAAATAATGTTGGTCTCCACCACCTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCCCATCTCTTGTTACACATTTTAATAAAATAAGGGTTGGCTTCTGAACCTA 2712
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCAAAAA#####AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CA#####AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 361
ACC86176
ID ACC86176 standard; cDNA; 2846 BP.
XX
XX ACC86176;
XX
DT 28-JUL-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003027263-A1.
XX
PD 06-FEB-2003.
XX
PF 18-JUN-2002; 2002US-00174572.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.

```
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCTCTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACCTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 362
ACD45167
ID ACD45167 standard; cDNA; 2846 BP.
AC ACD45167;
XX
DT 11-SEP-2003 (first entry)
DE Human secreted/transmembrane polypeptide PRO1344 cDNA.
XX
KW Human; ss; tumour; cancer; gene therapy; tissue typing; gene.
XX
OS Homo sapiens.
XX
PN US2003009012-A1.
XX
PD 09-JAN-2003.
XX
PF 01-MAY-2002; 2002US-00063517.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
```

```
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-447383/42.
DR P-PSDB; ABO27299.
XX
PT New isolated antibody specifically binding a PRO polypeptide, useful for
PT the preparation of a medicament for treating disorders with the aberrant
PT expression or activity of the PRO polypeptide, such as tumor conditions
PT and cancer.
XX
PS Disclosure; Fig 37; 223pp; English.
XX
CC The invention relates to an antibody that binds to a secreted and
CC transmembrane PRO polypeptide. The methods and compositions of the
CC present invention are useful for the preparation of a medicament for the
CC treatment of disorders associated with the aberrant expression or
CC activity of the PRO polypeptide, such as tumour conditions and cancer.
CC They can also be used to generate transgenic or knockout animals useful
CC in the development and screening of therapeutically useful reagents. The
CC PRO polypeptides and encoding nucleic acids can be used as molecular
CC weight markers for protein electrophoresis, chromosome identification and
CC tissue typing. The antibodies may be used in various diagnostic,
CC competitive binding and/or immunoprecipitation assays. The present
CC sequence represents a secreted and transmembrane PRO polypeptide cDNA
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCTCTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACCTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 363
ACCG90048
ID ACC90048 standard; cDNA; 2846 BP.
XX
AC ACC90048;
```

XX 11-AUG-2003 (first entry)
DT Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
DE
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003027271-A1.
XX
PD 06-FEB-2003.
XX
PF 21-JUN-2002; 2002US-00176488.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 15-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.

PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.


```
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
```

```
Query Match      3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCACTCTCTGTACACATTTTATAAAAAATAAGGTTGGCTTCTGAACCTA 2712

QY 2181 NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2240
Db 2713 CAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774
```

RESULT 364
ACD12656
ID ACD12656 standard; cDNA; 2846 BP.
XX

```
AC ACD12656;
XX 17-AUG-2003 (first entry)
DT
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003036125-A1.
XX
PD 20-FEB-2003.
XX
PF 26-JUN-2002; 2002US-00180999.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
```


XX ACF19886; 15-MAY-1998; 98US-0085579P.
AC XX 15-MAY-1998; 98US-0085580P.
DT 17-SEP-2003 (first entry) 15-MAY-1998; 98US-0085582P.
XX 15-MAY-1998; 98US-0085700P.
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169. 18-MAY-1998; 98US-0086023P.
XX 22-MAY-1998; 98US-0086392P.
KW 22-MAY-1998; 98US-0086486P.
KW Human; PRO; secreted protein; transmembrane protein; 28-MAY-1998; 98US-0087098P.
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha; 28-MAY-1998; 98US-0087208P.
KW chondrocyte; proliferation; differentiation; cartilage disorder; 02-JUN-1998; 98US-0087609P.
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis; 02-JUN-1998; 98US-0087759P.
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix; 03-JUN-1998; 98US-0087827P.
KW liver; drug screening; transgenic animal; genetic analysis; 04-JUN-1998; 98US-0088025P.
KW antiarthritic; vulnerary; gene therapy; gene; ss. 04-JUN-1998; 98US-0088028P.
XX Homo sapiens. 04-JUN-1998; 98US-0088029P.
OS 04-JUN-1998; 98US-0088033P.
XX 04-JUN-1998; 98US-0088326P.
PN 05-JUN-1998; 98US-0088167P.
XX 05-JUN-1998; 98US-0088202P.
PD 05-JUN-1998; 98US-0088212P.
XX 05-JUN-1998; 98US-0088217P.
PF 09-JUN-1998; 98US-0088655P.
XX 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.

PR	15-MAY-1998;	98US-0085582P;
PR	15-MAY-1998;	98US-0085700P;
PR	18-MAY-1998;	98US-0086023P;
PR	22-MAY-1998;	98US-0086392P;
PR	22-MAY-1998;	98US-0086486P;
PR	28-MAY-1998;	98US-0087098P;
PR	28-MAY-1998;	98US-0087208P;
PR	02-JUN-1998;	98US-0087609P;
PR	02-JUN-1998;	98US-0087759P;
PR	03-JUN-1998;	98US-0087827P;
PR	04-JUN-1998;	98US-0088025P;
PR	04-JUN-1998;	98US-0088028P;
PR	04-JUN-1998;	98US-0088029P;
PR	04-JUN-1998;	98US-0088033P;
PR	04-JUN-1998;	98US-0088326P;
PR	05-JUN-1998;	98US-0088167P;
PR	05-JUN-1998;	98US-0088202P;
PR	05-JUN-1998;	98US-0088212P;
PR	05-JUN-1998;	98US-0088217P;
PR	09-JUN-1998;	98US-0088655P;
PR	10-JUN-1998;	98US-0088722P;
PR	10-JUN-1998;	98US-0088738P;
PR	10-JUN-1998;	98US-0088740P;
PR	10-JUN-1998;	98US-0088811P;
PR	10-JUN-1998;	98US-0088824P;
PR	10-JUN-1998;	98US-0088825P;
PR	10-JUN-1998;	98US-0088826P;
PR	11-JUN-1998;	98US-0088861P;
PR	11-JUN-1998;	98US-0088863P;
PR	11-JUN-1998;	98US-0088876P;
PR	12-JUN-1998;	98US-0089090P;
PR	12-JUN-1998;	98US-0089105P;
PR	16-JUN-1998;	98US-0089512P;
PR	16-JUN-1998;	98US-0089514P;
PR	17-JUN-1998;	98US-0089538P;
PR	17-JUN-1998;	98US-0089598P;
PR	17-JUN-1998;	98US-0089653P;
PR	18-JUN-1998;	98US-0089908P;
PR	19-JUN-1998;	98US-0089952P;
PR	22-JUN-1998;	98US-0090246P;
PR	22-JUN-1998;	98US-0090252P;
PR	22-JUN-1998;	98US-0090254P;
PR	24-JUN-1998;	98US-0090429P;
PR	24-JUN-1998;	98US-0090435P;
PR	24-JUN-1998;	98US-0090444P;
PR	24-JUN-1998;	98US-0090461P;
PR	24-JUN-1998;	98US-0090535P;
PR	24-JUN-1998;	98US-0090540P;
PR	25-JUN-1998;	98US-0090676P;
PR	25-JUN-1998;	98US-0090678P;
PR	25-JUN-1998;	98US-0090688P;
PR	25-JUN-1998;	98US-0090690P;
PR	25-JUN-1998;	98US-0090694P;
PR	25-JUN-1998;	98US-0090695P;
PR	25-JUN-1998;	98US-0090696P;
PR	26-JUN-1998;	98US-00105413;
PR	26-JUN-1998;	98US-0090862P;
PR	26-JUN-1998;	98US-0090863P;
PR	26-JUN-1998;	98US-0091010P;
PR	01-JUL-1998;	98US-0091359P;
PR	01-JUL-1998;	98US-0091544P;
PR	02-JUL-1998;	98US-0091478P;
PR	02-JUL-1998;	98US-0091486P;
PR	02-JUL-1998;	98US-0091626P;
PR	02-JUL-1998;	98US-0091628P;
PR	02-JUL-1998;	98US-0091632P;
PR	24-JUL-1998;	98US-0094006P;
PR	04-AUG-1998;	98US-0095282P;
PR	10-AUG-1998;	98US-0095998P;
PR	10-AUG-1998;	98US-0096012P;
PR	17-AUG-1998;	98US-0096757P;
PR	17-AUG-1998;	98US-0096867P;
PR	17-AUG-1998;	98US-0096867P;

PR	17-AUG-1998;	98US-0096891P;
PR	17-AUG-1998;	98US-0096897P;
PR	18-AUG-1998;	98US-0096949P;
PR	18-AUG-1998;	98US-0096959P;
PR	18-AUG-1998;	98US-0097022P;
PR	26-AUG-1998;	98US-0097952P;
PR	26-AUG-1998;	98US-0097954P;
PR	26-AUG-1998;	98US-0097955P;
PR	26-AUG-1998;	98US-0097971P;
PR	26-AUG-1998;	98US-0097974P;
PR	26-AUG-1998;	98US-0098014P;
PR	01-SEP-1998;	98US-0098716P;
PR	01-SEP-1998;	98US-0098723P;
PR	02-SEP-1998;	98US-0098803P;
PR	02-SEP-1998;	98US-0098821P;
PR	02-SEP-1998;	98US-0098843P;
PR	09-SEP-1998;	98US-0099602P;
PR	10-SEP-1998;	98US-0099741P;
PR	10-SEP-1998;	98US-0099754P;
PR	10-SEP-1998;	98US-0099763P;
PR	10-SEP-1998;	98US-0099812P;
PR	15-SEP-1998;	98US-0100388P;
PR	16-SEP-1998;	98US-0100662P;
PR	16-SEP-1998;	98US-0100664P;
PR	16-SEP-1998;	98US-0101751P;
PR	16-SEP-1998;	98WO-US019330;
PR	17-SEP-1998;	98US-0100683P;
PR	17-SEP-1998;	98US-0100684P;
PR	17-SEP-1998;	98US-0100919P;
PR	17-SEP-1998;	98US-0100930P;
PR	18-SEP-1998;	98US-0100849P;
PR	18-SEP-1998;	98US-0101014P;
PR	18-SEP-1998;	98US-0101068P;
PR	23-SEP-1998;	98US-0101471P;
PR	23-SEP-1998;	98US-0101472P;
PR	23-SEP-1998;	98US-0101475P;
PR	23-SEP-1998;	98US-0101477P;
PR	24-SEP-1998;	98US-0101738P;
PR	24-SEP-1998;	98US-0101739P;
PR	24-SEP-1998;	98US-0101743P;
PR	24-SEP-1998;	98US-0101922P;
PR	25-SEP-1998;	98US-0101786P;
PR	29-SEP-1998;	98US-0102207P;
PR	29-SEP-1998;	98US-0102240P;
PR	29-SEP-1998;	98US-0102330P;
PR	29-SEP-1998;	98US-0102331P;
PR	30-SEP-1998;	98US-0102487P;
PR	30-SEP-1998;	98US-0102570P;
PR	30-SEP-1998;	98US-0102571P;
PR	01-OCT-1998;	98US-0102684P;
PR	01-OCT-1998;	98US-0102687P;
PR	02-OCT-1998;	98US-0102965P;
PR	06-OCT-1998;	98US-0103258P;
PR	06-OCT-1998;	98US-0103449P;

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;

[illegible]

Qy 2241 AA 2242
2773 AA 2774
Dp

RESULT 367

ACA73162
ID ACA73162 standard; cDNA; 2846 BP.
XX
AC ACA73162;
XX
DT 01-JUL-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PR01344 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; chromosome mapping;
KW gene mapping; transgenic animal; knockout animal; tissue typing; tumour;
KW chondrocyte cell proliferation; gene therapy;
KW chondrocyte cell differentiation; tumour necrosis factor-alpha release;
KW gene; ss.
XX
OS Homo sapiens.
XX
PN US2003022300-A1.
XX
PD 30-JAN-2003.
XX
PF 25-JUN-2002; 2002US-00180552.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083222P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.

PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.

PR	17-AUG-1998;	98US-0096766P.
PR	17-AUG-1998;	98US-0096867P.
PR	17-AUG-1998;	98US-0096891P.
PR	17-AUG-1998;	98US-0096897P.
PR	18-AUG-1998;	98US-0096949P.
PR	18-AUG-1998;	98US-0096959P.
PR	18-AUG-1998;	98US-0097022P.
PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.

Query Match

Best Local Similarity 3.0%; Score 66.6; DB 8; Length 2846;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY	2121	CCTTTGCTTTTACCACCTCTTTCTTTTATCTTATTATAAAAAATGTTGGTCTCCACCACTG	2180
Dd	2653	CCTTTCTCTCCCATCTCTGTACACATTTTATAAAAAATAAGGTTGGCTTCTGAACTA	2712
QY	2181	NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2240
Dd	2713	CAA	2772
QY	2241	AA	2242
Dd	2773	AA	2774

RESULT 368	
ACA68705	
ID	ACA68705 standard; cDNA; 2846 BP.
XX	
AC	ACA68705;
XX	
DT	09-JUL-2003 (revised)
DT	26-JUN-2003 (first entry)
XX	
DE	Novel human secreted and transmembrane protein PRO1344 cDNA.
XX	
KW	Human; secreted and transmembrane protein; PRO; cytostatic; gene therapy;
KW	TNF-Agonist-Alpha; chondrocyte stimulator; tumour; adrenal tumour;
KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW	cervical tumour; liver tumour; gene; ss.
XX	
OS	Homo sapiens.
XX	
PN	US2003036136-A1.
XX	
PD	20-FEB-2003.
XX	
PF	28-JUN-2002; 2002US-00184636.
XX	
PR	18-SEP-1997; 97US-0059263P.
PR	18-SEP-1997; 97US-0059266P.
PR	17-OCT-1997; 97US-0062250P.
PR	21-OCT-1997; 97US-0063486P.
PR	24-OCT-1997; 97US-0063120P.
PR	24-OCT-1997; 97US-0063121P.
PR	28-OCT-1997; 97US-0063540P.
PR	28-OCT-1997; 97US-0063541P.
PR	28-OCT-1997; 97US-0063544P.
PR	28-OCT-1997; 97US-0063564P.
PR	29-OCT-1997; 97US-0063734P.
PR	31-OCT-1997; 97US-0063870P.
PR	31-OCT-1997; 97US-0064103P.
PR	13-NOV-1997; 97US-0055311P.
PR	21-NOV-1997; 97US-0066120P.
PR	24-NOV-1997; 97US-0066466P.
PR	24-NOV-1997; 97US-0066772P.
PR	11-DEC-1997; 97US-0069335P.
PR	12-DEC-1997; 97US-0069425P.
PR	17-DEC-1997; 97US-0069870P.
PR	18-DEC-1997; 97US-0068017P.
PR	10-MAR-1998; 98US-0077450P.
PR	11-MAR-1998; 98US-0077632P.
PR	11-MAR-1998; 98US-0077649P.
PR	20-MAR-1998; 98US-0078886P.
PR	20-MAR-1998; 98US-0078939P.
PR	27-MAR-1998; 98US-0079664P.
PR	27-MAR-1998; 98US-0079786P.
PR	31-MAR-1998; 98US-0080107P.
PR	31-MAR-1998; 98US-0080194P.
PR	01-APR-1998; 98US-0080327P.
PR	01-APR-1998; 98US-0080333P.
PR	08-APR-1998; 98US-0081049P.
PR	08-APR-1998; 98US-0081070P.
PR	09-APR-1998; 98US-0081195P.
PR	15-APR-1998; 98US-0081838P.
PR	21-APR-1998; 98US-0082568P.
PR	21-APR-1998; 98US-0082569P.
PR	22-APR-1998; 98US-0082704P.
PR	22-APR-1998; 98US-0082797P.
PR	28-APR-1998; 98US-0083322P.
PR	29-APR-1998; 98US-0083495P.
PR	29-APR-1998; 98US-0083496P.
PR	29-APR-1998; 98US-0083499P.
PR	29-APR-1998; 98US-0083559P.
PR	05-MAY-1998; 98US-0084366P.
PR	06-MAY-1998; 98US-0084414P.
PR	07-MAY-1998; 98US-0084639P.
PR	07-MAY-1998; 98US-0084640P.

RESULT 369
ACA74549
ID ACA74549 standard; cdna; 2846 BP.
XX
AC ACA74549;
XX
DT 07-JUL-2003 (first entry)
XX
DE cdna encoding human PRO polypeptide #85.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW chromosome mapping; gene mapping; tumour; adrenal; lung; colon; breast;
KW prostate; rectal; cervical; liver; cancer; cytostatic; gene therapy;
KW gene; ss.
XX
OS Homo sapiens.
XX
PN US2003036138-A1.
XX
PD 20-FEB-2003.
XX
PF 28-JUN-2002; 2002US-00184650.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.

PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.

Db	2773 AA 2774		PR 07-MAY-1998;	98US-0084640P.
			PR 07-MAY-1998;	98US-0084643P.
			PR 15-MAY-1998;	98US-0085579P.
			PR 15-MAY-1998;	98US-0085580P.
			PR 15-MAY-1998;	98US-0085582P.
			PR 15-MAY-1998;	98US-0085700P.
			PR 18-MAY-1998;	98US-0086023P.
			PR 22-MAY-1998;	98US-0086392P.
			PR 22-MAY-1998;	98US-0086486P.
			PR 28-MAY-1998;	98US-0087098P.
			PR 28-MAY-1998;	98US-0087208P.
			PR 02-JUN-1998;	98US-0087609P.
			PR 02-JUN-1998;	98US-0087759P.
			PR 03-JUN-1998;	98US-0087827P.
			PR 04-JUN-1998;	98US-0088025P.
			PR 04-JUN-1998;	98US-0088028P.
			PR 04-JUN-1998;	98US-0088029P.
			PR 04-JUN-1998;	98US-0088033P.
			PR 04-JUN-1998;	98US-0088326P.
			PR 05-JUN-1998;	98US-0088167P.
			PR 05-JUN-1998;	98US-0088202P.
			PR 05-JUN-1998;	98US-0088212P.
			PR 05-JUN-1998;	98US-0088217P.
			PR 09-JUN-1998;	98US-0088655P.
			PR 10-JUN-1998;	98US-0088722P.
			PR 10-JUN-1998;	98US-0088738P.
			PR 10-JUN-1998;	98US-0088740P.
			PR 10-JUN-1998;	98US-0088811P.
			PR 10-JUN-1998;	98US-0088824P.
			PR 10-JUN-1998;	98US-0088825P.
			PR 10-JUN-1998;	98US-0088826P.
			PR 11-JUN-1998;	98US-0088861P.
			PR 11-JUN-1998;	98US-0088863P.
			PR 11-JUN-1998;	98US-0088876P.
			PR 12-JUN-1998;	98US-0089090P.
			PR 12-JUN-1998;	98US-0089105P.
			PR 16-JUN-1998;	98US-0089512P.
			PR 16-JUN-1998;	98US-0089514P.
			PR 17-JUN-1998;	98US-0089538P.
			PR 17-JUN-1998;	98US-0089588P.
			PR 17-JUN-1998;	98US-0089653P.
			PR 18-JUN-1998;	98US-0089908P.
			PR 19-JUN-1998;	98US-0089952P.
			PR 19-JUN-1998;	98US-0089952P.
			PR 22-JUN-1998;	98US-0090246P.
			PR 22-JUN-1998;	98US-0090252P.
			PR 22-JUN-1998;	98US-0090254P.
			PR 24-JUN-1998;	98US-0090429P.
			PR 24-JUN-1998;	98US-0090435P.
			PR 24-JUN-1998;	98US-0090444P.
			PR 24-JUN-1998;	98US-0090461P.
			PR 24-JUN-1998;	98US-0090535P.
			PR 24-JUN-1998;	98US-0090540P.
			PR 25-JUN-1998;	98US-0090676P.
			PR 25-JUN-1998;	98US-0090678P.
			PR 25-JUN-1998;	98US-0090688P.
			PR 25-JUN-1998;	98US-0090690P.
			PR 25-JUN-1998;	98US-0090694P.
			PR 25-JUN-1998;	98US-0090695P.
			PR 25-JUN-1998;	98US-0090696P.
			PR 26-JUN-1998;	98US-00105413.
			PR 26-JUN-1998;	98US-0090862P.
			PR 26-JUN-1998;	98US-0090863P.
			PR 26-JUN-1998;	98US-0091010P.
			PR 01-JUL-1998;	98US-0091359P.
			PR 01-JUL-1998;	98US-0091544P.
			PR 02-JUL-1998;	98US-0091478P.
			PR 02-JUL-1998;	98US-0091486P.
			PR 02-JUL-1998;	98US-0091626P.
			PR 02-JUL-1998;	98US-0091628P.
			PR 02-JUL-1998;	98US-0091632P.
			PR 24-JUL-1998;	98US-0094006P.
			PR 04-AUG-1998;	98US-0095282P.
			PR 10-AUG-1998;	98US-0095998P.
RESULT 371				
ACD14602				
ID ACD14602 standard; cDNA; 2846 BP.				
XX				
AC ACD14602;				
XX				
DT 19-AUG-2003 (first entry)				
XX				
DE Human PRO polynucleotide #85.				
XX				
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;				
KW cytotostatic; tumour necrosis factor-alpha; TNF-alpha; blood; tumour;				
KW chondrocyte cell; cancer.				
XX				
OS Homo sapiens.				
XX				
PN US2003040066-A1.				
XX				
PD 27-FEB-2003.				
XX				
PF 26-JUN-2002; 2002US-00183019.				
XX				
PR 18-SEP-1997; 97US-0059263P.				
PR 18-SEP-1997; 97US-0059266P.				
PR 17-OCT-1997; 97US-0062250P.				
PR 21-OCT-1997; 97US-0063486P.				
PR 24-OCT-1997; 97US-0063120P.				
PR 24-OCT-1997; 97US-0063121P.				
PR 28-OCT-1997; 97US-0063540P.				
PR 28-OCT-1997; 97US-0063541P.				
PR 28-OCT-1997; 97US-0063544P.				
PR 28-OCT-1997; 97US-0063564P.				
PR 29-OCT-1997; 97US-0063734P.				
PR 31-OCT-1997; 97US-0063870P.				
PR 31-OCT-1997; 97US-0064103P.				
PR 13-NOV-1997; 97US-0065311P.				
PR 21-NOV-1997; 97US-0066120P.				
PR 24-NOV-1997; 97US-0066466P.				
PR 24-NOV-1997; 97US-0066772P.				
PR 11-DEC-1997; 97US-0069335P.				
PR 12-DEC-1997; 97US-0069425P.				
PR 17-DEC-1997; 97US-0069870P.				
PR 18-DEC-1997; 97US-0068017P.				
PR 10-MAR-1998; 98US-0077450P.				
PR 11-MAR-1998; 98US-0077632P.				
PR 11-MAR-1998; 98US-0077649P.				
PR 20-MAR-1998; 98US-0078886P.				
PR 20-MAR-1998; 98US-0078939P.				
PR 27-MAR-1998; 98US-0079664P.				
PR 27-MAR-1998; 98US-0079786P.				
PR 31-MAR-1998; 98US-0080107P.				
PR 31-MAR-1998; 98US-0080194P.				
PR 01-APR-1998; 98US-0080327P.				
PR 01-APR-1998; 98US-0080333P.				
PR 08-APR-1998; 98US-0081049P.				
PR 08-APR-1998; 98US-0081070P.				
PR 09-APR-1998; 98US-0081195P.				
PR 15-APR-1998; 98US-0081838P.				
PR 21-APR-1998; 98US-0082568P.				
PR 21-APR-1998; 98US-0082569P.				
PR 22-APR-1998; 98US-0082704P.				
PR 22-APR-1998; 98US-0082797P.				
PR 28-APR-1998; 98US-0083322P.				
PR 29-APR-1998; 98US-0083495P.				
PR 29-APR-1998; 98US-0083496P.				
PR 29-APR-1998; 98US-0083499P.				
PR 29-APR-1998; 98US-0083559P.				
PR 05-MAY-1998; 98US-0084366P.				
PR 06-MAY-1998; 98US-0084414P.				
PR 07-MAY-1998; 98US-0084639P.				

PR	10-AUG-1998;	98US-0096012P.
PR	17-AUG-1998;	98US-0096757P.
PR	17-AUG-1998;	98US-0096766P.
PR	17-AUG-1998;	98US-0096867P.
PR	17-AUG-1998;	98US-0096891P.
PR	17-AUG-1998;	98US-0096897P.
PR	18-AUG-1998;	98US-0096949P.
PR	18-AUG-1998;	98US-0096959P.
PR	18-AUG-1998;	98US-0097022P.
PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.
PR	07-OCT-1998;	98US-00168978.
Query Match 3.0%; Score 66.6; DB 8; Length 2846;		
Best Local Similarity 71.3%; Pred. No. 0.0023;		
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;		
QY	2121 CCTTTGCTTTACCACCTCTTTCCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACTG	2180
Db		
	2653 CCTTTTCTTCCCATCTCTTGACACATTTTATAAAATAAGGTTGGCTTCTGAACATA	2712
QY	2181 NCTCCCAA	2240
Db		
	2713 CAAA	2772
QY	2241 AA	2242

Db	2773 AA	2774
RESULT 372		
ACA93715		
ID	ACA93715	standard; cDNA; 2846 BP.
XX	ACA93715;	
XX	ACA93715;	
DT	17-JUL-2003	(first entry)
XX		
DE	Human cDNA encoding secreted/transmembrane protein PRO1344.	
XX		
KW	Human; ss; gene; PRO; secreted protein; transmembrane protein; cytosolic; vulnary; osteopathic; antiarthritic; antirheumatic; lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour; liver tumour; tumour necrosis factor; pericyte cell proliferation; TNF-alpha; proteoglycans release; cartilage; cancer; wound healing; cartilage defect; osteoarthritis; rheumatoid arthritis.	
OS	Homo sapiens.	
XX		
PN	US2003045684-A1.	
XX		
PD	06-MAR-2003.	
XX		
PF	02-MAY-2002; 2002US-00063553.	
XX		
PR	30-DEC-1998;	98KR-00062142.
PR	08-MAR-1999;	99WO-US005028.
PR	14-MAY-1999;	99US-00311832.
PR	14-MAY-1999;	99WO-US010733.
PR	25-AUG-1999;	99US-00380137.
PR	25-AUG-1999;	99US-00380138.
PR	25-AUG-1999;	99US-00380139.
PR	25-AUG-1999;	99US-00380142.
PR	15-SEP-1999;	99US-00397342.
PR	18-OCT-1999;	99US-00403297.
PR	12-NOV-1999;	99US-00423844.
PR	30-DEC-1999;	99WO-US031274.
PR	18-FEB-2000;	2000WO-US004341.
PR	01-MAR-2000;	2000WO-US005601.
PR	02-MAR-2000;	2000WO-US005841.
PR	21-MAR-2000;	2000WO-US007532.
PR	22-MAY-2000;	2000WO-US014042.
PR	02-JUN-2000;	2000WO-US015264.
PR	22-AUG-2000;	2000US-00644848.
PR	24-AUG-2000;	2000WO-US023328.
PR	18-SEP-2000;	2000US-00664610.
PR	18-SEP-2000;	2000US-00665350.
PR	08-NOV-2000;	2000US-00709238.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001WO-US006520.
PR	22-MAR-2001;	2001US-00816744.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.
PR	30-MAY-2001;	2001US-00870574.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	29-JUN-2001;	2001US-00869599.
PR	18-JUL-2001;	2001US-00908827.
PR	06-DEC-2001;	2001US-00006867.
XX		
PA	(GETH) GENENTECH INC.	
XX		
PI	Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;	
PI	Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;	
XX		
DR	WPI; 2003-392892/37.	

DR P-PSDB; ABU92494.

XX

PT New PRO994 polypeptide, useful for detecting tumors, or for stimulating

PT Tumor Necrosis Factor alpha, or pericyte proliferation, especially for

PT treating cancer, cartilage defects, osteoarthritis and rheumatoid

PT arthritis in a mammal.

XX

PS Disclosure; Fig 37; 235pp; English.

XX

CC The invention relates to a new isolated PRO994 polypeptide comprises an

CC amino acid sequence appearing as ABU92499, PRO994 lacking its associated

CC signal peptide, the extracellular domain of PRO994, the extracellular

CC domain of PRO994 (lacking it associated signal peptide) or the protein

CC encoded by the full-length coding sequence of the cDNA ATCC 203018. Also

CC included is a chimaeric molecule comprising the PRO994 polypeptide fused

CC to a heterologous amino acid sequence. The PRO polypeptide is useful in

CC pharmaceuticals, diagnostics, biosensors or bioreactors. It is

CC particularly useful for detecting tumours (e.g. lung tumour, colon

CC tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)

CC in a mammal, for stimulating the release of tumour necrosis factor (TNF)-

CC alpha from human blood, for stimulating the proliferation of pericyte

CC cells, or stimulating the release of proteoglycans from cartilage. The

CC polypeptide may be employed for a variety of therapeutic purposes, e.g.

CC for treating cancer, wound healing, cartilage defects, osteoarthritis,

CC rheumatoid arthritis. Also disclosed are the cDNA encoding PRO994, 83

CC other PRO polypeptides and their encoding cDNAs. The present sequence

CC encodes a PRO polypeptide of the invention

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 8; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAAAATGGTCTCCACCACTG 2180

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2653 CCTTTTCTTCCCATCTCTTGTACACATTTTAATAAAATAAGGTTGGTCTCTGAACATA 2712

QY 2181 NCTCCCAA 2240

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2713 CAAA 2772

QY 2241 AA 2242

Db ||

2773 AA 2774

RESULT 373

ACA68274

ID ACA68274 standard; cDNA; 2846 BP.

XX

AC ACA68274;

XX

DT 25-JUN-2003 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX

KW Human; secreted and transmembrane protein; PRO; gene therapy;

KW chromosome mapping; gene mapping; tumor necrosis factor-alpha; blood;

KW chondrocyte differentiation stimulator;

KW chondrocyte proliferation stimulator; tumour; tissue typing; gene; ss.

XX

OS Homo sapiens.

XX

PN US2003032104-A1.

XX

PD 13-FEB-2003.

XX

PF 18-JUN-2002; 2002US-00174576.

XX

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 17-OCT-1997; 97US-0062250P.

PR

21-OCT-1997; 97US-0063486P.

24-OCT-1997; 97US-0063120P.

24-OCT-1997; 97US-0063121P.

28-OCT-1997; 97US-0063540P.

28-OCT-1997; 97US-0063541P.

28-OCT-1997; 97US-0063544P.

28-OCT-1997; 97US-0063564P.

29-OCT-1997; 97US-0063734P.

31-OCT-1997; 97US-0063870P.

31-OCT-1997; 97US-0064103P.

13-NOV-1997; 97US-0065311P.

21-NOV-1997; 97US-0066120P.

24-NOV-1997; 97US-0066466P.

24-NOV-1997; 97US-0066772P.

11-DEC-1997; 97US-0069335P.

12-DEC-1997; 97US-0069425P.

17-DEC-1997; 97US-0069870P.

18-DEC-1997; 97US-0068017P.

10-MAR-1998; 98US-0077450P.

11-MAR-1998; 98US-0077632P.

11-MAR-1998; 98US-0077649P.

20-MAR-1998; 98US-0078886P.

20-MAR-1998; 98US-0078939P.

27-MAR-1998; 98US-0079664P.

27-MAR-1998; 98US-0079786P.

31-MAR-1998; 98US-0080107P.

31-MAR-1998; 98US-0080194P.

01-APR-1998; 98US-0080327P.

01-APR-1998; 98US-0080333P.

08-APR-1998; 98US-0081049P.

08-APR-1998; 98US-0081070P.

09-APR-1998; 98US-0081195P.

15-APR-1998; 98US-0081838P.

21-APR-1998; 98US-0082568P.

21-APR-1998; 98US-0082569P.

22-APR-1998; 98US-0082704P.

22-APR-1998; 98US-0082797P.

28-APR-1998; 98US-0083322P.

29-APR-1998; 98US-0083495P.

29-APR-1998; 98US-0083496P.

29-APR-1998; 98US-0083499P.

29-APR-1998; 98US-0083559P.

05-MAY-1998; 98US-0084366P.

06-MAY-1998; 98US-0084414P.

07-MAY-1998; 98US-0084640P.

07-MAY-1998; 98US-0084643P.

15-MAY-1998; 98US-0085579P.

15-MAY-1998; 98US-0085580P.

15-MAY-1998; 98US-0085582P.

15-MAY-1998; 98US-0085700P.

18-MAY-1998; 98US-0086023P.

22-MAY-1998; 98US-0086392P.

22-MAY-1998; 98US-0086486P.

28-MAY-1998; 98US-0087098P.

28-MAY-1998; 98US-0087208P.

02-JUN-1998; 98US-0087609P.

02-JUN-1998; 98US-0087759P.

03-JUN-1998; 98US-0087827P.

04-JUN-1998; 98US-0088025P.

04-JUN-1998; 98US-0088028P.

04-JUN-1998; 98US-0088029P.

04-JUN-1998; 98US-0088033P.

04-JUN-1998; 98US-0088326P.

05-JUN-1998; 98US-0088167P.

05-JUN-1998; 98US-0088202P.

05-JUN-1998; 98US-0088212P.

05-JUN-1998; 98US-0088217P.

09-JUN-1998; 98US-0088655P.

10-JUN-1998; 98US-0088722P.

10-JUN-1998; 98US-0088738P.

10-JUN-1998; 98US-0088740P.

10-JUN-1998; 98US-0088811P.

PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.

PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.

PR	16-SEP-1998;	98US-0100664P.	
PR	16-SEP-1998;	98US-0101751P.	
PR	16-SEP-1998;	98WO-US019330.	
PR	17-SEP-1998;	98US-0100683P.	
PR	17-SEP-1998;	98US-0100684P.	
PR	17-SEP-1998;	98US-0100919P.	
PR	17-SEP-1998;	98US-0100930P.	
PR	18-SEP-1998;	98US-0100849P.	
PR	18-SEP-1998;	98US-0101014P.	
PR	18-SEP-1998;	98US-0101068P.	
PR	18-SEP-1998;	98US-0101068P.	
PR	23-SEP-1998;	98US-0101471P.	
PR	23-SEP-1998;	98US-0101472P.	
PR	23-SEP-1998;	98US-0101475P.	
PR	23-SEP-1998;	98US-0101477P.	
PR	24-SEP-1998;	98US-0101738P.	
PR	24-SEP-1998;	98US-0101739P.	
PR	24-SEP-1998;	98US-0101743P.	
PR	24-SEP-1998;	98US-0101922P.	
PR	25-SEP-1998;	98US-0101786P.	
PR	29-SEP-1998;	98US-0102207P.	
PR	29-SEP-1998;	98US-0102240P.	
PR	29-SEP-1998;	98US-0102330P.	
PR	29-SEP-1998;	98US-0102331P.	
PR	30-SEP-1998;	98US-0102487P.	
PR	30-SEP-1998;	98US-0102570P.	
PR	30-SEP-1998;	98US-0102571P.	
PR	01-OCT-1998;	98US-0102684P.	
PR	01-OCT-1998;	98US-0102687P.	
PR	02-OCT-1998;	98US-0102965P.	
PR	06-OCT-1998;	98US-0103258P.	
PR	06-OCT-1998;	98US-0103449P.	
<div>Query Match 3.0%; Score 66.6; DB 8; Length 2846; Best Local Similarity 71.3%; Pred. No. 0.00023; Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;</div>			
QY	2121	CCTTTGCTTTACCACCTCTTTCCTTTTATCTTATTATAAAAAATGTTGGTCTCCACCAC	2180
Db	2653	CCTTTCCTTCCCATCTCTGTACACATTTTATAATAAAGGTTGGCTTCTGAACTA	2712
QY	2181	NCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA	2240
Db	2713	CAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA	2772
QY	2241	AA	2242
Db	2773	AA	2774
RESULT 375			
ID	ACC81216 standard; cDNA; 2846 BP.		
XX	ACC81216;		
AC	ACC81216;		
XX	28-JUL-2003 (first entry)		
DT	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.		
DE	Human; PRO; secreted protein; transmembrane protein;		
XX	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;		
KW	chondrocyte; proliferation; differentiation; cartilage disorder;		
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;		
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;		
KW	liver; drug screening; transgenic animal; genetic analysis;		
KW	antiarthritic; vulnerary; gene therapy; gene; ss.		
XX	Homo sapiens.		
OS	US2003032120-A1.		
XX	13-FEB-2003.		
PN			
XX			
XX			
PD			
XX			

PF	25-JUN-2002;	2002US-00180546.
XX	18-SEP-1997;	97US-0059263P.
PR	18-SEP-1997;	97US-0059266P.
PR	17-OCT-1997;	97US-0062250P.
PR	21-OCT-1997;	97US-0063486P.
PR	24-OCT-1997;	97US-0063120P.
PR	24-OCT-1997;	97US-0063121P.
PR	28-OCT-1997;	97US-0063540P.
PR	28-OCT-1997;	97US-0063541P.
PR	28-OCT-1997;	97US-0063544P.
PR	28-OCT-1997;	97US-0063564P.
PR	29-OCT-1997;	97US-0063734P.
PR	31-OCT-1997;	97US-0063870P.
PR	31-OCT-1997;	97US-0064103P.
PR	13-NOV-1997;	97US-0065311P.
PR	21-NOV-1997;	97US-0066120P.
PR	24-NOV-1997;	97US-0066466P.
PR	24-NOV-1997;	97US-0066772P.
PR	11-DEC-1997;	97US-0069335P.
PR	12-DEC-1997;	97US-0069425P.
PR	17-DEC-1997;	97US-0069870P.
PR	18-DEC-1997;	97US-0068017P.
PR	10-MAR-1998;	98US-0077450P.
PR	11-MAR-1998;	98US-0077632P.
PR	11-MAR-1998;	98US-0077649P.
PR	20-MAR-1998;	98US-0078886P.
PR	20-MAR-1998;	98US-0078939P.
PR	27-MAR-1998;	98US-0079664P.
PR	27-MAR-1998;	98US-0079786P.
PR	31-MAR-1998;	98US-0080107P.
PR	31-MAR-1998;	98US-0080194P.
PR	01-APR-1998;	98US-0080327P.
PR	01-APR-1998;	98US-0080333P.
PR	08-APR-1998;	98US-0081049P.
PR	08-APR-1998;	98US-0081070P.
PR	09-APR-1998;	98US-0081195P.
PR	15-APR-1998;	98US-0081838P.
PR	21-APR-1998;	98US-0082568P.
PR	21-APR-1998;	98US-0082569P.
PR	22-APR-1998;	98US-0082704P.
PR	22-APR-1998;	98US-0082797P.
PR	28-APR-1998;	98US-0083322P.
PR	29-APR-1998;	98US-0083495P.
PR	29-APR-1998;	98US-0083496P.
PR	29-APR-1998;	98US-0083499P.
PR	29-APR-1998;	98US-0083559P.
PR	05-MAY-1998;	98US-0084366P.
PR	06-MAY-1998;	98US-0084414P.
PR	07-MAY-1998;	98US-0084639P.
PR	07-MAY-1998;	98US-0084640P.
PR	07-MAY-1998;	98US-0084643P.
PR	15-MAY-1998;	98US-0085579P.
PR	15-MAY-1998;	98US-0085580P.
PR	15-MAY-1998;	98US-0085582P.
PR	15-MAY-1998;	98US-0085700P.
PR	18-MAY-1998;	98US-0086023P.
PR	22-MAY-1998;	98US-0086392P.
PR	22-MAY-1998;	98US-0086486P.
PR	28-MAY-1998;	98US-0087098P.
PR	28-MAY-1998;	98US-0087208P.
PR	02-JUN-1998;	98US-0087609P.
PR	02-JUN-1998;	98US-0087759P.
PR	03-JUN-1998;	98US-0087827P.
PR	04-JUN-1998;	98US-0088025P.
PR	04-JUN-1998;	98US-0088028P.
PR	04-JUN-1998;	98US-0088029P.
PR	04-JUN-1998;	98US-0088033P.
PR	04-JUN-1998;	98US-0088326P.
PR	05-JUN-1998;	98US-0088167P.
PR	05-JUN-1998;	98US-0088202P.
PR	05-JUN-1998;	98US-0088212P.
PR	05-JUN-1998;	98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.

PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTCCTTTACCACTCTTTCCCTTTATCTTATTATAATAAATGTTGGTCTCCACCACTG 2180

Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACCTA 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 376

ACA95540

ID ACA95540 standard; cDNA; 2846 BP.

XX ACA95540;

XX ACA95540;

DT 11-AUG-2003 (first entry)

DE Novel human secreted and transmembrane protein PRO1344 cDNA.

XX Human; ss; gene therapy; TNF-alpha; chrondrocyte stimulator; tumour;
KW tumour necrosis factor alpha; adrenal tumour; lung tumour; colon tumour;
KW breast tumour; prostate tumour; rectal tumour; cervical tumour; gene;
KW liver tumour; bone disorder; cartilage disorder; sport injury; arthritis.
XX Homo sapiens.
OS US2003036155-A1.
XX PN
XX PD 20-FEB-2003.
XX PF 01-JUL-2002; 2002US-00187884.
XX

PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.

PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.

PR	15-SEP-1998;	98US-0100388P.	PR	18-SEP-1997;	97US-0059266P.
PR	16-SEP-1998;	98US-0100662P.	PR	17-OCT-1997;	97US-0062250P.
PR	16-SEP-1998;	98US-0100664P.	PR	21-OCT-1997;	97US-0063486P.
PR	16-SEP-1998;	98US-0101751P.	PR	24-OCT-1997;	97US-0063120P.
PR	16-SEP-1998;	98WO-US019330.	PR	28-OCT-1997;	97US-0063121P.
PR	17-SEP-1998;	98US-0100683P.	PR	28-OCT-1997;	97US-0063540P.
PR	17-SEP-1998;	98US-0100684P.	PR	28-OCT-1997;	97US-0063541P.
PR	17-SEP-1998;	98US-0100919P.	PR	28-OCT-1997;	97US-0063544P.
PR	17-SEP-1998;	98US-0100930P.	PR	29-OCT-1997;	97US-0063734P.
PR	18-SEP-1998;	98US-0100849P.	PR	31-OCT-1997;	97US-0063870P.
PR	18-SEP-1998;	98US-0101014P.	PR	31-OCT-1997;	97US-0064103P.
PR	18-SEP-1998;	98US-0101068P.	PR	31-OCT-1997;	97US-0065311P.
PR	23-SEP-1998;	98US-0101471P.	PR	13-NOV-1997;	97US-0066120P.
PR	23-SEP-1998;	98US-0101472P.	PR	21-NOV-1997;	97US-0066120P.
PR	23-SEP-1998;	98US-0101475P.	PR	24-NOV-1997;	97US-0066466P.
PR	23-SEP-1998;	98US-0101477P.	PR	24-NOV-1997;	97US-0066772P.
PR	24-SEP-1998;	98US-0101738P.	PR	11-DEC-1997;	97US-0069335P.
PR	24-SEP-1998;	98US-0101739P.	PR	12-DEC-1997;	97US-0069425P.
PR	24-SEP-1998;	98US-0101743P.	PR	17-DEC-1997;	97US-0069870P.
PR	24-SEP-1998;	98US-0101922P.	PR	18-DEC-1997;	97US-0068017P.
PR	25-SEP-1998;	98US-0101786P.	PR	10-MAR-1998;	97US-0077450P.
PR	29-SEP-1998;	98US-0102207P.	PR	11-MAR-1998;	98US-0077632P.
PR	29-SEP-1998;	98US-0102240P.	PR	11-MAR-1998;	98US-0077649P.
PR	29-SEP-1998;	98US-0102330P.	PR	20-MAR-1998;	98US-0078886P.
PR	29-SEP-1998;	98US-0102331P.	PR	20-MAR-1998;	98US-0078939P.
PR	30-SEP-1998;	98US-0102487P.	PR	27-MAR-1998;	98US-0079664P.
PR	30-SEP-1998;	98US-0102570P.	PR	27-MAR-1998;	98US-0079786P.
PR	30-SEP-1998;	98US-0102571P.	PR	31-MAR-1998;	98US-0080107P.
PR	01-OCT-1998;	98US-0102684P.	PR	31-MAR-1998;	98US-0080194P.
PR	01-OCT-1998;	98US-0102687P.	PR	01-APR-1998;	98US-0080327P.
PR	02-OCT-1998;	98US-0102965P.	PR	01-APR-1998;	98US-0080333P.
PR	06-OCT-1998;	98US-0103258P.	PR	08-APR-1998;	98US-0081049P.
PR	06-OCT-1998;	98US-0103449P.	PR	08-APR-1998;	98US-0081070P.
			PR	09-APR-1998;	98US-0081195P.
			PR	15-APR-1998;	98US-0081838P.
			PR	21-APR-1998;	98US-0082568P.
			PR	21-APR-1998;	98US-0082569P.
			PR	22-APR-1998;	98US-0082704P.
QY	2121 CCTTGGCTTTACCACTCTTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCAC	2180	PR	22-APR-1998;	98US-0082797P.
			PR	28-APR-1998;	98US-0083322P.
Db	2653 CCTTTTCCTTCCCATCTCTTGACACATTTTAATAAAATAGGGTTGGCTTCTGA	2712	PR	29-APR-1998;	98US-0083495P.
			PR	29-APR-1998;	98US-0083496P.
QY	2181 NCTCCCAA	2240	PR	29-APR-1998;	98US-0083499P.
			PR	29-APR-1998;	98US-0083559P.
Db	2713 CAAA	2772	PR	05-MAY-1998;	98US-0084366P.
			PR	06-MAY-1998;	98US-0084414P.
QY	2241 AA	2242	PR	07-MAY-1998;	98US-0084639P.
			PR	07-MAY-1998;	98US-0084640P.
Db	2773 AA	2774	PR	07-MAY-1998;	98US-0084643P.
			PR	15-MAY-1998;	98US-0085579P.
			PR	15-MAY-1998;	98US-0085580P.
			PR	15-MAY-1998;	98US-0085582P.
			PR	15-MAY-1998;	98US-0085700P.
			PR	18-MAY-1998;	98US-0086023P.
			PR	22-MAY-1998;	98US-0086392P.
			PR	22-MAY-1998;	98US-0086486P.
			PR	28-MAY-1998;	98US-0087098P.
			PR	28-MAY-1998;	98US-0087208P.
			PR	02-JUN-1998;	98US-0087609P.
			PR	02-JUN-1998;	98US-0087759P.
			PR	03-JUN-1998;	98US-0087827P.
			PR	04-JUN-1998;	98US-0088025P.
			PR	04-JUN-1998;	98US-0088028P.
			PR	04-JUN-1998;	98US-0088029P.
			PR	04-JUN-1998;	98US-0088033P.
			PR	04-JUN-1998;	98US-0088326P.
			PR	05-JUN-1998;	98US-0088167P.
			PR	05-JUN-1998;	98US-0088202P.
			PR	05-JUN-1998;	98US-0088212P.
			PR	05-JUN-1998;	98US-0088217P.
			PR	09-JUN-1998;	98US-0088655P.
			PR	10-JUN-1998;	98US-0088722P.
			PR	10-JUN-1998;	98US-0088738P.

RESULT 377
ACD04458
ID ACD04458 standard; cDNA; 2846 BP.
XX
AC ACD04458;
XX
DT 05-AUG-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW Human; ss; gene therapy; chondrocyte stimulator; tissue typing; tumour;
KW tumour necrosis factor alpha; TNF-alpha; gene.
XX
OS Homo sapiens.
XX
PN US2003022296-A1.
XX
PD 30-JAN-2003.
XX
PF 20-JUN-2002; 2002US-00176482.
XX
PR 18-SEP-1997; 97US-0059263P.

XX PD 06-FEB-2003.
XX PF 28-JUN-2002; 2002US-00184658.
XX PR 26-JUN-1998; 98US-00105413.
PR 16-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 07-DEC-1998; 98US-00202054.
PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 02-JUN-1999; 99WO-US010733.
PR 25-AUG-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021090.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028551.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.

(GETH) GENENTECH INC.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI XX
XX DR
DR P-PSDB; ABR66526.
XX PT
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful in
PT gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX PS
PS Claim 2; Fig 169; 707pp; English.
XX CC
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABR66442-ABR66746) and nucleic acids encoding them (ACC87815-ACC88119).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACC87815-ACC88119 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX SQ

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 8; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCCCTTTATCTTATTATAATAATGTTGGTCTCCACCACTG 2180

Db 2653 CCTTTTCCTTCCCATCTCTTGACACATTTTAATAAATAAGGTTGGCTTCTGAACCTA 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 379

ACF12561

ID ACF12561 standard; cDNA; 2846 BP.

XX

AC ACF12561;
XX
DT 09-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003040058-A1.
XX
PD 27-FEB-2003.
XX
PF 24-JUN-2002; 2002US-00179516.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.


```
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P..
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
```

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

```
QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTATAAAATGTTGGTCTCCACCACGTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCACTCTCTTGACACATTTTAATAAAATAAGGGTTGGCTTCTGAAC TA 2712

QY 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
      ||
Db 2773 AA 2774
```

RESULT 380
ACH66262
ID ACH66262 standard; cDNA; 2846 BP.

```
XX  
AC ACH66262;  
XX  
DT 14-OCT-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1344 cDNA.  
XX  
KW Human; secreted and transmembrane protein; PRO; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN US2003027986-A1.  
XX  
PD 06-FEB-2003.  
XX  
PF 02-MAY-2002; 2002US-00063549.  
XX  
PR 30-DEC-1998; 98KR-00062142.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 15-SEP-1999; 99US-00397342.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 30-DEC-1999; 99WO-US031274.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 22-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 30-MAY-2001; 2001US-00870574.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 29-JUN-2001; 2001US-00869599.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-DEC-2001; 2001US-00006867.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
XX  
DR WPI; 2003-456358/43.  
DR P-PSDB; ABO53279.  
XX  
PT PRO polypeptide, useful for preparing a medicament for treating a  
PT condition associated with PRO polypeptide.  
XX  
PS Disclosure; Fig 37; 222pp; English.  
XX  
CC The invention describes an isolated polypeptide having at least 80, 85,  
CC 90, 95 or 99% identity with: (a) a sequence having 46-335 amino acids, or  
CC its extracellular domain; (b) a sequence having 46-335 amino acids,  
CC lacking its associated signal peptide; or (c) an amino acid sequence  
CC encoded by the full-length coding sequence of the cDNA (ATCC accession
```



```
CC number 209956). The PRO (secreted and transmembrane) polypeptide is
CC useful for preparing a medicament for treating a condition associated
CC with PRO polypeptide. This sequence encodes a novel human secreted and
CC transmembrane PRO polypeptide
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCTCTTTTATCTTATTAATAATAATGTTGGTCTCCCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCCTTCCCACTCTCTGTACACATTTTAATAATAAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCCAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
      ||
Db 2773 AA 2774

RESULT 381
ABX79455
ID ABX79455 standard; cDNA; 2846 BP.
XX
AC ABX79455;
XX
DT 17-APR-2003 (first entry)
XX
DE Human secreted/transmembrane protein cDNA, #94.
XX
KW Human; Gene; ss; PRO; secreted; transmembrane; signal peptide;
KW pharmaceutical; diagnostic; biosensor; bioreactor; tumour; therapeutic;
KW colon cancer; lung cancer; breast cancer; cancer; gene therapy.
XX
OS Homo sapiens.
XX
PN US2002142961-A1.
XX
PD 03-OCT-2002.
XX
PF 19-NOV-2001; 2001US-00989721.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
```

```
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
```

(GETH) GENENTECH INC.

```
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
```


PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 17-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.

PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 18-JUN-1998; 98US-0089653P.
PR 19-JUN-1998; 98US-0089908P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090423P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.

PR	15-SEP-1998;	98US-0100388P.	
PR	16-SEP-1998;	98US-0100662P.	
PR	16-SEP-1998;	98US-0100664P.	
PR	16-SEP-1998;	98US-0101751P.	
PR	16-SEP-1998;	98WO-US019330.	
PR	17-SEP-1998;	98US-0100683P.	
PR	17-SEP-1998;	98US-0100684P.	
PR	17-SEP-1998;	98US-0100919P.	
PR	17-SEP-1998;	98US-0100930P.	
PR	18-SEP-1998;	98US-0100849P.	
PR	18-SEP-1998;	98US-0101014P.	
PR	18-SEP-1998;	98US-0101068P.	
PR	23-SEP-1998;	98US-0101471P.	
PR	23-SEP-1998;	98US-0101472P.	
PR	23-SEP-1998;	98US-0101475P.	
PR	23-SEP-1998;	98US-0101477P.	
PR	24-SEP-1998;	98US-0101738P.	
PR	24-SEP-1998;	98US-0101739P.	
PR	24-SEP-1998;	98US-0101743P.	
PR	24-SEP-1998;	98US-0101922P.	
PR	25-SEP-1998;	98US-0101786P.	
PR	29-SEP-1998;	98US-0102207P.	
PR	29-SEP-1998;	98US-0102240P.	
PR	29-SEP-1998;	98US-0102330P.	
PR	29-SEP-1998;	98US-0102331P.	
PR	30-SEP-1998;	98US-0102487P.	
PR	30-SEP-1998;	98US-0102570P.	
PR	30-SEP-1998;	98US-0102571P.	
PR	01-OCT-1998;	98US-0102684P.	
PR	01-OCT-1998;	98US-0102687P.	
PR	02-OCT-1998;	98US-0102965P.	
PR	06-OCT-1998;	98US-0103258P.	
PR	06-OCT-1998;	98US-0103449P.	
PR	07-OCT-1998;	98US-00168978.	
PR	07-OCT-1998;	98US-0103395P.	
Query Match 3.0%; Score 66.6; DB 8; Length 2846;			
Best Local Similarity 71.3%; Pred. No. 0.00023;			
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;			
QY	2121	CCTTTGCTTTACCACCTCTTCCTTTTATCTTATTAATAAATAATGTTGGTCTCCCACTG	2180
Db	2653	CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGAAC	2712
QY	2181	NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2240
Db	2713	CAAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2772
QY	2241	AA 2242	
Db	2773	AA 2774	
RESULT 384			
ACA73776			
ID	ACA73776 standard; cDNA; 2846 BP.		
XX			
AC	ACA73776;		
XX			
DT	02-JUL-2003 (first entry)		
XX			
DE	Human secreted/transmembrane protein (PRO) cDNA #85.		
XX			
KW	Human; ss; gene; PRO; secreted protein; transmembrane protein;		
KW	tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;		
KW	differentiation; chondrocyte; adrenal tumour; lung tumour; colon tumour;		
KW	breast tumour; prostate tumour; rectal tumour; cervical tumour;		
KW	liver tumour; gene therapy; cytostatic.		
XX			
OS	Homo sapiens.		
XX			
PN	US2003032129-A1.		
XX			

PD	13-FEB-2003.	
XX		
PF	28-JUN-2002; 2002US-00184623.	
XX		
PR	18-SEP-1997;	97US-0059263P.
PR	18-SEP-1997;	97US-0059266P.
PR	17-OCT-1997;	97US-0062250P.
PR	21-OCT-1997;	97US-0063486P.
PR	24-OCT-1997;	97US-0063120P.
PR	24-OCT-1997;	97US-0063121P.
PR	28-OCT-1997;	97US-0063540P.
PR	28-OCT-1997;	97US-0063541P.
PR	28-OCT-1997;	97US-0063544P.
PR	28-OCT-1997;	97US-0063564P.
PR	29-OCT-1997;	97US-0063734P.
PR	31-OCT-1997;	97US-0063870P.
PR	31-OCT-1997;	97US-0064103P.
PR	13-NOV-1997;	97US-0065311P.
PR	21-NOV-1997;	97US-0066120P.
PR	24-NOV-1997;	97US-0066466P.
PR	24-NOV-1997;	97US-0066772P.
PR	11-DEC-1997;	97US-0069335P.
PR	12-DEC-1997;	97US-0069425P.
PR	17-DEC-1997;	97US-0069870P.
PR	18-DEC-1997;	97US-0068017P.
PR	10-MAR-1998;	98US-0077450P.
PR	11-MAR-1998;	98US-0077632P.
PR	11-MAR-1998;	98US-0077649P.
PR	20-MAR-1998;	98US-0078886P.
PR	20-MAR-1998;	98US-0078939P.
PR	27-MAR-1998;	98US-0079664P.
PR	27-MAR-1998;	98US-0079786P.
PR	31-MAR-1998;	98US-0080107P.
PR	31-MAR-1998;	98US-0080194P.
PR	01-APR-1998;	98US-0080327P.
PR	01-APR-1998;	98US-0080333P.
PR	08-APR-1998;	98US-0081049P.
PR	08-APR-1998;	98US-0081070P.
PR	09-APR-1998;	98US-0081195P.
PR	15-APR-1998;	98US-0081838P.
PR	21-APR-1998;	98US-0082568P.
PR	21-APR-1998;	98US-0082569P.
PR	22-APR-1998;	98US-0082704P.
PR	22-APR-1998;	98US-0082797P.
PR	28-APR-1998;	98US-0083322P.
PR	29-APR-1998;	98US-0083495P.
PR	29-APR-1998;	98US-0083496P.
PR	29-APR-1998;	98US-0083499P.
PR	29-APR-1998;	98US-0083559P.
PR	05-MAY-1998;	98US-0084366P.
PR	06-MAY-1998;	98US-0084414P.
PR	07-MAY-1998;	98US-0084639P.
PR	07-MAY-1998;	98US-0084640P.
PR	07-MAY-1998;	98US-0084643P.
PR	15-MAY-1998;	98US-0085579P.
PR	15-MAY-1998;	98US-0085580P.
PR	15-MAY-1998;	98US-0085582P.
PR	15-MAY-1998;	98US-0085700P.
PR	18-MAY-1998;	98US-0086023P.
PR	22-MAY-1998;	98US-0086392P.
PR	22-MAY-1998;	98US-0086486P.
PR	28-MAY-1998;	98US-0087098P.
PR	28-MAY-1998;	98US-0087208P.
PR	02-JUN-1998;	98US-0087609P.
PR	02-JUN-1998;	98US-0087759P.
PR	03-JUN-1998;	98US-0087827P.
PR	04-JUN-1998;	98US-0088025P.
PR	04-JUN-1998;	98US-0088028P.
PR	04-JUN-1998;	98US-0088029P.
PR	04-JUN-1998;	98US-0088033P.
PR	04-JUN-1998;	98US-0088326P.
PR	05-JUN-1998;	98US-0088167P.
PR	05-JUN-1998;	98US-0088202P.

XX	13-FEB-2003.		PR	05-JUN-1998;	98US-0088202P.
PD			PR	05-JUN-1998;	98US-0088212P.
XX			PR	05-JUN-1998;	98US-0088217P.
PF	28-JUN-2002;	2002US-00184637.	PR	09-JUN-1998;	98US-0088655P.
XX			PR	10-JUN-1998;	98US-0088722P.
PR	18-SEP-1997;	97US-0059263P.	PR	10-JUN-1998;	98US-0088738P.
PR	18-SEP-1997;	97US-0059266P.	PR	10-JUN-1998;	98US-0088740P.
PR	17-OCT-1997;	97US-0062250P.	PR	10-JUN-1998;	98US-0088811P.
PR	21-OCT-1997;	97US-0063486P.	PR	10-JUN-1998;	98US-0088824P.
PR	24-OCT-1997;	97US-0063120P.	PR	10-JUN-1998;	98US-0088825P.
PR	24-OCT-1997;	97US-0063121P.	PR	10-JUN-1998;	98US-0088826P.
PR	28-OCT-1997;	97US-0063540P.	PR	11-JUN-1998;	98US-0088861P.
PR	28-OCT-1997;	97US-0063541P.	PR	11-JUN-1998;	98US-0088863P.
PR	28-OCT-1997;	97US-0063544P.	PR	11-JUN-1998;	98US-0088876P.
PR	28-OCT-1997;	97US-0063564P.	PR	12-JUN-1998;	98US-0089090P.
PR	29-OCT-1997;	97US-0063734P.	PR	12-JUN-1998;	98US-0089105P.
PR	31-OCT-1997;	97US-0063870P.	PR	16-JUN-1998;	98US-0089512P.
PR	31-OCT-1997;	97US-0064103P.	PR	16-JUN-1998;	98US-0089514P.
PR	13-NOV-1997;	97US-0065311P.	PR	17-JUN-1998;	98US-0089538P.
PR	21-NOV-1997;	97US-0066120P.	PR	17-JUN-1998;	98US-0089598P.
PR	21-NOV-1997;	97US-0066466P.	PR	17-JUN-1998;	98US-0089653P.
PR	24-NOV-1997;	97US-0066772P.	PR	18-JUN-1998;	98US-0089908P.
PR	11-DEC-1997;	97US-0069335P.	PR	19-JUN-1998;	98US-0089952P.
PR	12-DEC-1997;	97US-0069425P.	PR	22-JUN-1998;	98US-0090246P.
PR	17-DEC-1997;	97US-0069870P.	PR	22-JUN-1998;	98US-0090252P.
PR	18-DEC-1997;	97US-0068017P.	PR	22-JUN-1998;	98US-0090254P.
PR	10-MAR-1998;	98US-0077450P.	PR	24-JUN-1998;	98US-0090429P.
PR	11-MAR-1998;	98US-0077632P.	PR	24-JUN-1998;	98US-0090435P.
PR	11-MAR-1998;	98US-0077649P.	PR	24-JUN-1998;	98US-0090444P.
PR	20-MAR-1998;	98US-0078886P.	PR	24-JUN-1998;	98US-0090461P.
PR	27-MAR-1998;	98US-0078939P.	PR	24-JUN-1998;	98US-0090535P.
PR	27-MAR-1998;	98US-0079664P.	PR	24-JUN-1998;	98US-0090540P.
PR	27-MAR-1998;	98US-0079786P.	PR	25-JUN-1998;	98US-0090676P.
PR	31-MAR-1998;	98US-0080107P.	PR	25-JUN-1998;	98US-0090678P.
PR	31-MAR-1998;	98US-0080194P.	PR	25-JUN-1998;	98US-0090688P.
PR	01-APR-1998;	98US-0080327P.	PR	25-JUN-1998;	98US-0090690P.
PR	01-APR-1998;	98US-0080333P.	PR	25-JUN-1998;	98US-0090694P.
PR	08-APR-1998;	98US-0081049P.	PR	25-JUN-1998;	98US-0090695P.
PR	08-APR-1998;	98US-0081070P.	PR	25-JUN-1998;	98US-0090696P.
PR	09-APR-1998;	98US-0081195P.	PR	26-JUN-1998;	98US-00105413.
PR	15-APR-1998;	98US-0081838P.	PR	26-JUN-1998;	98US-0090862P.
PR	21-APR-1998;	98US-0082568P.	PR	26-JUN-1998;	98US-0090863P.
PR	21-APR-1998;	98US-0082569P.	PR	26-JUN-1998;	98US-0091010P.
PR	22-APR-1998;	98US-0082704P.	PR	01-JUL-1998;	98US-0091359P.
PR	22-APR-1998;	98US-0082797P.	PR	01-JUL-1998;	98US-0091544P.
PR	28-APR-1998;	98US-0083322P.	PR	02-JUL-1998;	98US-0091478P.
PR	29-APR-1998;	98US-0083495P.	PR	02-JUL-1998;	98US-0091486P.
PR	29-APR-1998;	98US-0083496P.	PR	02-JUL-1998;	98US-0091626P.
PR	29-APR-1998;	98US-0083499P.	PR	02-JUL-1998;	98US-0091628P.
PR	29-APR-1998;	98US-0083559P.	PR	02-JUL-1998;	98US-0091632P.
PR	05-MAY-1998;	98US-0084366P.	PR	24-JUL-1998;	98US-0094006P.
PR	06-MAY-1998;	98US-0084414P.	PR	04-AUG-1998;	98US-0095282P.
PR	07-MAY-1998;	98US-0084639P.	PR	10-AUG-1998;	98US-0095998P.
PR	07-MAY-1998;	98US-0084640P.	PR	10-AUG-1998;	98US-0096012P.
PR	07-MAY-1998;	98US-0084643P.	PR	17-AUG-1998;	98US-0096757P.
PR	15-MAY-1998;	98US-0085579P.	PR	17-AUG-1998;	98US-0096766P.
PR	15-MAY-1998;	98US-0085580P.	PR	17-AUG-1998;	98US-0096867P.
PR	15-MAY-1998;	98US-0085582P.	PR	17-AUG-1998;	98US-0096891P.
PR	15-MAY-1998;	98US-0085700P.	PR	17-AUG-1998;	98US-0096897P.
PR	18-MAY-1998;	98US-0086023P.	PR	18-AUG-1998;	98US-0096949P.
PR	22-MAY-1998;	98US-0086392P.	PR	18-AUG-1998;	98US-0096959P.
PR	22-MAY-1998;	98US-0086486P.	PR	18-AUG-1998;	98US-0097022P.
PR	28-MAY-1998;	98US-0087098P.	PR	26-AUG-1998;	98US-0097952P.
PR	28-MAY-1998;	98US-0087208P.	PR	26-AUG-1998;	98US-0097954P.
PR	02-JUN-1998;	98US-0087609P.	PR	26-AUG-1998;	98US-0097955P.
PR	02-JUN-1998;	98US-0087759P.	PR	26-AUG-1998;	98US-0097971P.
PR	03-JUN-1998;	98US-0087827P.	PR	26-AUG-1998;	98US-0097974P.
PR	04-JUN-1998;	98US-0088025P.	PR	26-AUG-1998;	98US-0098014P.
PR	04-JUN-1998;	98US-0088028P.	PR	01-SEP-1998;	98US-0098716P.
PR	04-JUN-1998;	98US-0088029P.	PR	01-SEP-1998;	98US-0098723P.
PR	04-JUN-1998;	98US-0088033P.	PR	02-SEP-1998;	98US-0098803P.
PR	04-JUN-1998;	98US-0088326P.	PR	02-SEP-1998;	98US-0098821P.
PR	05-JUN-1998;	98US-0088167P.	PR	02-SEP-1998;	98US-0098843P.

PN	US2003032107-A1.	PR	05-JUN-1998;	88US-0088167P.
XX		PR	05-JUN-1998;	88US-0088202P.
PD	13-FEB-2003.	PR	05-JUN-1998;	88US-0088212P.
XX		PR	05-JUN-1998;	88US-0088217P.
PF	19-JUN-2002; 2002US-00175747.	PR	09-JUN-1998;	88US-0088655P.
XX		PR	10-JUN-1998;	88US-0088722P.
PR	18-SEP-1997; 97US-0059263P.	PR	10-JUN-1998;	88US-0088738P.
PR	18-SEP-1997; 97US-0059266P.	PR	10-JUN-1998;	88US-0088740P.
PR	17-OCT-1997; 97US-0062250P.	PR	10-JUN-1998;	88US-0088811P.
PR	21-OCT-1997; 97US-0063486P.	PR	10-JUN-1998;	88US-0088824P.
PR	24-OCT-1997; 97US-0063120P.	PR	10-JUN-1998;	88US-0088825P.
PR	24-OCT-1997; 97US-0063121P.	PR	10-JUN-1998;	88US-0088826P.
PR	28-OCT-1997; 97US-0063540P.	PR	11-JUN-1998;	88US-0088861P.
PR	28-OCT-1997; 97US-0063541P.	PR	11-JUN-1998;	88US-0088863P.
PR	28-OCT-1997; 97US-0063544P.	PR	11-JUN-1998;	88US-0088876P.
PR	28-OCT-1997; 97US-0063564P.	PR	12-JUN-1998;	88US-0089090P.
PR	29-OCT-1997; 97US-0063734P.	PR	12-JUN-1998;	88US-0089105P.
PR	31-OCT-1997; 97US-0063870P.	PR	16-JUN-1998;	88US-0089512P.
PR	31-OCT-1997; 97US-0064103P.	PR	16-JUN-1998;	88US-0089514P.
PR	13-NOV-1997; 97US-0065311P.	PR	17-JUN-1998;	88US-0089538P.
PR	21-NOV-1997; 97US-0066120P.	PR	17-JUN-1998;	88US-0089598P.
PR	24-NOV-1997; 97US-0066466P.	PR	17-JUN-1998;	88US-0089653P.
PR	24-NOV-1997; 97US-0066772P.	PR	18-JUN-1998;	88US-0089908P.
PR	11-DEC-1997; 97US-0069335P.	PR	19-JUN-1998;	88US-0089952P.
PR	12-DEC-1997; 97US-0069425P.	PR	22-JUN-1998;	88US-0090246P.
PR	17-DEC-1997; 97US-0069870P.	PR	22-JUN-1998;	88US-0090252P.
PR	18-DEC-1997; 97US-0068017P.	PR	22-JUN-1998;	88US-0090254P.
PR	10-MAR-1998; 98US-0077450P.	PR	24-JUN-1998;	88US-0090429P.
PR	11-MAR-1998; 98US-0077632P.	PR	24-JUN-1998;	88US-0090435P.
PR	11-MAR-1998; 98US-0077649P.	PR	24-JUN-1998;	88US-0090444P.
PR	20-MAR-1998; 98US-0078866P.	PR	24-JUN-1998;	88US-0090461P.
PR	20-MAR-1998; 98US-0078939P.	PR	24-JUN-1998;	88US-0090535P.
PR	27-MAR-1998; 98US-0079664P.	PR	24-JUN-1998;	88US-0090540P.
PR	27-MAR-1998; 98US-0079786P.	PR	25-JUN-1998;	88US-0090676P.
PR	31-MAR-1998; 98US-0080107P.	PR	25-JUN-1998;	88US-0090678P.
PR	31-MAR-1998; 98US-0080194P.	PR	25-JUN-1998;	88US-0090688P.
PR	01-APR-1998; 98US-0080327P.	PR	25-JUN-1998;	88US-0090690P.
PR	01-APR-1998; 98US-0080333P.	PR	25-JUN-1998;	88US-0090694P.
PR	08-APR-1998; 98US-0081049P.	PR	25-JUN-1998;	88US-0090695P.
PR	08-APR-1998; 98US-0081070P.	PR	25-JUN-1998;	88US-0090696P.
PR	09-APR-1998; 98US-0081195P.	PR	26-JUN-1998;	88US-00105413.
PR	15-APR-1998; 98US-0081838P.	PR	26-JUN-1998;	88US-0090862P.
PR	21-APR-1998; 98US-0082568P.	PR	26-JUN-1998;	88US-0090863P.
PR	21-APR-1998; 98US-0082569P.	PR	26-JUN-1998;	88US-0091010P.
PR	22-APR-1998; 98US-0082704P.	PR	01-JUL-1998;	88US-0091359P.
PR	22-APR-1998; 98US-0082797P.	PR	01-JUL-1998;	88US-0091544P.
PR	28-APR-1998; 98US-0083322P.	PR	02-JUL-1998;	88US-0091478P.
PR	29-APR-1998; 98US-0083495P.	PR	02-JUL-1998;	88US-0091486P.
PR	29-APR-1998; 98US-0083496P.	PR	02-JUL-1998;	88US-0091626P.
PR	29-APR-1998; 98US-0083499P.	PR	02-JUL-1998;	88US-0091628P.
PR	29-APR-1998; 98US-0083559P.	PR	02-JUL-1998;	88US-0091632P.
PR	05-MAY-1998; 98US-0084366P.	PR	24-JUL-1998;	88US-0094006P.
PR	06-MAY-1998; 98US-0084414P.	PR	04-AUG-1998;	88US-0095282P.
PR	07-MAY-1998; 98US-0084639P.	PR	10-AUG-1998;	88US-0095998P.
PR	07-MAY-1998; 98US-0084640P.	PR	10-AUG-1998;	88US-0096012P.
PR	07-MAY-1998; 98US-0084643P.	PR	17-AUG-1998;	88US-0096757P.
PR	15-MAY-1998; 98US-0085579P.	PR	17-AUG-1998;	88US-0096766P.
PR	15-MAY-1998; 98US-0085580P.	PR	17-AUG-1998;	88US-0096867P.
PR	15-MAY-1998; 98US-0085582P.	PR	17-AUG-1998;	88US-0096891P.
PR	15-MAY-1998; 98US-0085700P.	PR	17-AUG-1998;	88US-0096897P.
PR	18-MAY-1998; 98US-0086023P.	PR	18-AUG-1998;	88US-0096949P.
PR	22-MAY-1998; 98US-0086392P.	PR	18-AUG-1998;	88US-0096959P.
PR	22-MAY-1998; 98US-0086486P.	PR	18-AUG-1998;	88US-0097022P.
PR	28-MAY-1998; 98US-0087098P.	PR	26-AUG-1998;	88US-0097952P.
PR	28-MAY-1998; 98US-0087208P.	PR	26-AUG-1998;	88US-0097954P.
PR	02-JUN-1998; 98US-0087609P.	PR	26-AUG-1998;	88US-0097955P.
PR	02-JUN-1998; 98US-0087759P.	PR	26-AUG-1998;	88US-0097971P.
PR	03-JUN-1998; 98US-0087827P.	PR	26-AUG-1998;	88US-0097974P.
PR	04-JUN-1998; 98US-0088025P.	PR	26-AUG-1998;	88US-0098014P.
PR	04-JUN-1998; 98US-0088028P.	PR	01-SEP-1998;	88US-0098716P.
PR	04-JUN-1998; 98US-0088029P.	PR	01-SEP-1998;	88US-0098723P.
PR	04-JUN-1998; 98US-0088033P.	PR	02-SEP-1998;	88US-0098803P.
PR	04-JUN-1998; 98US-0088326P.	PR	02-SEP-1998;	88US-0098821P.

PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.

Query Match3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity71.3%; Pred. No. 0.00023;
Matches87; Conservative0; Mismatches35; Indels0; Gaps0;

OY2121CCTTTGCTTTACCACCTCTTCTCTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACGTG2180
|||||

Db2653CCTTTCTCTCCCATCTCTGTGTACACATTTTAAATAAAAAAAGGGTTGGCTTCTGAACATA2712
|||||

OY2181NCTCCCAA2240
|||||

Db2713CAA2772
|||||

OY2241AA2242
||

Db2773AA2774

RESULT388
ACC91385
IDACC91385standard; cDNA; 2846 BP.
XX
ACACC91385;
XX
DT19-AUG-2003(first entry)
XX
DEHuman secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KWHuman; PRO; secreted protein; transmembrane protein;
KWextracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KWchondrocyte; proliferation; differentiation; cartilage disorder;
KWbone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KWadrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KWliver; drug screening; transgenic animal; Genetic analysis;

KW	antiarthritic; vulnerary; gene therapy; gene; ss.
XX	Homo sapiens.
OS	US2003032139-A1.
XX	13-FEB-2003.
PN	01-JUL-2002; 2002US-00187886.
XX	18-SEP-1997; 97US-0059263P.
PR	18-SEP-1997; 97US-0059266P.
PR	17-OCT-1997; 97US-0062250P.
PR	21-OCT-1997; 97US-0063486P.
PR	24-OCT-1997; 97US-0063120P.
PR	24-OCT-1997; 97US-0063121P.
PR	28-OCT-1997; 97US-0063540P.
PR	28-OCT-1997; 97US-0063541P.
PR	28-OCT-1997; 97US-0063544P.
PR	28-OCT-1997; 97US-0063564P.
PR	29-OCT-1997; 97US-0063734P.
PR	31-OCT-1997; 97US-0063870P.
PR	31-OCT-1997; 97US-0064103P.
PR	13-NOV-1997; 97US-0065311P.
PR	21-NOV-1997; 97US-0066120P.
PR	24-NOV-1997; 97US-0066466P.
PR	24-NOV-1997; 97US-0066772P.
PR	11-DEC-1997; 97US-0069335P.
PR	12-DEC-1997; 97US-0069425P.
PR	17-DEC-1997; 97US-0069870P.
PR	18-DEC-1997; 97US-0068017P.
PR	10-MAR-1998; 98US-0077450P.
PR	11-MAR-1998; 98US-0077632P.
PR	11-MAR-1998; 98US-0077649P.
PR	20-MAR-1998; 98US-0078886P.
PR	20-MAR-1998; 98US-0078939P.
PR	27-MAR-1998; 98US-0079664P.
PR	27-MAR-1998; 98US-0079786P.
PR	31-MAR-1998; 98US-0080107P.
PR	31-MAR-1998; 98US-0080194P.
PR	01-APR-1998; 98US-0080327P.
PR	01-APR-1998; 98US-0080333P.
PR	08-APR-1998; 98US-0081049P.
PR	08-APR-1998; 98US-0081070P.
PR	09-APR-1998; 98US-0081195P.
PR	15-APR-1998; 98US-0081838P.
PR	21-APR-1998; 98US-0082568P.
PR	21-APR-1998; 98US-0082569P.
PR	22-APR-1998; 98US-0082704P.
PR	22-APR-1998; 98US-0082797P.
PR	28-APR-1998; 98US-0083322P.
PR	29-APR-1998; 98US-0083495P.
PR	29-APR-1998; 98US-0083496P.
PR	29-APR-1998; 98US-0083499P.
PR	29-APR-1998; 98US-0083559P.
PR	05-MAY-1998; 98US-0084366P.
PR	06-MAY-1998; 98US-0084414P.
PR	07-MAY-1998; 98US-0084639P.
PR	07-MAY-1998; 98US-0084643P.
PR	15-MAY-1998; 98US-0085579P.
PR	15-MAY-1998; 98US-0085580P.
PR	15-MAY-1998; 98US-0085582P.
PR	15-MAY-1998; 98US-0085700P.
PR	18-MAY-1998; 98US-0086023P.
PR	22-MAY-1998; 98US-0086392P.
PR	22-MAY-1998; 98US-0086486P.
PR	28-MAY-1998; 98US-0087098P.
PR	28-MAY-1998; 98US-0087208P.
PR	02-JUN-1998; 98US-0087609P.
PR	02-JUN-1998; 98US-0087759P.
PR	03-JUN-1998; 98US-0087827P.
PR	04-JUN-1998; 98US-0088025P.

PR	04-JUN-1998;	98US-0088028P.
PR	04-JUN-1998;	98US-0088029P.
PR	04-JUN-1998;	98US-0088033P.
PR	04-JUN-1998;	98US-0088326P.
PR	05-JUN-1998;	98US-0088167P.
PR	05-JUN-1998;	98US-0088202P.
PR	05-JUN-1998;	98US-0088212P.
PR	05-JUN-1998;	98US-0088217P.
PR	09-JUN-1998;	98US-0088655P.
PR	10-JUN-1998;	98US-0088722P.
PR	10-JUN-1998;	98US-0088738P.
PR	10-JUN-1998;	98US-0088740P.
PR	10-JUN-1998;	98US-0088811P.
PR	10-JUN-1998;	98US-0088824P.
PR	10-JUN-1998;	98US-0088825P.
PR	10-JUN-1998;	98US-0088826P.
PR	11-JUN-1998;	98US-0088861P.
PR	11-JUN-1998;	98US-0088863P.
PR	11-JUN-1998;	98US-0088876P.
PR	12-JUN-1998;	98US-0089090P.
PR	12-JUN-1998;	98US-0089105P.
PR	16-JUN-1998;	98US-0089512P.
PR	16-JUN-1998;	98US-0089514P.
PR	17-JUN-1998;	98US-0089538P.
PR	17-JUN-1998;	98US-0089598P.
PR	17-JUN-1998;	98US-0089653P.
PR	18-JUN-1998;	98US-0089908P.
PR	19-JUN-1998;	98US-0089952P.
PR	22-JUN-1998;	98US-0090246P.
PR	22-JUN-1998;	98US-0090252P.
PR	22-JUN-1998;	98US-0090254P.
PR	24-JUN-1998;	98US-0090429P.
PR	24-JUN-1998;	98US-0090444P.
PR	24-JUN-1998;	98US-0090435P.
PR	24-JUN-1998;	98US-0090461P.
PR	24-JUN-1998;	98US-0090535P.
PR	24-JUN-1998;	98US-0090540P.
PR	25-JUN-1998;	98US-0090676P.
PR	25-JUN-1998;	98US-0090678P.
PR	25-JUN-1998;	98US-0090688P.
PR	25-JUN-1998;	98US-0090690P.
PR	25-JUN-1998;	98US-0090694P.
PR	25-JUN-1998;	98US-0090695P.
PR	25-JUN-1998;	98US-0090696P.
PR	26-JUN-1998;	98US-00105413.
PR	26-JUN-1998;	98US-0090862P.
PR	26-JUN-1998;	98US-0090863P.
PR	26-JUN-1998;	98US-0091010P.
PR	01-JUL-1998;	98US-0091359P.
PR	01-JUL-1998;	98US-0091544P.
PR	02-JUL-1998;	98US-0091478P.
PR	02-JUL-1998;	98US-0091486P.
PR	02-JUL-1998;	98US-0091626P.
PR	02-JUL-1998;	98US-0091628P.
PR	02-JUL-1998;	98US-0091632P.
PR	24-JUL-1998;	98US-0094006P.
PR	04-AUG-1998;	98US-0095282P.
PR	10-AUG-1998;	98US-0095998P.
PR	10-AUG-1998;	98US-0096012P.
PR	17-AUG-1998;	98US-0096757P.
PR	17-AUG-1998;	98US-0096766P.
PR	17-AUG-1998;	98US-0096867P.
PR	17-AUG-1998;	98US-0096891P.
PR	17-AUG-1998;	98US-0096897P.
PR	18-AUG-1998;	98US-0096949P.
PR	18-AUG-1998;	98US-0096959P.
PR	18-AUG-1998;	98US-0097022P.
PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98US-0101751P.
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
<div>Query Match 3.0%; Score 66.6; DB 8; Length 2846; Best Local Similarity 71.3%; Pred. No. 0.00023; Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;</div>		
Qy	2121	CCTTTGCTTTACCACCTCTTTCCTTTTATCTTATTATAATAAAATGTTGGTCTCCACCACTG 2180
Db	2653	CCTTTTCCTTCCCATCTCTGTACACATTTTATAATAAATAAGGTTGGCTTCTGAACTA 2712
Qy	2181	NCTCCCAA 2240
Db	2713	CAA 2772
Qy	2241	AA 2242
Db	2773	AA 2774
RESULT 389		
ACA93476		
ID	ACA93476 standard; cDNA; 2846 BP.	
XX	ACA93476;	
AC	ACA93476;	
XX	16-JUL-2003 (first entry)	
DT	Novel human secreted and transmembrane protein PRO1344 cDNA.	
XX	Human; secreted and transmembrane protein; PRO; PRO183; PRO184; PRO185;	
KW	PRO943; PRO1133; PRO331; PRO1387; PRO363; PRO5723; PRO1114; PRO3301;	
KW	PRO9940; PRO1181; PRO7170; PRO361; PRO846; bioactive molecule; toxin;	
KW	radiolabel; antibody; cell death; tissue typing; gene therapy;	
KW	cytostatic; chromosome mapping; gene mapping; transgenic animal;	


```
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 20-FEB-1999; 99WO-US030911.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 02-MAR-2000; 2000WO-US005004.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
```

```
Query Match      3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred.No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTATAAAAAATGTTGGTCTCCACCACTG 2180
      ||||| || || || || || || || || || || || || || || || || || || || ||
Db 2653 CCTTTTCTTCCCATCTCTTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
      ||
Db 2773 AA 2774
```

```
RESULT 390
ACD02720
ID ACD02720 standard; cDNA; 2846 BP.
XX
AC ACD02720;
XX
DT 01-AUG-2003 (first entry)
XX cDNA encoding human PRO polypeptide #85.
XX Human; PRO polypeptide; secreted protein; transmembrane protein;
KW chromosome mapping; gene mapping; tumour; adrenal; lung; colon; breast;
KW prostate; rectal; cervical; liver; cancer; TNF-alpha;
KW tumour necrosis factor-alpha; cell proliferation; chondrocyte;
```

```
KW cell differentiation; gene therapy; gene; ss.
XX Homo sapiens.
OS
XX US2003022301-A1.
PN
XX 30-JAN-2003.
PD
XX 25-JUN-2002; 2002US-00180557.
PF
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
```


Qy 2241 AA 2242
Db 2773 AA 2774

RESULT 392
ACC85869
ID ACC85869 standard; cdna; 2846 BP.
XX
AC ACC85869;
XX
DT 28-JUL-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003027262-A1.
XX
PD 06-FEB-2003.
XX
PF 17-JUN-2002; 2002US-00173700.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.

PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.

PR	02-JUL-1998;	98US-0091628P.	
PR	02-JUL-1998;	98US-0091628P.	
PR	02-JUL-1998;	98US-0091632P.	
PR	24-JUL-1998;	98US-0094006P.	
PR	04-AUG-1998;	98US-0095282P.	
PR	10-AUG-1998;	98US-0095998P.	
PR	10-AUG-1998;	98US-0096012P.	
PR	17-AUG-1998;	98US-0096757P.	
PR	17-AUG-1998;	98US-0096766P.	
PR	17-AUG-1998;	98US-0096867P.	
PR	17-AUG-1998;	98US-0096891P.	
PR	17-AUG-1998;	98US-0096897P.	
PR	18-AUG-1998;	98US-0096949P.	
PR	18-AUG-1998;	98US-0096959P.	
PR	18-AUG-1998;	98US-0097022P.	
PR	26-AUG-1998;	98US-0097952P.	
PR	26-AUG-1998;	98US-0097954P.	
PR	26-AUG-1998;	98US-0097955P.	
PR	26-AUG-1998;	98US-0097971P.	
PR	26-AUG-1998;	98US-0097974P.	
PR	26-AUG-1998;	98US-0098014P.	
PR	01-SEP-1998;	98US-0098716P.	
PR	01-SEP-1998;	98US-0098723P.	
PR	02-SEP-1998;	98US-0098803P.	
PR	02-SEP-1998;	98US-0098821P.	
PR	02-SEP-1998;	98US-0098843P.	
PR	09-SEP-1998;	98US-0099602P.	
PR	10-SEP-1998;	98US-0099741P.	
PR	10-SEP-1998;	98US-0099754P.	
PR	10-SEP-1998;	98US-0099763P.	
PR	10-SEP-1998;	98US-0099812P.	
PR	15-SEP-1998;	98US-0100388P.	
PR	16-SEP-1998;	98US-0100662P.	
PR	16-SEP-1998;	98US-0100664P.	
PR	16-SEP-1998;	98US-0101751P.	
PR	16-SEP-1998;	98WO-US019330.	
PR	17-SEP-1998;	98US-0100683P.	
PR	17-SEP-1998;	98US-0100684P.	
PR	17-SEP-1998;	98US-0100919P.	
PR	17-SEP-1998;	98US-0100930P.	
PR	18-SEP-1998;	98US-0100849P.	
PR	18-SEP-1998;	98US-0101014P.	
PR	18-SEP-1998;	98US-0101068P.	
PR	23-SEP-1998;	98US-0101471P.	
PR	23-SEP-1998;	98US-0101472P.	
PR	23-SEP-1998;	98US-0101475P.	
PR	23-SEP-1998;	98US-0101477P.	
PR	24-SEP-1998;	98US-0101738P.	
PR	24-SEP-1998;	98US-0101739P.	
PR	24-SEP-1998;	98US-0101743P.	
PR	24-SEP-1998;	98US-0101922P.	
PR	25-SEP-1998;	98US-0101786P.	
PR	29-SEP-1998;	98US-0102207P.	
PR	29-SEP-1998;	98US-0102240P.	
PR	29-SEP-1998;	98US-0102330P.	
PR	29-SEP-1998;	98US-0102331P.	
PR	30-SEP-1998;	98US-0102487P.	
PR	30-SEP-1998;	98US-0102570P.	
PR	30-SEP-1998;	98US-0102571P.	
PR	01-OCT-1998;	98US-0102684P.	
PR	01-OCT-1998;	98US-0102687P.	
Query Match 3.0%; Score 66.6; DB 8; Length 2846;			
Best Local Similarity 71.3%; Pred. No. 0.00023;			
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;			
Qy	2121	CCTTTGCTTTACCACCTCTTCCTTTTATCTTATTATAAAATGTTGGTCTCCACCACTG	2180
Db	2653	CCTTTTCCTTCCCCATCTCTGTACACATTTTATAAAATAAGGTTGGCTTCTGAAC	2712
Qy	2181	NCTCCCAAAAAA	2240
Db	2713	CAAAAAA	2772

QY	2241	AA	2242
Db	2773	AA	2774

RESULT 393
ABX81158
ID ABX81158 standard; DNA; 2846 BP.
XX AC ABX81158;
XX DT 22-APR-2003 (first entry)
XX DE Human secreted or transmembrane protein related PCR primer #50.
XX KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosum; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis; PCR; primer; ss.
XX OS Homo sapiens.
XX PN US2003027985-A1.
XX PD 06-FEB-2003.
XX PF 14-NOV-2001; 2001US-00990562.
XX PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.

PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.

PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACTCTTTCTCTTTATCTTATTAATAAAAAATGTTGGTCTCCCACTG 2180

Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGGTTGGCTTCTGAAC TA 2712

Qy 2181 NCTCCCAA 2240

PR	24-JUL-1998;	98US-0094006P.
PR	04-AUG-1998;	98US-0095282P.
PR	10-AUG-1998;	98US-0095998P.
PR	10-AUG-1998;	98US-0095012P.
PR	17-AUG-1998;	98US-0096757P.
PR	17-AUG-1998;	98US-0096766P.
PR	17-AUG-1998;	98US-0096867P.
PR	17-AUG-1998;	98US-0096891P.
PR	17-AUG-1998;	98US-0096897P.
PR	18-AUG-1998;	98US-0096949P.
PR	18-AUG-1998;	98US-0096959P.
PR	18-AUG-1998;	98US-0097022P.
PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.
PR	07-OCT-1998;	98US-00168978.
PR	07-OCT-1998;	98US-0103395P.
Query Match 3.0%; Score 66.6; DB 8; Length 2846;		
Best Local Similarity 71.3%; Pred. No. 0.00023;		
Matches	87; Conservative	0; Mismatches 35; Indels 0; Gaps 0;
QY	2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTATAATAAAATGTTGGTCTCCACCACTG	2180
Db	2653 CCTTTTCTTCCCATCTCTTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAACATA	2712
QY	2181 NCTCCCAA	2240

Db	2713 CAAA	2772
QY	2241 AA 2242	
Db	2773 AA 2774	
RESULT 395		
ACA94174		
ID	ACA94174 standard; cDNA; 2846 BP.	
XX		
AC	ACA94174;	
XX		
DT	18-JUL-2003 (first entry)	
XX		
DE	Human secreted/transmembrane protein (PRO) cDNA #85.	
XX		
KW	Human; ss; gene; PRO; secreted protein; transmembrane protein;	
KW	tumour necrosis factor alpha; TNF-alpha; blood; proliferation;	
KW	differentiation; chondrocyte cell; cytostatic; tumour; gene therapy.	
XX		
OS	Homo sapiens.	
XX		
PN	US2003036142-A1.	
XX		
PD	20-FEB-2003.	
XX		
PF	01-JUL-2002; 2002US-00187598.	
XX		
PR	18-SEP-1997; 97US-0059263P.	
PR	18-SEP-1997; 97US-0059266P.	
PR	17-OCT-1997; 97US-0062250P.	
PR	21-OCT-1997; 97US-0063486P.	
PR	24-OCT-1997; 97US-0063120P.	
PR	24-OCT-1997; 97US-0063121P.	
PR	28-OCT-1997; 97US-0063540P.	
PR	28-OCT-1997; 97US-0063541P.	
PR	28-OCT-1997; 97US-0063544P.	
PR	28-OCT-1997; 97US-0063564P.	
PR	29-OCT-1997; 97US-0063734P.	
PR	31-OCT-1997; 97US-0063870P.	
PR	31-OCT-1997; 97US-0064103P.	
PR	13-NOV-1997; 97US-0065311P.	
PR	21-NOV-1997; 97US-0066120P.	
PR	24-NOV-1997; 97US-0066466P.	
PR	24-NOV-1997; 97US-0066772P.	
PR	11-DEC-1997; 97US-0069335P.	
PR	17-DEC-1997; 97US-0069425P.	
PR	17-DEC-1997; 97US-0069870P.	
PR	18-DEC-1997; 97US-0068017P.	
PR	10-MAR-1998; 98US-0077450P.	
PR	11-MAR-1998; 98US-0077632P.	
PR	11-MAR-1998; 98US-0077649P.	
PR	20-MAR-1998; 98US-007886P.	
PR	20-MAR-1998; 98US-0078939P.	
PR	27-MAR-1998; 98US-0079664P.	
PR	27-MAR-1998; 98US-0079786P.	
PR	31-MAR-1998; 98US-0080107P.	
PR	31-MAR-1998; 98US-0080194P.	
PR	01-APR-1998; 98US-0080327P.	
PR	01-APR-1998; 98US-0080333P.	
PR	08-APR-1998; 98US-0081049P.	
PR	08-APR-1998; 98US-0081070P.	
PR	09-APR-1998; 98US-0081195P.	
PR	15-APR-1998; 98US-0081838P.	
PR	21-APR-1998; 98US-0082568P.	
PR	21-APR-1998; 98US-0082569P.	
PR	22-APR-1998; 98US-0082704P.	
PR	22-APR-1998; 98US-0082797P.	
PR	28-APR-1998; 98US-0083322P.	
PR	29-APR-1998; 98US-0083495P.	
PR	29-APR-1998; 98US-0083496P.	

QY 2181 NCTCCCAAA 2240
Db 2713 CAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 396
ACA97918
ID ACA97918 standard; cDNA; 2846 BP.
XX
AC ACA97918;
XX
DT 25-JUL-2003 (first entry)
DE Human PRO polynucleotide #85.
XX
KW Human; PRO; gene; ss; cytostatic; tumour necrosis factor-alpha; blood;
KW TNF-alpha; chondrocyte cell; tumour; cancer.
XX
OS Homo sapiens.
XX
PN US2003036145-A1.
PD 20-FEB-2003.
XX
PF 02-JUL-2002; 2002US-00187602.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-00633486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 28-APR-1998; 98US-0082797P.
PR 29-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.

PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.

PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103395P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGGCTTTACACTCTTTTCCTTTTATCTTATTATAAAATGTTGGTCTCCACCACGTG 2180
DB 2653 CCTTTCTCTCCCATCTCTTGTACACATTTTATAAAATAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAA 2240
Db 2713 CAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 397
ACA91420
ID ACA91420 standard; cDNA; 2846 BP.
XX AC ACA91420;
XX 14-JUL-2003 (first entry)
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX Human; secreted and transmembrane protein; PRO; cytostatic; gene therapy;
KW antisense gene therapy; TNF-alpha release;
KW tumour necrosis factor-alpha release; chondrocyte proliferation;
KW chondrocyte differentiation; tumour; adrenal tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; gene; ss.
XX Homo sapiens.
OS
XX US2003036154-A1.
PN 20-FEB-2003.
PD
XX 02-JUL-2002; 2002US-00187757.
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.

Db	2653	CCTTTTCCTCCCATCTCTGTACACATTTTAAATAAAATAAGGTTGGCTTCTGAACTA	2712	PR	28-APR-1998;	98US-0083322P.
				PR	29-APR-1998;	98US-0083495P.
Qy	2181	NCTCCCAA	2240	PR	29-APR-1998;	98US-0083496P.
				PR	29-APR-1998;	98US-0083499P.
Db	2713	CAA	2772	PR	29-APR-1998;	98US-0083559P.
				PR	05-MAY-1998;	98US-0084366P.
Qy	2241	AA 2242		PR	06-MAY-1998;	98US-0084414P.
				PR	07-MAY-1998;	98US-0084639P.
Db	2773	AA 2774		PR	07-MAY-1998;	98US-0084640P.
				PR	07-MAY-1998;	98US-0084643P.
				PR	15-MAY-1998;	98US-0085579P.
				PR	15-MAY-1998;	98US-0085580P.
				PR	15-MAY-1998;	98US-0085582P.
				PR	15-MAY-1998;	98US-0085700P.
				PR	18-MAY-1998;	98US-0086023P.
				PR	22-MAY-1998;	98US-0086392P.
				PR	22-MAY-1998;	98US-0086486P.
				PR	28-MAY-1998;	98US-0087098P.
				PR	28-MAY-1998;	98US-0087208P.
				PR	02-JUN-1998;	98US-0087609P.
				PR	02-JUN-1998;	98US-0087759P.
				PR	03-JUN-1998;	98US-0087827P.
				PR	04-JUN-1998;	98US-0088025P.
				PR	04-JUN-1998;	98US-0088028P.
				PR	04-JUN-1998;	98US-0088029P.
				PR	04-JUN-1998;	98US-0088033P.
				PR	04-JUN-1998;	98US-0088326P.
				PR	05-JUN-1998;	98US-0088167P.
				PR	05-JUN-1998;	98US-0088202P.
				PR	05-JUN-1998;	98US-0088212P.
				PR	05-JUN-1998;	98US-0088217P.
				PR	09-JUN-1998;	98US-0088655P.
				PR	10-JUN-1998;	98US-0088722P.
				PR	10-JUN-1998;	98US-0088738P.
				PR	10-JUN-1998;	98US-0088740P.
				PR	10-JUN-1998;	98US-0088811P.
				PR	10-JUN-1998;	98US-0088824P.
				PR	10-JUN-1998;	98US-0088825P.
				PR	10-JUN-1998;	98US-0088826P.
				PR	11-JUN-1998;	98US-0088861P.
				PR	11-JUN-1998;	98US-0088863P.
				PR	11-JUN-1998;	98US-0088876P.
				PR	12-JUN-1998;	98US-0089090P.
				PR	12-JUN-1998;	98US-0089105P.
				PR	16-JUN-1998;	98US-0089512P.
				PR	16-JUN-1998;	98US-0089514P.
				PR	17-JUN-1998;	98US-0089538P.
				PR	17-JUN-1998;	98US-0089589P.
				PR	17-JUN-1998;	98US-0089653P.
				PR	18-JUN-1998;	98US-0089908P.
				PR	19-JUN-1998;	98US-0089952P.
				PR	22-JUN-1998;	98US-0090246P.
				PR	22-JUN-1998;	98US-0090252P.
				PR	22-JUN-1998;	98US-0090254P.
				PR	24-JUN-1998;	98US-0090429P.
				PR	24-JUN-1998;	98US-0090435P.
				PR	24-JUN-1998;	98US-0090444P.
				PR	24-JUN-1998;	98US-0090461P.
				PR	24-JUN-1998;	98US-0090535P.
				PR	24-JUN-1998;	98US-0090540P.
				PR	25-JUN-1998;	98US-0090676P.
				PR	25-JUN-1998;	98US-0090678P.
				PR	25-JUN-1998;	98US-0090688P.
				PR	25-JUN-1998;	98US-0090690P.
				PR	25-JUN-1998;	98US-0090694P.
				PR	25-JUN-1998;	98US-0090695P.
				PR	25-JUN-1998;	98US-0090696P.
				PR	26-JUN-1998;	98US-00105413.
				PR	26-JUN-1998;	98US-0090862P.
				PR	26-JUN-1998;	98US-0090863P.
				PR	26-JUN-1998;	98US-0091010P.
				PR	01-JUL-1998;	98US-0091359P.
				PR	01-JUL-1998;	98US-0091544P.

RESULT 398
ACA90634
ID ACA90634 standard; cDNA; 2846 BP.
XX
AC ACA90634;
XX
DT 11-AUG-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW Human; ss; gene therapy; tumour necrosis factor-alpha release; TNF;
KW chondrocyte proliferation; chondrocyte differentiation; tumour; gene;
KW tissue typing.
XX
OS Homo sapiens.
XX
PN US2003036153-A1.
PD
PD 20-FEB-2003.
XX
XX 02-JUL-2002; 2002US-00187754.
PR
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 11-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080327P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.

PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGTCTTACCACCTCTTCTCTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACCTG 2180

Db 2653 CCTTTCTCCCATCTCTTGACACATTTTATAAAATAAGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAA 2240
Db 2713 CAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 399
ACD16181
ID ACD16181 standard; cDNA; 2846 BP.
XX
AC ACD16181;
XX
DT 19-AUG-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
DE
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX Homo sapiens.
XX
PN US2003044931-A1.
XX
PD 06-MAR-2003.
XX
PF 28-JUN-2002; 2002US-00184656.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.

PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.

PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 02-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy	2121	CCTTTGGCTTTACCACTCTTTCCTTTTATCTTATTATAATAAATGTTGGTCTCCACCACTG	2180	PR	21-APR-1998;	98US-0082569P.
				PR	22-APR-1998;	98US-0082704P.
Db	2653	CCTTTCTCTCCCACTCTTGTAACACATTTTAATAAATAAGGTTGGCTTCTGAACTA	2712	PR	22-APR-1998;	98US-0082797P.
				PR	28-APR-1998;	98US-0083322P.
Qy	2181	NCTCCCAA	2240	PR	29-APR-1998;	98US-0083495P.
				PR	29-APR-1998;	98US-0083496P.
Db	2713	CAA	2772	PR	29-APR-1998;	98US-0083499P.
				PR	29-APR-1998;	98US-0083559P.
Qy	2241	AA 2242		PR	05-MAY-1998;	98US-0084366P.
				PR	06-MAY-1998;	98US-0084414P.
Db	2773	AA 2774		PR	07-MAY-1998;	98US-0084639P.
				PR	07-MAY-1998;	98US-0084640P.
				PR	07-MAY-1998;	98US-0084643P.
				PR	15-MAY-1998;	98US-0085579P.
				PR	15-MAY-1998;	98US-0085580P.
				PR	15-MAY-1998;	98US-0085582P.
				PR	15-MAY-1998;	98US-0085700P.
				PR	18-MAY-1998;	98US-0086023P.
				PR	22-MAY-1998;	98US-0086392P.
				PR	22-MAY-1998;	98US-0086486P.
				PR	28-MAY-1998;	98US-0087098P.
				PR	28-MAY-1998;	98US-0087208P.
				PR	02-JUN-1998;	98US-0087609P.
				PR	02-JUN-1998;	98US-0087759P.
				PR	03-JUN-1998;	98US-0087827P.
				PR	04-JUN-1998;	98US-0088025P.
				PR	04-JUN-1998;	98US-0088028P.
				PR	04-JUN-1998;	98US-0088029P.
				PR	04-JUN-1998;	98US-0088033P.
				PR	04-JUN-1998;	98US-0088326P.
				PR	05-JUN-1998;	98US-0088167P.
				PR	05-JUN-1998;	98US-0088202P.
				PR	05-JUN-1998;	98US-0088212P.
				PR	05-JUN-1998;	98US-0088217P.
				PR	09-JUN-1998;	98US-0088655P.
				PR	10-JUN-1998;	98US-0088722P.
				PR	10-JUN-1998;	98US-0088738P.
				PR	10-JUN-1998;	98US-0088740P.
				PR	10-JUN-1998;	98US-0088811P.
				PR	10-JUN-1998;	98US-0088824P.
				PR	10-JUN-1998;	98US-0088825P.
				PR	10-JUN-1998;	98US-0088826P.
				PR	11-JUN-1998;	98US-0088861P.
				PR	11-JUN-1998;	98US-0088863P.
				PR	11-JUN-1998;	98US-0088876P.
				PR	12-JUN-1998;	98US-0089090P.
				PR	12-JUN-1998;	98US-0089105P.
				PR	16-JUN-1998;	98US-0089512P.
				PR	16-JUN-1998;	98US-0089514P.
				PR	17-JUN-1998;	98US-0089538P.
				PR	17-JUN-1998;	98US-0089598P.
				PR	17-JUN-1998;	98US-0089653P.
				PR	18-JUN-1998;	98US-0089908P.
				PR	19-JUN-1998;	98US-0089952P.
				PR	22-JUN-1998;	98US-0090246P.
				PR	22-JUN-1998;	98US-0090252P.
				PR	22-JUN-1998;	98US-0090254P.
				PR	24-JUN-1998;	98US-0090429P.
				PR	24-JUN-1998;	98US-0090435P.
				PR	24-JUN-1998;	98US-0090444P.
				PR	24-JUN-1998;	98US-0090461P.
				PR	24-JUN-1998;	98US-0090535P.
				PR	24-JUN-1998;	98US-0090540P.
				PR	25-JUN-1998;	98US-0090676P.
				PR	25-JUN-1998;	98US-0090678P.
				PR	25-JUN-1998;	98US-0090688P.
				PR	25-JUN-1998;	98US-0090690P.
				PR	25-JUN-1998;	98US-0090694P.
				PR	25-JUN-1998;	98US-0090695P.
				PR	25-JUN-1998;	98US-0090696P.
				PR	26-JUN-1998;	98US-00105413.
				PR	26-JUN-1998;	98US-0090862P.
				PR	26-JUN-1998;	98US-0090863P.

PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.

PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;	
QY 2121 CCTTGGCTTACCACCTCTTTCCCTTTTATCTTATTATAATAAATGGTGGTCTCCACCACTG 2180	
Db 2653 CCTTTCCCTCCCATCTCTTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAACATA 2712	
QY 2181 NCTCCCAAA 2240	
Db 2713 CAAA 2772	
QY 2241 AA 2242	
Db 2773 AA 2774	
RESULT 402	
ACD02316	
ID ACD02316 standard; cDNA; 2846 BP.	
XX ACD02316;	
XX 30-JUL-2003 (first entry)	
DT Novel human secreted and transmembrane protein PRO1344 cDNA.	
DE Human; secreted and transmembrane protein; PRO; cytosstatic; gene therapy;	
KW cancer; chromosome mapping; gene mapping; diagnostic; biosensor;	
KW bioreactor; gene; ss.	
XX Homo sapiens.	
OS US2002183493-A1.	
XX 05-DEC-2002.	
XX 02-MAY-2002; 2002US-00063530.	
PR 30-DEC-1998; 98KR-00062142.	
PR 08-MAR-1999; 99WO-US005028.	
PR 14-MAY-1999; 99US-00311832.	
PR 14-MAY-1999; 99WO-US010733.	
PR 25-AUG-1999; 99US-00380137.	
PR 25-AUG-1999; 99US-00380138.	
PR 25-AUG-1999; 99US-00380139.	
PR 25-AUG-1999; 99US-00380142.	
PR 15-SEP-1999; 99US-00397342.	
PR 18-OCT-1999; 99US-00403297.	
PR 12-NOV-1999; 99US-00423844.	
PR 30-DEC-1999; 99WO-US031274.	
PR 18-FEB-2000; 2000WO-US004341.	
PR 01-MAR-2000; 2000WO-US005601.	
PR 02-MAR-2000; 2000WO-US005841.	
PR 21-MAR-2000; 2000WO-US007532.	
PR 02-JUN-2000; 2000WO-US014042.	
PR 02-AUG-2000; 2000US-00644848.	
PR 24-AUG-2000; 2000WO-US023328.	
PR 18-SEP-2000; 2000US-00664610.	
PR 18-SEP-2000; 2000US-00665350.	
PR 08-NOV-2000; 2000US-00709238.	
PR 10-NOV-2000; 2000WO-US030873.	
PR 01-DEC-2000; 2000WO-US032678.	
PR 20-DEC-2000; 2000US-00747259.	
PR 20-DEC-2000; 2000WO-US034956.	
PR 28-FEB-2001; 2001WO-US006520.	
PR 22-MAR-2001; 2001US-00816744.	
PR 10-MAY-2001; 2001US-00854208.	
PR 10-MAY-2001; 2001US-00854280.	
PR 30-MAY-2001; 2001US-00870574.	
PR 01-JUN-2001; 2001WO-US017800.	
PR 05-JUN-2001; 2001US-00874503.	
PR 29-JUN-2001; 2001US-00869599.	
PR 18-JUL-2001; 2001US-00908827.	
Query Match 3.0%; Score 66.6; DB 8; Length 2846;	
Best Local Similarity 71.3%; Pred. No. 0.00023;	
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;	
QY 2121 CCTTGGCTTACCACCTCTTTCCCTTTTATCTTATTATAATAAATGGTGGTCTCCACCACTG 2180	
Db 2653 CCTTTCCCTCCCATCTCTTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAACATA 2712	
QY 2181 NCTCCCAAA 2240	
Db 2713 CAAA 2772	
QY 2241 AA 2242	
Db 2773 AA 2774	
RESULT 403	
ACA74856	
ID ACA74856 standard; cDNA; 2846 BP.	
XX ACA74856;	
XX 07-JUL-2003 (first entry)	
DT cDNA encoding human PRO polypeptide #85.	
DE Human; PRO polypeptide; secreted protein; transmembrane protein; breast;	
KW chromosome mapping; gene mapping; tumour; adrenal; lung; colon; breast;	
KW prostate; rectal; cervical; liver; cancer; TNF-alpha;	
KW tumour necrosis factor-alpha; proliferation; differentiation;	
KW chondrocyte cell; bone disorder; cartilage disorder; sports injury;	
KW arthritis; cytostatic; antiarthritic; osteopathic; gene therapy; gene;	
XX ss.	

OS	Homo sapiens.		
XX		PR	04-JUN-1998;
PN	US2003022293-A1.	PR	04-JUN-1998;
XX		PR	05-JUN-1998;
PD	30-JAN-2003.	PR	05-JUN-1998;
XX		PR	05-JUN-1998;
PF		PR	05-JUN-1998;
XX	17-JUN-2002; 2002US-00173706.	PR	09-JUN-1998;
		PR	10-JUN-1998;
	18-SEP-1997;	PR	10-JUN-1998;
PR	18-SEP-1997;	PR	10-JUN-1998;
PR	17-OCT-1997;	PR	10-JUN-1998;
PR	21-OCT-1997;	PR	10-JUN-1998;
PR	24-OCT-1997;	PR	10-JUN-1998;
PR	24-OCT-1997;	PR	10-JUN-1998;
PR	28-OCT-1997;	PR	10-JUN-1998;
PR	28-OCT-1997;	PR	11-JUN-1998;
PR	28-OCT-1997;	PR	11-JUN-1998;
PR	28-OCT-1997;	PR	11-JUN-1998;
PR	29-OCT-1997;	PR	12-JUN-1998;
PR	31-OCT-1997;	PR	16-JUN-1998;
PR	31-OCT-1997;	PR	16-JUN-1998;
PR	13-NOV-1997;	PR	17-JUN-1998;
PR	21-NOV-1997;	PR	17-JUN-1998;
PR	24-NOV-1997;	PR	17-JUN-1998;
PR	11-DEC-1997;	PR	18-JUN-1998;
PR	12-DEC-1997;	PR	19-JUN-1998;
PR	17-DEC-1997;	PR	22-JUN-1998;
PR	18-DEC-1997;	PR	22-JUN-1998;
PR	10-MAR-1998;	PR	24-JUN-1998;
PR	11-MAR-1998;	PR	24-JUN-1998;
PR	20-MAR-1998;	PR	24-JUN-1998;
PR	20-MAR-1998;	PR	24-JUN-1998;
PR	27-MAR-1998;	PR	24-JUN-1998;
PR	27-MAR-1998;	PR	25-JUN-1998;
PR	31-MAR-1998;	PR	25-JUN-1998;
PR	31-MAR-1998;	PR	25-JUN-1998;
PR	01-APR-1998;	PR	25-JUN-1998;
PR	08-APR-1998;	PR	25-JUN-1998;
PR	08-APR-1998;	PR	25-JUN-1998;
PR	09-APR-1998;	PR	25-JUN-1998;
PR	15-APR-1998;	PR	26-JUN-1998;
PR	21-APR-1998;	PR	26-JUN-1998;
PR	21-APR-1998;	PR	26-JUN-1998;
PR	22-APR-1998;	PR	26-JUN-1998;
PR	22-APR-1998;	PR	01-JUL-1998;
PR	28-APR-1998;	PR	01-JUL-1998;
PR	29-APR-1998;	PR	02-JUL-1998;
PR	29-APR-1998;	PR	02-JUL-1998;
PR	29-APR-1998;	PR	02-JUL-1998;
PR	05-MAY-1998;	PR	02-JUL-1998;
PR	06-MAY-1998;	PR	24-JUL-1998;
PR	07-MAY-1998;	PR	04-AUG-1998;
PR	07-MAY-1998;	PR	10-AUG-1998;
PR	07-MAY-1998;	PR	10-AUG-1998;
PR	15-MAY-1998;	PR	17-AUG-1998;
PR	15-MAY-1998;	PR	17-AUG-1998;
PR	15-MAY-1998;	PR	17-AUG-1998;
PR	15-MAY-1998;	PR	17-AUG-1998;
PR	18-MAY-1998;	PR	17-AUG-1998;
PR	22-MAY-1998;	PR	18-AUG-1998;
PR	22-MAY-1998;	PR	18-AUG-1998;
PR	22-MAY-1998;	PR	18-AUG-1998;
PR	28-MAY-1998;	PR	26-AUG-1998;
PR	02-JUN-1998;	PR	26-AUG-1998;
PR	02-JUN-1998;	PR	26-AUG-1998;
PR	03-JUN-1998;	PR	26-AUG-1998;
PR	04-JUN-1998;	PR	26-AUG-1998;
PR	04-JUN-1998;	PR	01-SEP-1998;
PR	04-JUN-1998;	PR	01-SEP-1998;

98US-0088033P.	98US-0088326P.
98US-0088167P.	98US-0088202P.
98US-0088212P.	98US-0088217P.
98US-0088655P.	98US-0088722P.
98US-0088738P.	98US-0088740P.
98US-0088811P.	98US-0088824P.
98US-0088825P.	98US-0088826P.
98US-0088861P.	98US-0088863P.
98US-0088876P.	98US-0089090P.
98US-0089105P.	98US-0089512P.
98US-0089514P.	98US-0089538P.
98US-0089598P.	98US-0089653P.
98US-0089908P.	98US-0089952P.
98US-0090246P.	98US-0090252P.
98US-0090254P.	98US-0090429P.
98US-0090435P.	98US-0090444P.
98US-0090461P.	98US-0090535P.
98US-0090540P.	98US-0090676P.
98US-0090678P.	98US-0090688P.
98US-0090690P.	98US-0090694P.
98US-0090695P.	98US-0090696P.
98US-00105413.	98US-0090862P.
98US-0090863P.	98US-0091010P.
98US-0091359P.	98US-0091544P.
98US-0091478P.	98US-0091486P.
98US-0091626P.	98US-0091628P.
98US-0091632P.	98US-0091632P.
98US-0094006P.	98US-0095282P.
98US-0095998P.	98US-0096012P.
98US-0096757P.	98US-0096766P.
98US-0096867P.	98US-0096891P.
98US-0096897P.	98US-0096949P.
98US-0096959P.	98US-0097022P.
98US-0097952P.	98US-0097954P.
98US-0097955P.	98US-0097971P.
98US-0097974P.	98US-0098014P.
98US-0098716P.	98US-0098723P.

PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
Query Match 3.0%; Score 66.6; DB 8; Length 2846;		
Best Local Similarity 71.3%; Pred. No. 0.00023;		
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;		
QY	2121	CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTATAAAAAATGTTGGTCTCCACCACTG 2180
Db	2653	CCTTTTCCTTCCCATCTCTTGACACATTTTAATAAAAAATAAGGTTGGCTTCTGAACATA 2712
QY	2181	NCTCCCAA 2240
Db	2713	CAA 2772
QY	2241	AA 2242
Db	2773	AA 2774
RESULT 404		
ACA91727		
ID	ACA91727 standard; cDNA; 2846 BP.	
XX		
AC	ACA91727;	
XX		
DT	14-JUL-2003 (first entry)	
XX	Human PRO polynucleotide #85.	
DE		
XX	Human; PRO; gene; ss; cytostatic; secreted polypeptide; cancer; tumour;	
KW	transmembrane polypeptide; adrenal; lung; colon; breast; prostate; liver;	
KW	rectum; cervix.	
XX		
OS	Homo sapiens.	
XX	US2003032128-A1.	
PN		

XX	13-FEB-2003.	
PD		
XX		
PF	27-JUN-2002; 2002US-00184614.	
XX		
PR	18-SEP-1997;	97US-0059263P.
PR	18-SEP-1997;	97US-0059266P.
PR	17-OCT-1997;	97US-0062250P.
PR	21-OCT-1997;	97US-0063486P.
PR	24-OCT-1997;	97US-0063120P.
PR	24-OCT-1997;	97US-0063121P.
PR	28-OCT-1997;	97US-0063540P.
PR	28-OCT-1997;	97US-0063541P.
PR	28-OCT-1997;	97US-0063544P.
PR	28-OCT-1997;	97US-0063564P.
PR	29-OCT-1997;	97US-0063734P.
PR	31-OCT-1997;	97US-0063870P.
PR	31-OCT-1997;	97US-0064103P.
PR	13-NOV-1997;	97US-0065311P.
PR	21-NOV-1997;	97US-0066120P.
PR	24-NOV-1997;	97US-0066466P.
PR	24-NOV-1997;	97US-0066772P.
PR	11-DEC-1997;	97US-0069335P.
PR	12-DEC-1997;	97US-0069425P.
PR	17-DEC-1997;	97US-0069870P.
PR	18-DEC-1997;	97US-0068017P.
PR	10-MAR-1998;	98US-0077450P.
PR	11-MAR-1998;	98US-0077632P.
PR	11-MAR-1998;	98US-0077649P.
PR	20-MAR-1998;	98US-0078866P.
PR	20-MAR-1998;	98US-0078939P.
PR	27-MAR-1998;	98US-0079664P.
PR	27-MAR-1998;	98US-0079786P.
PR	31-MAR-1998;	98US-0080107P.
PR	31-MAR-1998;	98US-0080194P.
PR	01-APR-1998;	98US-0080327P.
PR	01-APR-1998;	98US-0080333P.
PR	08-APR-1998;	98US-0081049P.
PR	08-APR-1998;	98US-0081070P.
PR	09-APR-1998;	98US-0081195P.
PR	15-APR-1998;	98US-0081838P.
PR	21-APR-1998;	98US-0082568P.
PR	21-APR-1998;	98US-0082569P.
PR	22-APR-1998;	98US-0082704P.
PR	22-APR-1998;	98US-0082797P.
PR	28-APR-1998;	98US-0083322P.
PR	29-APR-1998;	98US-0083495P.
PR	29-APR-1998;	98US-0083496P.
PR	29-APR-1998;	98US-0083499P.
PR	29-APR-1998;	98US-0083559P.
PR	05-MAY-1998;	98US-0084366P.
PR	06-MAY-1998;	98US-0084414P.
PR	07-MAY-1998;	98US-0084639P.
PR	07-MAY-1998;	98US-0084640P.
PR	07-MAY-1998;	98US-0084643P.
PR	15-MAY-1998;	98US-0085579P.
PR	15-MAY-1998;	98US-0085580P.
PR	15-MAY-1998;	98US-0085700P.
PR	18-MAY-1998;	98US-0086023P.
PR	22-MAY-1998;	98US-0086392P.
PR	22-MAY-1998;	98US-0086486P.
PR	28-MAY-1998;	98US-0087098P.
PR	28-MAY-1998;	98US-0087208P.
PR	02-JUN-1998;	98US-0087609P.
PR	02-JUN-1998;	98US-0087759P.
PR	03-JUN-1998;	98US-0087827P.
PR	04-JUN-1998;	98US-0088025P.
PR	04-JUN-1998;	98US-0088028P.
PR	04-JUN-1998;	98US-0088029P.
PR	04-JUN-1998;	98US-0088033P.
PR	04-JUN-1998;	98US-0088326P.
PR	05-JUN-1998;	98US-0088167P.

[illegible]

PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.

PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy	2121	CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTATAATAAATGTTGGTCTCCACCACTG	2180	PR	08-APR-1998;	98US-0081070P.
				PR	09-APR-1998;	98US-0081195P.
Db	2653	CCTTTTCCTTCCCATCTCTTGTAACATTTTAATAAATAAGGGTTGGCTTCTGAACTA	2712	PR	15-APR-1998;	98US-0081838P.
				PR	21-APR-1998;	98US-0082568P.
Qy	2181	NCTCCCAA	2240	PR	21-APR-1998;	98US-0082569P.
				PR	22-APR-1998;	98US-0082704P.
Db	2713	CAA	2772	PR	22-APR-1998;	98US-0082797P.
				PR	28-APR-1998;	98US-0083322P.
Qy	2241	AA 2242		PR	29-APR-1998;	98US-0083495P.
				PR	29-APR-1998;	98US-0083496P.
Db	2773	AA 2774		PR	29-APR-1998;	98US-0083499P.
				PR	29-APR-1998;	98US-0083559P.
				PR	05-MAY-1998;	98US-0084366P.
				PR	06-MAY-1998;	98US-0084414P.
				PR	07-MAY-1998;	98US-0084639P.
				PR	07-MAY-1998;	98US-0084640P.
				PR	07-MAY-1998;	98US-0084643P.
				PR	15-MAY-1998;	98US-0085579P.
				PR	15-MAY-1998;	98US-0085580P.
				PR	15-MAY-1998;	98US-0085582P.
				PR	15-MAY-1998;	98US-0085700P.
				PR	18-MAY-1998;	98US-0086023P.
				PR	22-MAY-1998;	98US-0086392P.
				PR	22-MAY-1998;	98US-0086486P.
				PR	28-MAY-1998;	98US-0087098P.
				PR	28-MAY-1998;	98US-0087208P.
				PR	02-JUN-1998;	98US-0087609P.
				PR	02-JUN-1998;	98US-0087759P.
				PR	03-JUN-1998;	98US-0087827P.
				PR	04-JUN-1998;	98US-0088025P.
				PR	04-JUN-1998;	98US-0088028P.
				PR	04-JUN-1998;	98US-0088029P.
				PR	04-JUN-1998;	98US-0088033P.
				PR	04-JUN-1998;	98US-0088326P.
				PR	05-JUN-1998;	98US-0088167P.
				PR	05-JUN-1998;	98US-0088202P.
				PR	05-JUN-1998;	98US-0088212P.
				PR	05-JUN-1998;	98US-0088217P.
				PR	09-JUN-1998;	98US-0088655P.
				PR	10-JUN-1998;	98US-0088722P.
				PR	10-JUN-1998;	98US-0088738P.
				PR	10-JUN-1998;	98US-0088740P.
				PR	10-JUN-1998;	98US-0088811P.
				PR	10-JUN-1998;	98US-0088824P.
				PR	10-JUN-1998;	98US-0088825P.
				PR	10-JUN-1998;	98US-0088826P.
				PR	11-JUN-1998;	98US-0088861P.
				PR	11-JUN-1998;	98US-0088863P.
				PR	11-JUN-1998;	98US-0088876P.
				PR	12-JUN-1998;	98US-0089090P.
				PR	12-JUN-1998;	98US-0089105P.
				PR	16-JUN-1998;	98US-0089512P.
				PR	16-JUN-1998;	98US-0089514P.
				PR	17-JUN-1998;	98US-0089538P.
				PR	17-JUN-1998;	98US-0089598P.
				PR	17-JUN-1998;	98US-0089653P.
				PR	18-JUN-1998;	98US-0089908P.
				PR	19-JUN-1998;	98US-0089952P.
				PR	22-JUN-1998;	98US-0090246P.
				PR	22-JUN-1998;	98US-0090252P.
				PR	22-JUN-1998;	98US-0090254P.
				PR	24-JUN-1998;	98US-0090429P.
				PR	24-JUN-1998;	98US-0090435P.
				PR	24-JUN-1998;	98US-0090444P.
				PR	24-JUN-1998;	98US-0090461P.
				PR	24-JUN-1998;	98US-0090535P.
				PR	24-JUN-1998;	98US-0090540P.
				PR	25-JUN-1998;	98US-0090676P.
				PR	25-JUN-1998;	98US-0090678P.
				PR	25-JUN-1998;	98US-0090688P.
				PR	25-JUN-1998;	98US-0090690P.
				PR	25-JUN-1998;	98US-0090694P.
				PR	25-JUN-1998;	98US-0090695P.

PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.

PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.

Query Match

3.0%; Score 66.6; DB 8; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712
QY 2181 NCTCCCAA 2240
Db 2713 CAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 409
ACA68944
ID ACA68944 standard; cDNA; 2846 BP.
AC ACA68944;
XX
DT 26-JUN-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO1344 cDNA.
DE Human; secreted and transmembrane protein; PRO; cytostatic;
KW immunotherapy; cancer; gene; ss.
XX Homo sapiens.

XX US2002183494-A1.
PD 05-DEC-2002.
XX 02-MAY-2002; 2002US-00063551.
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.

PR 06-DEC-2001; 2001US-00006867.
XX (GETH) GENENTECH INC.
PA Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX WPI; 2003-340981/32.
DR P-PSDB; ABU82493.
XX New antibody that specifically binds to a PRO polypeptide, useful in
PT preparing a medicament for treating a condition, e.g. cancer, responsive
PT to the antibody, and in diagnostic and purification assays for the PRO
PT polypeptide.
XX PS Disclosure; Fig 37; 235pp; English.
XX The invention describes an antibody that binds to a novel human secreted
CC and transmembrane PRO polypeptide. The antibody is useful in preparing a
CC medicament for treating a condition e.g. cancer. The antibody may also be
CC used in diagnostic assays for PRO polypeptide in specific cells, tissue
CC or serum, and in affinity purification of the polypeptide. This sequence
CC encodes a novel human secreted and transmembrane PRO polypeptide
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712
QY 2181 NCTCCCAA 2240
Db 2713 CAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 410
ACA92974
ID ACA92974 standard; cDNA; 2846 BP.
XX ACA92974;
AC ACA92974;
XX 16-JUL-2003 (first entry)
DT Novel human secreted and transmembrane protein PRO1344 cDNA.
XX Human; secreted and transmembrane protein; PRO; nootropic;
KW neuroprotective; antiparkinsonian; cytostatic; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW neurodegenerative disorder; Parkinson's disease; Alzheimer's disease;
KW gene; ss.
XX Homo sapiens.
OS US2003017476-A1.
PN 23-JAN-2003.
XX 20-NOV-2001; 2001US-00989724.
XX 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.

PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.

PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.

PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.

PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.
Query Match 3.0%; Score 66.6; DB 8; Length 2846;		
Best Local Similarity 71.3%; Pred. No. 0.00023;		
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;		
QY	2121 CCTTTGCTTACCACTCTTTCCCTTTTATCTTATTATAAATAAGTTGGTCTCCACCACACTG	2180
Db		2712
QY	2181 NCTCCCCAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2240
Db		2772
QY	2241 AA 2242	
Db		
Db	2773 AA 2774	
RESULT 413		
ACD15567		
ID	ACD15567 standard; cDNA; 2846 BP.	
XX	AC	ACD15567;
XX	DT	17-AUG-2003 (first entry)
DE	Human secreted/transmembrane protein (PRO) cdna #85.	
XX	KW	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW	KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW	KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW	KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX	OS	Homo sapiens.
XX	PX	US2003036152-A1.
XX	PX	20-FEB-2003.
XX	PX	02-JUL-2002; 2002US-00187753.
XX	PX	18-SEP-1997; 97US-0059263P.
PR	18-SEP-1997;	97US-0059266P.
PR	17-OCT-1997;	97US-0062250P.
PR	21-OCT-1997;	97US-0063486P.

PR	10-JUN-1998;	98US-0088825P;
PR	10-JUN-1998;	98US-0088826P;
PR	11-JUN-1998;	98US-0088861P;
PR	11-JUN-1998;	98US-0088863P;
PR	11-JUN-1998;	98US-0088876P;
PR	12-JUN-1998;	98US-0089090P;
PR	12-JUN-1998;	98US-0089105P;
PR	16-JUN-1998;	98US-0089512P;
PR	16-JUN-1998;	98US-0089514P;
PR	17-JUN-1998;	98US-0089538P;
PR	17-JUN-1998;	98US-0089598P;
PR	17-JUN-1998;	98US-0089653P;
PR	18-JUN-1998;	98US-0089908P;
PR	19-JUN-1998;	98US-0089952P;
PR	22-JUN-1998;	98US-0090246P;
PR	22-JUN-1998;	98US-0090252P;
PR	22-JUN-1998;	98US-0090254P;
PR	24-JUN-1998;	98US-0090429P;
PR	24-JUN-1998;	98US-0090435P;
PR	24-JUN-1998;	98US-0090444P;
PR	24-JUN-1998;	98US-0090461P;
PR	24-JUN-1998;	98US-0090535P;
PR	24-JUN-1998;	98US-0090540P;
PR	25-JUN-1998;	98US-0090676P;
PR	25-JUN-1998;	98US-0090678P;
PR	25-JUN-1998;	98US-0090688P;
PR	25-JUN-1998;	98US-0090690P;
PR	25-JUN-1998;	98US-0090694P;
PR	25-JUN-1998;	98US-0090695P;
PR	26-JUN-1998;	98US-0090696P;
PR	26-JUN-1998;	98US-00105413;
PR	26-JUN-1998;	98US-0090862P;
PR	26-JUN-1998;	98US-0090863P;
PR	26-JUN-1998;	98US-0091010P;
PR	01-JUL-1998;	98US-0091359P;
PR	01-JUL-1998;	98US-0091544P;
PR	02-JUL-1998;	98US-0091478P;
PR	02-JUL-1998;	98US-0091486P;
PR	02-JUL-1998;	98US-0091622P;
PR	02-JUL-1998;	98US-0091628P;
PR	02-JUL-1998;	98US-0091632P;
PR	24-JUL-1998;	98US-0094006P;
PR	04-AUG-1998;	98US-0095282P;
PR	10-AUG-1998;	98US-0095998P;
PR	10-AUG-1998;	98US-0096012P;
PR	17-AUG-1998;	98US-0096757P;
PR	17-AUG-1998;	98US-0096766P;
PR	17-AUG-1998;	98US-0096867P;
PR	17-AUG-1998;	98US-0096891P;
PR	17-AUG-1998;	98US-0096897P;
PR	18-AUG-1998;	98US-0096949P;
PR	18-AUG-1998;	98US-0096959P;
PR	18-AUG-1998;	98US-0097022P;
PR	26-AUG-1998;	98US-0097952P;
PR	26-AUG-1998;	98US-0097954P;
PR	26-AUG-1998;	98US-0097955P;
PR	26-AUG-1998;	98US-0097971P;
PR	26-AUG-1998;	98US-0097974P;
PR	01-SEP-1998;	98US-0098014P;
PR	01-SEP-1998;	98US-0098716P;
PR	01-SEP-1998;	98US-0098723P;
PR	02-SEP-1998;	98US-0098803P;
PR	02-SEP-1998;	98US-0098821P;
PR	02-SEP-1998;	98US-0098843P;
PR	09-SEP-1998;	98US-0099602P;
PR	10-SEP-1998;	98US-0099741P;
PR	10-SEP-1998;	98US-0099754P;
PR	10-SEP-1998;	98US-0099763P;
PR	10-SEP-1998;	98US-0099812P;
PR	15-SEP-1998;	98US-0100388P;
PR	16-SEP-1998;	98US-0100662P;
PR	16-SEP-1998;	98US-0100664P;
PR	16-SEP-1998;	98US-0100664P;

PR	16-SEP-1998;	98WO-US0192330
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

[illegible]

RESULT 414	
ACA98466	
ID	ACA98466 standard; cDNA; 2846 BP.
XX	
AC	ACA98466;
XX	
DT	25-JUL-2003 (first entry)
XX	
DE	Human PRO polynucleotide #19.
XX	
KW	Human; PRO; gene; ss; affinity purification.
XX	
OS	Homo sapiens.
XX	
PN	US2003027993-A1.
XX	
PD	06-FEB-2003.
XX	
PF	02-MAY-2002; 2002US-00063537.
XX	
PR	30-DEC-1998; 98XR-00062142.
PR	08-MAR-1999; 99WO-US005028.
PR	14-MAY-1999; 99US-00311832.
PR	14-MAY-1999; 99WO-US010733.
PR	25-AUG-1999; 99US-00380137.
PR	25-AUG-1999; 99US-00380138.

```
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-417284/39.
DR P-PSDB; ABU96457.
XX
XX New anti-PRO antibody, useful in diagnostic assays for PRO polypeptide or
PT for affinity purification of PRO from the recombinant cell culture or
PT natural source.
XX
PS Disclosure; Fig 37; 236pp; English.
XX
CC The invention relates to an antibody which binds to a PRO polypeptide.
CC The antibody is useful in diagnostic assays for the PRO polypeptide or
CC for affinity purification of PRO from a recombinant cell culture or
CC natural source. Sequences ACA98448-ACA98531 represent cDNA molecules
CC encoding human PRO polypeptides of the invention
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 8; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACCTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCATCTCTTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db ||
Db 2773 AA 2774

RESULT 415
ABX17058
```

```
ID ABX17058 standard; cDNA; 2846 BP.
XX
AC ABX17058;
XX
DT 04-FEB-2003 (first entry)
XX
DE Human PRO polynucleotide #65.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW toxin; radiolabel; cell death; gene mapping; chromosome mapping;
KW protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;
KW antibacterial.
XX
OS Homo sapiens.
XX
XX US2002123463-A1.
PN
XX
PD 05-SEP-2002.
XX
PF 19-NOV-2001; 2001US-00989732.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
```


PR	11-MAR-1998;	98US-0077632P.	PT	PRO1316, PRO1183, PRO1343, PRO1760, PRO1567 or PRO4333, useful for
PR	11-MAR-1998;	98US-0077649P.	PT	stimulating release of tumor necrosis factor-alpha from human blood.
PR	20-MAR-1998;	98US-0078886P.	XX	Claim 2; Fig 169; 701pp; English.
PR	20-MAR-1998;	98US-0078939P.	PS	
PR	27-MAR-1998;	98US-0079664P.	XX	The invention relates to an isolated PRO polypeptide comprising at least
PR	27-MAR-1998;	98US-0079786P.	CC	80% sequence identity to the protein sequences appearing as ABU10510-
PR	31-MAR-1998;	98US-0080107P.	CC	ABU10814 (including a version lacking its associated signal peptide, or
PR	31-MAR-1998;	98US-0080194P.	CC	an isolated extracellular domain of a PRO polypeptide with or without its
PR	01-APR-1998;	98US-0080327P.	CC	associated signal peptide. Also included are the nucleic acids encoding
PR	01-APR-1998;	98US-0080333P.	CC	the PRO proteins (being secreted and transmembrane proteins) appearing as
PR	08-APR-1998;	98US-0081049P.	CC	ABX16586-ABX16590, PRO expression vectors, host cells, chimaeric PRO
PR	08-APR-1998;	98US-0081070P.	CC	fusion proteins, an anti-PRO antibody and a PRO derived oligonucleotide
PR	15-APR-1998;	98US-0081838P.	CC	sequence. The PRO polypeptides are useful for stimulating release of
PR	15-APR-1998;	98US-0082568P.	CC	tumour necrosis factor-alpha from human blood. The PRO polypeptide
PR	21-APR-1998;	98US-0082569P.	CC	PRO6029 is useful for stimulating proliferation or differentiation of
PR	22-APR-1998;	98US-0082704P.	CC	chondrocyte cells. The PRO polypeptides as specified in the specification
PR	22-APR-1998;	98US-0082797P.	CC	and having differential expression in tumour cells, are useful for
PR	28-APR-1998;	98US-0083322P.	CC	detecting presence of tumour in a mammal (such as adrenal tumour, lung
PR	29-APR-1998;	98US-0083495P.	CC	tumour, colon tumour, breast tumour, prostate tumour, rectal tumour,
PR	29-APR-1998;	98US-0083496P.	CC	cervical tumour or liver tumour. The PRO polypeptide PRO6029 is useful
PR	29-APR-1998;	98US-0083499P.	CC	for treating various bone and/or cartilage disorders such as arthritis,
PR	29-APR-1998;	98US-0083559P.	CC	and sports injuries. The PRO polypeptides are useful for screening
PR	05-MAY-1998;	98US-0084366P.	CC	compounds to identify ant/agonists. PRO nucleic acids are useful as
PR	06-MAY-1998;	98US-0084414P.	CC	hybridisation probes, in chromosome and gene mapping, in the generation
PR	07-MAY-1998;	98US-0084639P.	CC	of anti-sense RNA and DNA, for the preparation of PRO polypeptides and
PR	07-MAY-1998;	98US-0084640P.	CC	for generating knock-out animals. The present sequence encodes a PRO
PR	07-MAY-1998;	98US-0084643P.	CC	polypeptide
PR	16-SEP-1998;	98WO-US019330.	XX	
PR	07-OCT-1998;	98WO-US021141.	SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
PR	01-DEC-1998;	98WO-US025108.		Query Match 3.0%; Score 66.6; DB 8; Length 2846;
PR	08-MAR-1999;	99WO-US005028.		Best Local Similarity 71.3%; Pred. No. 0.00023;
PR	14-MAY-1999;	99WO-US010733.		Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
PR	02-JUN-1999;	99WO-US012252.		
PR	01-SEP-1999;	99WO-US020111.	Qy	2121 CCTTGCCTTTACCACTCTTCTTTTATCTTATTATAATAAATGTTGGTCTCCACCACTG 2180
PR	15-SEP-1999;	99WO-US021090.		
PR	01-DEC-1999;	99WO-US028301.	Db	2653 CCTTTCCTTCCCATCTCTGTACACATTTTATAATAAATAAGGTTGGCTTCTGAAC TA 2712
PR	02-DEC-1999;	99WO-US028551.		
PR	30-DEC-1999;	99WO-US031274.	Qy	2181 NCTCCCAA 2240
PR	06-JAN-2000;	2000WO-US000219.		
PR	18-FEB-2000;	2000WO-US004341.	Db	2713 CAAA 2772
PR	18-FEB-2000;	2000WO-US004342.		
PR	22-FEB-2000;	2000WO-US004414.	Qy	2241 AA 2242
PR	24-FEB-2000;	2000WO-US005004.		
PR	01-MAR-2000;	2000WO-US005601.	Db	2773 AA 2774
PR	02-MAR-2000;	2000WO-US005841.		
PR	15-MAR-2000;	2000WO-US006884.		
PR	30-MAR-2000;	2000WO-US008439.		
PR	17-MAY-2000;	2000WO-US013705.		
PR	22-MAY-2000;	2000WO-US014042.		
PR	30-MAY-2000;	2000WO-US014941.		
PR	02-JUN-2000;	2000WO-US015264.		
PR	28-JUL-2000;	2000WO-US020710.		
PR	24-AUG-2000;	2000WO-US023328.		
PR	08-NOV-2000;	2000WO-US030952.		
PR	01-DEC-2000;	2000WO-US032678.		
PR	20-DEC-2000;	2000WO-US034956.		
PR	28-FEB-2001;	2001WO-US006520.		
PR	01-JUN-2001;	2001WO-US017800.		
PR	20-JUN-2001;	2001WO-US019692.		
PR	29-JUN-2001;	2001WO-US021066.		
PR	09-JUL-2001;	2001WO-US021735.		
PR	29-AUG-2001;	2001WO-US027099.		
XX				Human; secreted and transmembrane protein; gene therapy; PRO; PRO943;
PA	(GETH) GENENTECH INC.			PRO183; PRO184; PRO185; PRO331; PRO1133; PRO363; PRO5723; PRO1387;
XX	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;			PRO1114; PRO3301; PRO9940; PRO1181; PRO7170; PRO361; PRO846;
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;			bioactive molecule; toxin; radiolabel; antibody; cell death; cancer;
XX				autoimmune disease; chromosome mapping; gene mapping; transgenic animal;
DR	WPI; 2003-066893/06.			knockout animal; septic shock; gene; ss.
DR	P-PSDB; ABU10594.			
XX				Homo sapiens.
PT	Novel isolated PRO polypeptides e.g., PRO1079, PRO827, PRO791, PRO1131,			US2002177164-A1.

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 418

ACA63391
ID ACA63391 standard; cDNA; 2846 BP.
XX
AC ACA63391;
XX
DT 13-JUN-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #19.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
KW anti-PRO antibody; diagnostic assay; gene expression; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003023042-A1.
XX
PD 30-JAN-2003.
XX
PF 01-MAY-2002; 2002US-00063502.
XX
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2003-331484/31.
DR P-PSDB; ABU72127.
XX
PT Novel monoclonal antibody that binds to secreted and transmembrane
PT polypeptide, useful for detecting and purifying the polypeptide and also
PT for treating conditions responsive to the antibody.
XX
PS Disclosure; Fig 37; 408pp; English.
XX

CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides and polynucleotides are useful for preparing a medicament
CC useful in the treatment of a condition responsive to anti-PRO antibody.
CC Anti-PRO antibodies are useful in diagnostic assays for PRO, by detecting
CC its expression in specific cells, tissues or serum, and for affinity
CC purification of PRO from recombinant cell culture or natural sources.
CC ACA63373-ACA63456 represent cDNA sequences encoding the human PRO
CC polypeptides of the invention
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTATCTTATTATAATAATGTTGGTCTCCCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTGACACATTTTAATAATAAAGGGTTGGCTTCTGAAC 2712
QY 2181 NCTCCAAAAA
Db 2713 CAAAAA

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 419

ACA97611
ID ACA97611 standard; cDNA; 2846 BP.
XX
AC ACA97611;
XX
DT 25-JUL-2003 (first entry)
XX
DE Human PRO polynucleotide #85.
XX
KW Human; PRO; gene; ss; cytostatic; tumour necrosis factor-alpha; blood;
KW TNF-alpha; chondrocyte cell; tumour; cancer.
XX
OS Homo sapiens.
XX
PN US2003032115-A1.
XX
PD 13-FEB-2003.
XX
PF 21-JUN-2002; 2002US-00176925.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR

PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.

PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy	2121	CCTTTGCTTTACCACCTCTTTCCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCAC	2180
Db	2653		
Qy	2181	NCTCCCAAA	2240
Db	2713	CAAA	
Qy	2241	AA 2242	
Db	2773	AA 2774	

RESULT 420
ACA99060
ID ACA99060 standard; cDNA; 2846 BP.
XX
AC ACA99060;
XX
DT 29-JUL-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW Human; ss; tissue typing; tumour; chondrocyte stimulator; gene therapy;
KW tumour necrosis factor-alpha release; affinity purification; gene.
XX
OS Homo sapiens.
XX
PN US2003032140-A1.
XX
PD 13-FEB-2003.
XX
PF 19-JUL-2002; 2002US-00199464.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR

PR 15-MAY-1998;
PR 15-MAY-1998;
PR 18-MAY-1998;
PR 22-MAY-1998;
PR 22-MAY-1998;
PR 28-MAY-1998;
PR 28-MAY-1998;
PR 02-JUN-1998;
PR 02-JUN-1998;
PR 03-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 05-JUN-1998;
PR 05-JUN-1998;
PR 05-JUN-1998;
PR 09-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;
PR 11-JUN-1998;
PR 11-JUN-1998;
PR 11-JUN-1998;
PR 12-JUN-1998;
PR 12-JUN-1998;
PR 16-JUN-1998;
PR 16-JUN-1998;
PR 17-JUN-1998;
PR 17-JUN-1998;
PR 18-JUN-1998;
PR 19-JUN-1998;
PR 22-JUN-1998;
PR 22-JUN-1998;
PR 22-JUN-1998;
PR 24-JUN-1998;
PR 24-JUN-1998;
PR 24-JUN-1998;
PR 24-JUN-1998;
PR 24-JUN-1998;
PR 25-JUN-1998;
PR 25-JUN-1998;
PR 25-JUN-1998;
PR 25-JUN-1998;
PR 25-JUN-1998;
PR 26-JUN-1998;
PR 26-JUN-1998;
PR 26-JUN-1998;
PR 01-JUL-1998;
PR 01-JUL-1998;
PR 02-JUL-1998;
PR 02-JUL-1998;
PR 02-JUL-1998;
PR 02-JUL-1998;
PR 02-JUL-1998;
PR 02-JUL-1998;
PR 24-JUL-1998;
PR 04-AUG-1998;
PR 10-AUG-1998;
PR 10-AUG-1998;
PR 17-AUG-1998;
PR 17-AUG-1998;
PR 17-AUG-1998;
PR 17-AUG-1998;
98US-0085582P.
98US-0085700P.
98US-0086023P.
98US-0086392P.
98US-0086486P.
98US-0087098P.
98US-0087208P.
98US-0087609P.
98US-0087759P.
98US-0087827P.
98US-0088025P.
98US-0088028P.
98US-0088029P.
98US-0088033P.
98US-0088326P.
98US-0088167P.
98US-0088202P.
98US-0088212P.
98US-0088217P.
98US-0088655P.
98US-0088722P.
98US-0088738P.
98US-0088740P.
98US-0088811P.
98US-0088824P.
98US-0088825P.
98US-0088826P.
98US-0088861P.
98US-0088863P.
98US-0088876P.
98US-0089090P.
98US-0089105P.
98US-0089512P.
98US-0089514P.
98US-0089538P.
98US-0089598P.
98US-0089653P.
98US-0089908P.
98US-0089952P.
98US-0090246P.
98US-0090252P.
98US-0090254P.
98US-0090429P.
98US-0090435P.
98US-0090444P.
98US-0090461P.
98US-0090535P.
98US-0090540P.
98US-0090676P.
98US-0090678P.
98US-0090688P.
98US-0090690P.
98US-0090694P.
98US-0090695P.
98US-0090696P.
98US-00105413.
98US-0090862P.
98US-0090863P.
98US-0091010P.
98US-0091359P.
98US-0091544P.
98US-0091478P.
98US-0091486P.
98US-0091626P.
98US-0091628P.
98US-0091632P.
98US-0094006P.
98US-0095282P.
98US-0095998P.
98US-0096012P.
98US-0096757P.
98US-0096766P.
98US-0096867P.

PR

PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-342069/32.
DR P-PSDB; ABR70657.
XX
PT Three hundred and five nucleic acids encoding a PRO polypeptide, e.g.
PT PRO1079 or PRO827, useful in molecular biology, chromosome and gene
PT mapping, in gene therapy and for treating tumors.
XX
PS Claim 2; Fig 169; 706pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABR70573-ABR70877) and nucleic acids encoding them (ACC91608-ACC91912).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACC91608-ACC91912 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACCTCTTTCCTTTTATCTTATTATAATAAATGTTGGTCTCCACCACGTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTTCCCCATCTCTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAACATA 2712

Qy 2181 NCTCCCAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAA 2772

Qy 2241 AA 2242
||
Db 2773 AA 2774

RESULT 422
ACD11103
ID ACD11103 standard; cDNA; 2846 BP.
XX
AC ACD11103;
XX
DT 12-AUG-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1344 cDNA.
XX
KW Human; ds; gene; gene therapy; tumour necrosis factor-alpha; tumour;
KW chondrocyte stimulation; tissue typing.
XX
OS Homo sapiens.
XX
PN US2003008352-A1.
XX
PD 09-JAN-2003.
XX
PF 18-JUN-2002; 2002US-00174590.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.

PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.

PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 02-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.

```
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTCTTTTATCTTATTATAAAAAATGTTGGTCTCCACCAC TG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTTGTTACACATTTTATAAAAAAAGGTTGGCTTCTGAAC TA 2712
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 424
ACA88362
ID ACA88362 standard; cDNA; 2846 BP.
XX
AC ACA88362;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human secreted and transmembrane polypeptide PRO1344 cDNA.
XX
KW Human; gene; ss; gene therapy; cancer; retinal disorder; wound healing;
KW kidney disorder.
XX
OS Homo sapiens.
XX
PN US2002197615-A1.
XX
PD 26-DEC-2002.
XX
PF 16-NOV-2001; 2001US-00991181.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
```

```
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 16-DEC-1999; 99WO-US028634.
PR 20-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
```

PA (GETH) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;

PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;

PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;

PI Zhang Z;

XX WPI; 2003-370792/35.

DR P-PSDB; ABU88570.

DR

XX New secreted and transmembrane nucleic acids and polypeptides, designated

PT as PRO, useful for the preparation of a medicament for treating a

PT condition that is responsive to the PRO polypeptide. e.g., cancer.

PT

XX Claim 2; Fig 158; 647pp; English.

PS

XX The invention relates to an isolated nucleic acid encoding a PRO

CC polypeptide. The polypeptide, agonist, antagonist and antibody are useful

CC for the preparation of a medicament for treating a condition that is

CC responsive to the PRO polypeptide. The nucleotide sequence is useful in

CC molecular biology including being used as hybridisation probes, in

CC chromosome and gene mapping and in the generation of anti-sense RNA and

CC DNA. The PRO polypeptides can also be used in the treatment of e.g.

CC cancer, retinal disorders, wound healing and kidney disorders. The

CC present sequence represents a cDNA encoding a human secreted and

CC transmembrane PRO polypeptide of the present invention. Note: The

CC sequence data for this patent did not form part of the printed

CC specification but was obtained in electronic format directly from USPTO

CC at seqdata.uspto.gov/sequence.html?DocID=20020197615

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTTCCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG 2180

DB 2653 CCTTTTCCTTCCCATCTCTTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAA 2240

DB 2713 CAAAAAATAA 2772

QY 2241 AA 2242

DB 2773 AA 2774

RESULT 425

ACD81869

ID ACD81869 standard; cDNA; 2846 BP.

XX

AC ACD81869;

XX

DT 19-SEP-2003 (first entry)

XX

DE cDNA encoding human PRO1344 polypeptide.

XX

KW Human; PRO polypeptide; secreted protein; transmembrane protein;

KW biosensor; bioreactor; tumour; cancer; diabetes; ALS; ulcer;

KW rheumatoid arthritis; amyotrophic lateral sclerosis; cytostatic;

KW antidiabetic; antiarthritic; antirheumatic; antiulcer; gene therapy;

KW gene; ss.

XX

OS Homo sapiens.

XX

PN US2003017981-A1.

XX

PD 23-JAN-2003.

XX

PF 20-NOV-2001; 2001US-00989728.

XX 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088734P.

PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088742P.

PR 10-JUN-1998; 98US-0088810P.

PR 10-JUN-1998; 98US-0088824P.

PR 10-JUN-1998; 98US-0088826P.

PR 11-JUN-1998; 98US-0088858P.

PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088876P.

PR 12-JUN-1998; 98US-0089105P.

PR 16-JUN-1998; 98US-0089440P.

PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.

PR 17-JUN-1998; 98US-0089532P.

PR 17-JUN-1998; 98US-0089538P.

PR 17-JUN-1998; 98US-0089598P.

PR 17-JUN-1998; 98US-0089599P.

PR 17-JUN-1998; 98US-0089600P.

PR 17-JUN-1998; 98US-0089653P.

PR 18-JUN-1998; 98US-0089801P.

PR 18-JUN-1998; 98US-0089907P.

PR 18-JUN-1998; 98US-0089908P.

PR 19-JUN-1998; 98US-0089947P.

PR 19-JUN-1998; 98US-0089948P.

PR 19-JUN-1998; 98US-0089952P.

PR 22-JUN-1998; 98US-0090246P.

PR 22-JUN-1998; 98US-0090252P.

PR 22-JUN-1998; 98US-0090254P.

PR 23-JUN-1998; 98US-0090349P.

PR 23-JUN-1998; 98US-0090355P.

PR 24-JUN-1998; 98US-0090429P.

PR 24-JUN-1998; 98US-0090431P.

PR 24-JUN-1998; 98US-0090435P.

PR 24-JUN-1998; 98US-0090444P.

PR 24-JUN-1998; 98US-0090445P.

PR 24-JUN-1998; 98US-0090472P.

PR 24-JUN-1998; 98US-0090535P.

PR 24-JUN-1998; 98US-0090540P.

PR 24-JUN-1998; 98US-0090542P.

PR 24-JUN-1998; 98US-0090557P.

PR 25-JUN-1998; 98US-0090676P.

PR 25-JUN-1998; 98US-0090678P.

PR 25-JUN-1998; 98US-0090690P.

PR 25-JUN-1998; 98US-0090694P.

XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.

ID ACF02527 standard; cDNA; 2846 BP.
XX AC ACF02527;
XX DT 05-SEP-2003 (first entry)
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumor necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulneryary; gene therapy; gene; ss.
XX OS Homo sapiens.
XX PN US2003049741-A1.
XX PD 13-MAR-2003.
XX PF 02-JUL-2002; 2002US-00188780.
XX PR 26-JUN-1998; 98US-00105413.
PR 16-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 07-DEC-1998; 98US-00202054.
PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021090.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028551.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 30-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-555152/52.
DR P-PSDB; ABR80901.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for stimulating tumor necrosis factor alpha or chondrocyte proliferation
PT in a mammal.
XX Claim 2; Fig 169; 701pp; English.
PS The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABR80817-ABR81121) and nucleic acids encoding them (ACF02443-ACF02747).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumor necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF02443-ACF02747 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;

KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003068685-A1.
XX
PD 10-APR-2003.
XX
PF 27-JUN-2002; 2002US-00184639.
XX
PR 08-OCT-1998; 98US-0103633P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-605911/57.
DR P-PSDB; ABO28809.
XX
PT New PRO nucleic acid, useful for the manufacture of a medicament for
PT diagnosing or treating tumor or for tissue typing.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCACTCTCTGTGACACATTTTAATAAATAAGGTTGGCTTCTGAACATA 2712
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCCAAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAATAAA 2772
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
||

Db 2773 AA 2774
RESULT 435
ACD49466
ID ACD49466 standard; cDNA; 2846 BP.
XX
AC ACD49466;
XX
DT 05-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003068725-A1.
XX
PD 10-APR-2003.
XX
PF 18-JUL-2002; 2002US-00199315.
XX
PR 05-JUN-1998; 98US-0088167P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-605920/57.
DR P-PSDB; ABO31554.
XX
PT New secreted and transmembrane PRO nucleic acid, useful for the
PT manufacture of a medicament for diagnosing or treating tumor or for
PT tissue typing.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

PR	06-NOV-1998;	98US-00187368.	PS	Claim 2; Fig 169; 701pp; English.
PR	01-DEC-1998;	98WO-US025108.	XX	
PR	07-DEC-1998;	98US-00202054.	CC	The invention discloses human nucleic acids encoding secreted and
PR	03-MAR-1999;	99US-00254311.	CC	transmembrane (PRO) polypeptides, with or without their associated signal
PR	08-MAR-1999;	99WO-US005028.	CC	peptide. Also disclosed is an antibody that specifically binds to the PRO
PR	14-MAY-1999;	99US-00311832.	CC	polypeptide, a method for stimulating the release of tumour necrosis
PR	14-MAY-1999;	99WO-US010733.	CC	factor alpha (TNF-alpha) from human blood by contacting the blood with a
PR	02-JUN-1999;	99WO-US012252.	CC	PRO polypeptide, a method for stimulating the proliferation or
PR	25-AUG-1999;	99US-00380137.	CC	differentiation of chondrocyte cells by contacting the cells with a PRO
PR	25-AUG-1999;	99US-00380138.	CC	polypeptide, a method for detecting the presence of a tumour in a mammal
PR	25-AUG-1999;	99US-00380139.	CC	and an oligonucleotide probe derived from any of the PRO nucleotide
PR	01-SEP-1999;	99WO-US020111.	CC	sequences. The nucleotide sequences are useful as probes, in chromosomal
PR	15-SEP-1999;	99US-00403297.	CC	and gene mapping, in generating antisense RNA and DNA, in preparing PRO
PR	18-OCT-1999;	99US-00403297.	CC	polypeptides by recombinant techniques and in gene therapy (e.g. for
PR	12-NOV-1999;	99US-00423844.	CC	replacement of defective gene). The PRO polypeptides are useful as
PR	01-DEC-1999;	99WO-US028301.	CC	molecular weight markers for protein electrophoresis purposes, for
PR	30-DEC-1999;	99WO-US031274.	CC	chromosome identification, as chromosome markers, as therapeutic agents,
PR	05-JAN-2000;	2000WO-US000219.	CC	for stimulating the release of TNF-alpha from human blood, for
PR	18-FEB-2000;	2000WO-US004341.	CC	stimulating the proliferation or differentiation of chondrocytes and
PR	18-FEB-2000;	2000WO-US004342.	CC	detecting the presence, prevention and/or treatment of a tumour, such as
PR	22-FEB-2000;	2000WO-US004414.	CC	adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
PR	24-FEB-2000;	2000WO-US005004.	CC	The PRO polypeptides and nucleic acids may also be used diagnostically
PR	01-MAR-2000;	2000WO-US005601.	CC	for tissue typing. The sequence presented is a cDNA encoding one of the
PR	02-MAR-2000;	2000WO-US005841.	CC	PRO polypeptides of the invention. Note: The sequence data for this
PR	15-MAR-2000;	2000WO-US006884.	CC	patent can also be obtained in electronic format directly from USPTO at
PR	30-MAR-2000;	2000WO-US008439.	CC	seqdata.uspto.gov/sequence.html
PR	17-MAY-2000;	2000WO-US013705.	XX	
PR	22-MAY-2000;	2000WO-US014042.	SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
PR	30-MAY-2000;	2000WO-US014941.		
PR	02-JUN-2000;	2000WO-US015264.		
PR	28-JUL-2000;	2000WO-US020710.		
PR	22-AUG-2000;	2000US-00644848.		
PR	24-AUG-2000;	2000WO-US023328.		
PR	18-SEP-2000;	2000US-00664610.		
PR	18-SEP-2000;	2000US-00665350.		
PR	08-NOV-2000;	2000US-00709238.		
PR	08-NOV-2000;	2000WO-US030952.		
PR	01-DEC-2000;	2000WO-US032678.		
PR	20-DEC-2000;	2000US-00747259.		
PR	20-DEC-2000;	2000WO-US034956.		
PR	28-FEB-2001;	2001WO-US006520.		
PR	22-MAR-2001;	2001US-00816744.		
PR	10-MAY-2001;	2001US-00854208.		
PR	25-MAY-2001;	2001US-00866028.		
PR	01-JUN-2001;	2001WO-US017800.		
PR	05-JUN-2001;	2001US-00874503.		
PR	20-JUN-2001;	2001WO-US019692.		
PR	29-JUN-2001;	2001WO-US021066.		
PR	09-JUL-2001;	2001WO-US021735.		
PR	18-JUL-2001;	2001US-00908827.		
PR	30-JUL-2001;	2001US-00918585.		
PR	06-AUG-2001;	2001US-00924419.		
PR	13-AUG-2001;	2001US-00929404.		
PR	16-AUG-2001;	2001US-00931836.		
PR	28-AUG-2001;	2001US-00941992.		
PR	29-AUG-2001;	2001WO-US027099.		
PR	04-SEP-2001;	2001US-00946374.		
PR	15-JAN-2002;	2002US-00052586.		
XX				
XX	(GETH) GENENTECH INC.			
XX				
PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;			
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;			
XX				
XX	WPI; 2003-625459/59.			
DR	P-PSDB; ABO40451.			
XX				
PT	New PRO nucleic acid, useful for the manufacture of a medicament for			
PT	diagnosing or treating tumor or for tissue typing.			
XX				

QY	2121	CCTTTGCTTTACCACTCTTCTCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACTG	2180
Db	2653	CCTTTTCCTTCCCACTCTCTGTACACATTTTAATAAAATGTTGGTCTCTGAACATA	2712
QY	2181	NCTCCCAAA	2240
Db	2713	CAAA	2772
QY	2241	AA 2242	
Db	2773	AA 2774	
RESULT 438			
ACD84318			
ID	ACD84318 standard; cDNA; 2846 BP.		
XX			
AC	ACD84318;		
XX			
DT	22-SEP-2003 (first entry)		
XX			
DE	Human PRO polynucleotide #85.		
XX			
KW	Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;		
KW	cytostatic; tumour necrosis factor-alpha; TNF-alpha; blood; tumour;		
KW	chondrocyte cell; cancer.		
XX			
OS	Homo sapiens.		
XX			
PN	US2003068701-A1.		
XX			
PD	10-APR-2003.		
XX			
PF	12-JUL-2002; 2002US-00194424.		
XX			
PR	05-JUN-2000; 2000US-0209832P.		
PR	28-FEB-2001; 2001WO-US006520.		
PR	15-JAN-2002; 2002US-00052586.		
XX			
PA	(GETH) GENENTECH INC.		

PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.

PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG 2180

Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAATAAAATAAGGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAA 2240

Db 2713 CAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 442

ACD09154

ID ACD09154 standard; cDNA; 2846 BP.

XX

AC ACD09154;

XX

DT 09-AUG-2003 (first entry)

XX DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX DE
KW Human; gene; ss; secreted and transmembrane protein;. PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour; arthritis.
XX OS
OS Homo sapiens.
XX PN US2003036131-A1.
XX PD
PD 20-FEB-2003.
XX PF
PF 27-JUN-2002; 2002US-00184628.
XX PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 18-AUG-1998;

PR	26-AUG-1998;	98US-0097952P;
PR	26-AUG-1998;	98US-0097954P;
PR	26-AUG-1998;	98US-0097955P;
PR	26-AUG-1998;	98US-0097971P;
PR	26-AUG-1998;	98US-0097974P;
PR	26-AUG-1998;	98US-0098014P;
PR	01-SEP-1998;	98US-0098716P;
PR	01-SEP-1998;	98US-0098723P;
PR	02-SEP-1998;	98US-0098803P;
PR	02-SEP-1998;	98US-0098821P;
PR	02-SEP-1998;	98US-0098843P;
PR	09-SEP-1998;	98US-0099602P;
PR	10-SEP-1998;	98US-0099741P;
PR	10-SEP-1998;	98US-0099754P;
PR	10-SEP-1998;	98US-0099763P;
PR	10-SEP-1998;	98US-0099812P;
PR	15-SEP-1998;	98US-0100388P;
PR	16-SEP-1998;	98US-0100662P;
PR	16-SEP-1998;	98US-0100664P;
PR	16-SEP-1998;	98US-0101751P;
PR	16-SEP-1998;	98WO-US019330;
PR	17-SEP-1998;	98US-0100683P;
PR	17-SEP-1998;	98US-0100684P;
PR	17-SEP-1998;	98US-0100919P;
PR	17-SEP-1998;	98US-0100930P;
PR	18-SEP-1998;	98US-0100849P;
PR	18-SEP-1998;	98US-0101014P;
PR	18-SEP-1998;	98US-0101068P;
PR	23-SEP-1998;	98US-0101471P;
PR	23-SEP-1998;	98US-0101472P;
PR	23-SEP-1998;	98US-0101475P;
PR	23-SEP-1998;	98US-0101477P;
PR	24-SEP-1998;	98US-0101738P;
PR	24-SEP-1998;	98US-0101739P;
PR	24-SEP-1998;	98US-0101743P;
PR	24-SEP-1998;	98US-0101922P;
PR	25-SEP-1998;	98US-0101786P;
PR	29-SEP-1998;	98US-0102207P;
PR	29-SEP-1998;	98US-0102240P;
PR	29-SEP-1998;	98US-0102330P;
PR	29-SEP-1998;	98US-0102331P;
PR	30-SEP-1998;	98US-0102487P;
PR	30-SEP-1998;	98US-0102570P;
PR	30-SEP-1998;	98US-0102571P;
PR	01-OCT-1998;	98US-0102684P;
PR	01-OCT-1998;	98US-0102687P;
PR	02-OCT-1998;	98US-0102965P;
PR	06-OCT-1998;	98US-0103258P;
PR	06-OCT-1998;	98US-0103449P;

	Query Match	3.0%;	Score 66.6;	DB 9;	Length 2846;
	Best Local Similarity	71.3%;	Pred. No.	0.00023;	
Matches	87; Conservative	0;	Mismatches	35; Indels	0; Gaps
Qy	2121	CCTTTGCTTACCACTCTTTCCCTTTATCTATTATAAAAAAGTTGGTCGCCACTGT	2180		
Dd	2653	CCTTTTCCTTCCCACATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAACA	2712		
Qy	2181	NCTCCCCAAA	2240		
Dd	2713	CAA	2772		
Qy	2241	AA 2242 			
Dd	2773	AA 2774			

RESULT 443
ACF11947
ID ACF11947 standard; cDNA; 2846 bp.
XX
XX ACF11947;
XX

DT	13-SEP-2003	(first entry)
XX		
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.	
XX		
KW	Human; PRO; secreted protein; transmembrane protein; extracellular domain; tumour necrosis factor-alpha; TNF-alpha; chondrocyte; proliferation; differentiation; cartilage disorder; bone disorder; arthritis; sports injury; cancer; tumour; diagnosis; adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix; liver; drug screening; transgenic animal; genetic analysis; antiarthritic; vulnerary; gene therapy; gene; ss.	
KW		
XX		
OS	Homo sapiens.	
XX		
PN	US2003040075-A1.	
XX		
PD	27-FEB-2003.	
XX		
PF	02-JUL-2002; 2002US-00188775.	
XX		
PR	18-SEP-1997; 97US-0059263P.	
PR	18-SEP-1997; 97US-0059266P.	
PR	17-OCT-1997; 97US-0062250P.	
PR	21-OCT-1997; 97US-0063486P.	
PR	24-OCT-1997; 97US-0063120P.	
PR	24-OCT-1997; 97US-0063121P.	
PR	28-OCT-1997; 97US-0063540P.	
PR	28-OCT-1997; 97US-0063541P.	
PR	28-OCT-1997; 97US-0063544P.	
PR	28-OCT-1997; 97US-0063564P.	
PR	29-OCT-1997; 97US-0063734P.	
PR	31-OCT-1997; 97US-0063870P.	
PR	31-OCT-1997; 97US-0064103P.	
PR	13-NOV-1997; 97US-0065311P.	
PR	21-NOV-1997; 97US-0066120P.	
PR	24-NOV-1997; 97US-0066466P.	
PR	24-NOV-1997; 97US-0066772P.	
PR	11-DEC-1997; 97US-0069335P.	
PR	12-DEC-1997; 97US-0069425P.	
PR	17-DEC-1997; 97US-0069870P.	
PR	18-DEC-1997; 97US-0068017P.	
PR	10-MAR-1998; 98US-0077450P.	
PR	11-MAR-1998; 98US-0077632P.	
PR	11-MAR-1998; 98US-0077649P.	
PR	20-MAR-1998; 98US-0078886P.	
PR	20-MAR-1998; 98US-0078939P.	
PR	27-MAR-1998; 98US-0079664P.	
PR	27-MAR-1998; 98US-0079786P.	
PR	31-MAR-1998; 98US-0080107P.	
PR	31-MAR-1998; 98US-0080194P.	
PR	01-APR-1998; 98US-0080327P.	
PR	01-APR-1998; 98US-0080333P.	
PR	08-APR-1998; 98US-0081049P.	
PR	08-APR-1998; 98US-0081070P.	
PR	09-APR-1998; 98US-0081195P.	
PR	15-APR-1998; 98US-0081838P.	
PR	21-APR-1998; 98US-0082568P.	
PR	21-APR-1998; 98US-0082569P.	
PR	22-APR-1998; 98US-0082704P.	
PR	22-APR-1998; 98US-0082797P.	
PR	28-APR-1998; 98US-0083322P.	
PR	29-APR-1998; 98US-0083495P.	
PR	29-APR-1998; 98US-0083496P.	
PR	29-APR-1998; 98US-0083499P.	
PR	29-APR-1998; 98US-0083559P.	
PR	05-MAY-1998; 98US-0084366P.	
PR	06-MAY-1998; 98US-0084414P.	
PR	07-MAY-1998; 98US-0084639P.	
PR	07-MAY-1998; 98US-0084640P.	
PR	07-MAY-1998; 98US-0084643P.	
PR	15-MAY-1998; 98US-0085579P.	
PR	15-MAY-1998; 98US-0085580P.	
PR	15-MAY-1998; 98US-0085582P.	

PR	15-MAY-1998;	98US-0085700P.	PR	17-AUG-1998;	98US-0096897P.
PR	18-MAY-1998;	98US-0086023P.	PR	18-AUG-1998;	98US-0096949P.
PR	22-MAY-1998;	98US-0086392P.	PR	18-AUG-1998;	98US-0096959P.
PR	22-MAY-1998;	98US-0086486P.	PR	18-AUG-1998;	98US-0097022P.
PR	28-MAY-1998;	98US-0087098P.	PR	26-AUG-1998;	98US-0097952P.
PR	28-MAY-1998;	98US-0087208P.	PR	26-AUG-1998;	98US-0097954P.
PR	02-JUN-1998;	98US-0087609P.	PR	26-AUG-1998;	98US-0097955P.
PR	02-JUN-1998;	98US-0087759P.	PR	26-AUG-1998;	98US-0097971P.
PR	03-JUN-1998;	98US-0087827P.	PR	26-AUG-1998;	98US-0097974P.
PR	04-JUN-1998;	98US-0088025P.	PR	26-AUG-1998;	98US-0098014P.
PR	04-JUN-1998;	98US-0088028P.	PR	01-SEP-1998;	98US-0098716P.
PR	04-JUN-1998;	98US-0088029P.	PR	01-SEP-1998;	98US-0098723P.
PR	04-JUN-1998;	98US-0088033P.	PR	02-SEP-1998;	98US-0098803P.
PR	04-JUN-1998;	98US-0088326P.	PR	02-SEP-1998;	98US-0098821P.
PR	05-JUN-1998;	98US-0088167P.	PR	02-SEP-1998;	98US-0098843P.
PR	05-JUN-1998;	98US-0088202P.	PR	09-SEP-1998;	98US-0099602P.
PR	05-JUN-1998;	98US-0088212P.	PR	10-SEP-1998;	98US-0099741P.
PR	05-JUN-1998;	98US-0088217P.	PR	10-SEP-1998;	98US-0099754P.
PR	09-JUN-1998;	98US-0088655P.	PR	10-SEP-1998;	98US-0099763P.
PR	10-JUN-1998;	98US-0088738P.	PR	10-SEP-1998;	98US-0099812P.
PR	10-JUN-1998;	98US-0088740P.	PR	15-SEP-1998;	98US-0100388P.
PR	10-JUN-1998;	98US-0088811P.	PR	16-SEP-1998;	98US-0100662P.
PR	10-JUN-1998;	98US-0088824P.	PR	16-SEP-1998;	98US-0100664P.
PR	10-JUN-1998;	98US-0088825P.	PR	16-SEP-1998;	98US-0101751P.
PR	10-JUN-1998;	98US-0088826P.	PR	16-SEP-1998;	98US-0101751P.
PR	11-JUN-1998;	98US-0088861P.	PR	17-SEP-1998;	98US-0100683P.
PR	11-JUN-1998;	98US-0088863P.	PR	17-SEP-1998;	98US-0100684P.
PR	11-JUN-1998;	98US-0088876P.	PR	17-SEP-1998;	98US-0100919P.
PR	12-JUN-1998;	98US-0089090P.	PR	17-SEP-1998;	98US-0100930P.
PR	12-JUN-1998;	98US-0089105P.	PR	18-SEP-1998;	98US-0100849P.
PR	16-JUN-1998;	98US-0089512P.	PR	18-SEP-1998;	98US-0101014P.
PR	16-JUN-1998;	98US-0089514P.	PR	18-SEP-1998;	98US-0101068P.
PR	17-JUN-1998;	98US-0089538P.	PR	23-SEP-1998;	98US-0101471P.
PR	17-JUN-1998;	98US-0089598P.	PR	23-SEP-1998;	98US-0101472P.
PR	17-JUN-1998;	98US-0089653P.	PR	23-SEP-1998;	98US-0101475P.
PR	18-JUN-1998;	98US-0089908P.	PR	23-SEP-1998;	98US-0101477P.
PR	19-JUN-1998;	98US-0089952P.	PR	24-SEP-1998;	98US-0101738P.
PR	22-JUN-1998;	98US-0090246P.	PR	24-SEP-1998;	98US-0101739P.
PR	22-JUN-1998;	98US-0090252P.	PR	24-SEP-1998;	98US-0101743P.
PR	22-JUN-1998;	98US-0090254P.	PR	25-SEP-1998;	98US-0101922P.
PR	24-JUN-1998;	98US-0090429P.	PR	25-SEP-1998;	98US-0101786P.
PR	24-JUN-1998;	98US-0090435P.	PR	29-SEP-1998;	98US-0102207P.
PR	24-JUN-1998;	98US-0090444P.	PR	29-SEP-1998;	98US-0102240P.
PR	24-JUN-1998;	98US-0090461P.	PR	29-SEP-1998;	98US-0102330P.
PR	24-JUN-1998;	98US-0090535P.	PR	29-SEP-1998;	98US-0102331P.
PR	24-JUN-1998;	98US-0090540P.	PR	30-SEP-1998;	98US-0102487P.
PR	25-JUN-1998;	98US-0090676P.	PR	30-SEP-1998;	98US-0102570P.
PR	25-JUN-1998;	98US-0090678P.	PR	30-SEP-1998;	98US-0102571P.
PR	25-JUN-1998;	98US-0090688P.	PR	01-OCT-1998;	98US-0102684P.
PR	25-JUN-1998;	98US-0090690P.	PR	01-OCT-1998;	98US-0102687P.
PR	25-JUN-1998;	98US-0090694P.	Query Match 3.0%; Score 66.6; DB 9; Length 2846;		
PR	25-JUN-1998;	98US-0090695P.	Best Local Similarity 71.3%; Pred. No. 0.00023;		
PR	25-JUN-1998;	98US-0090696P.	Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;		
PR	26-JUN-1998;	98US-00105413.	QY	2121 CCTTTGCTTTACCACCTCTTTCCCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCAC	2180
PR	26-JUN-1998;	98US-0090862P.	Db	2653 CCTTTTCCTTCCCCATCTCTTGACACATTTTAATAAAATAAGGGTTGGCTTCTGAACTA	2712
PR	26-JUN-1998;	98US-0091010P.	QY	2181 NCTCCCAAA	2240
PR	01-JUL-1998;	98US-0091359P.	Db	2713 CAA	2772
PR	01-JUL-1998;	98US-0091544P.	QY	2241 AA 2242	
PR	02-JUL-1998;	98US-0091478P.	Db	2773 AA 2774	
PR	02-JUL-1998;	98US-0091486P.			
PR	02-JUL-1998;	98US-0091626P.			
PR	02-JUL-1998;	98US-0091628P.			
PR	02-JUL-1998;	98US-0091632P.			
PR	24-JUL-1998;	98US-0094006P.			
PR	04-AUG-1998;	98US-0095282P.			
PR	10-AUG-1998;	98US-0095998P.			
PR	10-AUG-1998;	98US-0096012P.			
PR	17-AUG-1998;	98US-0096757P.			
PR	17-AUG-1998;	98US-0096766P.			
PR	17-AUG-1998;	98US-0096871P.			
PR	17-AUG-1998;	98US-0096891P.			
RESULT 444			ACF41181		
ID ACF41181 standard; cDNA; 2846 BP.			XX		
			AC ACF41181;		

XX 06-NOV-2003 (first entry)
DT Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003054459-A1.
XX
PD 20-MAR-2003.
XX
PF 12-JUL-2002; 2002US-00194461.
XX
PR 26-JUN-1998; 98US-00105413.
PR 16-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 07-DEC-1998; 98US-00202054.
PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021090.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028551.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 15-SEP-2000; 2000US-0232887P.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 25-MAY-2001; 2001US-00854280.
PR

PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-492350/46.
DR P-PSDB; ABM17248.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
PT colon, breast, prostate, rectal, cervical or liver tumors.
XX
PS Claim 2; Fig 169; 701pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC and nucleic acids encoding them, the invention also provides recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of antisense RNA and DNA and in gene
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. The present sequence appears in the
CC exemplification of the specification. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTAATAAAAAATGTTGGTCTCCACCACTG 2180

Db	2653	CCTTTTCCTTCCCATCTCTTGTAACATTTTAATAAAATAAGGGTTGGCTTCTGAAC	TA 2712
QY	2181	NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	AAAAA 2240
Db	2713	CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	AAAAA 2772
QY	2241	AA 2242	
Db	2773	AA 2774	
RESULT 445			
ID	ACF15795	standard; cDNA; 2846 BP.	
AC	ACF15795;		
DT	13-SEP-2003	(first entry)	
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.		
KW	Human; PRO; secreted protein; transmembrane protein;		
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;		
KW	chondrocyte; proliferation; differentiation; cartilage disorder;		
KW	bone disorder; arthritis; sports injury; cancer; diagnosis;		
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;		
KW	liver; drug screening; transgenic animal; genetic analysis;		
KW	antiarthritic; vulneryary; gene therapy; gene; ss.		
OS	Homo sapiens.		
PN	US2003044930-A1.		
PD	06-MAR-2003.		
PF	28-JUN-2002; 2002US-00184644.		
PR	18-SEP-1997;	97US-0059263P.	
PR	18-SEP-1997;	97US-0059266P.	
PR	17-OCT-1997;	97US-0062250P.	
PR	21-OCT-1997;	97US-0063486P.	
PR	24-OCT-1997;	97US-0063120P.	
PR	24-OCT-1997;	97US-0063121P.	
PR	28-OCT-1997;	97US-0063540P.	
PR	28-OCT-1997;	97US-0063541P.	
PR	28-OCT-1997;	97US-0063544P.	
PR	28-OCT-1997;	97US-0063564P.	
PR	29-OCT-1997;	97US-0063734P.	
PR	31-OCT-1997;	97US-0063870P.	
PR	31-OCT-1997;	97US-0064103P.	
PR	13-NOV-1997;	97US-0065311P.	
PR	21-NOV-1997;	97US-0066120P.	
PR	24-NOV-1997;	97US-0066466P.	
PR	11-DEC-1997;	97US-0066772P.	
PR	12-DEC-1997;	97US-0069335P.	
PR	17-DEC-1997;	97US-0069425P.	
PR	18-DEC-1997;	97US-0069870P.	
PR	10-MAR-1998;	97US-0068017P.	
PR	11-MAR-1998;	97US-0077632P.	
PR	11-MAR-1998;	97US-0077649P.	
PR	20-MAR-1998;	97US-0078886P.	
PR	27-MAR-1998;	97US-0078939P.	
PR	27-MAR-1998;	97US-0079664P.	
PR	31-MAR-1998;	97US-0079786P.	
PR	31-MAR-1998;	97US-0080107P.	
PR	01-APR-1998;	97US-0080194P.	
PR	01-APR-1998;	97US-0080327P.	
PR	08-APR-1998;	97US-0080333P.	
PR	08-APR-1998;	97US-0081049P.	
PR	08-APR-1998;	97US-0081070P.	
PR	09-APR-1998;	97US-0081195P.	
PR	15-APR-1998;	97US-0081838P.	
PR	21-APR-1998;	97US-0082568P.	
PR	21-APR-1998;	97US-0082569P.	
PR	22-APR-1998;	97US-0082704P.	
PR	22-APR-1998;	97US-0082797P.	
PR	28-APR-1998;	97US-0083322P.	
PR	29-APR-1998;	97US-0083495P.	
PR	29-APR-1998;	97US-0083496P.	
PR	29-APR-1998;	97US-0083499P.	
PR	29-APR-1998;	97US-0083559P.	
PR	05-MAY-1998;	97US-0084366P.	
PR	06-MAY-1998;	97US-0084414P.	
PR	07-MAY-1998;	97US-0084639P.	
PR	07-MAY-1998;	97US-0084640P.	
PR	07-MAY-1998;	97US-0084643P.	
PR	15-MAY-1998;	97US-0085579P.	
PR	15-MAY-1998;	97US-0085580P.	
PR	15-MAY-1998;	97US-0085582P.	
PR	15-MAY-1998;	97US-0085700P.	
PR	18-MAY-1998;	97US-0086023P.	
PR	22-MAY-1998;	97US-0086392P.	
PR	22-MAY-1998;	97US-0086486P.	
PR	28-MAY-1998;	97US-0087098P.	
PR	28-MAY-1998;	97US-0087208P.	
PR	02-JUN-1998;	97US-0087609P.	
PR	02-JUN-1998;	97US-0087759P.	
PR	03-JUN-1998;	97US-0087827P.	
PR	04-JUN-1998;	97US-0088025P.	
PR	04-JUN-1998;	97US-0088028P.	
PR	04-JUN-1998;	97US-0088029P.	
PR	04-JUN-1998;	97US-0088033P.	
PR	04-JUN-1998;	97US-0088326P.	
PR	05-JUN-1998;	97US-0088167P.	
PR	05-JUN-1998;	97US-0088202P.	
PR	05-JUN-1998;	97US-0088212P.	
PR	05-JUN-1998;	97US-0088217P.	
PR	09-JUN-1998;	97US-0088655P.	
PR	10-JUN-1998;	97US-0088722P.	
PR	10-JUN-1998;	97US-0088738P.	

Db2713 CAAA2772

QY2241 AA 2242

Db2773 AA 2774

RESULT 449

ACF18737

ID ACF18737 standard; cDNA; 2846 BP.

XX

AC

XXACF18737;

DT17-SEP-2003 (first entry)

XX

DEHuman secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX

KWHuman; PRO; secreted protein; transmembrane protein;

KWextracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KWchondrocyte; proliferation; differentiation; cartilage disorder;

KWbone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KWadrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KWliver; drug screening; transgenic animal; genetic analysis;

KWantiarthritic; vulnery; gene therapy; gene; ss.

XX

OSHomo sapiens.

XX

PNUS2003064452-A1.

XX

PD03-APR-2003.

XX

PF17-JUL-2002; 2002US-00197704.

XX

PR29-OCT-1997; 97US-0063734P.

PR

PR16-SEP-1998; 98WO-US019330.

PR

PR25-AUG-1999; 99US-00380139.

PR

PR28-FEB-2001; 2001WO-US006520.

PR

PR15-JAN-2002; 2002US-00052586.

XX

PA(GETH) GENENTECH INC.

XX

PIBaker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PIPan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX

WPI; 2003-567183/53.

DR

DRP-PSDB; ABR97801.

XX

PTNew secreted and transmembrane PRO polypeptides and nucleic acids, useful

PTin gene therapy and for preparing a medicament for treating a condition

PTthat is responsive to a PRO polypeptide or anti-PRO antibody.

XX

PSClaim 2; Fig 169; 699pp; English.

XX

CCThe invention relates to human PRO secreted/transmembrane polypeptides

CC(ABR97717-ABR98021) and nucleic acids encoding them (ACF18653-ACF18957).

CC

CCThe invention also relates to sequences at least 80% identical to the PRO

CCnucleic acid and polypeptide sequences of the invention, recombinant

CCvectors and host cells comprising a PRO nucleic acid, a method for the

CCrecombinant production of a PRO polypeptide, antibodies against a PRO

CCpolypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic

CCacids encoding PRO polypeptides of the invention were initially

CCidentified via homology screening using consensus sequences based on the

CCextracellular domain sequences from known secreted proteins. Human cDNA

CClibraries containing sequences of interest were identified using

CColigonucleotides based on the consensus sequences, and cDNA clones were

CCisolated and characterised. The PRO polypeptides are useful for

CCstimulating release of tumour necrosis factor-alpha (TNF-alpha) from

CChuman blood and may thus be used in the treatment of conditions in which

CCenhanced TNF-alpha release would be beneficial. They are also useful for

CCstimulating the proliferation or differentiation of chondrocytes and as

CCsuch may be used in the treatment of various bone and/or cartilage

CCdisorders such as arthritis and sports injuries. The PRO polypeptides may

CCbe used in a method for detecting the presence of a tumour (e.g., an

CCadrenal tumour, lung tumour, colon tumour, breast tumour, prostate

CCtumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This

CCmethod involves comparing the level of expression of the PRO polypeptide

CCin test and control samples, where a higher level of expression of PRO

CCpolypeptide in the test sample as compared to the control sample is

CCindicative of the presence of a tumour. The PRO polypeptides are

CCadditionally useful for in drug screening to identify agonists and

CCantagonists of PRO polypeptides. PRO nucleic acids are useful as

CChybridisation probes (for isolation of cDNA molecules), in chromosome and

CCgene mapping, in the generation of antisense RNA and DNA and in gene

CCtherapy. The nucleic acids can also be used for mapping genes encoding

CCPRO polypeptides, for genetic analysis of individuals with genetic

CCdisorders, and for generating either transgenic animals or knock-out

CCanimals which are useful in the development and screening of

CCtherapeutically useful compounds. Sequences ACF18653-ACF18957 represent

CCcDNAs encoding the human PRO secreted/transmembrane polypeptides of the

CCinvention. Note: The sequence data for this patent is also available in

CCelectronic format from USPTO at seqdata.uspto.gov/sequence.html

XX

SQSequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity71.3%; Pred. No. 0.00023;

Matches87; Conservative0; Mismatches35; Indels0; Gaps0;

QY2121 CCTTTGCTTTACCACTCTCTTTCTTTTATCTTATTAATAAATGTTGGTCTCCACCACCTG2180

Db2653 CCTTTCTCTTCCCACTCTCTTGACACATTTAATAAATAAGGTTGGCTTCTGAACATA2712

QY2181 NCTCCCAA2240

Db2713 CAAA2772

QY2241 AA 2242

Db2773 AA 2774

RESULT 450

ACF09184

ID ACF09184 standard; cDNA; 2846 BP.

XX

ACACF09184;

XX

DT06-SEP-2003 (first entry)

XX

DEHuman secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX

KWHuman; PRO; secreted protein; transmembrane protein;

KWextracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KWchondrocyte; proliferation; differentiation; cartilage disorder;

KWbone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KWadrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KWliver; drug screening; transgenic animal; genetic analysis;

KWantiarthritic; vulnery; gene therapy; gene; ss.

XX

OSHomo sapiens.

XX

PNUS2003068705-A1.

XX

PD10-APR-2003.

XX

PF15-JUL-2002; 2002US-00195886.

XX

PR15-SEP-2000; 2000US-0232887P.

PR

PR28-FEB-2001; 2001WO-US006520.

PR

PR15-JAN-2002; 2002US-00052586.

XX

PA(GETH) GENENTECH INC.

XX

PIBaker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PIPan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX

CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human CDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and CDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of CDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF26307-ACF26611 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTCTTTATCTTATTATAAATGTTGGTCTCCACCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCATCTCTTGTACACATTTTATAAATAAGGGTTGGCTTCTGAAC TA 2712

QY 2181 NCTCCCAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 454
ACF24184
ID ACF24184 standard; cDNA; 2846 BP.
XX
AC ACF24184;
XX
DT 26-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX

OS Homo sapiens.
XX US2003068722-A1.
PN
XX
PD 10-APR-2003.
XX
PF 18-JUL-2002; 2002US-00199301.
XX
PR 28-MAY-1998; 98US-0087208P.
PR 08-MAR-1999; 99WO-US005028.
PR 25-AUG-1999; 99US-00380138.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-615885/58.
DR P-PSDB; ABM03647.
XX
PT New secreted and transmembrane PRO nucleic acid, useful for the
PT manufacture of a medicament for diagnosing or treating tumor or for
PT tissue typing.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM03563-ACM03867) and nucleic acids encoding them (ACF24100-ACF24404).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human CDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and CDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of CDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF24100-ACF24404 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTCTTTATCTTATTATAAATGTTGGTCTCCACCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCATCTCTTGTACACATTTTATAAATAAGGGTTGGCTTCTGAAC TA 2712

QY 2181 NCTCCCAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

Db 2653 CCTTTCTCCCATCTCTTGACACATTTTAAATAAATAAGGTTGGCTTCTGAAC TA 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 458

ACF13646

ID ACF13646 standard; cDNA; 2846 BP.

XX ACF13646;

DT 02-OCT-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein; extracellular domain; tumour necrosis factor-alpha; TNF-alpha; chondrocyte; proliferation; differentiation; cartilage disorder; bone disorder; arthritis; sports injury; cancer; tumour; diagnosis; adrenal tumour; lung; colon; breast; prostate; kidney; cervix; liver; drug screening; transgenic animal; genetic analysis; antiarthritic; vulnerary; gene therapy; gene; ss.

XX Homo sapiens.

OS US2003064462-A1.

XX 03-APR-2003.

PF 26-JUL-2002; 2002US-00206919.

XX 15-SEP-2000; 2000US-0232887P.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL; Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-531720/50.

DR P-PSDB; ABR92859.

XX Three hundred and five nucleic acids encoding PRO polypeptides, useful in gene therapy, chromosome identification, tissue typing, or as hybridization probes in chromosome and gene mapping.

PS Claim 2; Fig 169; 699pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides (ABR92775-ABR93079) and nucleic acids encoding them (ACF13562-ACF13866).

CC The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage

CC disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF13562-ACF13866 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACCTCTTCTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180

Db 2653 CCTTTTCTCTCCCATCTCTTGACACATTTTAAATAAATAGGGTTGGCTTCTGAAC TA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240

Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 459

ACD41572

ID ACD41572 standard; cDNA; 2846 BP.

XX ACD41572;

DT 11-SEP-2003 (first entry)

XX Human secreted/transmembrane protein (PRO) cDNA #85.

XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha; tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy; tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour; cervical tumour; liver tumour.

OS Homo sapiens.

XX US2003065159-A1.

XX 03-APR-2003.

PF 16-JUL-2002; 2002US-00196757.

PR 25-APR-2000; 2000US-0199550P.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL; Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-531737/50.

DR P-PSDB; ABO24620.

XX Three hundred and five nucleic acids encoding PRO polypeptides, useful

PT for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation

PT in a mammal.

XX Claim 2; Fig 169; 700pp; English.

PS The invention discloses human nucleic acids encoding secreted and

XX transmembrane (PRO) polypeptides, with or without their associated signal

CC peptide. Also disclosed is an antibody that specifically binds to the PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor alpha (TNF-alpha) from human blood by contacting the blood with a

CC PRO polypeptide, a method for stimulating the proliferation or

CC differentiation of chondrocyte cells by contacting the cells with a PRO

CC polypeptide, a method for detecting the presence of a tumour in a mammal

CC and an oligonucleotide probe derived from any of the PRO nucleotide

CC sequences. The nucleotide sequences are useful as probes, in chromosome

CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO

CC polypeptides by recombinant techniques and in gene therapy (e.g. for

CC replacement of defective gene). The PRO polypeptides are useful as

CC molecular weight markers for protein electrophoresis purposes, for

CC chromosome identification, as chromosome markers, as therapeutic agents,

CC for stimulating the release of TNF-alpha from human blood, for

CC stimulating the proliferation or differentiation of chondrocytes and

CC detecting the presence, prevention and/or treatment of a tumour, such as

CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.

CC The PRO polypeptides and nucleic acids may also be used diagnostically

CC for tissue typing. The sequence presented is a cDNA encoding one of the

CC PRO polypeptides of the invention. Note: The sequence data for this

CC patent can also be obtained in electronic format directly from USPTO at

CC seqdata.uspto.gov/sequence.html

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGGTCTCCACCACTG 2180

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2653 CCTTTTCCTCCCATCTCTTGTACACATTTTAATAAATAAGGTTGGCTTCTGAAC TA 2712

QY 2181 NCTCCCAA 2240

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2713 CAAAAA AA 2772

QY 2241 AA 2242

Db ||

2773 AA 2774

RESULT 460

ADA37741

ID ADA37741 standard; cDNA; 2846 BP.

XX

AC ADA37741;

XX

DT 20-NOV-2003 (first entry)

XX

DE Human cDNA encoding secreted/transmembrane protein PRO1344.

XX

KW PRO; secreted protein; transmembrane protein;

KW hypertrophy of neonatal heart; angiogenesis;

KW vascular endothelial growth factor; VEGF-stimulated proliferation;

KW endothelial cell; T-lymphocyte proliferation; retinal neuron;

KW c-fos induction; adipocyte cell; chondrocyte differentiation;

KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;

KW cancer; human; ss; gene; colon cancer; lung cancer; breast cancer;

KW rod photoreceptor cell.

XX

OS Homo sapiens.

XX

PN US2003008297-A1.

XX

PD 09-JAN-2003.

XX

PF 15-NOV-2001; 2001US-00997653.

XX

PR 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088734P.

PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088742P.

PR 10-JUN-1998; 98US-0088810P.

PR 10-JUN-1998; 98US-0088824P.

PR 10-JUN-1998; 98US-0088826P.

PR 11-JUN-1998; 98US-0088858P.

PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088876P.

PR 12-JUN-1998; 98US-0089105P.

PR 16-JUN-1998; 98US-0089440P.

PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.

PR 17-JUN-1998; 98US-0089532P.

PR 17-JUN-1998; 98US-0089538P.

PR 17-JUN-1998; 98US-0089598P.

PR 17-JUN-1998; 98US-0089599P.

PR 17-JUN-1998; 98US-0089600P.

PR 17-JUN-1998; 98US-0089653P.

PR 18-JUN-1998; 98US-0089801P.

PR 18-JUN-1998; 98US-0089907P.

PR 18-JUN-1998; 98US-0089908P.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 02-JUN-1999; 99WO-US012252.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.

PR

RESULT 463
ACF39953
ID ACF39953 standard; cDNA; 2846 BP.
XX
AC ACF39953;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003064463-A1.
XX
PD 03-APR-2003.
XX
PF 26-JUL-2002; 2002US-00206922.
XX
PR 15-SEP-2000; 2000US-0232887P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-596623/56.
DR P-PSDB; ABM16028.
XX
PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing and in treating
PT a condition responsive to the polypeptide e.g., cancer.
XX
PS Claim 2; Fig 169; 699pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC and nucleic acids encoding them, the invention also provides recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding

CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. The present sequence appears in the
CC exemplification of the specification. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. NO. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCTTCCCACTCTCTTGACACATTTTAATAAAAGGTTGGCTTCTGAAC 2712

QY 2181 NCTCCCAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 464
ACD45475
ID ACD45475 standard; cDNA; 2846 BP.
XX
AC ACD45475;
XX
DT 13-SEP-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003064451-A1.
XX
PD 03-APR-2003.
XX
PF 16-JUL-2002; 2002US-00196755.
XX
PR 21-MAR-2000; 2000US-0191048P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-605858/57.
DR P-PSDB; ABO27589.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.,
PT cancer.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis

AC ACF27312;
XX 20-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX OS
XX PN US2003068699-A1.
XX PD 10-APR-2003.
XX PF 12-JUL-2002; 2002US-00194364.
XX PR 05-JUN-2000; 2000US-0209832P.
XX PR 28-FEB-2001; 2001WO-US006520.
XX PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-615875/58.
XX DR P-PSDB; ABM07056.
XX PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for diagnosing, preventing and/or treating tumors, such as
XX PT adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
XX PS Claim 2; Fig 169; 705pp; English.
XX CC The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM06972-ABM07276) and nucleic acids encoding them (ACF27228-ACF27532).
XX CC The invention also relates to sequences at least 80% identical to the PRO
XX CC nucleic acid and polypeptide sequences of the invention, recombinant
XX CC vectors and host cells comprising a PRO nucleic acid, a method for the
XX CC recombinant production of a PRO polypeptide, antibodies against a PRO
XX CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
XX CC acids encoding PRO polypeptides of the invention were initially
XX CC identified via homology screening using consensus sequences based on the
XX CC extracellular domain sequences from known secreted proteins. Human cDNA
XX CC libraries containing sequences of interest were identified using
XX CC oligonucleotides based on the consensus sequences, and cDNA clones were
XX CC isolated and characterised. The PRO polypeptides are useful for
XX CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
XX CC human blood and may thus be used in the treatment of conditions in which
XX CC enhanced TNF-alpha release would be beneficial. They are also useful for
XX CC stimulating the proliferation or differentiation of chondrocytes and as
XX CC such may be used in the treatment of various bone and/or cartilage
XX CC disorders such as arthritis and sports injuries. The PRO polypeptides may
XX CC be used in a method for detecting the presence of a tumour (e.g., an
XX CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
XX CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
XX CC method involves comparing the level of expression of the PRO polypeptide
XX CC in test and control samples, where a higher level of expression of PRO
XX CC polypeptide in the test sample as compared to the control sample is
XX CC indicative of the presence of a tumour. The PRO polypeptides are
XX CC additionally useful for in drug screening to identify agonists and
XX CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
XX CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
XX CC gene mapping, in the generation of antisense RNA and DNA and in gene
XX CC therapy. The nucleic acids can also be used for mapping genes encoding
XX CC PRO polypeptides, for genetic analysis of individuals with genetic
XX CC disorders, and for generating either transgenic animals or knock-out

CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF27228-ACF27532 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTCTTTTATCTTTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db .||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
2653 CCTTTTCTTCCCACTCTCTTGACACATTTTATAATAAAGGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAAA 2240
Db ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
2713 CAA 2772
QY 2241 AA 2242
Db ||
2773 AA 2774
RESULT 467
ACF45150
ID ACF45150 standard; cDNA; 2846 BP.
XX AC ACF45150;
XX DT 08-OCT-2003 (first entry)
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX OS Homo sapiens.
XX PN US2003068707-A1.
XX PD 10-APR-2003.
XX PF 16-JUL-2002; 2002US-00196746.
XX PR 21-MAR-2000; 2000US-0191048P.
XX PR 28-FEB-2001; 2001WO-US006520.
XX PR 15-JAN-2002; 2002US-00052586.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-615878/58.
XX DR P-PSDB; ABM21150.
XX PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX PT in gene therapy, as diagnostic markers for the presence of a disease
XX PT condition, or as therapeutic targets for treating tumors, sports injuries
XX or arthritis.
XX PS Claim 2; Fig 169; 700pp; English.
XX CC The invention relates to human PRO secreted/transmembrane polypeptides
XX (ABM21066-ABM21370) and nucleic acids encoding them (ACF45066-ACF45370).
XX CC The invention also relates to sequences at least 80% identical to the PRO

Db 2653 CCTTTTCTCCCATCTCTTGACACATTTTAAATAAAATAAGGTTGGTCTCTGAACTA 2712
QY 2181 NCTCCCAAAAAA 2240
Db 2713 CAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 469
ACD89844
ID ACD89844 standard; cDNA; 2846 BP.
XX
AC ACD89844;
XX
DT 08-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003068695-A1.
XX
PD 10-APR-2003.
XX
PF 09-JUL-2002; 2002US-00192012.
XX
PR 15-SEP-2000; 2000US-0232887P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-625463/59.
DR P-PSDB; ABO41366.
XX
PT New PRO nucleic acid, useful for the manufacture of a medicament for
diagnosing or treating tumor or for tissue typing.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
transmembrane (PRO) polypeptides, with or without their associated signal
peptide. Also disclosed is an antibody that specifically binds to the PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor alpha (TNF-alpha) from human blood by contacting the blood with a
PRO polypeptide, a method for stimulating the proliferation or
differentiation of chondrocyte cells by contacting the cells with a PRO
polypeptide, a method for detecting the presence of a tumour in a mammal
and an oligonucleotide probe derived from any of the PRO nucleotide
sequences. The nucleotide sequences are useful as probes, in chromosome
and gene mapping, in generating antisense RNA and DNA, in preparing PRO
polypeptides by recombinant techniques and in gene therapy (e.g. for
replacement of defective gene). The PRO polypeptides are useful as
molecular weight markers for protein electrophoresis purposes, for
chromosome identification, as chromosome markers, as therapeutic agents,
for stimulating the release of TNF-alpha from human blood, for
stimulating the proliferation or differentiation of chondrocytes and
detecting the presence, prevention and/or treatment of a tumour, such as
adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
for tissue typing. The sequence presented is a cDNA encoding one of the
PRO polypeptides of the invention. Note: The sequence data for this

CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. NO. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACTG 2180
Db 2653 CCTTTTCTCCCATCTCTTGACACATTTTAAATAAAATAAGGTTGGTCTCTGAACTA 2712
QY 2181 NCTCCCAAAAAA 2240
Db 2713 CAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 470
ACD84625
ID ACD84625 standard; cDNA; 2846 BP.
XX
AC ACD84625;
XX
DT 22-SEP-2003 (first entry)
XX
DE Human PRO polynucleotide #85.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW cytostatic; tumour necrosis factor-alpha; TNF-alpha; blood; tumour;
KW chondrocyte cell; cancer; antiarthritic; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2003068703-A1.
XX
PD 10-APR-2003.
XX
PF 11-JUL-2002; 2002US-00194459.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-625465/59.
DR P-PSDB; ABO36181.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
in gene therapy, as diagnostic markers for the presence of a disease
condition, or as therapeutic targets for treating tumors, sports injuries
or arthritis.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal. The polynucleotides are
useful in molecular biology, including uses as hybridisation probes, in
chromosome and gene mapping, in generating antisense RNA and DNA and in
gene therapy. The polynucleotides may also be used in preparing PRO

PR 11-DEC-1997; 97US-0069333SP.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088812P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.

PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.

PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.

PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACACTCTTTCCCTTTTATCTTATTATAAAAAATGTTGGTCTCCACCACTG 2180

Db 2653 CCTTTTCCTTCCCATCTCTTGACACATTTTAATAAAATAAGGGTTGGCTTCTGAACCTA 2712

Qy 2181 NCTCCCAAA 2240

Db 2713 CAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 476

ADA21427
+ID ADA21427 standard; cdna; 2846 BP.

XX AC ADA21427;

XX DT 20-NOV-2003 (first entry)

XX DE Human cdna encoding secreted/transmembrane polypeptide PRO1344.

PR	31-AUG-1998;	98US-0098525P.	
PR	16-SEP-1998;	98US-0100634P.	
PR	16-SEP-1998;	98WO-US019330.	
PR	17-SEP-1998;	98US-0100858P.	
PR	17-SEP-1998;	98WO-US019437.	
PR	07-OCT-1998;	98WO-US021141.	
PR	01-DEC-1998;	98WO-US025108.	
PR	22-DEC-1998;	98US-0113296P.	
PR	05-JAN-1999;	99WO-US000106.	
PR	08-MAR-1999;	99WO-US005028.	
PR	12-MAR-1999;	99US-0123957P.	
PR	02-JUN-1999;	99WO-US012252.	
PR	23-JUN-1999;	99US-0141037P.	
PR	07-JUL-1999;	99US-0143048P.	
PR	20-JUL-1999;	99US-0144758P.	
PR	26-JUL-1999;	99US-0145698P.	
PR	28-JUL-1999;	99US-0146222P.	
PR	17-AUG-1999;	99US-0149396P.	
PR	15-SEP-1999;	99WO-US021090.	
PR	15-SEP-1999;	99WO-US021547.	
PR	08-OCT-1999;	99US-0158663P.	
PR	30-NOV-1999;	99WO-US028313.	
PR	01-DEC-1999;	99WO-US028301.	
PR	01-DEC-1999;	99WO-US028634.	
PR	16-DEC-1999;	99WO-US030095.	
PR	20-DEC-1999;	99WO-US030911.	
PR	05-JAN-2000;	2000WO-US000219.	
PR	06-JAN-2000;	2000WO-US000376.	
PR	11-FEB-2000;	2000WO-US003565.	
PR	18-FEB-2000;	2000WO-US004341.	
PR	22-FEB-2000;	2000WO-US004414.	
PR	24-FEB-2000;	2000WO-US004914.	
PR	24-FEB-2000;	2000WO-US005004.	
PR	02-MAR-2000;	2000WO-US005841.	
PR	10-MAR-2000;	2000WO-US006319.	
PR	15-MAR-2000;	2000WO-US006884.	
PR	20-MAR-2000;	2000WO-US007377.	
PR	30-MAR-2000;	2000WO-US008439.	
PR	15-MAY-2000;	2000WO-US013358.	
PR	17-MAY-2000;	2000WO-US013705.	
PR	22-MAY-2000;	2000WO-US014042.	
PR	30-MAY-2000;	2000WO-US014941.	
PR	02-JUN-2000;	2000WO-US015264.	
PR	23-JUN-2000;	2000US-0213637P.	
PR	28-JUL-2000;	2000WO-US020710.	
PR	11-AUG-2000;	2000WO-US022031.	
PR	23-AUG-2000;	2000WO-US023522.	
Query Match 3.0%; Score 66.6; DB 9; Length 2846;			
Best Local Similarity 71.3%; Pred. No. 0.00023;			
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;			
QY	2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTTATTAATAAAATGTTGGTCTCCCACTG	2180	
Db	2653 CCTTTTCCTTCCCACTCTCTGTGTACACATTTTATAAAATAAGGTTGGCTTCTGAACTA	2712	
QY	2181 NCTCCCAA	2240	
Db	2713 CAAAAAATAA	2772	
QY	2241 AA 2242		
Db	2773 AA 2774		
RESULT 477			
ACD09461			
ID	ACD09461 standard; cDNA; 2846 BP.		
XX			
AC	ACD09461;		
XX			
DT	09-AUG-2003 (first entry)		
XX			

DE	Human secreted/transmembrane protein (PRO) cDNA #85.
XX	
KW	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour; arthritis.
XX	
OS	Homo sapiens.
XX	
PN	US2003036127-A1.
XX	
PD	20-FEB-2003.
XX	
PF	27-JUN-2002; 2002US-00184612.
XX	
PR	18-SEP-1997; 97US-0059263P.
PR	18-SEP-1997; 97US-0059266P.
PR	17-OCT-1997; 97US-0062250P.
PR	21-OCT-1997; 97US-0063486P.
PR	24-OCT-1997; 97US-0063120P.
PR	24-OCT-1997; 97US-0063121P.
PR	28-OCT-1997; 97US-0063540P.
PR	28-OCT-1997; 97US-0063541P.
PR	28-OCT-1997; 97US-0063544P.
PR	28-OCT-1997; 97US-0063564P.
PR	29-OCT-1997; 97US-0063734P.
PR	31-OCT-1997; 97US-0063870P.
PR	31-OCT-1997; 97US-0064103P.
PR	13-NOV-1997; 97US-0065311P.
PR	21-NOV-1997; 97US-0066120P.
PR	24-NOV-1997; 97US-0066466P.
PR	24-NOV-1997; 97US-0066772P.
PR	11-DEC-1997; 97US-0069335P.
PR	12-DEC-1997; 97US-0069425P.
PR	17-DEC-1997; 97US-0069870P.
PR	18-DEC-1997; 97US-0068017P.
PR	10-MAR-1998; 98US-0077450P.
PR	11-MAR-1998; 98US-0077632P.
PR	11-MAR-1998; 98US-0077649P.
PR	20-MAR-1998; 98US-0078886P.
PR	20-MAR-1998; 98US-0078939P.
PR	27-MAR-1998; 98US-0079664P.
PR	27-MAR-1998; 98US-0079786P.
PR	31-MAR-1998; 98US-0080107P.
PR	31-MAR-1998; 98US-0080194P.
PR	01-APR-1998; 98US-0080327P.
PR	01-APR-1998; 98US-0080333P.
PR	08-APR-1998; 98US-0081049P.
PR	08-APR-1998; 98US-0081070P.
PR	09-APR-1998; 98US-0081195P.
PR	15-APR-1998; 98US-0081838P.
PR	21-APR-1998; 98US-0082568P.
PR	21-APR-1998; 98US-0082569P.
PR	22-APR-1998; 98US-0082704P.
PR	22-APR-1998; 98US-0082797P.
PR	28-APR-1998; 98US-0083322P.
PR	29-APR-1998; 98US-0083495P.
PR	29-APR-1998; 98US-0083496P.
PR	29-APR-1998; 98US-0083499P.
PR	29-APR-1998; 98US-0083559P.
PR	05-MAY-1998; 98US-0084366P.
PR	06-MAY-1998; 98US-0084414P.
PR	07-MAY-1998; 98US-0084639P.
PR	07-MAY-1998; 98US-0084640P.
PR	07-MAY-1998; 98US-0084643P.
PR	15-MAY-1998; 98US-0085579P.
PR	15-MAY-1998; 98US-0085580P.
PR	15-MAY-1998; 98US-0085582P.
PR	15-MAY-1998; 98US-0085700P.
PR	18-MAY-1998; 98US-0086023P.
PR	22-MAY-1998; 98US-0086392P.
PR	22-MAY-1998; 98US-0086486P.
PR	28-MAY-1998; 98US-0087098P.

XX Human secreted/transmembrane protein (PRO) cDNA #85.
DE
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003040061-A1.
XX
PD 27-FEB-2003.
XX
PF 25-JUN-2002; 2002US-00180540.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087208P.
PR 28-MAY-1998; 98US-0087209P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.

PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100583P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.

DT	26-SEP-2003	(first entry)
XX		
DE	Human secreted/transmembrane polypeptide PRO 1344	cDNA.
XX		
KW	Human; ss; tumour; cancer; tissue typing; gene.	
XX		
OS	Homo sapiens.	
XX		
PN	US2003018172-A1.	
XX		
PD	23-JAN-2003.	
XX		
PF	01-MAY-2002; 2002US-00063513.	
XX		
PR	06-DEC-2001; 2001US-00006867.	
XX		
PA	(GETH) GENENTECH INC.	
XX		
PI	Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;	
PI	Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;	
XX		
DR	WPI; 2003-479475/45.	
DR	P-PSDB; ABO44257.	
XX		
PT	Isolated antibody specifically binding a PRO polypeptide, useful for the	
PT	diagnosis and treatment of disorders with the aberrant expression or	
PT	activity of the PRO polypeptide, such as tumor conditions and cancer.	
XX		
PS	Disclosure; Fig 37; 409pp; English.	
XX		
CC	The invention relates to an antibody that binds to a fully defined PRO	
CC	polypeptide. The antibody is useful for the diagnosis, prevention and/or	
CC	treatment of disorders associated with the aberrant expression or	
CC	activity of the PRO polypeptide, such as tumour conditions and cancer.	
CC	They can also be used to generate transgenic or knockout animals useful	
CC	in the development and screening of therapeutically useful reagents. The	
CC	PRO polypeptides and encoding nucleic acids can be used as molecular	
CC	weight markers for protein electrophoresis, chromosome identification and	
CC	tissue typing. The antibodies may be used in various diagnostic,	
CC	competitive binding and/or immunoprecipitation assays. The present	
CC	sequence represents cDNA encoding a human secreted and transmembrane PRO	
CC	polypeptide	
XX		
SO	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;	

PR	26-AUG-1998;	98US-0097954P.	KW	Human; PRO; secreted protein; transmembrane protein;
PR	26-AUG-1998;	98US-0097955P.	KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
PR	26-AUG-1998;	98US-0097971P.	KW	chondrocyte; proliferation; differentiation; cartilage disorder;
PR	26-AUG-1998;	98US-0097974P.	KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
PR	26-AUG-1998;	98US-0098014P.	KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
PR	01-SEP-1998;	98US-0098716P.	KW	liver; drug screening; transgenic animal; genetic analysis;
PR	01-SEP-1998;	98US-0098723P.	KW	antiarthritic; vulnerary; gene therapy; gene; ss.
PR	02-SEP-1998;	98US-0098803P.	XX	
PR	02-SEP-1998;	98US-0098821P.	OS	Homo sapiens.
PR	02-SEP-1998;	98US-0098843P.	XX	
PR	09-SEP-1998;	98US-0099602P.	PN	US2003054468-A1.
PR	10-SEP-1998;	98US-0099741P.	XX	
PR	10-SEP-1998;	98US-0099754P.	PD	20-MAR-2003.
PR	10-SEP-1998;	98US-0099763P.	XX	
PR	10-SEP-1998;	98US-0099812P.	PF	19-JUL-2002; 2002US-00199462.
PR	15-SEP-1998;	98US-0100388P.	XX	
PR	16-SEP-1998;	98US-0100662P.	PR	26-JUN-1998; 98US-00105413.
PR	16-SEP-1998;	98US-0100664P.	PR	16-SEP-1998; 98WO-US019330.
PR	16-SEP-1998;	98US-0101751P.	PR	07-OCT-1998; 98US-00168978.
PR	16-SEP-1998;	98WO-US019330.	PR	07-OCT-1998; 98WO-US021141.
PR	17-SEP-1998;	98US-0100683P.	PR	06-NOV-1998; 98US-00187368.
PR	17-SEP-1998;	98US-0100684P.	PR	01-DEC-1998; 98WO-US025108.
PR	17-SEP-1998;	98US-0100919P.	PR	07-DEC-1998; 98US-00202054.
PR	17-SEP-1998;	98US-0100930P.	PR	03-MAR-1999; 99US-00254311.
PR	18-SEP-1998;	98US-0100849P.	PR	08-MAR-1999; 99WO-US005028.
PR	18-SEP-1998;	98US-0101014P.	PR	14-MAY-1999; 99US-00311832.
PR	18-SEP-1998;	98US-0101068P.	PR	14-MAY-1999; 99WO-US010733.
PR	23-SEP-1998;	98US-0101471P.	PR	02-JUN-1999; 99WO-US012252.
PR	23-SEP-1998;	98US-0101472P.	PR	25-AUG-1999; 99US-00380137.
PR	23-SEP-1998;	98US-0101475P.	PR	25-AUG-1999; 99US-00380138.
PR	23-SEP-1998;	98US-0101477P.	PR	25-AUG-1999; 99US-00380139.
PR	24-SEP-1998;	98US-0101738P.	PR	25-AUG-1999; 99US-00380142.
PR	24-SEP-1998;	98US-0101739P.	PR	01-SEP-1999; 99WO-US020111.
PR	24-SEP-1998;	98US-0101743P.	PR	15-SEP-1999; 99WO-US021090.
PR	24-SEP-1998;	98US-0101922P.	PR	18-OCT-1999; 99US-00403297.
PR	25-SEP-1998;	98US-0101786P.	PR	12-NOV-1999; 99US-00423844.
PR	29-SEP-1998;	98US-0102207P.	PR	01-DEC-1999; 99WO-US028301.
PR	29-SEP-1998;	98US-0102240P.	PR	02-DEC-1999; 99WO-US028551.
PR	29-SEP-1998;	98US-0102330P.	PR	30-DEC-1999; 99WO-US031274.
PR	29-SEP-1998;	98US-0102331P.	PR	05-JAN-2000; 2000WO-US000219.
PR	30-SEP-1998;	98US-0102487P.	PR	18-FEB-2000; 2000WO-US004341.
PR	30-SEP-1998;	98US-0102570P.	PR	18-FEB-2000; 2000WO-US004342.
PR	30-SEP-1998;	98US-0102571P.	PR	22-FEB-2000; 2000WO-US004414.
PR	01-OCT-1998;	98US-0102684P.	PR	24-FEB-2000; 2000WO-US005004.
PR	01-OCT-1998;	98US-0102687P.	PR	01-MAR-2000; 2000WO-US005601.
			PR	02-MAR-2000; 2000WO-US005841.
			PR	15-MAR-2000; 2000WO-US006884.
			PR	30-MAR-2000; 2000WO-US008439.
			PR	17-MAY-2000; 2000WO-US013705.
			PR	22-MAY-2000; 2000WO-US014042.
QY	2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAAAATGTGGTCTCCACCACTG	2180	PR	30-MAY-2000; 2000WO-US014941.
Db			PR	02-JUN-2000; 2000WO-US015264.
	2653 CCTTTCCCTCCCATCTCTTGACACATTTTAATAAAATAAGGGTTGGCTTCTGAAC	2712	PR	28-JUL-2000; 2000WO-US020710.
			PR	22-AUG-2000; 2000US-00644848.
QY	2181 NCTCCCAA	2240	PR	24-AUG-2000; 2000WO-US023328.
Db			PR	18-SEP-2000; 2000US-00664610.
	2713 CAAAAA	2772	PR	18-SEP-2000; 2000US-00665350.
			PR	08-NOV-2000; 2000US-00709238.
QY	2241 AA	2242	PR	08-NOV-2000; 2000WO-US030952.
Db			PR	01-DEC-2000; 2000WO-US032678.
	2773 AA	2774	PR	20-DEC-2000; 2000US-00747259.
			PR	20-DEC-2000; 2000WO-US034956.
			PR	28-FEB-2001; 2001WO-US006520.
			PR	22-MAR-2001; 2001US-00816744.
			PR	10-MAY-2001; 2001US-00854208.
			PR	10-MAY-2001; 2001US-00854280.
			PR	25-MAY-2001; 2001US-00866028.
			PR	01-JUN-2001; 2001WO-US017800.
			PR	05-JUN-2001; 2001US-00874503.
			PR	20-JUN-2001; 2001WO-US019692.
			PR	29-JUN-2001; 2001WO-US021066.
			PR	09-JUL-2001; 2001WO-US021735.
			PR	18-JUL-2001; 2001US-00908827.
Query Match				
Best Local Similarity 3.0%; Score 66.6; DB 9; Length 2846;				
Matches 87; Conservative 71.3%; Pred. No. 0.00023;				
Mismatches 35; Indels 0; Gaps 0;				
RESULT 481				
ACC94762				
ID	ACC94762 standard; cDNA; 2846 BP.			
XX				
AC	ACC94762;			
XX				
DT	29-AUG-2003 (first entry)			
XX				
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.			
XX				


```
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACACTCTTTCCCTTTTATCTTATTATAAAAAATGTTGGTCTCCACCACGTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTCCCATCTCTTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
      ||
Db 2773 AA 2774

RESULT 483
ACF15181
ID ACF15181 standard; cDNA; 2846 BP.
XX
AC ACF15181;
XX
DT 13-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003044917-A1.
XX
PD 06-MAR-2003.
XX
PF 20-JUN-2002; 2002US-00176753.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
```

PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.

PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCAC TG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCCTTCCCATCTCTTGACACATTTTAATAAAATAAGGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 484
ACC97276
ID ACC97276 standard; cDNA; 2846 BP.
XX
AC ACC97276;
XX
DT 19-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003044929-A1.
XX
PD 06-MAR-2003.
XX
PF 28-JUN-2002; 2002US-00184643.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.

PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.

PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.

CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules); in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF14176-ACF14480 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGTCTTACCACCTCTTCTCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACGTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAAATAAAGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAA 2772
QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 488
ADA10214
ID ADA10214 standard; cDNA; 2846 BP.
XX
AC ADA10214;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO1344.
XX
KW ss; gene; PRO; secreted protein; transmembrane protein; human;
KW septic shock.
XX
OS Homo sapiens.
XX
PN US2003059831-A1.
XX
PD 27-MAR-2003.
XX
PF 19-NOV-2001; 2001US-00989729.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.

XX 20-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX US2003068772-A1.
PN
XX
PD 10-APR-2003.
XX
PF 29-JUL-2002; 2002US-00208022.
XX
PR 21-MAR-2000; 2000US-0190828P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-615909/58.
DR P-PSDB; ABM08886.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
PT particularly for treating e.g. lung or breast tumors, or arthritis in a
PT mammal.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM08802-ABM09106) and nucleic acids encoding them (ACF29070-ACF29374).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out

CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF29070-ACF29374 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGCTTTTACCACCTCTTCTCTTTTATCTTATTATAATAAATGTTGGTCTCCACCCTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTTCCCATCTCTGTACACATTTTAATAATAAAGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAA 2772
QY 2241 AA 2242
||
Db 2773 AA 2774
RESULT 495
ACD84932
ID ACD84932 standard; cDNA; 2846 BP.
XX
AC ACD84932;
XX
DT 05-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003068714-A1.
XX
PD 10-APR-2003.
XX
PF 17-JUL-2002; 2002US-00197698.
XX
PR 27-OCT-1998; 98US-0105882P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-625466/59.
DR P-PSDB; AB036486.
XX
PT New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT manufacture of a medicament for diagnosing or treating tumors or for
PT tissue typing.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a

XX PA (GETH) GENENTECH INC.

XX KW Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-625482/59.

DR P-PSDB; ABO39536.

XX PT Novel secreted and transmembrane polypeptides, PRO polypeptides useful

PT for stimulating release of Tumor Necrosis Factor-alpha from human blood

PT and for stimulating the proliferation or differentiation of chondrocyte

PT cells.

XX Claim 2; Fig 169; 700pp; English.

XX The invention discloses human nucleic acids encoding secreted and

CC transmembrane (PRO) polypeptides, with or without their associated signal

CC peptide. Also disclosed is an antibody that specifically binds to the PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor alpha (TNF-alpha) from human blood by contacting the blood with a

CC PRO polypeptide, a method for stimulating the proliferation or

CC differentiation of chondrocyte cells by contacting the cells with a PRO

CC polypeptide, a method for detecting the presence of a tumour in a mammal

CC and an oligonucleotide probe derived from any of the PRO nucleotide

CC sequences. The nucleotide sequences are useful as probes, in chromosome

CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO

CC polypeptides by recombinant techniques and in gene therapy (e.g. for

CC replacement of defective gene). The PRO polypeptides are useful as

CC molecular weight markers for protein electrophoresis purposes, for

CC chromosome identification, as chromosome markers, as therapeutic agents,

CC for stimulating the release of TNF-alpha from human blood, for

CC stimulating the proliferation or differentiation of chondrocytes and

CC detecting the presence, prevention and/or treatment of a tumour, such as

CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.

CC The PRO polypeptides and nucleic acids may also be used diagnostically

CC for tissue typing and for treating disorders such as sports injuries and

CC arthritis. The sequence presented is a cDNA encoding one of the PRO

CC polypeptides of the invention. Note: The sequence data for this patent

CC can also be obtained in electronic format directly from USPTO at

CC seqdata.uspto.gov/sequence.html

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

SQ

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. NO. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACTCTTTCCCTTTTATCTTATTATAATAAAATGTTGGTCTCCACACTG 2180

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2653 CCTTTTCTTCCCATCTCTTGACACATTTTAATAAATAAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAA 2240

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2713 CAAA 2772

QY 2241 AA 2242

Db ||

2773 AA 2774

RESULT 498

ACF30689

ID ACF30689 standard; cDNA; 2846 BP.

XX AC ACF30689;

XX 20-SEP-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

DE Human; PRO; secreted protein; transmembrane protein;

XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; proliferation; differentiation; cartilage disorder;

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; drug screening; transgenic animal; genetic analysis;

KW antiarthritic; vulneryary; gene therapy; gene; ss.

XX Homo sapiens.

OS US2003069407-A1.

XX 10-APR-2003.

XX 29-AUG-2002; 2002US-00232232.

XX 21-APR-1998; 98US-0082568P.

PR 08-MAR-1999; 99WO-US005028.

PR 25-AUG-1999; 99US-00380138.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

PI WPI; 2003-625495/59.

XX P-PSDB; ABM10411.

PT Three hundred and five nucleic acids encoding PRO polypeptides, useful

PT for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation.

XX Claim 2; Fig 169; 700pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides

CC (ABM10327-ABM10631) and nucleic acids encoding them (ACF30605-ACF30909).

CC The invention also relates to sequences at least 80% identical to the PRO

CC nucleic acid and polypeptide sequences of the invention, recombinant

CC vectors and host cells comprising a PRO nucleic acid, a method for the

CC recombinant production of a PRO polypeptide, antibodies against a PRO

CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic

CC acids encoding PRO polypeptides of the invention were initially

CC identified via homology screening using consensus sequences based on the

CC extracellular domain sequences from known secreted proteins. Human cDNA

CC libraries containing sequences of interest were identified using

CC oligonucleotides based on the consensus sequences, and cDNA clones were

CC isolated and characterised. The PRO polypeptides are useful for

CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from

CC human blood and may thus be used in the treatment of conditions in which

CC enhanced TNF-alpha release would be beneficial. They are also useful for

CC stimulating the proliferation or differentiation of chondrocytes and as

CC such may be used in the treatment of various bone and/or cartilage

CC disorders such as arthritis and sports injuries. The PRO polypeptides may

CC be used in a method for detecting the presence of a tumour (e.g., an

CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate

CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This

CC method involves comparing the level of expression of the PRO polypeptide

CC in test and control samples, where a higher level of expression of PRO

CC polypeptide in the test sample as compared to the control sample is

CC indicative of the presence of a tumour. The PRO polypeptides are

CC additionally useful for in drug screening to identify agonists and

CC antagonists of PRO polypeptides. PRO nucleic acids are useful as

CC hybridisation probes (for isolation of cDNA molecules), in chromosome and

CC gene mapping, in the generation of antisense RNA and DNA and in gene

CC therapy. The nucleic acids can also be used for mapping genes encoding

CC PRO polypeptides, for genetic analysis of individuals with genetic

CC disorders, and for generating either transgenic animals or knock-out

CC animals which are useful in the development and screening of

CC therapeutically useful compounds. Sequences ACF30605-ACF30909 represent

CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the

CC invention. Note: The sequence data for this patent is also available in

CC electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

SQ

XX 02-MAY-2002; 2002US-00063567.
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH) GENENTECH INC.
XX

Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ,
Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

WPI; 2003-669950/63.
P-PSDB; ADA19900.

New isolated PRO polypeptide, useful in the preparation of a medicament
for treating a condition responsive to PRO polypeptide, as therapeutic
agent e.g. vaccine, and as molecular weight marker.

Disclosure; Fig 37; 239pp; English.

This invention relates to novel nucleic acids encoding human PRO secreted
and transmembrane proteins. Extracellular proteins play important roles
in the formation, differentiation and maintenance of multicellular
organisms. The fate of many individual cells (for example proliferation,
migration or differentiation) is typically governed by information
received from other cells and the immediate environment. The information
is often transmitted by secreted polypeptides (for example mitogenic
factors, survival factors, cytotoxic factors, differentiation factors,
neuropeptides and hormones) which are received and interpreted by diverse
cell receptors or membrane bound proteins. These membrane bound proteins
and receptors may be of use as pharmaceutical and diagnostic agents, such
as in the blocking of receptor-ligand interactions. The current invention
provides the amino acid sequences of novel human membrane bound receptors
and proteins, along with the cDNA sequences encoding them. The novel
proteins of the invention may have cytostatic activities through the
stimulation of chondrocytes. The nucleic acids of the invention may be
useful for the manufacture of a medicament for diagnosing or treating a
tumour in a mammal. In addition, they may be useful for measuring or

CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAATAAAATAAGGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAA 2772
QY 2241 AA 2242
||
Db 2773 AA 2774
RESULT 503
ACD40651
ID ACD40651 standard; cDNA; 2846 BP.
XX
AC ACD40651;
XX
DT 10-SEP-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
DE
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003032134-A1.
XX
PD 13-FEB-2003.
XX
PF 27-JUN-2002; 2002US-00184652.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.

PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.

PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

[illegible]

RESULT 504
ADB17282
ID ADB17282 standard; cDNA; 2846 BP.

AC ADB17282;

DT 20-NOV-2003 (first entry)

Human cDNA clone (SeqID 37) encoding the transmembrane PRO protein.

ss; gene; PRO; transmembrane; immunoconjugate; cytotoxic; gene therapy; cytostatic; cancer; human.

OS Homo sapiens.

PN US2003050465-A1.

PD 13-MAR-2003.

26-AUG-2002: 2002US-00227693.

PR	10-AUG-1998;	98US-0096012P;
PR	02-JUN-1999;	99WO-US012252.
PR	25-AUG-1999;	99US-00380137.
PR	24-AUG-2000;	2000WO-US023328.
PR	06-DEC-2001;	2001US-00006867.

PA (GETH) GENENTECH INC.

Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PPI
PPI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
PPI

DR WPI; 2003-521821/49.
DR P-PSDB; ADB17283.

New PRO nucleic acid, useful for manufacturing a medicament for diagnosing or treating tumor or for tissue typing.

PS Claim 2; Fig 37; 406pp; English.

This invention relates to a novel isolated and secreted PRO polypeptide. PRO is a transmembrane protein involved in the formation, differentiation and maintenance of multicellular organisms, and more particularly the proliferation, differentiation and migration of individual cells. The invention describes screening compounds to identify PRO polypeptide agonists and antagonists, anti-PRO antibodies, and immunoconjugates comprising an antibody conjugated to a cytotoxic agent. Specifically, the heterologous protein of the chimeric polypeptide is an epitope tag or an Fc region of an immunoglobulin. Through the use of gene therapy, the PRO

PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-009057P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.

PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnetary; gene therapy; gene; ss.
OS Homo sapiens.
XX US2003049778-A1.
PN 13-MAR-2003.
PD 24-JUL-2002; 2002US-00205504.
XX 28-OCT-1998; 98US-0106178P.
PF 01-SEP-1999; 99WO-US020111.
XX 18-OCT-1999; 99US-00403297.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-567066/53.
DR P-PSDB; ABR86979.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for the manufacture of a medicament for diagnosing or treating tumor or
PT for tissue typing.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABR86895-ABR87199) and nucleic acids encoding them (ACF08486-ACF08790).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of antisense RNA and DNA and in gene
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF08486-ACF08790 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACCTCTTTCCTTTTATCTTATTATAAAAAATGTTGGTCTCCACCACCTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCTTCCCCATCTCTGTACACATTTTATAATAAAGGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAAAAAA AA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 508
ACF31371
ID ACF31371 standard; cDNA; 2846 BP.
XX AC ACF31371;
XX 24-SEP-2003 (first entry)
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnetary; gene therapy; gene; ss.
XX Homo sapiens.
OS US2003049782-A1.
XX 13-MAR-2003.
PF 26-JUL-2002; 2002US-00205900.
XX 03-MAR-2000; 2000US-0187202P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-576294/54.
DR P-PSDB; ABM11021.
XX New PRO nucleic acid, useful for the manufacture of a medicament for
PT diagnosing or treating tumor or for tissue typing.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM10937-ABM11241) and nucleic acids encoding them (ACF31287-ACF31591).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 510
ACD50080
ID ACD50080 standard; cDNA; 2846 BP.
XX AC
AC ACD50080;
XX
DT 05-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003068733-A1.
XX
PD 10-APR-2003.
XX
PF 22-JUL-2002; 2002US-00201321.
XX
PR 03-NOV-1998; 98US-0106902P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 28-FEB-2001; 2001WO-US0006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-605922/57.
DR P-PSDB; ABO32164.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
PT PRO827, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGCCTTACCACCTCTTCTTTTATCTTATTATAAAAAATGTTGGTCTCCACCACCTG 2180
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAATAAGGTTGGCTTCTGAACATA 2712
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2181 NCTCCAAAAA AA 2240
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2713 CAAAAA AA 2772
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 511
ACF38783
ID ACF38783 standard; cDNA; 2846 BP.
XX
AC ACF38783;
XX
DT 08-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulneryary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003068692-A1.
XX
PD 10-APR-2003.
XX
PF 09-JUL-2002; 2002US-00192006.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 28-FEB-2001; 2001WO-US0006520.
PR 15-JAN-2002; 2002US-00052586.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-615872/58.
DR P-PSDB; ABM15291.
XX
PT New PRO nucleic acid, useful for the manufacture of a medicament for
PT diagnosing or treating tumor or for tissue typing.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM14902-ABM15206) and nucleic acids encoding them (ACF38392-ACF38696).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using

RESULT 513
ACF24798
XX ACF24798 standard; cDNA; 2846 BP.
AC ACF24798;
XX
DT 01-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003068716-A1.
XX
PD 10-APR-2003.
XX
PF 17-JUL-2002; 2002US-00197711.
XX
PR 21-OCT-1997; 97US-0063486P.
PR 16-SEP-1998; 98WO-US019330.
PR 25-AUG-1999; 99US-00380139.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-615883/58.
DR P-PSDB; ABM04257.
XX
PT New PRO nucleic acid, useful for the manufacture of a medicament for
PT diagnosing or treating tumor or for tissue typing.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM04173-ABM04477) and nucleic acids encoding them (ACF24714-ACF25018).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are

CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF24714-ACF25018 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGTCTTTACCACTCTTCTCTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCCTTCCCCATCTCTGTGTACACATTTTAATAAAATGTTGGTCTCTGAACTA 2712
QY 2181 NCTCCCAA 2240
Db 2713 CAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 514
ACF46378
ID ACF46378 standard; cDNA; 2846 BP.
XX
AC ACF46378;
XX
DT 09-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003068740-A1.
XX
PD 10-APR-2003.
XX
PF 22-JUL-2002; 2002US-00201771.
XX
PR 26-AUG-1998; 98US-0097955P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-615892/58.
DR P-PSDB; ABM22370.
XX
PT New isolated nucleic acid encoding a secreted and transmembrane PRO


```
XX
SQ      Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
      Query Match          3.0%; Score 66.6; DB 9; Length 2846;
      Best Local Similarity 71.3%; Pred. No. 0.00023;
      Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY      2121 CCITTCGTTTACCACACTCTTTCCITTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      2653 CCITTTCTCTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712

QY      2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY      2241 AA 2242
      ||
Db      2773 AA 2774

RESULT 516
ACD89230
ID      ACD89230 standard; cDNA; 2846 BP.
XX
AC      ACD89230;
XX
DT      09-OCT-2003 (first entry)
XX
DE      Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW      Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW      tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW      tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW      prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS      Homo sapiens.
XX
PN      US2003068684-A1.
XX
PD      10-APR-2003.
XX
PF      28-JUN-2002; 2002US-00184634.
XX
PR      26-JUN-1998; 98US-00105413.
PR      16-SEP-1998; 98WO-US019330.
PR      07-OCT-1998; 98US-00168978.
PR      07-OCT-1998; 98WO-US021141.
PR      06-NOV-1998; 98US-00187368.
PR      01-DEC-1998; 98WO-US025108.
PR      07-DEC-1998; 98US-00202054.
PR      03-MAR-1999; 99US-00254311.
PR      08-MAR-1999; 99WO-US005028.
PR      14-MAY-1999; 99US-00311832.
PR      14-MAY-1999; 99WO-US010733.
PR      02-JUN-1999; 99WO-US012252.
PR      25-AUG-1999; 99US-00380137.
PR      25-AUG-1999; 99US-00380138.
PR      25-AUG-1999; 99US-00380139.
PR      25-AUG-1999; 99US-00380142.
PR      01-SEP-1999; 99WO-US020111.
PR      15-SEP-1999; 99WO-US021090.
PR      18-OCT-1999; 99US-00403297.
PR      12-NOV-1999; 99US-00423844.
PR      01-DEC-1999; 99WO-US028301.
PR      02-DEC-1999; 99WO-US028551.
PR      30-DEC-1999; 99WO-US031274.
PR      05-JAN-2000; 2000WO-US000219.
PR      18-FEB-2000; 2000WO-US004341.
PR      18-FEB-2000; 2000WO-US004342.
PR      22-FEB-2000; 2000WO-US004414.
PR      24-FEB-2000; 2000WO-US005004.
PR      01-MAR-2000; 2000WO-US005601.
PR      02-MAR-2000; 2000WO-US005841.
```

```
PR      15-MAR-2000; 2000WO-US006884.
PR      30-MAR-2000; 2000WO-US008439.
PR      17-MAY-2000; 2000WO-US013705.
PR      22-MAY-2000; 2000WO-US014042.
PR      30-MAY-2000; 2000WO-US014941.
PR      02-JUN-2000; 2000WO-US015264.
PR      28-JUL-2000; 2000WO-US020710.
PR      22-AUG-2000; 2000US-00644848.
PR      24-AUG-2000; 2000WO-US023328.
PR      18-SEP-2000; 2000US-00664610.
PR      18-SEP-2000; 2000US-00665350.
PR      08-NOV-2000; 2000US-00709238.
PR      08-NOV-2000; 2000WO-US030952.
PR      01-DEC-2000; 2000WO-US032678.
PR      20-DEC-2000; 2000US-00747259.
PR      20-DEC-2000; 2000WO-US034956.
PR      28-FEB-2001; 2001WO-US006520.
PR      22-MAR-2001; 2001US-00816744.
PR      10-MAY-2001; 2001US-00854208.
PR      10-MAY-2001; 2001US-00854280.
PR      25-MAY-2001; 2001US-00866028.
PR      01-JUN-2001; 2001WO-US017800.
PR      05-JUN-2001; 2001US-00874503.
PR      20-JUN-2001; 2001WO-US019692.
PR      29-JUN-2001; 2001WO-US021066.
PR      09-JUL-2001; 2001WO-US021735.
PR      18-JUL-2001; 2001US-00908827.
PR      30-JUL-2001; 2001US-00918585.
PR      06-AUG-2001; 2001US-00924419.
PR      13-AUG-2001; 2001US-00929404.
PR      16-AUG-2001; 2001US-00931836.
PR      28-AUG-2001; 2001US-00941992.
PR      29-AUG-2001; 2001WO-US027099.
PR      04-SEP-2001; 2001US-00946374.
PR      15-JAN-2002; 2002US-00052586.
XX
PA      (GETH ) GENENTECH INC.
XX
PI      Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI      Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR      WPI; 2003-625460/59.
DR      P-PSDB; ABO40756.
XX
PT      New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT      manufacture of a medicament for diagnosing or treating tumors or for
PT      tissue typing.
XX
PS      Claim 2; Fig 169; 706pp; English.
XX
CC      The invention discloses human nucleic acids encoding secreted and
CC      transmembrane (PRO) polypeptides, with or without their associated signal
CC      peptide. Also disclosed is an antibody that specifically binds to the PRO
CC      polypeptide, a method for stimulating the release of tumour necrosis
CC      factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC      PRO polypeptide, a method for stimulating the proliferation or
CC      differentiation of chondrocyte cells by contacting the cells with a PRO
CC      polypeptide, a method for detecting the presence of a tumour in a mammal
CC      and an oligonucleotide probe derived from any of the PRO nucleotide
CC      sequences. The nucleotide sequences are useful as probes, in chromosome
CC      and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC      polypeptides by recombinant techniques and in gene therapy (e.g. for
CC      replacement of defective gene). The PRO polypeptides are useful as
CC      molecular weight markers for protein electrophoresis purposes, for
CC      chromosome identification, as chromosome markers, as therapeutic agents,
CC      for stimulating the release of TNF-alpha from human blood, for
CC      stimulating the proliferation or differentiation of chondrocytes and
CC      detecting the presence, prevention and/or treatment of a tumour, such as
CC      adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC      The PRO polypeptides and nucleic acids may also be used diagnostically
CC      for tissue typing. The sequence presented is a cDNA encoding one of the
CC      PRO polypeptides of the invention. Note: The sequence data for this
CC      patent can also be obtained in electronic format directly from USPTO at
```



```
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCTCTTATCTTATTAATAAATAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 517
ACF63802
ID ACF63802 standard; cDNA; 2846 BP.
XX
AC ACF63802;
XX
DT 10-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003073179-A1.
XX
PD 17-APR-2003.
XX
PF 19-JUL-2002; 2002US-00199302.
XX
PR 24-JUN-1998; 98US-0090461P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-657646/62.
DR P-PSDB; ABM35403.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
PT useful for diagnosing or treating tumors.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC and nucleic acids encoding them, the invention also provides recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
```

```
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. The present sequence appears in the
CC exemplification of the specification. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCTCTTATCTTATTAATAAATAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 518
ACF60442
ID ACF60442 standard; cDNA; 2846 BP.
XX
AC ACF60442;
XX
DT 10-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003087374-A1.
XX
PD 08-MAY-2003.
```

XX			
PF	21-JUN-2002;	2002US-00176979.	
XX	18-SEP-1997;	97US-0059263P.	
PR	18-SEP-1997;	97US-0059266P.	
PR	17-OCT-1997;	97US-0062250P.	
PR	21-OCT-1997;	97US-0063486P.	
PR	24-OCT-1997;	97US-0063120P.	
PR	24-OCT-1997;	97US-0063121P.	
PR	28-OCT-1997;	97US-0063540P.	
PR	28-OCT-1997;	97US-0063541P.	
PR	28-OCT-1997;	97US-0063544P.	
PR	28-OCT-1997;	97US-0063564P.	
PR	29-OCT-1997;	97US-0063734P.	
PR	31-OCT-1997;	97US-0063870P.	
PR	31-OCT-1997;	97US-0064103P.	
PR	13-NOV-1997;	97US-0065311P.	
PR	21-NOV-1997;	97US-0066120P.	
PR	24-NOV-1997;	97US-0066466P.	
PR	24-NOV-1997;	97US-0066772P.	
PR	11-DEC-1997;	97US-0069335P.	
PR	12-DEC-1997;	97US-0069425P.	
PR	17-DEC-1997;	97US-0069870P.	
PR	18-DEC-1997;	97US-0068017P.	
PR	10-MAR-1998;	98US-0077450P.	
PR	11-MAR-1998;	98US-0077632P.	
PR	11-MAR-1998;	98US-0077649P.	
PR	20-MAR-1998;	98US-0078886P.	
PR	20-MAR-1998;	98US-0078939P.	
PR	27-MAR-1998;	98US-0079664P.	
PR	27-MAR-1998;	98US-0079786P.	
PR	31-MAR-1998;	98US-0080107P.	
PR	31-MAR-1998;	98US-0080194P.	
PR	01-APR-1998;	98US-0080327P.	
PR	01-APR-1998;	98US-0080333P.	
PR	08-APR-1998;	98US-0081049P.	
PR	08-APR-1998;	98US-0081070P.	
PR	09-APR-1998;	98US-0081195P.	
PR	15-APR-1998;	98US-0081838P.	
PR	21-APR-1998;	98US-0082568P.	
PR	21-APR-1998;	98US-0082569P.	
PR	22-APR-1998;	98US-0082704P.	
PR	22-APR-1998;	98US-0082797P.	
PR	28-APR-1998;	98US-0083322P.	
PR	29-APR-1998;	98US-0083495P.	
PR	29-APR-1998;	98US-0083496P.	
PR	29-APR-1998;	98US-0083499P.	
PR	29-APR-1998;	98US-0083559P.	
PR	05-MAY-1998;	98US-0084366P.	
PR	06-MAY-1998;	98US-0084414P.	
PR	07-MAY-1998;	98US-0084639P.	
PR	07-MAY-1998;	98US-0084640P.	
PR	15-MAY-1998;	98US-0085579P.	
PR	15-MAY-1998;	98US-0085580P.	
PR	15-MAY-1998;	98US-0085582P.	
PR	15-MAY-1998;	98US-0085700P.	
PR	18-MAY-1998;	98US-0086023P.	
PR	22-MAY-1998;	98US-0086392P.	
PR	22-MAY-1998;	98US-0086486P.	
PR	28-MAY-1998;	98US-0087098P.	
PR	28-MAY-1998;	98US-0087208P.	
PR	02-JUN-1998;	98US-0087609P.	
PR	02-JUN-1998;	98US-0087759P.	
PR	03-JUN-1998;	98US-0087827P.	
PR	04-JUN-1998;	98US-0088025P.	
PR	04-JUN-1998;	98US-0088028P.	
PR	04-JUN-1998;	98US-0088029P.	
PR	04-JUN-1998;	98US-0088033P.	
PR	04-JUN-1998;	98US-0088326P.	
PR	05-JUN-1998;	98US-0088167P.	
PR	05-JUN-1998;	98US-0088202P.	
PR	05-JUN-1998;	98US-0088212P.	
PR	05-JUN-1998;	98US-0088217P.	
PR	09-JUN-1998;	98US-0089598P.	
PR	18-JUN-1998;	98US-0089598P.	
PR	17-JUN-1998;	98US-0089653P.	
PR	18-JUN-1998;	98US-0089908P.	
PR	19-JUN-1998;	98US-0089952P.	
PR	22-JUN-1998;	98US-0090246P.	
PR	22-JUN-1998;	98US-0090252P.	
PR	22-JUN-1998;	98US-0090254P.	
PR	24-JUN-1998;	98US-0090429P.	
PR	24-JUN-1998;	98US-0090435P.	
PR	24-JUN-1998;	98US-0090444P.	
PR	24-JUN-1998;	98US-0090461P.	
PR	24-JUN-1998;	98US-0090535P.	
PR	24-JUN-1998;	98US-0090540P.	
PR	25-JUN-1998;	98US-0090676P.	
PR	25-JUN-1998;	98US-0090678P.	
PR	25-JUN-1998;	98US-0090688P.	
PR	25-JUN-1998;	98US-0090690P.	
PR	25-JUN-1998;	98US-0090694P.	
PR	25-JUN-1998;	98US-0090695P.	
PR	25-JUN-1998;	98US-0090696P.	
PR	26-JUN-1998;	98US-00105413.	
PR	26-JUN-1998;	98US-0090862P.	
PR	26-JUN-1998;	98US-0090863P.	
PR	26-JUN-1998;	98US-0091010P.	
PR	01-JUL-1998;	98US-0091359P.	
PR	01-JUL-1998;	98US-0091544P.	
PR	02-JUL-1998;	98US-0091478P.	
PR	02-JUL-1998;	98US-0091486P.	
PR	02-JUL-1998;	98US-0091626P.	
PR	02-JUL-1998;	98US-0091628P.	
PR	02-JUL-1998;	98US-0091632P.	
PR	24-JUL-1998;	98US-0094006P.	
PR	04-AUG-1998;	98US-0095282P.	
PR	10-AUG-1998;	98US-0095998P.	
PR	10-AUG-1998;	98US-0096012P.	
PR	17-AUG-1998;	98US-0096757P.	
PR	17-AUG-1998;	98US-0096766P.	
PR	17-AUG-1998;	98US-0096867P.	
PR	17-AUG-1998;	98US-0096891P.	
PR	17-AUG-1998;	98US-0096897P.	
PR	18-AUG-1998;	98US-0096949P.	
PR	18-AUG-1998;	98US-0096959P.	
PR	18-AUG-1998;	98US-0097022P.	
PR	26-AUG-1998;	98US-0097952P.	
PR	26-AUG-1998;	98US-0097954P.	
PR	26-AUG-1998;	98US-0097955P.	
PR	26-AUG-1998;	98US-0097971P.	
PR	26-AUG-1998;	98US-0097974P.	
PR	26-AUG-1998;	98US-0098014P.	
PR	01-SEP-1998;	98US-0098716P.	
PR	01-SEP-1998;	98US-0098723P.	
PR	02-SEP-1998;	98US-0098803P.	
PR	02-SEP-1998;	98US-0098821P.	
PR	02-SEP-1998;	98US-0098843P.	
PR	09-SEP-1998;	98US-0099602P.	
PR	10-SEP-1998;	98US-0099741P.	
PR	10-SEP-1998;	98US-0099754P.	


```
XX 11-APR-2000; 2000US-0196820P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-669851/63.
DR P-PSDB; ABO50252.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for the manufacture of a medicament for diagnosing or treating tumor or
PT for tissue typing.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTATAATAATGTTGGTCTCCACCACTG 2180
      ||||| | || | || | || | || | || | || | || | || | || | || | || |
Db 2653 CCTTTTCCTTCCCATCTCTTGACACATTTTAATAATAAGGGTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
      ||
Db 2773 AA 2774

RESULT 521
ACD03844
ID ACD03844 standard; cDNA; 2846 BP.
XX
AC ACD03844;
XX
DT 08-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
```

```
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003040055-A1.
XX
PD 27-FEB-2003.
XX
PF 21-JUN-2002; 2002US-00176748.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
```

PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.

PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY	2121	CCTTTGCTTTACCACTCTTTCCTTTTATCTTATTATAAAATGTTGGTCTCCACCAC	TG	2180
Db	2653	CCTTTTCCTTCCCATCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGAAC	TA	2712
QY	2181	NCTCCCAA	AAAA	2240
Db	2713	CAAA	AAAA	2772
QY	2241	AA	2242	
Db	2773	AA	2774	

RESULT 522

ACD10382; ID ACD10382 standard; cDNA; 2846 BP.

XX ACD10382;

XX 12-AUG-2003 (first entry)

DE Human secreted/transmembrane protein (PRO) cDNA #85.

XX	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;	PR	02-JUN-1998;	98US-0087609P.
KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;	PR	02-JUN-1998;	98US-0087759P.
KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;	PR	03-JUN-1998;	98US-0087827P.
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.	PR	04-JUN-1998;	98US-0088025P.
XX		PR	04-JUN-1998;	98US-0088028P.
OS	Homo sapiens.	PR	04-JUN-1998;	98US-0088029P.
XX		PR	04-JUN-1998;	98US-0088033P.
PN	US2003036164-A1.	PR	04-JUN-1998;	98US-0088326P.
XX		PR	05-JUN-1998;	98US-0088167P.
PD		PR	05-JUN-1998;	98US-0088202P.
XX		PR	05-JUN-1998;	98US-0088212P.
PF	15-JUL-2002; 2002US-00195897.	PR	05-JUN-1998;	98US-0088217P.
XX		PR	09-JUN-1998;	98US-0088655P.
PR	18-SEP-1997; 97US-0059263P.	PR	10-JUN-1998;	98US-0088722P.
PR	18-SEP-1997; 97US-0059266P.	PR	10-JUN-1998;	98US-0088738P.
PR	17-OCT-1997; 97US-0062250P.	PR	10-JUN-1998;	98US-0088740P.
PR	21-OCT-1997; 97US-0063486P.	PR	10-JUN-1998;	98US-0088811P.
PR	24-OCT-1997; 97US-0063120P.	PR	10-JUN-1998;	98US-0088824P.
PR	24-OCT-1997; 97US-0063121P.	PR	10-JUN-1998;	98US-0088825P.
PR	28-OCT-1997; 97US-0063540P.	PR	10-JUN-1998;	98US-0088826P.
PR	28-OCT-1997; 97US-0063541P.	PR	11-JUN-1998;	98US-0088861P.
PR	28-OCT-1997; 97US-0063544P.	PR	11-JUN-1998;	98US-0088863P.
PR	28-OCT-1997; 97US-0063564P.	PR	11-JUN-1998;	98US-0088876P.
PR	29-OCT-1997; 97US-0063734P.	PR	12-JUN-1998;	98US-0089090P.
PR	31-OCT-1997; 97US-0063870P.	PR	12-JUN-1998;	98US-0089105P.
PR	31-OCT-1997; 97US-0064103P.	PR	16-JUN-1998;	98US-0089512P.
PR	13-NOV-1997; 97US-0065311P.	PR	16-JUN-1998;	98US-0089514P.
PR	21-NOV-1997; 97US-0066120P.	PR	17-JUN-1998;	98US-0089538P.
PR	24-NOV-1997; 97US-0066466P.	PR	17-JUN-1998;	98US-0089598P.
PR	24-NOV-1997; 97US-0066772P.	PR	17-JUN-1998;	98US-0089653P.
PR	11-DEC-1997; 97US-0069335P.	PR	18-JUN-1998;	98US-0089908P.
PR	12-DEC-1997; 97US-0069425P.	PR	19-JUN-1998;	98US-0089952P.
PR	17-DEC-1997; 97US-0069870P.	PR	22-JUN-1998;	98US-0090246P.
PR	18-DEC-1997; 97US-0068017P.	PR	22-JUN-1998;	98US-0090252P.
PR	10-MAR-1998; 98US-0077450P.	PR	22-JUN-1998;	98US-0090254P.
PR	11-MAR-1998; 98US-0077632P.	PR	24-JUN-1998;	98US-0090429P.
PR	11-MAR-1998; 98US-0077649P.	PR	24-JUN-1998;	98US-0090435P.
PR	20-MAR-1998; 98US-0078886P.	PR	24-JUN-1998;	98US-0090444P.
PR	20-MAR-1998; 98US-0078939P.	PR	24-JUN-1998;	98US-0090461P.
PR	27-MAR-1998; 98US-0079664P.	PR	24-JUN-1998;	98US-0090535P.
PR	27-MAR-1998; 98US-0079786P.	PR	24-JUN-1998;	98US-0090540P.
PR	31-MAR-1998; 98US-0080107P.	PR	25-JUN-1998;	98US-0090676P.
PR	31-MAR-1998; 98US-0080194P.	PR	25-JUN-1998;	98US-0090678P.
PR	01-APR-1998; 98US-0080327P.	PR	25-JUN-1998;	98US-0090688P.
PR	01-APR-1998; 98US-0080333P.	PR	25-JUN-1998;	98US-0090690P.
PR	08-APR-1998; 98US-0081049P.	PR	25-JUN-1998;	98US-0090694P.
PR	08-APR-1998; 98US-0081070P.	PR	25-JUN-1998;	98US-0090695P.
PR	09-APR-1998; 98US-0081195P.	PR	25-JUN-1998;	98US-0090696P.
PR	15-APR-1998; 98US-0081838P.	PR	26-JUN-1998;	98US-00105413.
PR	21-APR-1998; 98US-0082568P.	PR	26-JUN-1998;	98US-0090862P.
PR	21-APR-1998; 98US-0082569P.	PR	26-JUN-1998;	98US-0090863P.
PR	22-APR-1998; 98US-0082704P.	PR	26-JUN-1998;	98US-0091010P.
PR	28-APR-1998; 98US-0083222P.	PR	01-JUL-1998;	98US-0091359P.
PR	29-APR-1998; 98US-0083495P.	PR	01-JUL-1998;	98US-0091544P.
PR	29-APR-1998; 98US-0083496P.	PR	02-JUL-1998;	98US-0091478P.
PR	29-APR-1998; 98US-0083499P.	PR	02-JUL-1998;	98US-0091486P.
PR	29-APR-1998; 98US-0083559P.	PR	02-JUL-1998;	98US-0091626P.
PR	05-MAY-1998; 98US-0084366P.	PR	02-JUL-1998;	98US-0091632P.
PR	06-MAY-1998; 98US-0084414P.	PR	24-JUL-1998;	98US-0094006P.
PR	07-MAY-1998; 98US-0084639P.	PR	04-AUG-1998;	98US-0095282P.
PR	07-MAY-1998; 98US-0084640P.	PR	10-AUG-1998;	98US-0095998P.
PR	07-MAY-1998; 98US-0084643P.	PR	10-AUG-1998;	98US-0096012P.
PR	15-MAY-1998; 98US-0085579P.	PR	17-AUG-1998;	98US-0096757P.
PR	15-MAY-1998; 98US-0085580P.	PR	17-AUG-1998;	98US-0096766P.
PR	15-MAY-1998; 98US-0085700P.	PR	17-AUG-1998;	98US-0096891P.
PR	18-MAY-1998; 98US-0086023P.	PR	17-AUG-1998;	98US-0096897P.
PR	22-MAY-1998; 98US-0086392P.	PR	18-AUG-1998;	98US-0096949P.
PR	22-MAY-1998; 98US-0086486P.	PR	18-AUG-1998;	98US-0096959P.
PR	28-MAY-1998; 98US-0087098P.	PR	18-AUG-1998;	98US-0097022P.
PR	28-MAY-1998; 98US-0087208P.	PR	26-AUG-1998;	98US-0097952P.
		PR	26-AUG-1998;	98US-0097954P.

PR	02-JUN-1998;	98US-0087609P;
PR	02-JUN-1998;	98US-0087759P;
PR	03-JUN-1998;	98US-0087827P;
PR	04-JUN-1998;	98US-0088025P;
PR	04-JUN-1998;	98US-0088028P;
PR	04-JUN-1998;	98US-0088029P;
PR	04-JUN-1998;	98US-0088033P;
PR	04-JUN-1998;	98US-0088326P;
PR	05-JUN-1998;	98US-0088167P;
PR	05-JUN-1998;	98US-0088202P;
PR	05-JUN-1998;	98US-0088212P;
PR	05-JUN-1998;	98US-0088217P;
PR	09-JUN-1998;	98US-0088655P;
PR	10-JUN-1998;	98US-0088722P;
PR	10-JUN-1998;	98US-0088738P;
PR	10-JUN-1998;	98US-0088740P;
PR	10-JUN-1998;	98US-0088811P;
PR	10-JUN-1998;	98US-0088824P;
PR	10-JUN-1998;	98US-0088825P;
PR	10-JUN-1998;	98US-0088826P;
PR	11-JUN-1998;	98US-0088861P;
PR	11-JUN-1998;	98US-0088863P;
PR	11-JUN-1998;	98US-0088876P;
PR	12-JUN-1998;	98US-0089090P;
PR	12-JUN-1998;	98US-0089105P;
PR	16-JUN-1998;	98US-0089512P;
PR	16-JUN-1998;	98US-0089514P;
PR	17-JUN-1998;	98US-0089538P;
PR	17-JUN-1998;	98US-0089598P;
PR	17-JUN-1998;	98US-0089653P;
PR	18-JUN-1998;	98US-0089908P;
PR	19-JUN-1998;	98US-0089952P;
PR	22-JUN-1998;	98US-0090246P;
PR	22-JUN-1998;	98US-0090252P;
PR	22-JUN-1998;	98US-0090254P;
PR	24-JUN-1998;	98US-0090429P;
PR	24-JUN-1998;	98US-0090435P;
PR	24-JUN-1998;	98US-0090444P;
PR	24-JUN-1998;	98US-0090461P;
PR	24-JUN-1998;	98US-0090535P;
PR	24-JUN-1998;	98US-0090540P;
PR	25-JUN-1998;	98US-0090676P;
PR	25-JUN-1998;	98US-0090678P;
PR	25-JUN-1998;	98US-0090688P;
PR	25-JUN-1998;	98US-0090690P;
PR	25-JUN-1998;	98US-0090694P;
PR	25-JUN-1998;	98US-0090695P;
PR	25-JUN-1998;	98US-0090696P;
PR	26-JUN-1998;	98US-00105413;
PR	26-JUN-1998;	98US-0090862P;
PR	26-JUN-1998;	98US-0090863P;
PR	26-JUN-1998;	98US-0091010P;
PR	01-JUL-1998;	98US-0091359P;
PR	01-JUL-1998;	98US-0091544P;
PR	02-JUL-1998;	98US-0091478P;
PR	02-JUL-1998;	98US-0091486P;
PR	02-JUL-1998;	98US-0091626P;
PR	02-JUL-1998;	98US-0091628P;
PR	02-JUL-1998;	98US-0091632P;
PR	24-JUL-1998;	98US-0094006P;
PR	04-AUG-1998;	98US-0095282P;
PR	10-AUG-1998;	98US-0095998P;
PR	10-AUG-1998;	98US-0096012P;
PR	17-AUG-1998;	98US-0096757P;
PR	17-AUG-1998;	98US-0096766P;
PR	17-AUG-1998;	98US-0096867P;
PR	17-AUG-1998;	98US-0096891P;
PR	17-AUG-1998;	98US-0096897P;
PR	18-AUG-1998;	98US-0096949P;
PR	18-AUG-1998;	98US-0096959P;
PR	18-AUG-1998;	98US-0097022P;
PR	26-AUG-1998;	98US-0097952P;
PR	26-AUG-1998;	98US-0097954P;

PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.
PR	07-OCT-1998;	98US-00168978.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches	87;	Conservative	0;	Mismatches	35;	Indels	0;	Gaps	0;
---------	-----	--------------	----	------------	-----	--------	----	------	----

[illegible]

Ov 2241 AA 2242

$$=$$

RESULT 524
ACF42409
ID ACF42409 standard; cDNA; 2846 BP.
XX
XX ACF42409;
XX AC
DT 06-NOV-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX Human; PRO; secreted protein; transmembrane protein;

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; proliferation; differentiation; cartilage disorder;

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; drug screening; transgenic animal; genetic analysis;

KW antiarthritic; vulnery; gene therapy; gene; ss.

XX Homo sapiens.

OS US2003054480-A1.

XX 20-MAR-2003.

XX 24-JUL-2002; 2002US-00205507.

XX 22-MAY-1998; 98US-0086392P.

PR 08-MAR-1999; 99WO-US005028.

PR 25-AUG-1999; 99US-00380138.

PR 18-FEB-2000; 2000WO-US004341.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

PI WPI; 2003-503632/47.

DR P-PSDB; ABM18468.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful

PT in gene therapy, or for preparing a medicament for treating a condition

PT that is responsive to the PRO polypeptide or anti-PRO antibody.

XX Claim 2; Fig 169; 699pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides

CC and nucleic acids encoding them, the invention also provides recombinant

CC vectors and host cells comprising a PRO nucleic acid, a method for the

CC recombinant production of a PRO polypeptide, antibodies against a PRO

CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic

CC acids encoding PRO polypeptides of the invention were initially

CC identified via homology screening using consensus sequences based on the

CC extracellular domain sequences from known secreted proteins. Human cDNA

CC libraries containing sequences of interest were identified using

CC oligonucleotides based on the consensus sequences, and cDNA clones were

CC isolated and characterised. The PRO polypeptides are useful for

CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from

CC human blood and may thus be used in the treatment of conditions in which

CC enhanced TNF-alpha release would be beneficial. They are also useful for

CC stimulating the proliferation or differentiation of chondrocytes and as

CC such may be used in the treatment of various bone and/or cartilage

CC disorders such as arthritis and sports injuries. The PRO polypeptides may

CC be used in a method for detecting the presence of a tumour (e.g., an

CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate

CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This

CC method involves comparing the level of expression of the PRO polypeptide

CC in test and control samples, where a higher level of expression of PRO

CC polypeptide in the test sample as compared to the control sample is

CC indicative of the presence of a tumour. The PRO polypeptides are

CC additionally useful for in drug screening to identify agonists and

CC antagonists of PRO polypeptides. PRO nucleic acids are useful as

CC hybridisation probes (for isolation of antisense RNA and DNA and in gene

CC gene mapping, in the generation of antisense RNA and DNA and in gene

CC therapy. The nucleic acids can also be used for mapping genes encoding

CC PRO polypeptides, for genetic analysis of individuals with genetic

CC disorders, and for generating either transgenic animals or knock-out

CC animals which are useful in the development and screening of

CC therapeutically useful compounds. The present sequence appears in the

CC exemplification of the specification. Note: The sequence data for this

CC patent is also available in electronic format from USPTO at

CC seqdata.uspto.gov/sequence.html

XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180

Db 2653 CCTTTTCTTCCCATCTCTTGACACATTTAATAAATAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 525

ADA27866

ID ADA27866 standard; cDNA; 2846 BP.

XX AC ADA27866;

XX DT 20-NOV-2003 (first entry)

XX Human cDNA encoding secreted/transmembrane protein PRO1344.

DE PRO; secreted protein; transmembrane protein;

XX hypetrophy of neonatal heart; angiogenesis;

KW vascular endothelial growth factor; VEGF-stimulated proliferation;

KW endothelial cell; T-lymphocyte proliferation; retinal neuron;

KW rod photoreceptor cell; c-fos induction; adipocyte cell;

XX chondrocyte differentiation;

KW pancreatic beta-cell precursor differentiation;

KW cardiac insufficiency disorder; wound; cancerous tumour;

KW retinal disorders; loss of sight; retinitis pigmentosum; kidney disorder;

KW obesity; diabetes; hyperinsulinaemia; hypoinsulinaemia; bone disorder;

KW cartilage disorder; sports injury; arthritis; cancer; human; ss; gene.

XX Homo sapiens.

XX US2003054359-A1.

XX 20-MAR-2003.

XX 14-NOV-2001; 2001US-00990726.

XX 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.

PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.

CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF21644-ACF21948 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCTCTTTTATCTTATTATAAAATGTTGGTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCTCCCATCTCTTGTTACACATTTTATAAAATAAGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAA 2772

QY 2241 AA 2242
Db ||
2773 AA 2774

RESULT 529
ACF10412
ID ACF10412 standard; cDNA; 2846 BP.

XX AC
AC ACF10412;
XX
DT 06-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.

OS Homo sapiens.

XX US2003073169-A1.

PN 17-APR-2003.

XX 17-JUN-2002; 2002US-00173693.

PF 18-SEP-1997; 97US-0059263P.

XX 18-SEP-1997; 97US-0059266P.

PR 17-OCT-1997; 97US-0062250P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063120P.

PR 28-OCT-1997; 97US-0063121P.

PR 28-OCT-1997; 97US-0063540P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.

PRO polypeptide, a method for stimulating the proliferation or differentiation of chondrocyte cells by contacting the cells with a PRO polypeptide, a method for detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the PRO nucleotide sequences. The nucleotide sequences are useful as probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant techniques and in gene therapy (e.g. for replacement of defective gene). The PRO polypeptides are useful as molecular weight markers for protein electrophoresis purposes, for chromosome identification, as chromosome markers, as therapeutic agents, for stimulating the release of TNF-alpha from human blood, for stimulating the proliferation or differentiation of chondrocytes and detecting the presence, prevention and/or treatment of a tumour, such as adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour. The PRO polypeptides and nucleic acids may also be used diagnostically for tissue typing. The sequence presented is a cDNA encoding one of the PRO polypeptides of the invention. Note: The sequence data for this patent can also be obtained in electronic format directly from USPTO at seqdata.uspto.gov/sequence.html

```

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY      2121 CCTTTGGCTTACCACACTCTTTCCCTTTATCTATTATAAATAAGTTGGTCTCCACCACTG 2180
        ||||| | || || || || | | || | | | | | | | | | | | | | | |
Db       2653 CCTTTTCCTTCCCACATCTCTTGTAACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712
        ||||| | || || || || | | || | | | | | | | | | | | | | | |
QY      2181 NCTCCCCAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
        ||||| | || || || || || | | || | | | | | | | | | | | | | | |
Db       2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
        ||||| | || || || || || | | || | | | | | | | | | | | | | | |
QY      2241 AA 2242
        ||
Db       2773 AA 2774

RESULT 533
ACD91071
ID    ACD91071 standard; cDNA; 2846 BP.
XX
AC    ACD91071;
XX
DT    09-OCT-2003 (first entry)
XX
Human secreted/transmembrane protein (PRO) cDNA #85.

```

XX	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX	
OS	Homo sapiens.
XX	
PN	US2003049751-A1.
XX	
PD	13-MAR-2003.
XX	
PF	17-JUL-2002; 2002US-00197700.
XX	
PR	18-SEP-1997; 97US-0059266P.
PR	16-SEP-1998; 98WO-US019330.
PR	25-AUG-1999; 99US-00380139.
PR	28-FEB-2001; 2001WO-US006520.
PR	15-JAN-2002; 2002US-00052586.
XX	
PA	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX	

DR WPI; 2003-625419/59.
DR P-PSDB; ABO42586.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
PT in tissue typing, and in identifying chromosome.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGCTTTACCACCTCTTCTCTTTATCTTATTATAATAAATGTTGGTCTCCACCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCCTTCCCATCTCTGTACACATTTTATAATAAATAAGGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 534
ACF30382
ID ACF30382 standard; cDNA; 2846 BP.
XX
AC ACF30382;
XX
DT 20-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX Homo sapiens.
OS
XX

PN US2003067478-A1.
XX
PD 10-APR-2003.
XX
PF 16-JUL-2002; 2002US-00196754.
XX
PR 21-MAR-2000; 2000US-0190828P.
PR 28-FEB-2001; 2001WO-US0006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-625450/59.
DR P-PSDB; ABM10106.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for stimulating the release of tumor necrosis factor alpha from human
PT blood and for stimulating the proliferation or differentiation of
PT chondrocyte cells.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM10022-ABM10326) and nucleic acids encoding them (ACF30298-ACF30602).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF30298-ACF30602 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACCTCTTCTCTTTATCTTATTATAATAAATGTTGGTCTCCACCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCATCTCTGTACACATTTTATAATAAATAAGGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 534
ACF30382
ID ACF30382 standard; cDNA; 2846 BP.
XX
AC ACF30382;
XX
DT 20-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX Homo sapiens.
OS
XX

```
QY      2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db      2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY      2241 AA 2242
Db      2773 AA 2774

RESULT 535
ACD87081
ID      ACD87081 standard; cDNA; 2846 BP.
XX
AC      ACD87081;
XX
DT      06-OCT-2003 (first entry)
XX
DE      Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW      Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW      tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW      tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW      prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS      Homo sapiens.
XX
PN      US2003068773-A1.
XX
PD      10-APR-2003.
XX
PF      29-JUL-2002; 2002US-00208023.
XX
PR      15-SEP-2000; 2000US-0232887P.
PR      28-FEB-2001; 2001WO-US006520.
PR      15-JAN-2002; 2002US-00052586.
XX
PA      (GETH ) GENENTECH INC.
XX
PI      Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI      Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR      WPI; 2003-625479/59.
DR      P-PSDB; ABO38621.
XX
PT      Novel isolated PRO polypeptides e.g. PRO1079, PRO827 and PRO791, useful
PT      for stimulating the release of TNF alpha from human blood and for
PT      stimulating the proliferation or differentiation of chondrocyte cells.
XX
PS      Claim 2; Fig 169; 700pp; English.
XX
CC      The invention discloses human nucleic acids encoding secreted and
CC      transmembrane (PRO) polypeptides, with or without their associated signal
CC      peptide. Also disclosed is an antibody that specifically binds to the PRO
CC      polypeptide, a method for stimulating the release of tumour necrosis
CC      factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC      PRO polypeptide, a method for stimulating the proliferation or
CC      differentiation of chondrocyte cells by contacting the cells with a PRO
CC      polypeptide, a method for detecting the presence of a tumour in a mammal
CC      and an oligonucleotide probe derived from any of the PRO nucleotide
CC      sequences. The nucleotide sequences are useful as probes, in chromosome
CC      and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC      polypeptides by recombinant techniques and in gene therapy (e.g. for
CC      replacement of defective gene). The PRO polypeptides are useful as
CC      molecular weight markers for protein electrophoresis purposes, for
CC      chromosome identification, as chromosome markers, as therapeutic agents,
CC      for stimulating the release of TNF-alpha from human blood, for
CC      stimulating the proliferation or differentiation of chondrocytes and
CC      detecting the presence, prevention and/or treatment of a tumour, such as
CC      adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC      The PRO polypeptides and nucleic acids may also be used diagnostically
CC      for tissue typing. The sequence presented is a cDNA encoding one of the
CC      PRO polypeptides of the invention. Note: The sequence data for this
```

```
CC      patent can also be obtained in electronic format directly from USPTO at
CC      seqdata.uspto.gov/sequence.html
XX
SQ      Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

      Query Match      3.0%; Score 66.6; DB 9; Length 2846;
      Best Local Similarity 71.3%; Pred. No. 0.00023;
      Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY      2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAAAATGTTGGTCTCCCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      2653 CCTTTCTCTCCCATCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAACATA 2712
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY      2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY      2241 AA 2242
Db      2773 AA 2774

RESULT 536
ACF60135
ID      ACF60135 standard; cDNA; 2846 BP.
XX
AC      ACF60135;
XX
DT      06-OCT-2003 (first entry)
XX
DE      Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW      Human; PRO; secreted protein; transmembrane protein;
KW      extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW      chondrocyte; proliferation; differentiation; cartilage disorder;
KW      bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW      adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW      liver; drug screening; transgenic animal; genetic analysis;
KW      antiarthritic; vulneryary; gene therapy; gene; ss.
XX
OS      Homo sapiens.
XX
PN      US2003073185-A1.
XX
PD      17-APR-2003.
XX
PF      29-JUL-2002; 2002US-00207924.
XX
PR      18-APR-2000; 2000US-0198585P.
PR      28-FEB-2001; 2001WO-US006520.
PR      15-JAN-2002; 2002US-00052586.
XX
PA      (GETH ) GENENTECH INC.
XX
PI      Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI      Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR      WPI; 2003-657649/62.
DR      P-PSDB; ABM32861.
XX
PT      Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT      for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
PT      useful diagnosing or treating tumors.
XX
PS      Claim 2; Fig 169; 700pp; English.
XX
CC      The invention relates to human PRO secreted/transmembrane polypeptides
CC      and nucleic acids encoding them, the invention also provides recombinant
CC      vectors and host cells comprising a PRO nucleic acid, a method for the
CC      recombinant production of a PRO polypeptide, antibodies against a PRO
CC      polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC      acids encoding PRO polypeptides of the invention were initially
CC      identified via homology screening using consensus sequences based on the
```


CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. The present sequence appears in the
CC exemplification of the specification. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC segdata.uspto.gov/sequence.html
XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTTACCACCTCTTCTCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACTG 2180
||||| ||||| ||||| || ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCTTCCCACTCTCTGTACACATTTTATAATAAATGTTGGTCTCTGAACATA 2712

QY 2181 NCTCCCAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 537
ACF46685
ID ACF46685 standard; cDNA; 2846 BP.
XX AC ACF46685;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003087373-A1.
XX
PD 08-MAY-2003.
XX

PF 20-JUN-2002; 2002US-00176491.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.

RESULT 539
ADA79713
ID ADA79713 standard; cDNA; 2846 BP.
XX
XX ADA79713;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour; tumour.
XX
OS Homo sapiens.
XX
PN US2003073173-A1.
XX
PD 17-APR-2003.
XX
PF 21-JUN-2002; 2002US-00176986.


```
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACCTCTTCTCTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACCTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTGTACACATTTTATAAAAAATAAGGTTGGTCTTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 541
ACF22956
ID ACF22956 standard; cDNA; 2846 BP.
XX AC ACF22956;
XX
DT 19-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulneryary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
```

```
PN US2003059886-A1.
XX 27-MAR-2003.
XX 25-JUL-2002; 2002US-00205897.
XX 05-JUN-2000; 2000US-0209832P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH ) GENENTECH INC.
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
PI WPI; 2003-555484/52.
XX P-PSDB; ABM02427.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM02343-ABM02647) and nucleic acids encoding them (ACF22872-ACF23176).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF22872-ACF23176 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACCTCTTCTCTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACCTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTGTACACATTTTATAAAAAATAAGGTTGGTCTTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 541
ACF22956
ID ACF22956 standard; cDNA; 2846 BP.
XX AC ACF22956;
XX
DT 19-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulneryary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
```

Qy 2181 NCTCCAAAAA 2240
Db 2713 CAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774
RESULT 542
ACF07956
ID ACF07956 standard; cDNA; 2846 BP.
XX
AC ACF07956;
XX
DT 06-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003049758-A1.
XX
PD 13-MAR-2003.
XX
PF 19-JUL-2002; 2002US-00199305.
XX
PR 10-JUN-1998; 98US-0088722P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanbe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-567064/53.
DR P-PSDB; ABR86369.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
PT colon, breast, prostate, rectal, cervical or liver tumors.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABR86285-ABR86589) and nucleic acids encoding them (ACF07872-ACF08176).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage

CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF07872-ACF08176 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy 2121 CCTTGTCTTACCACCTCTTCTCTTTATCTTATTAATAAATGTTGGTCTCCACCCTG 2180
Db 2653 CCTTTCCTTCCCATCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGAACCTA 2712
Qy 2181 NCTCCAAAAA 2240
Db 2713 CAAAAA 2772
Qy 2241 AA 2242
Db 2773 AA 2774
RESULT 543
ACF08263
ID ACF08263 standard; cDNA; 2846 BP.
XX
AC ACF08263;
XX
DT 06-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003049772-A1.
XX
PD 13-MAR-2003.
XX
PF 23-JUL-2002; 2002US-00202470.
XX
PR 14-OCT-1998; 98US-0104257P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.


```
CC therapeutically useful compounds. The present sequence appears in the
CC exemplification of the specification. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACCTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCATCTCTGTGACACATTTTAATAAAATAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
      ||
Db 2773 AA 2774

RESULT 545
ACF53746
ID ACF53746 standard; cDNA; 2846 BP.
XX
AC ACF53746;
XX
DT 10-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003064456-A1.
XX
PD 03-APR-2003.
XX
PF 19-JUL-2002; 2002US-00199304.
XX
PR 28-OCT-1998; 98US-0106029P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Deanoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-596620/56.
DR P-PSDB; ABM29690.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM29606-ABM29910) and nucleic acids encoding them (ACF53662-ACF53966).
CC The invention also relates to sequences at least 80% identical to the PRO
```


XX	US2003068742-A1.	2121	CCTTTGCTTTACCACTCTTTCTCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG	2180
PN				
XX		2653	CCTTTTCTCTCCCACTCTCTGTACACATTTTATAAAAAATAAGGGTTGGCTTCTGAACTA	2712
PD	10-APR-2003.			
XX	23-JUL-2002; 2002US-00202410.	2181	NCTCCAAAAA	2240
PR	17-SEP-1998; 98US-0100919P.	2713	CAAAAAA	2772
PR	01-SEP-1999; 99WO-US020111.			
PR	18-OCT-1999; 99US-00403297.			
PR	28-FEB-2001; 2001WO-US006520.			
PR	15-JAN-2002; 2002US-00052586.			
XX				
PA	(GETH) GENENTECH INC.			
XX				
PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;			
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;			
XX				
DR	WPI; 2003-615894/58.			
DR	P-PSDB; ABM22065.			
XX				
PT	New isolated nucleic acid encoding a secreted and transmembrane PRO			
PT	polypeptide e.g. PRO1079 or PRO827, useful in molecular biology,			
PT	chromosome and gene mapping, in generating antisense RNA and DNA, and in			
PT	gene therapy for cancer.			
XX				
PS	Claim 2; Fig 169; 700pp; English.			
XX				
CC	The invention relates to human PRO secreted/transmembrane polypeptides			
CC	(ABM21981-ABM22285) and nucleic acids encoding them (ACF45987-ACF46291).			
CC	The invention also relates to sequences at least 80% identical to the PRO			
CC	nucleic acid and polypeptide sequences of the invention, recombinant			
CC	vectors and host cells comprising a PRO nucleic acid, a method for the			
CC	recombinant production of a PRO polypeptide, antibodies against a PRO			
CC	polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic			
CC	acids encoding PRO polypeptides of the invention were initially			
CC	identified via homology screening using consensus sequences based on the			
CC	extracellular domain sequences from known secreted proteins. Human cDNA			
CC	libraries containing sequences of interest were identified using			
CC	oligonucleotides based on the consensus sequences, and cDNA clones were			
CC	isolated and characterised. The PRO polypeptides are useful for			
CC	stimulating release of tumour necrosis factor-alpha (TNF-alpha) from			
CC	human blood and may thus be used in the treatment of conditions in which			
CC	enhanced TNF-alpha release would be beneficial. They are also useful for			
CC	stimulating the proliferation or differentiation of chondrocytes and as			
CC	such may be used in the treatment of various bone and/or cartilage			
CC	disorders such as arthritis and sports injuries. The PRO polypeptides may			
CC	be used in a method for detecting the presence of a tumour (e.g., an			
CC	adrenal tumour, lung tumour, colon tumour, breast tumour, prostate			
CC	tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This			
CC	method involves comparing the level of expression of the PRO polypeptide			
CC	in test and control samples, where a higher level of expression of PRO			
CC	polypeptide in the test sample as compared to the control sample is			
CC	indicative of the presence of a tumour. The PRO polypeptides are			
CC	additionally useful for in drug screening to identify agonists and			
CC	antagonists of PRO polypeptides. PRO nucleic acids are useful as			
CC	hybridisation probes (for isolation of cDNA molecules), in chromosome and			
CC	gene mapping, in the generation of antisense RNA and DNA and in gene			
CC	therapy. The nucleic acids can also be used for mapping genes encoding			
CC	PRO polypeptides, for genetic analysis of individuals with genetic			
CC	disorders, and for generating either transgenic animals or knock-out			
CC	animals which are useful in the development and screening of			
CC	therapeutically useful compounds. Sequences ACF46292-ACF46293 represent			
CC	cDNAs encoding the human PRO secreted/transmembrane polypeptides of the			
CC	invention. Note: The sequence data for this patent is also available in			
CC	electronic format from USPTO at seqdata.uspto.gov/sequence.html			
XX				
SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;			
	Query Match 3.0%; Score 66.6; DB 9; Length 2846;			
	Best Local Similarity 71.3%; Pred. No. 0.00023;			
	Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;			

PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 16-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.

PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.

antiarthritic; vulnerary; gene therapy; gene; ss.		Matches	87;	Conservative	0;	Mismatches	35;	Indels	0;	Gaps	0;
XX	Homo sapiens.	QY	2121	CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCAC	TG	2180					
XX	US2003104547-A1.	Db	2653	CCTTTTCTCCCATCTCTTGACACATTTTAATAAAATAAGGGTTGGCTTCTGAAC	TA	2712					
XX	05-JUN-2003.	QY	2181	NCTCCCAAAAAA	AA	2240					
XX	17-JUL-2002; 2002US-00197701.	Db	2713	CAAAAAA	AA	2772					
XX	28-OCT-1997; 97US-0063564P.	QY	2241	AA	2242						
PR	16-SEP-1998; 98WO-US019330.	Db	2773	AA	2774						
PR	25-AUG-1999; 99US-00380139.										
PR	28-FEB-2001; 2001WO-US006520.										
PR	15-JAN-2002; 2002US-00052586.										
XX	(GETH) GENENTECH INC.	RESULT 555									
PA	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;	ACF61363									
XX	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;	ID	ACF61363	standard; cDNA; 2846 BP.							
PI		AC	ACF61363;								
PI		XX									
XX	WPI; 2003-658684/62.	DT	10-OCT-2003	(first entry)							
DR	P-PSDB; ABM75801.	DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.								
DR		XX	Human; PRO; secreted protein; transmembrane protein;								
XX	Three hundred and five nucleic acids encoding PRO polypeptides, useful	KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;								
PT	for diagnosing, preventing and/or treating tumors, such as adrenal, lung,	KW	chondrocyte; proliferation; differentiation; cartilage disorder;								
PT	colon, breast, prostate, rectal, cervical or liver tumors.	KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;								
XX	Claim 2; Fig 169; 700pp; English.	KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;								
PS	The invention relates to human PRO secreted/transmembrane polypeptides	KW	liver; drug screening; transgenic animal; genetic analysis;								
CC	(ABM75717-ABM76021) and nucleic acids encoding them (ACF76379-ACF76683).	XX	antiarthritic; vulnerary; gene therapy; gene; ss.								
CC	The invention also relates to sequences at least 80% identical to the PRO	OS	Homo sapiens.								
CC	nucleic acid and polypeptide sequences of the invention, recombinant	XX	US2003096359-A1.								
CC	vectors and host cells comprising a PRO nucleic acid, a method for the	PN	22-MAY-2003.								
CC	recombinant production of a PRO polypeptide, antibodies against a PRO	XX	26-JUL-2002; 2002US-00205910.								
CC	polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic	PD	15-SEP-2000; 2000US-0232887P.								
CC	acids encoding PRO polypeptides of the invention were initially	XX	28-FEB-2001; 2001WO-US006520.								
CC	identified via homology screening using consensus sequences based on the	XX	15-JAN-2002; 2002US-00052586.								
CC	extracellular domain sequences from known secreted proteins. Human cDNA	XX	(GETH) GENENTECH INC.								
CC	libraries containing sequences of interest were identified using	PA	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;								
CC	oligonucleotides based on the consensus sequences, and cDNA clones were	PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;								
CC	isolated and characterised. The PRO polypeptides are useful for	XX	WPI; 2003-658684/62.								
CC	stimulating release of tumour necrosis factor-alpha (TNF-alpha) from	DR	P-PSDB; ABM75801.								
CC	human blood and may thus be used in the treatment of conditions in which	XX	Three hundred and five nucleic acids encoding PRO polypeptides, useful								
CC	enhanced TNF-alpha release would be beneficial. They are also useful for	PT	for diagnosing, preventing and/or treating tumors, such as adrenal, lung,								
CC	stimulating the proliferation or differentiation of chondrocytes and as	PT	colon, breast, prostate, rectal, cervical or liver tumors.								
CC	such may be used in the treatment of various bone and/or cartilage	XX	Claim 2; Fig 169; 700pp; English.								
CC	disorders such as arthritis and sports injuries. The PRO polypeptides may	PS	The invention relates to human PRO secreted/transmembrane polypeptides								
CC	be used in a method for detecting the presence of a tumour (e.g., an	CC	(ABM75717-ABM76021) and nucleic acids encoding them (ACF76379-ACF76683).								
CC	adrenal tumour, lung tumour, colon tumour, breast tumour, prostate	CC	The invention also relates to sequences at least 80% identical to the PRO								
CC	tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This	CC	nucleic acid and polypeptide sequences of the invention, recombinant								
CC	method involves comparing the level of expression of the PRO polypeptide	CC	vectors and host cells comprising a PRO nucleic acid, a method for the								
CC	in test and control samples, where a higher level of expression of PRO	CC	recombinant production of a PRO polypeptide, antibodies against a PRO								
CC	polypeptide in the test sample as compared to the control sample is	CC	polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic								
CC	indicative of the presence of a tumour. The PRO polypeptides are	CC	acids encoding PRO polypeptides of the invention were initially								
CC	additionally useful for in drug screening to identify agonists and	CC	identified via homology screening using consensus sequences based on the								
CC	antagonists of PRO polypeptides. PRO nucleic acids are useful as	CC	extracellular domain sequences from known secreted proteins. Human cDNA								
CC	hybridisation probes (for isolation of cDNA molecules), in chromosome and	CC	libraries containing sequences of interest were identified using								
CC	gene mapping, in the generation of antisense RNA and DNA and in gene	CC	oligonucleotides based on the consensus sequences, and cDNA clones were								
CC	therapy. The nucleic acids can also be used for mapping genes encoding	CC	isolated and characterised. The PRO polypeptides are useful for								
CC	PRO polypeptides, for genetic analysis of individuals with genetic	CC	stimulating release of tumour necrosis factor-alpha (TNF-alpha) from								
CC	disorders, and for generating either transgenic animals or knock-out	CC	human blood and may thus be used in the treatment of conditions in which								
CC	animals which are useful in the development and screening of	CC	enhanced TNF-alpha release would be beneficial. They are also useful for								
CC	therapeutically useful compounds. Sequences ACF76379-ACF76683 represent	CC	stimulating the proliferation or differentiation of chondrocytes and as								
CC	cDNAs encoding the human PRO secreted/transmembrane polypeptides of the	CC	such may be used in the treatment of various bone and/or cartilage								
CC	invention. Note: The sequence data for this patent is also available in	CC	disorders such as arthritis and sports injuries. The PRO polypeptides may								
CC	electronic format from USPTO at segdata.uspto.gov/sequence.html	CC	be used in a method for detecting the presence of a tumour (e.g., an								
XX	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;	CC	adrenal tumour, lung tumour, colon tumour, breast tumour, prostate								
SQ	Query Match 3.0%; Score 66.6; DB 9; Length 2846;	CC	tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This								
	Best Local Similarity 71.3%; Pred. NO. 0.00023;	CC	method involves comparing the level of expression of the PRO polypeptide								

CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF61279-ACF61583 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACCTCTTCTCTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCTCTCCCACTCTCTGTACACATTTTAATAAAAAAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAA AA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 556
ACF61670
ID ACF61670 standard; cDNA; 2846 BP.
XX
AC ACF61670;
XX
DT 13-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003100061-A1.
XX
PD 29-MAY-2003.
XX
PF 24-JUN-2002; 2002US-00179526.
XX
PR 26-JUN-1998; 98US-00105413.
PR 16-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98US-00168978.

PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 07-DEC-1998; 98US-00202054.
PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021090.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028551.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 30-JUL-2001; 2001US-00918585.
PR 06-AUG-2001; 2001US-00924419.
PR 13-AUG-2001; 2001US-00929404.
PR 16-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 29-AUG-2001; 2001WO-US027099.
PR 04-SEP-2001; 2001US-00946374.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-670164/63.
DR P-PSDB; ABM34386.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for the manufacture of a medicament for diagnosing or treating tumor or

KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX Homo sapiens.

OS US2003054454-A1.

PN 20-MAR-2003.

XX PD

XX PF 26-JUN-2002; 2002US-00183002.

XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090423P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.

PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTATCTTATTATAAAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCTTCCCATCTCTGTACACATTTTATAAAAAATAAGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAAAAAA AA 2240
Db 2713 CAAAAA AA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 559
ACD32543
ID ACD32543 standard; cDNA; 2846 BP.
XX
AC ACD32543;
XX
DT 09-SEP-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.

XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX Homo sapiens.
OS
XX
PN US2003054477-A1.
XX
PD 20-MAR-2003.
XX
PF 23-JUL-2002; 2002US-00202411.
XX
PR 17-NOV-1998; 98US-0108806P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-521852/49.
DR P-PSDB; ABO22147.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTATCTTATTATAAAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCTTCCCATCTCTGTACACATTTTATAAAAAATAAGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAAAAAA AA 2240
Db 2713 CAAAAA AA 2772

PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX

PA (GETH) GENENTECH INC.

PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

DR WPI; 2003-521927/49.
DR P-PSDB; ABO34185.

PT New PRO polypeptide, useful for preparing a composition for diagnosing or
PT treating cancer or for tissue typing.

XX Disclosure; Fig 37; 236pp; English.

CC The invention relates to an isolated PRO polypeptide. The polypeptide is
CC useful for preparing a composition for diagnosing or treating cancer or
CC for tissue typing. The present sequence represents cDNA encoding a human
CC secreted/transmembrane PRO polypeptide

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTCTTTATCTTATTAATAAAATGTTGGTCTCCCACTG 2180

Db 2653 CCTTTTCTTCCCATCTCTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAAC 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 562
ACF17509

ID ACF17509 standard; cDNA; 2846 BP.
XX
AC ACF17509;
XX
DT 17-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnary; Gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003054460-A1.
XX
PD 20-MAR-2003.
XX
PF 15-JUL-2002; 2002US-00195892.
XX
PR 26-JUN-1998; 98US-00105413.
PR 16-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 07-DEC-1998; 98US-00202054.
PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021090.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028551.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.

PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.

PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.


```

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGCCTTACCACCTCTTCCCTTTATCTTATTAATAAATAATGTTGGTCTCCACACTG 2180
    ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAATAAATAAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 564
ACF07342
ID ACF07342 standard; cDNA; 2846 BP.
XX
AC ACF07342;
XX
DT 06-SEP-2003 (first entry)
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003049753-A1.
XX
PD 13-MAR-2003.
XX
PF 17-JUL-2002; 2002US-00197708.
XX
PR 05-MAY-1998; 98US-0084366P.
PR 08-MAR-1999; 99WO-US005028.
PR 25-AUG-1999; 99US-00380138.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-555156/52.
DR P-PSDB; ABR85759.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful in
PT gene therapy, in chromosome and gene mapping, as chromosome markers, in
PT tissue typing, and in identifying chromosome.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABR85675-ABR85979) and nucleic acids encoding them (ACF07258-ACF07562).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
```

```

libraries containing sequences of interest were identified using
oligonucleotides based on the consensus sequences, and cDNA clones were
isolated and characterised. The PRO polypeptides are useful for
stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
human blood and may thus be used in the treatment of conditions in which
enhanced TNF-alpha release would be beneficial. They are also useful for
stimulating the proliferation or differentiation of chondrocytes and as
such may be used in the treatment of various bone and/or cartilage
disorders such as arthritis and sports injuries. The PRO polypeptides may
be used in a method for detecting the presence of a tumour (e.g., an
adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
method involves comparing the level of expression of the PRO polypeptide
in test and control samples, where a higher level of expression of PRO
polypeptide in the test sample as compared to the control sample is
indicative of the presence of a tumour. The PRO polypeptides are
additionally useful for in drug screening to identify agonists and
antagonists of PRO polypeptides. PRO nucleic acids are useful as
hybridisation probes (for isolation of cDNA molecules), in chromosome and
gene mapping, in the generation of antisense RNA and DNA and in gene
therapy. The nucleic acids can also be used for mapping genes encoding
PRO polypeptides, for genetic analysis of individuals with genetic
disorders, and for generating either transgenic animals or knock-out
animals which are useful in the development and screening of
therapeutically useful compounds. Sequences ACF07258-ACF07562 represent
cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
invention. Note: The sequence data for this patent is also available in
electronic format from USPTO at seqdata.uspto.gov/sequence.html

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGCCTTACCACCTCTTCCCTTTATCTTATTAATAAATAATGTTGGTCTCCACACTG 2180
    ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAATAAATAAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 565
ACF20500
ID ACF20500 standard; cDNA; 2846 BP.
XX
AC ACF20500;
XX
DT 18-SEP-2003 (first entry)
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003049763-A1.
XX
PD 13-MAR-2003.
XX
PF 19-JUL-2002; 2002US-00199317.
```


Qy	2241 AA 2242	PR	29-APR-1998;	98US-0083496P.
		PR	29-APR-1998;	98US-0083499P.
Db	2773 AA 2774	PR	29-APR-1998;	98US-0083559P.
		PR	05-MAY-1998;	98US-0084366P.
		PR	06-MAY-1998;	98US-0084414P.
		PR	07-MAY-1998;	98US-0084639P.
		PR	07-MAY-1998;	98US-0084640P.
		PR	07-MAY-1998;	98US-0084643P.
		PR	15-MAY-1998;	98US-0085579P.
		PR	15-MAY-1998;	98US-0085580P.
		PR	15-MAY-1998;	98US-0085582P.
		PR	15-MAY-1998;	98US-0085700P.
		PR	18-MAY-1998;	98US-0086023P.
		PR	22-MAY-1998;	98US-0086392P.
		PR	22-MAY-1998;	98US-0086486P.
		PR	28-MAY-1998;	98US-0087098P.
		PR	28-MAY-1998;	98US-0087208P.
		PR	02-JUN-1998;	98US-0087609P.
		PR	02-JUN-1998;	98US-0087759P.
		PR	03-JUN-1998;	98US-0087827P.
		PR	04-JUN-1998;	98US-0088025P.
		PR	04-JUN-1998;	98US-0088028P.
		PR	04-JUN-1998;	98US-0088029P.
		PR	04-JUN-1998;	98US-0088033P.
		PR	04-JUN-1998;	98US-0088326P.
		PR	05-JUN-1998;	98US-0088167P.
		PR	05-JUN-1998;	98US-0088202P.
		PR	05-JUN-1998;	98US-0088212P.
		PR	05-JUN-1998;	98US-0088217P.
		PR	09-JUN-1998;	98US-0088655P.
		PR	10-JUN-1998;	98US-0088722P.
		PR	10-JUN-1998;	98US-0088738P.
		PR	10-JUN-1998;	98US-0088740P.
		PR	10-JUN-1998;	98US-0088811P.
		PR	10-JUN-1998;	98US-0088824P.
		PR	10-JUN-1998;	98US-0088825P.
		PR	10-JUN-1998;	98US-0088826P.
		PR	11-JUN-1998;	98US-0088861P.
		PR	11-JUN-1998;	98US-0088863P.
		PR	11-JUN-1998;	98US-0088876P.
		PR	12-JUN-1998;	98US-0089090P.
		PR	12-JUN-1998;	98US-0089105P.
		PR	16-JUN-1998;	98US-0089512P.
		PR	16-JUN-1998;	98US-0089514P.
		PR	17-JUN-1998;	98US-0089538P.
		PR	17-JUN-1998;	98US-0089598P.
		PR	17-JUN-1998;	98US-0089653P.
		PR	18-JUN-1998;	98US-0089908P.
		PR	19-JUN-1998;	98US-0089952P.
		PR	22-JUN-1998;	98US-0090246P.
		PR	22-JUN-1998;	98US-0090252P.
		PR	22-JUN-1998;	98US-0090254P.
		PR	24-JUN-1998;	98US-0090429P.
		PR	24-JUN-1998;	98US-0090444P.
		PR	24-JUN-1998;	98US-0090435P.
		PR	24-JUN-1998;	98US-0090461P.
		PR	24-JUN-1998;	98US-0090535P.
		PR	24-JUN-1998;	98US-0090540P.
		PR	25-JUN-1998;	98US-0090676P.
		PR	25-JUN-1998;	98US-0090678P.
		PR	25-JUN-1998;	98US-0090688P.
		PR	25-JUN-1998;	98US-0090690P.
		PR	25-JUN-1998;	98US-0090694P.
		PR	25-JUN-1998;	98US-0090695P.
		PR	25-JUN-1998;	98US-0090696P.
		PR	26-JUN-1998;	98US-00105413.
		PR	26-JUN-1998;	98US-0090862P.
		PR	26-JUN-1998;	98US-0090863P.
		PR	26-JUN-1998;	98US-0091010P.
		PR	01-JUL-1998;	98US-0091359P.
		PR	01-JUL-1998;	98US-0091544P.
		PR	02-JUL-1998;	98US-0091478P.
		PR	02-JUL-1998;	98US-0091486P.

RESULT 567

ACF21114

ID ACF21114 standard; cDNA; 2846 BP.

XX

AC ACF21114;

XX

DT 18-SEP-2003 (first entry)

XX

DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX

KW Human; PRO; secreted protein; transmembrane protein;

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; proliferation; differentiation; cartilage disorder;

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; drug screening; transgenic animal; genetic analysis;

KW antiarthritic; vulnerary; gene therapy; gene; ss.

XX

OS Homo sapiens.

XX

PN US2003073172-A1.

XX

PD 17-APR-2003.

XX

PF 19-JUN-2002; 2002US-00175750.

XX

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 17-OCT-1997; 97US-0062250P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 28-OCT-1997; 97US-0063540P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063734P.

PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066120P.

PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066772P.

PR 11-DEC-1997; 97US-0069335P.

PR 12-DEC-1997; 97US-0069425P.

PR 17-DEC-1997; 97US-0069870P.

PR 18-DEC-1997; 97US-0068017P.

PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077649P.

PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078939P.

PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079786P.

PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080194P.

PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080333P.

PR 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.

PR 09-APR-1998; 98US-0081195P.

PR 15-APR-1998; 98US-0081838P.

PR 21-APR-1998; 98US-0082568P.

PR 21-APR-1998; 98US-0082569P.

PR 22-APR-1998; 98US-0082704P.

PR 22-APR-1998; 98US-0082797P.

PR 28-APR-1998; 98US-0083322P.

PR 29-APR-1998; 98US-0083495P.

PR	02-JUL-1998;	98US-0091626P.	
PR	02-JUL-1998;	98US-0091628P.	
PR	02-JUL-1998;	98US-0091632P.	
PR	24-JUL-1998;	98US-0094006P.	
PR	04-AUG-1998;	98US-0095282P.	
PR	10-AUG-1998;	98US-0095998P.	
PR	10-AUG-1998;	98US-0096012P.	
PR	17-AUG-1998;	98US-0096757P.	
PR	17-AUG-1998;	98US-0096766P.	
PR	17-AUG-1998;	98US-0096867P.	
PR	17-AUG-1998;	98US-0096891P.	
PR	17-AUG-1998;	98US-0096897P.	
PR	18-AUG-1998;	98US-0096949P.	
PR	18-AUG-1998;	98US-0097022P.	
PR	26-AUG-1998;	98US-0097952P.	
PR	26-AUG-1998;	98US-0097954P.	
PR	26-AUG-1998;	98US-0097955P.	
PR	26-AUG-1998;	98US-0097971P.	
PR	26-AUG-1998;	98US-0097974P.	
PR	26-AUG-1998;	98US-0098014P.	
PR	01-SEP-1998;	98US-0098716P.	
PR	01-SEP-1998;	98US-0098723P.	
PR	02-SEP-1998;	98US-0098803P.	
PR	02-SEP-1998;	98US-0098821P.	
PR	02-SEP-1998;	98US-0098843P.	
PR	09-SEP-1998;	98US-0099602P.	
PR	10-SEP-1998;	98US-0099741P.	
PR	10-SEP-1998;	98US-0099754P.	
PR	10-SEP-1998;	98US-0099763P.	
PR	10-SEP-1998;	98US-0099812P.	
PR	15-SEP-1998;	98US-0100388P.	
PR	16-SEP-1998;	98US-0100662P.	
PR	16-SEP-1998;	98US-0100664P.	
PR	16-SEP-1998;	98US-0101751P.	
PR	16-SEP-1998;	98WO-US019330.	
PR	17-SEP-1998;	98US-0100683P.	
PR	17-SEP-1998;	98US-0100684P.	
PR	17-SEP-1998;	98US-0100919P.	
PR	17-SEP-1998;	98US-0100930P.	
PR	18-SEP-1998;	98US-0100849P.	
PR	18-SEP-1998;	98US-0101014P.	
PR	18-SEP-1998;	98US-0101068P.	
PR	23-SEP-1998;	98US-0101471P.	
PR	23-SEP-1998;	98US-0101472P.	
PR	23-SEP-1998;	98US-0101475P.	
PR	23-SEP-1998;	98US-0101477P.	
PR	24-SEP-1998;	98US-0101738P.	
PR	24-SEP-1998;	98US-0101739P.	
PR	24-SEP-1998;	98US-0101743P.	
PR	24-SEP-1998;	98US-0101922P.	
PR	25-SEP-1998;	98US-0101786P.	
PR	29-SEP-1998;	98US-0102207P.	
PR	29-SEP-1998;	98US-0102240P.	
PR	29-SEP-1998;	98US-0102330P.	
PR	29-SEP-1998;	98US-0102331P.	
PR	30-SEP-1998;	98US-0102487P.	
PR	30-SEP-1998;	98US-0102570P.	
PR	30-SEP-1998;	98US-0102571P.	
PR	01-OCT-1998;	98US-0102684P.	
PR	01-OCT-1998;	98US-0102687P.	
Query Match 3.0%; Score 66.6; DB 9; Length 2846;			
Best Local Similarity 71.3%; Pred. No. 0.00023;			
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;			
QY	2121	CCTTTGCTTTACCACTCTTTCCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACTG	2180
DB	2653	CCTTTTCCTTCCCACTCTGTGTACACATTTTAAATAAAGGTTGGCTTCTGAACATA	2712
QY	2181	NCTCCCAAAAAA	2240
DB	2713	CAAAAAA	2772

Qy

2241

AA

2242

Db

2773

AA

2774

RESULT 568

ACD47624

ID

ACD47624

standard;

cdna;

2846

BP.

XX

AC

ACD47624;

XX

DT

13-SEP-2003

(first entry)

XX

DE

Human

secreted/transmembrane protein (PRO)

cdna #85.

XX

KW

Human;

gene;

ss;

secreted and transmembrane protein;

PRO;

TNF-alpha;

tumour

necrosis

factor

alpha;

chondrocyte

cell;

tumour;

gene

therapy;

KW

tissue

typing;

adrenal

tumour;

lung

tumour;

colon

tumour;

breast

tumour;

KW

prostate

tumour;

rectal

tumour;

cervical

tumour;

liver

tumour.

XX

OS

Homo sapiens.

XX

PN

US2003068700-A1.

XX

PD

10-APR-2003.

XX

PF

11-JUL-2002;

2002US-00194395.

XX

PR

05-JUN-2000;

2000US-0209832P.

PR

28-FEB-2001;

2001WO-US006520.

PR

15-JAN-2002;

2002US-00052586.

XX

PA

(GETH)

GENENTECH INC.

XX

PI

Baker KP,

Chen J,

Desnoyers L,

Goddard A,

Godowski PJ,

Gurney AL;

PI

Pan J,

Smith V,

Watanabe CK,

Wood WI,

Zhang Z;

XX

DR

WPI;

2003-605914/57.

DR

P-PSDB;

ABO29724.

XX

PT

New isolated,

secreted and transmembrane PRO polypeptides and nucleic

PT

acids,

useful for

diagnosing,

preventing and/or

treating

tumors,

such as

PT

adrenal,

lung,

colon,

breast,

prostate,

rectal,

cervical

or

liver

tumors.

XX

PS

Claim 2;

Fig 169;

700pp;

English.

XX

CC

The invention discloses human nucleic acids encoding secreted and

CC

transmembrane (PRO) polypeptides, with or without their associated signal

CC

peptide. Also disclosed is an antibody that specifically binds to the PRO

CC

polypeptide, a method for stimulating the release of tumour necrosis

CC

factor alpha (TNF-alpha) from human blood by contacting the blood with a

CC

PRO polypeptide, a method for stimulating the proliferation or

CC

differentiation of chondrocyte cells by contacting the cells with a PRO

CC

polypeptide, a method for detecting the presence of a tumour in a mammal

CC

and an oligonucleotide probe derived from any of the PRO nucleotide

CC

sequences. The nucleotide sequences are useful as probes, in chromosome

CC

and gene mapping, in generating antisense RNA and DNA, in preparing PRO

CC

polypeptides by recombinant techniques and in gene therapy (e.g. for

CC

replacement of defective gene). The PRO polypeptides are useful as

CC

molecular weight markers for protein electrophoresis purposes, for

CC

chromosome identification, as chromosome markers, as therapeutic agents,

CC

for stimulating the release of TNF-alpha from human blood, for

CC

stimulating the proliferation or differentiation of chondrocytes and

CC

detecting the presence, prevention and/or treatment of a tumour, such as

CC

adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.

CC

The PRO polypeptides and nucleic acids may also be used diagnostically

CC

for tissue typing. The sequence presented is a cdna encoding one of the

CC

PRO polypeptides of the invention. Note: The sequence data for this

CC

patent can also be obtained in electronic format directly from USPTO at

CC

seqdata.uspto.gov/sequence.html

XX

SQ

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

PR	04-JUN-1998;	98US-0088025P;
PR	04-JUN-1998;	98US-0088028P;
PR	04-JUN-1998;	98US-0088029P;
PR	04-JUN-1998;	98US-0088033P;
PR	04-JUN-1998;	98US-0088326P;
PR	05-JUN-1998;	98US-0088167P;
PR	05-JUN-1998;	98US-0088202P;
PR	05-JUN-1998;	98US-0088212P;
PR	05-JUN-1998;	98US-0088217P;
PR	09-JUN-1998;	98US-0088655P;
PR	10-JUN-1998;	98US-0088722P;
PR	10-JUN-1998;	98US-0088738P;
PR	10-JUN-1998;	98US-0088740P;
PR	10-JUN-1998;	98US-0088811P;
PR	10-JUN-1998;	98US-0088824P;
PR	10-JUN-1998;	98US-0088825P;
PR	10-JUN-1998;	98US-0088826P;
PR	11-JUN-1998;	98US-0088861P;
PR	11-JUN-1998;	98US-0088863P;
PR	11-JUN-1998;	98US-0088876P;
PR	12-JUN-1998;	98US-0089090P;
PR	12-JUN-1998;	98US-0089105P;
PR	16-JUN-1998;	98US-0089512P;
PR	16-JUN-1998;	98US-0089514P;
PR	17-JUN-1998;	98US-0089538P;
PR	17-JUN-1998;	98US-0089598P;
PR	17-JUN-1998;	98US-0089653P;
PR	18-JUN-1998;	98US-0089908P;
PR	19-JUN-1998;	98US-0089952P;
PR	22-JUN-1998;	98US-0090246P;
PR	22-JUN-1998;	98US-0090252P;
PR	22-JUN-1998;	98US-0090254P;
PR	24-JUN-1998;	98US-0090429P;
PR	24-JUN-1998;	98US-0090435P;
PR	24-JUN-1998;	98US-0090444P;
PR	24-JUN-1998;	98US-0090461P;
PR	24-JUN-1998;	98US-0090535P;
PR	24-JUN-1998;	98US-0090540P;
PR	25-JUN-1998;	98US-0090676P;
PR	25-JUN-1998;	98US-0090678P;
PR	25-JUN-1998;	98US-0090688P;
PR	25-JUN-1998;	98US-0090690P;
PR	25-JUN-1998;	98US-0090694P;
PR	25-JUN-1998;	98US-0090695P;
PR	25-JUN-1998;	98US-0090696P;
PR	26-JUN-1998;	98US-00105413;
PR	26-JUN-1998;	98US-0090862P;
PR	26-JUN-1998;	98US-0090863P;
PR	26-JUN-1998;	98US-0091010P;
PR	01-JUL-1998;	98US-0091359P;
PR	01-JUL-1998;	98US-0091544P;
PR	02-JUL-1998;	98US-0091478P;
PR	02-JUL-1998;	98US-0091486P;
PR	02-JUL-1998;	98US-0091626P;
PR	02-JUL-1998;	98US-0091628P;
PR	02-JUL-1998;	98US-0091632P;
PR	04-AUG-1998;	98US-0094006P;
PR	04-AUG-1998;	98US-0095282P;
PR	10-AUG-1998;	98US-0095998P;
PR	10-AUG-1998;	98US-0096012P;
PR	17-AUG-1998;	98US-0096757P;
PR	17-AUG-1998;	98US-0096766P;
PR	17-AUG-1998;	98US-0096867P;
PR	17-AUG-1998;	98US-0096891P;
PR	17-AUG-1998;	98US-0096897P;
PR	18-AUG-1998;	98US-0096949P;
PR	18-AUG-1998;	98US-0096959P;
PR	18-AUG-1998;	98US-0097022P;
PR	26-AUG-1998;	98US-0097952P;
PR	26-AUG-1998;	98US-0097954P;
PR	26-AUG-1998;	98US-0097955P;
PR	26-AUG-1998;	98US-0097971P;
PR	26-AUG-1998;	98US-0097974P;

PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No: 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0

QY	2121	CCTTTGCTTTACCACTCTTTTCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG	2180
Db	2653	CCTTTTCTTCCCATCTCTTGTACACATTTTAATAAAAAAAGGGTTGGCTTCTGAACTA	2712
QY	2181	NTCCCAAA	2240
Db	2713	CAAA	2772
QY	2241	AA	2242
Db	2773	AA	2774

RESULT 577	
ACD39724	
ID	ACD39724 standard; cDNA; 2846 BP.
XX	
AC	ACD39724;
XX	
DT	04-SEP-2003 (first entry)
XX	
DE	cDNA encoding human PRO polypeptide
XX	
KW	Human; PRO polypeptide; secreted

KW chromosome mapping; gene mapping; biosensor; bioreactor; tumour;
KW tumour necrosis factor-alpha; TNF-alpha; proliferation; differentiation;
KW chondrocyte cell; gene therapy; gene; ss.

OS Homo sapiens.

XX US2003027265-A1.

PN

XX PD 06-FEB-2003.

XX PF 18-JUN-2002; 2002US-00174582.

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 17-OCT-1997; 97US-0062250P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 28-OCT-1997; 97US-0063540P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063734P.

PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066120P.

PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066772P.

PR 11-DEC-1997; 97US-0069335P.

PR 12-DEC-1997; 97US-0069425P.

PR 17-DEC-1997; 97US-0069870P.

PR 18-DEC-1997; 97US-0068017P.

PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077649P.

PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078939P.

PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079786P.

PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080194P.

PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080333P.

PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.

RESULT 582	
ACF11333	
ID ACF11333 standard; cDNA; 2846 BP.	
XX AC ACF11333;	
XX DT	09-SEP-2003 (first entry)
XX DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.	
XX KW Human; PRO; secreted protein; transmembrane protein; extracellular domain; tumour necrosis factor-alpha; TNF-alpha; chondrocyte; proliferation; differentiation; cartilage disorder; bone disorder; arthritis; sports injury; cancer; tumour; diagnosis; adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix; liver; drug screening; transgenic animal; genetic analysis; antiarthritic; vulneryary; gene therapy; gene; ss.	
OS Homo sapiens.	
XX US2003073171-A1.	
XX PD 17-APR-2003.	
XX PF 19-JUN-2002; 2002US-Q0175741.	
XX PR 18-SEP-1997; 97US-0059263P.	
PR 18-SEP-1997; 97US-0059266P.	
PR 17-OCT-1997; 97US-0062250P.	
PR 21-OCT-1997; 97US-0063486P.	
PR 24-OCT-1997; 97US-0063120P.	
PR 24-OCT-1997; 97US-0063121P.	
PR 28-OCT-1997; 97US-0063540P.	
PR 28-OCT-1997; 97US-0063541P.	
PR 28-OCT-1997; 97US-0063544P.	
PR 28-OCT-1997; 97US-0063564P.	
PR 29-OCT-1997; 97US-0063734P.	
PR 31-OCT-1997; 97US-0063870P.	
PR 31-OCT-1997; 97US-0064103P.	
PR 13-NOV-1997; 97US-0065311P.	
PR 21-NOV-1997; 97US-0066120P.	
PR 24-NOV-1997; 97US-0066466P.	
PR 24-NOV-1997; 97US-0066772P.	
PR 11-DEC-1997; 97US-0069335P.	
PR 12-DEC-1997; 97US-0069425P.	
PR 17-DEC-1997; 97US-0069870P.	
PR 18-DEC-1997; 97US-0068017P.	
PR 10-MAR-1998; 98US-0077450P.	
PR 11-MAR-1998; 98US-0077632P.	
PR 11-MAR-1998; 98US-0077649P.	
PR 20-MAR-1998; 98US-0078886P.	
PR 20-MAR-1998; 98US-0078939P.	
PR 27-MAR-1998; 98US-0079664P.	
PR 27-MAR-1998; 98US-0079786P.	
PR 31-MAR-1998; 98US-0080107P.	
PR 31-MAR-1998; 98US-0080194P.	
PR 01-APR-1998; 98US-0080327P.	
PR 01-APR-1998; 98US-0080333P.	
PR 08-APR-1998; 98US-0081049P.	
PR 08-APR-1998; 98US-0081070P.	
PR 09-APR-1998; 98US-0081195P.	
PR 15-APR-1998; 98US-0081838P.	
PR 21-APR-1998; 98US-0082568P.	
PR 21-APR-1998; 98US-0082569P.	
PR 22-APR-1998; 98US-0082704P.	
PR 22-APR-1998; 98US-0082797P.	
PR 28-APR-1998; 98US-0083322P.	
PR 29-APR-1998; 98US-0083495P.	
PR 29-APR-1998; 98US-0083496P.	
PR 29-APR-1998; 98US-0083499P.	
PR 29-APR-1998; 98US-0083559P.	
PR 05-MAY-1998; 98US-0084366P.	

PR	04-AUG-1998;	98US-0095282P;
PR	10-AUG-1998;	98US-0095998P;
PR	10-AUG-1998;	98US-0096012P;
PR	17-AUG-1998;	98US-0096757P;
PR	17-AUG-1998;	98US-0096766P;
PR	17-AUG-1998;	98US-0096867P;
PR	17-AUG-1998;	98US-0096891P;
PR	17-AUG-1998;	98US-0096897P;
PR	18-AUG-1998;	98US-0096949P;
PR	18-AUG-1998;	98US-0096959P;
PR	18-AUG-1998;	98US-0097022P;
PR	26-AUG-1998;	98US-0097952P;
PR	26-AUG-1998;	98US-0097954P;
PR	26-AUG-1998;	98US-0097955P;
PR	26-AUG-1998;	98US-0097971P;
PR	26-AUG-1998;	98US-0097974P;
PR	26-AUG-1998;	98US-0098014P;
PR	01-SEP-1998;	98US-0098716P;
PR	01-SEP-1998;	98US-0098723P;
PR	02-SEP-1998;	98US-0098803P;
PR	02-SEP-1998;	98US-0098821P;
PR	02-SEP-1998;	98US-0098843P;
PR	09-SEP-1998;	98US-0098602P;
PR	10-SEP-1998;	98US-0099741P;
PR	10-SEP-1998;	98US-0099754P;
PR	10-SEP-1998;	98US-0099763P;
PR	10-SEP-1998;	98US-0099812P;
PR	15-SEP-1998;	98US-0100388P;
PR	16-SEP-1998;	98US-0100662P;
PR	16-SEP-1998;	98US-0100664P;
PR	16-SEP-1998;	98US-0101751P;
PR	16-SEP-1998;	98WO-US019330;
PR	17-SEP-1998;	98US-0100683P;
PR	17-SEP-1998;	98US-0100684P;
PR	17-SEP-1998;	98US-0100919P;
PR	17-SEP-1998;	98US-0100930P;
PR	18-SEP-1998;	98US-0100849P;
PR	18-SEP-1998;	98US-0101014P;
PR	18-SEP-1998;	98US-0101068P;
PR	23-SEP-1998;	98US-0101471P;
PR	23-SEP-1998;	98US-0101472P;
PR	23-SEP-1998;	98US-0101475P;
PR	23-SEP-1998;	98US-0101477P;
PR	24-SEP-1998;	98US-0101738P;
PR	24-SEP-1998;	98US-0101739P;
PR	24-SEP-1998;	98US-0101743P;
PR	24-SEP-1998;	98US-0101922P;
PR	25-SEP-1998;	98US-0101786P;
PR	29-SEP-1998;	98US-0102207P;
PR	29-SEP-1998;	98US-0102240P;
PR	29-SEP-1998;	98US-0102330P;
PR	29-SEP-1998;	98US-0102331P;
PR	30-SEP-1998;	98US-0102487P;
PR	30-SEP-1998;	98US-0102570P;
PR	30-SEP-1998;	98US-0102571P;
PR	01-OCT-1998;	98US-0102684P;
PR	01-OCT-1998;	98US-0102687P;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

[illegible]

Qy 2241 AA 2242

DB 2773 AA 2774

Db 2773 AA 2774

RESULT 584

ACF34171

ID ACF34171 standard; cDNA; 2846 BP.

XX

AC ACF34171;

XX

DT 25-SEP-2003 (first entry)

XX

DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX

KW Human; PRO; secreted protein; transmembrane protein;

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; proliferation; differentiation; cartilage disorder;

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; drug screening; transgenic animal; genetic analysis;

KW antiarthritic; vulnerary; gene therapy; gene; ss.

XX

OS Homo sapiens.

XX

PN US2003064458-A1.

XX

PD 03-APR-2003.

XX

PF 18-JUL-2002; 2002US-00199313.

XX

PR 26-AUG-1998; 98US-0097952P.

PR 02-JUN-1999; 99WO-US012252.

PR 25-AUG-1999; 99US-00380137.

PR 30-MAR-2000; 2000WO-US008439.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX

PA (GETH) GENENTECH INC.

XX

PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-596622/56.

DR P-PSDB; ABM13766.

XX

PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful in gene therapy, or for preparing a medicament for treating a condition that is responsive to the PRO polypeptide or anti-PRO antibody, e.g., cancer.

XX

PS Claim 2; Fig 169; 700pp; English.

XX

CC The invention relates to human PRO secreted/transmembrane polypeptides and nucleic acids encoding them, the invention also provides recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO

CC polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. The present sequence appears in the exemplification of the specification. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTCTTTTATCTTATTAATAAAATGTTGGTCTCCACTG 2180

Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 585

ACD46396

ID ACD46396 standard; cDNA; 2846 BP.

XX

AC ACD46396;

XX

DT 13-SEP-2003 (first entry)

XX

DE Human secreted/transmembrane protein (PRO) cDNA #85.

XX

KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;

KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;

KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;

KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX

OS Homo sapiens.

XX

PN US2003064460-A1.

XX

PD 03-APR-2003.

XX

PF 22-JUL-2002; 2002US-00201329.

XX

PR 02-SEP-1998; 98US-0098843P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX

PA (GETH) GENENTECH INC.

XX

PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-605862/57.

DR P-PSDB; ABO28504.

XX

PT Isolated secreted and transmembrane PRO polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy for cancers, chromosome

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003068702-A1.
PN 10-APR-2003.
XX 12-JUL-2002; 2002US-00194458.
XX 05-JUN-2000; 2000US-0209832P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-615876/58.
DR P-PSDB; ABM07361.
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for diagnosing, preventing and/or treating tumors, such as
PT adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM07277-ABM07581) and nucleic acids encoding them (ACF27535-ACF27839).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour). This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF27535-ACF27839 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCTCCCATCTCTTGTTACACATTTTATAAAAAATAAGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCAAAAA AA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAAAAA AA 2772
QY 2241 AA 2242
Db ||
2773 AA 2774
RESULT 588
ACF24491
ID ACF24491 standard; cDNA; 2846 BP.
XX AC ACF24491;
XX 01-OCT-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
OS Homo sapiens.
XX US2003068734-A1.
PN 10-APR-2003.
XX 22-JUL-2002; 2002US-00201322.
PR 10-JUN-1998; 98US-0088738P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-615890/58.
DR P-PSDB; ABM03952.
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
PT PRO827, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy for cancers.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM03868-ABM04172) and nucleic acids encoding them (ACF24407-ACF24711).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the

```
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF24407-ACF24711 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCCACTG 2180
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAAC 2712
Db  ||||| CCTTTCTCTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2241 AA 2242
Db  |||
QY 2773 AA 2774

RESULT 589
ACD85546
ID ACD85546 standard; cDNA; 2846 BP.
XX
AC ACD85546;
XX
DT 05-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003068719-A1.
XX
PD 10-APR-2003.
XX
PF 19-JUL-2002; 2002US-00198762.
XX
PR 15-MAY-1998; 98US-0085580P.

08-MAR-1999; 99WO-US005028.
25-AUG-1999; 99US-00380138.
28-FEB-2001; 2001WO-US006520.
15-JAN-2002; 2002US-00052586.
(GETH ) GENENTECH INC.
Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-625468/59.
P-PSDB; ABO37096.
New PRO nucleic acid, useful for the manufacture of a medicament for
diagnosing or treating tumors or for tissue typing.
Claim 2; Fig 169; 700pp; English.
The invention discloses human nucleic acids encoding secreted and
transmembrane (PRO) polypeptides, with or without their associated signal
peptide. Also disclosed is an antibody that specifically binds to the PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor alpha (TNF-alpha) from human blood by contacting the blood with a
PRO polypeptide, a method for stimulating the proliferation or
differentiation of chondrocyte cells by contacting the cells with a PRO
polypeptide, a method for detecting the presence of a tumour in a mammal
and an oligonucleotide probe derived from any of the PRO nucleotide
sequences. The nucleotide sequences are useful as probes, in chromosome
and gene mapping, in generating antisense RNA and DNA, in preparing PRO
polypeptides by recombinant techniques and in gene therapy (e.g. for
replacement of defective gene). The PRO polypeptides are useful as
molecular weight markers for protein electrophoresis purposes, for
chromosome identification, as chromosome markers, as therapeutic agents,
for stimulating the release of TNF-alpha from human blood, for
stimulating the proliferation or differentiation of chondrocytes and
detecting the presence, prevention and/or treatment of a tumour, such as
adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
The PRO polypeptides and nucleic acids may also be used diagnostically
for tissue typing. The sequence presented is a cDNA encoding one of the
PRO polypeptides of the invention. Note: The sequence data for this
patent can also be obtained in electronic format directly from USPTO at
seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCCACTG 2180
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAAC 2712
Db  ||||| CCTTTCTCTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2241 AA 2242
Db  |||
QY 2773 AA 2774

RESULT 590
ACD90151
ID ACD90151 standard; cDNA; 2846 BP.
XX
AC ACD90151;
XX
DT 09-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
```


QY	2121	CCTTTGCTTACCACCTCTTTCCCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCAC	2180	PR	09-APR-1998;	98US-0081195P.
				PR	15-APR-1998;	98US-0081838P.
Db	2653	CCTTTCCCTCCCACTCTCTGTGACACATTTTAATAAAATAAGGTTGGCTTCTGAAC	2712	PR	21-APR-1998;	98US-0082568P.
				PR	21-APR-1998;	98US-0082569P.
QY	2181	NCTCCCAA	2240	PR	22-APR-1998;	98US-0082704P.
				PR	22-APR-1998;	98US-0082797P.
Db	2713	CAA	2772	PR	28-APR-1998;	98US-0083322P.
				PR	29-APR-1998;	98US-0083495P.
QY	2241	AA 2242		PR	29-APR-1998;	98US-0083496P.
				PR	29-APR-1998;	98US-0083499P.
Db	2773	AA 2774		PR	29-APR-1998;	98US-0083559P.
				PR	05-MAY-1998;	98US-0084366P.
				PR	06-MAY-1998;	98US-0084414P.
				PR	07-MAY-1998;	98US-0084639P.
				PR	07-MAY-1998;	98US-0084640P.
				PR	07-MAY-1998;	98US-0084643P.
				PR	15-MAY-1998;	98US-0085579P.
				PR	15-MAY-1998;	98US-0085580P.
				PR	15-MAY-1998;	98US-0085582P.
				PR	15-MAY-1998;	98US-0085700P.
				PR	18-MAY-1998;	98US-0086023P.
				PR	22-MAY-1998;	98US-0086392P.
				PR	22-MAY-1998;	98US-0086486P.
				PR	28-MAY-1998;	98US-0087098P.
				PR	28-MAY-1998;	98US-0087208P.
				PR	02-JUN-1998;	98US-0087609P.
				PR	02-JUN-1998;	98US-0087759P.
				PR	03-JUN-1998;	98US-0087827P.
				PR	04-JUN-1998;	98US-0088025P.
				PR	04-JUN-1998;	98US-0088028P.
				PR	04-JUN-1998;	98US-0088029P.
				PR	04-JUN-1998;	98US-0088033P.
				PR	04-JUN-1998;	98US-0088326P.
				PR	05-JUN-1998;	98US-0088167P.
				PR	05-JUN-1998;	98US-0088202P.
				PR	05-JUN-1998;	98US-0088212P.
				PR	05-JUN-1998;	98US-0088217P.
				PR	09-JUN-1998;	98US-0088655P.
				PR	10-JUN-1998;	98US-0088722P.
				PR	10-JUN-1998;	98US-0088738P.
				PR	10-JUN-1998;	98US-0088740P.
				PR	10-JUN-1998;	98US-0088811P.
				PR	10-JUN-1998;	98US-0088824P.
				PR	10-JUN-1998;	98US-0088825P.
				PR	10-JUN-1998;	98US-0088826P.
				PR	11-JUN-1998;	98US-0088861P.
				PR	11-JUN-1998;	98US-0088863P.
				PR	11-JUN-1998;	98US-0088876P.
				PR	12-JUN-1998;	98US-0089090P.
				PR	12-JUN-1998;	98US-0089105P.
				PR	16-JUN-1998;	98US-0089512P.
				PR	16-JUN-1998;	98US-0089514P.
				PR	17-JUN-1998;	98US-0089538P.
				PR	17-JUN-1998;	98US-0089598P.
				PR	17-JUN-1998;	98US-0089653P.
				PR	18-JUN-1998;	98US-0089908P.
				PR	19-JUN-1998;	98US-0089952P.
				PR	22-JUN-1998;	98US-0090246P.
				PR	22-JUN-1998;	98US-0090252P.
				PR	22-JUN-1998;	98US-0090254P.
				PR	24-JUN-1998;	98US-0090429P.
				PR	24-JUN-1998;	98US-0090435P.
				PR	24-JUN-1998;	98US-0090444P.
				PR	24-JUN-1998;	98US-0090461P.
				PR	24-JUN-1998;	98US-0090535P.
				PR	24-JUN-1998;	98US-0090540P.
				PR	25-JUN-1998;	98US-0090676P.
				PR	25-JUN-1998;	98US-0090678P.
				PR	25-JUN-1998;	98US-0090688P.
				PR	25-JUN-1998;	98US-0090690P.
				PR	25-JUN-1998;	98US-0090694P.
				PR	25-JUN-1998;	98US-0090695P.
				PR	25-JUN-1998;	98US-0090696P.

DR P-PSDB; ABO48422.

XX Three hundred and five nucleic acids encoding PRO polypeptides, useful in

PT gene therapy, in chromosome and gene mapping, as chromosome markers, in

PT tissue typing, and in identifying chromosome.

XX Claim 2; Fig 169; 700pp; English.

PS

XX The invention discloses human nucleic acids encoding secreted and

CC transmembrane (PRO) polypeptides, with or without their associated signal

CC peptide. Also disclosed is an antibody that specifically binds to the PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor alpha (TNF-alpha) from human blood by contacting the blood with a

CC PRO polypeptide, a method for stimulating the proliferation or

CC differentiation of chondrocyte cells by contacting the cells with a PRO

CC polypeptide, a method for detecting the presence of a tumour in a mammal

CC and an oligonucleotide probe derived from any of the PRO nucleotide

CC sequences. The nucleotide sequences are useful as probes, in chromosome

CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO

CC polypeptides by recombinant techniques and in gene therapy (e.g. for

CC replacement of defective gene). The PRO polypeptides are useful as

CC molecular weight markers for protein electrophoresis purposes, for

CC chromosome identification, as chromosome markers, as therapeutic agents,

CC for stimulating the release of TNF-alpha from human blood, for

CC stimulating the proliferation or differentiation of chondrocytes and

CC detecting the presence, prevention and/or treatment of a tumour, such as

CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.

CC The PRO polypeptides and nucleic acids may also be used diagnostically

CC for tissue typing. The sequence presented is a cDNA encoding one of the

CC PRO polypeptides of the invention. Note: The sequence data for this

CC patent can also be obtained in electronic format directly from USPTO at

CC seqdata.uspto.gov/sequence.html

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACCTG 2180

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2653 CCTTTCTCTCCCATCTCTTGACACATTTTAAATAAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAA 2240

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2713 CAAA 2772

QY 2241 AA 2242

Db ||

2773 AA 2774

RESULT 596

ACH11338

ID ACH11338 standard; cDNA; 2846 BP.

XX

AC ACH11338;

XX

DT 13-OCT-2003 (first entry)

XX

DE cDNA encoding human PRO polypeptide #85.

XX

XX Human; PRO polypeptide; secreted protein; transmembrane protein;

KW molecular biology; hybridisation probe; chromosome mapping; gene mapping;

KW cytostatic; gene; ss.

XX

OS Homo sapiens.

XX

PN US2003049766-A1.

XX

PD 13-MAR-2003.

PF 19-JUL-2002; 2002US-00199669.

XX 05-JUN-1998; 98US-0088212P.

PR 02-JUN-1999; 99WO-US012252.

PR 25-AUG-1999; 99US-00380137.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX

PA (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-669843/63.

DR P-PSDB; ABO51472.

XX

PT Three hundred and five nucleic acids encoding PRO polypeptides, useful in

PT gene therapy, chromosome identification, tissue typing, or as

PT hybridization probes in chromosome and gene mapping.

XX

PS Claim 2; Fig 169; 700pp; English.

XX

CC The present invention relates to the isolation of novel human PRO

CC polypeptides, and the polynucleotide sequences encoding them. The PRO

CC polypeptides are secreted and transmembrane proteins. The PRO

CC polynucleotide sequences are useful in molecular biology as hybridisation

CC probes, in chromosome and gene mapping, in generating antisense RNA and

CC DNA, and in gene therapy. The PRO polypeptides are useful as molecular

CC weight markers for protein electrophoresis purposes. The anti-PRO

CC antibodies may be used in diagnostic assays for PRO, or for the affinity

CC purification of PRO from recombinant cell culture or natural sources.

CC ACH11254-ACH11558 represent cDNA sequences encoding the human PRO

CC polypeptides of the invention. Note: The sequence data for this patent

CC was obtained in electronic format directly from the USPTO web site at

CC seqdata.uspto.gov/psipsIDEntry.html

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACCTG 2180

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2653 CCTTTCTCTCCCATCTCTTGACACATTTTAAATAAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAA 2240

Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

2713 CAAA 2772

QY 2241 AA 2242

Db ||

2773 AA 2774

RESULT 597

ACH11645

ID ACH11645 standard; cDNA; 2846 BP.

XX

AC ACH11645;

XX

DT 13-OCT-2003 (first entry)

XX

DE cDNA encoding human PRO polypeptide #85.

XX

XX Human; PRO polypeptide; secreted protein; transmembrane protein;

KW molecular biology; hybridisation probe; chromosome mapping; gene mapping;

KW cytostatic; gene; ss.

XX

OS Homo sapiens.

XX

PN US2003049767-A1.

XX

PD 13-MAR-2003.

```

XX 22-JUL-2002; 2002US-00201534.
XX PF
XX XX
XX 03-MAR-2000; 2000US-0187202P.
XX PR
XX 28-FEB-2001; 2001WO-US006520.
XX PR
XX 15-JAN-2002; 2002US-00052586.
XX PR
XX (GETH ) GENENTECH INC.
XX PA
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX PI
XX WPI; 2003-669844/63.
XX DR P-PSDB; ABO51777.
XX DR
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful in
XX PT gene therapy, chromosome identification, tissue typing, or as
XX PT hybridization probes in chromosome and gene mapping.
XX PT
XX Claim 2; Fig 169; 700pp; English.
XX PS
XX The present invention relates to the isolation of novel human PRO
XX CC polypeptides, and the polynucleotide sequences encoding them. The PRO
XX CC polypeptides are secreted and transmembrane proteins. The PRO
XX CC polynucleotide sequences are useful in molecular biology as hybridisation
XX CC probes, in chromosome and gene mapping, in generating antisense RNA and
XX CC DNA, and in gene therapy. The PRO polypeptides are useful as molecular
XX CC weight markers for protein electrophoresis purposes. The anti-PRO
XX CC antibodies may be used in diagnostic assays for PRO, or for the affinity
XX CC purification of PRO from recombinant cell culture or natural sources.
XX CC ACH11561-ACH11865 represent cDNA sequences encoding the human PRO
XX CC polypeptides of the invention. Note: The sequence data for this patent
XX CC was obtained in electronic format directly from the USPTO web site at
XX CC seqdata.uspto.gov/psipsDIDentry.html
XX CC
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
XX SQ
XX Query Match 3.0%; Score 66.6; DB 9; Length 2846;
XX Best Local Similarity 71.3%; Pred. No. 0.00023;
XX Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
XX
XX QY 2121 CCTTTGCTTTACCACTCTTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG 2180
XX Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 2653 CCTTTTCTTCCCATCTCTTGTCACACATTTTATAAATAAGGTTGGCTTCTGAACCTA 2712
XX
XX QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
XX Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
XX
XX QY 2241 AA 2242
XX Db ||
XX 2773 AA 2774
XX
XX RESULT 598
XX ACH10296
XX ID ACH10296 standard; cDNA; 2846 BP.
XX XX
XX AC ACH10296;
XX XX
XX 10-OCT-2003 (first entry)
XX DT
XX DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX XX
XX KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
XX KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX XX
XX OS Homo sapiens.
XX PN
XX US2003049779-A1.
XX XX

```

AC	ACF01299;		PR	15-MAY-1998;	98US-0085580P.
XX			PR	15-MAY-1998;	98US-0085582P.
DT	13-SEP-2003 (first entry)		PR	15-MAY-1998;	98US-0085700P.
XX			PR	18-MAY-1998;	98US-0086023P.
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.		PR	22-MAY-1998;	98US-0086392P.
XX			PR	22-MAY-1998;	98US-0086486P.
KW	Human; PRO; secreted protein; transmembrane protein;		PR	28-MAY-1998;	98US-0087098P.
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;		PR	28-MAY-1998;	98US-0087208P.
KW	chondrocyte; proliferation; differentiation; cartilage disorder;		PR	02-JUN-1998;	98US-0087609P.
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;		PR	02-JUN-1998;	98US-0087759P.
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;		PR	03-JUN-1998;	98US-0087827P.
KW	liver; drug screening; transgenic animal; genetic analysis;		PR	04-JUN-1998;	98US-0088025P.
KW	antiarthritic; vulneryary; gene therapy; gene; ss.		PR	04-JUN-1998;	98US-0088028P.
XX			PR	04-JUN-1998;	98US-0088029P.
OS	Homo sapiens.		PR	04-JUN-1998;	98US-0088033P.
XX			PR	04-JUN-1998;	98US-0088326P.
PN	US2003040059-A1.		PR	05-JUN-1998;	98US-0088167P.
XX			PR	05-JUN-1998;	98US-0088202P.
PD	27-FEB-2003.		PR	05-JUN-1998;	98US-0088212P.
XX			PR	05-JUN-1998;	98US-0088217P.
PF	24-JUN-2002; 2002US-00179519.		PR	09-JUN-1998;	98US-0088655P.
XX			PR	10-JUN-1998;	98US-0088722P.
PR	18-SEP-1997; 97US-0059263P.		PR	10-JUN-1998;	98US-0088738P.
PR	18-SEP-1997; 97US-0059266P.		PR	10-JUN-1998;	98US-0088740P.
PR	17-OCT-1997; 97US-0062250P.		PR	10-JUN-1998;	98US-0088811P.
PR	21-OCT-1997; 97US-0063486P.		PR	10-JUN-1998;	98US-0088824P.
PR	24-OCT-1997; 97US-0063120P.		PR	10-JUN-1998;	98US-0088825P.
PR	24-OCT-1997; 97US-0063121P.		PR	10-JUN-1998;	98US-0088826P.
PR	28-OCT-1997; 97US-0063540P.		PR	11-JUN-1998;	98US-0088861P.
PR	28-OCT-1997; 97US-0063541P.		PR	11-JUN-1998;	98US-0088863P.
PR	28-OCT-1997; 97US-0063544P.		PR	11-JUN-1998;	98US-0088876P.
PR	28-OCT-1997; 97US-0063564P.		PR	12-JUN-1998;	98US-0089090P.
PR	29-OCT-1997; 97US-0063734P.		PR	12-JUN-1998;	98US-0089105P.
PR	31-OCT-1997; 97US-0063870P.		PR	16-JUN-1998;	98US-0089512P.
PR	31-OCT-1997; 97US-0064103P.		PR	17-JUN-1998;	98US-0089538P.
PR	13-NOV-1997; 97US-0065311P.		PR	17-JUN-1998;	98US-0089598P.
PR	21-NOV-1997; 97US-0066120P.		PR	17-JUN-1998;	98US-0089653P.
PR	24-NOV-1997; 97US-0066466P.		PR	18-JUN-1998;	98US-0089908P.
PR	24-NOV-1997; 97US-0066772P.		PR	19-JUN-1998;	98US-0089952P.
PR	11-DEC-1997; 97US-0069335P.		PR	22-JUN-1998;	98US-0090246P.
PR	12-DEC-1997; 97US-0069425P.		PR	22-JUN-1998;	98US-0090252P.
PR	17-DEC-1997; 97US-0069870P.		PR	22-JUN-1998;	98US-0090254P.
PR	18-DEC-1997; 97US-0068017P.		PR	24-JUN-1998;	98US-0090429P.
PR	10-MAR-1998; 98US-0077450P.		PR	24-JUN-1998;	98US-0090435P.
PR	11-MAR-1998; 98US-0077632P.		PR	24-JUN-1998;	98US-0090444P.
PR	11-MAR-1998; 98US-0077649P.		PR	24-JUN-1998;	98US-0090461P.
PR	20-MAR-1998; 98US-0078886P.		PR	24-JUN-1998;	98US-0090535P.
PR	20-MAR-1998; 98US-0078939P.		PR	24-JUN-1998;	98US-0090540P.
PR	27-MAR-1998; 98US-0079664P.		PR	25-JUN-1998;	98US-0090676P.
PR	27-MAR-1998; 98US-0079786P.		PR	25-JUN-1998;	98US-0090678P.
PR	31-MAR-1998; 98US-0080107P.		PR	25-JUN-1998;	98US-0090688P.
PR	31-MAR-1998; 98US-0080194P.		PR	25-JUN-1998;	98US-0090690P.
PR	01-APR-1998; 98US-0080327P.		PR	25-JUN-1998;	98US-0090694P.
PR	01-APR-1998; 98US-0080333P.		PR	25-JUN-1998;	98US-0090695P.
PR	08-APR-1998; 98US-0081049P.		PR	25-JUN-1998;	98US-0090696P.
PR	08-APR-1998; 98US-0081070P.		PR	25-JUN-1998;	98US-0090696P.
PR	09-APR-1998; 98US-0081195P.		PR	26-JUN-1998;	98US-00105413.
PR	15-APR-1998; 98US-0081838P.		PR	26-JUN-1998;	98US-0090862P.
PR	21-APR-1998; 98US-0082568P.		PR	26-JUN-1998;	98US-0090863P.
PR	21-APR-1998; 98US-0082569P.		PR	26-JUN-1998;	98US-0091010P.
PR	22-APR-1998; 98US-0082704P.		PR	01-JUL-1998;	98US-0091359P.
PR	22-APR-1998; 98US-0082797P.		PR	01-JUL-1998;	98US-0091544P.
PR	28-APR-1998; 98US-0083322P.		PR	02-JUL-1998;	98US-0091478P.
PR	29-APR-1998; 98US-0083495P.		PR	02-JUL-1998;	98US-0091486P.
PR	29-APR-1998; 98US-0083496P.		PR	02-JUL-1998;	98US-0091626P.
PR	29-APR-1998; 98US-0083499P.		PR	02-JUL-1998;	98US-0091628P.
PR	29-APR-1998; 98US-0083559P.		PR	02-JUL-1998;	98US-0091632P.
PR	05-MAY-1998; 98US-0084366P.		PR	24-JUL-1998;	98US-0094006P.
PR	06-MAY-1998; 98US-0084414P.		PR	04-AUG-1998;	98US-0095282P.
PR	07-MAY-1998; 98US-0084639P.		PR	10-AUG-1998;	98US-0095998P.
PR	07-MAY-1998; 98US-0084640P.		PR	10-AUG-1998;	98US-0096012P.
PR	07-MAY-1998; 98US-0084643P.		PR	17-AUG-1998;	98US-0096757P.
PR	15-MAY-1998; 98US-0085579P.		PR	17-AUG-1998;	98US-0096766P.

PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.

PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;

	Matches	87;	Conservative	0;	Mismatches	35;	Indels	0;	Gaps	0;
Qy	2121	CCTTTGCTTTTACCAC	CTCTTTCTTTTATCTTATTA	TAFAAAAAATGTTGGTCTCCACC	ACTG	2180				
Db	2653	CCTTTCTCTCCCATCTCT	GTGTACACATTTTAAATAAATAA	AGGGTTGGCTTCTGAACTA	2712					
Qy	2181	NCTCCCAAAAAA	AAAAAAAAAAAAAAAAAAAAAAAA	AAAAAAAAAAAAAAAAAAAAA	2240					
Db	2713	CAAAAAA	AAAAAAAAAAAAAAAAAAAAA	AAAAAAAAAAAAAAAAAAAAA	2772					
Qy	2241	AA	2242							
Db	2773	AA	2774							
RESULT 603										
ACF17816										
ID	ACF17816 standard; cDNA; 2846 BP.									
XX										
AC	ACF17816;									
XX										
DT	17-SEP-2003 (first entry)									
XX										
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.									
XX										
KW	Human; PRO; secreted protein; transmembrane protein;									
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;									
KW	chondrocyte; proliferation; differentiation; cartilage disorder;									
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;									
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;									
KW	liver; drug screening; transgenic animal; genetic analysis;									
KW	antiarthritic; vulnery; gene therapy; gene; ss.									
XX										
OS	Homo sapiens.									
XX										
PN	US2003054462-A1.									
XX										
PD	20-MAR-2003.									
XX										
PF	17-JUL-2002; 2002US-00197694.									
XX										
PR	16-SEP-1998; 98WO-US019330.									
PR	25-AUG-1999; 99US-00380139.									
PR	28-FEB-2001; 2001WO-US006520.									
PR	15-JAN-2002; 2002US-00052586.									
XX										
PA	(GETH) GENENTECH INC.									
XX										
PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;									
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;									
XX										
DR	WPI; 2003-540608/51.									
DR	P-PSDB; ABR96886.									
XX										
PT	New isolated, secreted and transmembrane PRO polypeptides and nucleic									
PT	acids, useful for diagnosing, preventing and/or treating tumors, such as									
PT	adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.									
XX										
PS	Claim 2; Fig 169; 700pp; English.									
XX										
CC	The invention relates to human PRO secreted/transmembrane polypeptides									
CC	(ABR96802-ABR97106) and nucleic acids encoding them (ACF17732-ACF18036).									
CC	The invention also relates to sequences at least 80% identical to the PRO									
CC	nucleic acid and polypeptide sequences of the invention, recombinant									
CC	vectors and host cells comprising a PRO nucleic acid, a method for the									
CC	recombinant production of a PRO polypeptide, antibodies against a PRO									
CC	polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic									
CC	acids encoding PRO polypeptides of the invention were initially									
CC	identified via homology screening using consensus sequences based on the									
CC	extracellular domain sequences from known secreted proteins. Human cDNA									
CC	libraries containing sequences of interest were identified using									
CC	oligonucleotides based on the consensus sequences, and cDNA clones were									
CC	isolated and characterised. The PRO polypeptides are useful for									

CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF17732-ACF18036 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCACTCTCTGTGACACATTTTATATAAAATAGGGTTGGCTTCTGAAC 2712

QY 2181 NCTCCCAAAAAA AA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 604
ADA38671
ID ADA38671 standard; cDNA; 2846 BP.
XX
AC ADA38671;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein PRO1344.
XX
KW PRO; secreted protein; transmembrane protein; gene therapy; tumour;
KW cancer; human; ss; gene; colon cancer; lung cancer; breast cancer.
XX
OS Homo sapiens.
XX
PN US2003059780-A1.
XX
PD 27-MAR-2003.
XX
PF 14-NOV-2001; 2001US-00991854.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.

PR	02-JUL-1998;	98US-00916262P.
PR	02-JUL-1998;	98US-00916282P.
PR	02-JUL-1998;	98US-00916333P.
PR	02-JUL-1998;	98US-00916466P.
PR	02-JUL-1998;	98US-00916733P.
PR	07-JUL-1998;	98US-00919787P.
PR	07-JUL-1998;	98US-00919822P.
PR	09-JUL-1998;	98US-00921822P.
PR	10-JUL-1998;	98US-00924722P.
PR	20-JUL-1998;	98US-00933339P.
PR	30-JUL-1998;	98US-00946511P.
PR	04-AUG-1998;	98US-00952822P.
PR	04-AUG-1998;	98US-00952852P.
PR	04-AUG-1998;	98US-00953012P.
PR	04-AUG-1998;	98US-00953022P.
PR	04-AUG-1998;	98US-00953182P.
PR	04-AUG-1998;	98US-00953212P.
PR	04-AUG-1998;	98US-00953252P.
PR	10-AUG-1998;	98US-00959162P.
PR	10-AUG-1998;	98US-00959292P.
PR	10-AUG-1998;	98US-00960122P.
PR	11-AUG-1998;	98US-00961432P.
PR	11-AUG-1998;	98US-00961462P.
PR	12-AUG-1998;	98US-00963292P.
PR	17-AUG-1998;	98US-00967572P.
PR	17-AUG-1998;	98US-00967662P.
PR	17-AUG-1998;	98US-00967682P.
PR	17-AUG-1998;	98US-00967732P.
PR	17-AUG-1998;	98US-00967912P.
PR	17-AUG-1998;	98US-00968672P.
PR	17-AUG-1998;	98US-00968912P.
PR	17-AUG-1998;	98US-00968942P.
PR	17-AUG-1998;	98US-00968952P.
PR	17-AUG-1998;	98US-00968972P.
PR	18-AUG-1998;	98US-00969492P.
PR	18-AUG-1998;	98US-00969502P.
PR	18-AUG-1998;	98US-00969502P.
PR	18-AUG-1998;	98US-00969602P.
PR	18-AUG-1998;	98US-00970222P.
PR	19-AUG-1998;	98US-00971412P.
PR	20-AUG-1998;	98US-00972182P.
PR	24-AUG-1998;	98US-00976612P.
PR	26-AUG-1998;	98US-00979522P.
PR	26-AUG-1998;	98US-00979542P.
PR	26-AUG-1998;	98US-00979552P.
PR	26-AUG-1998;	98US-00979712P.
PR	26-AUG-1998;	98US-00979742P.
PR	26-AUG-1998;	98US-00979782P.
PR	26-AUG-1998;	98US-00979792P.
PR	26-AUG-1998;	98US-00979862P.
PR	26-AUG-1998;	98US-00980142P.
PR	31-AUG-1998;	98US-00985252P.
PR	16-SEP-1998;	98US-01006342P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-01008582P.
PR	17-SEP-1998;	98WO-US019437.
PR	07-OCT-1998;	98WO-US021141.
PR	01-DEC-1998;	98WO-US025108.
PR	22-DEC-1998;	98US-01132962P.
PR	05-JAN-1999;	99WO-US000106.
PR	08-MAR-1999;	99WO-US005028.
PR	12-MAR-1999;	99US-01239572P.
PR	02-JUN-1999;	99WO-US012252.
PR	23-JUN-1999;	99US-01410372P.
PR	07-JUL-1999;	99US-01430482P.
PR	20-JUL-1999;	99US-01447582P.
PR	26-JUL-1999;	99US-01456982P.
PR	28-JUL-1999;	99US-01462222P.
PR	17-AUG-1999;	99US-01493962P.
PR	15-SEP-1999;	99WO-US021090.
PR	15-SEP-1999;	99WO-US021547.
PR	08-OCT-1999;	99US-01586632P.
PR	30-NOV-1999;	99WO-US028313.

PR	01-DEC-1999;	99WO-US028301.
PR	01-DEC-1999;	99WO-US028634.
PR	16-DEC-1999;	99WO-US030095.
PR	20-DEC-1999;	99WO-US030911.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004914.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006319.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	30-MAR-2000;	2000WO-US008439.
PR	15-MAY-2000;	2000WO-US013358.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	23-JUN-2000;	2000US-0213637P.
PR	28-JUL-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US022031.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	07-SEP-2000;	2000US-0230978P.
PR	08-NOV-2000;	2000WO-US030952.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

[illegible]

RESULT 605	
ACF32599	
ID	ACF32599 standard; cDNA; 2846 BP.
XX	
AC	ACF32599;
XX	
DT	24-SEP-2003 (first entry)
DE	
XX	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
KW	Human; PRO; secreted protein; transmembrane protein;
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW	chondrocyte; proliferation; differentiation; cartilage disorder;
KW	bone disorder; arthritis; sports injury; cancer; tumour; cervix;
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW	liver; drug screening; transgenic animal; genetic analysis;
KW	antiarthritic; vulnerability; gene therapy; gene; ss.
OS	Homo sapiens.
XX	
PN	US2003064445-A1.
XX	
PD	03-APR-2003.
XX	
PF	12-JUL-2002; 2002US-00194363.
XX	
PR	05-JUN-2000; 2000US-0209832P.

```
PR 28-FEB-2001; 2001WO-US0006520.
PR 15-JAN-2002; 2002US-00052586.
XX
XX
PA (GETH ) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-567181/53.
DR P-PSDB; ABM12241.
XX
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for diagnosing, preventing and/or treating tumors, such as
PT adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
XX
XX Claim 2; Fig 169; 699pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM12157-ABM12461) and nucleic acids encoding them (ACF32515-ACF32819).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour). This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF32515-ACF32819 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGCCTTACCACCTCTTCCTTTTATCTTATTATAAAAAATGTTGGTCTCCACCACTG 2180
D5 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCCTTCCCATCTCTGTACACATTTTATAATAAATAAGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
D5 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
D5 ||
Db 2773 AA 2774
```

```
RESULT 606
ACF40260
ID ACF40260 standard; cDNA; 2846 BP.
XX
AC ACF40260;
XX
XX 06-NOV-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003064449-A1.
XX
XX 03-APR-2003.
XX
XX 15-JUL-2002; 2002US-00195884.
XX
XX 15-SEP-2000; 2000US-0232887P.
XX 28-FEB-2001; 2001WO-US006520.
XX 15-JAN-2002; 2002US-00052586.
XX
XX (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-596618/56.
DR P-PSDB; ABM16333.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody.
XX
XX Claim 2; Fig 169; 699pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC and nucleic acids encoding them, the invention also provides recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour). This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
```

```
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. The present sequence appears in the
CC exemplification of the specification. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match          3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCATCTCTTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
      ||
Db 2773 AA 2774

RESULT 607
ID ACF48220 standard; cDNA; 2846 BP.
XX
AC ACF48220;
XX
DT 07-OCT-2003 (first entry)
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003064441-A1.
XX
PD 03-APR-2003.
XX
PF 26-JUN-2002; 2002US-00183014.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-006672P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997;
PR 17-DEC-1997;
PR 18-DEC-1997;
PR 10-MAR-1998;
PR 11-MAR-1998;
PR 20-MAR-1998;
PR 20-MAR-1998;
PR 27-MAR-1998;
PR 27-MAR-1998;
PR 31-MAR-1998;
PR 31-MAR-1998;
PR 01-APR-1998;
PR 01-APR-1998;
PR 08-APR-1998;
PR 08-APR-1998;
PR 09-APR-1998;
PR 15-APR-1998;
PR 21-APR-1998;
PR 21-APR-1998;
PR 22-APR-1998;
PR 22-APR-1998;
PR 28-APR-1998;
PR 29-APR-1998;
PR 29-APR-1998;
PR 29-APR-1998;
PR 05-MAY-1998;
PR 06-MAY-1998;
PR 07-MAY-1998;
PR 07-MAY-1998;
PR 07-MAY-1998;
PR 15-MAY-1998;
PR 15-MAY-1998;
PR 15-MAY-1998;
PR 15-MAY-1998;
PR 18-MAY-1998;
PR 22-MAY-1998;
PR 22-MAY-1998;
PR 28-MAY-1998;
PR 28-MAY-1998;
PR 02-JUN-1998;
PR 02-JUN-1998;
PR 02-JUN-1998;
PR 03-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 05-JUN-1998;
PR 05-JUN-1998;
PR 05-JUN-1998;
PR 05-JUN-1998;
PR 09-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;
PR 11-JUN-1998;
PR 11-JUN-1998;
PR 11-JUN-1998;
PR 12-JUN-1998;
PR 12-JUN-1998;
PR 16-JUN-1998;
PR 16-JUN-1998;
PR 17-JUN-1998;
PR 17-JUN-1998;
PR 17-JUN-1998;
PR 18-JUN-1998;
PR 19-JUN-1998;
PR 18-DEC-1997;
PR 17-DEC-1997;
PR 18-DEC-1997;
PR 10-MAR-1998;
PR 11-MAR-1998;
PR 20-MAR-1998;
PR 20-MAR-1998;
PR 27-MAR-1998;
PR 27-MAR-1998;
PR 31-MAR-1998;
PR 31-MAR-1998;
PR 01-APR-1998;
PR 01-APR-1998;
PR 08-APR-1998;
PR 08-APR-1998;
PR 09-APR-1998;
PR 15-APR-1998;
PR 21-APR-1998;
PR 21-APR-1998;
PR 22-APR-1998;
PR 22-APR-1998;
PR 28-APR-1998;
PR 29-APR-1998;
PR 29-APR-1998;
PR 29-APR-1998;
PR 05-MAY-1998;
PR 06-MAY-1998;
PR 07-MAY-1998;
PR 07-MAY-1998;
PR 07-MAY-1998;
PR 15-MAY-1998;
PR 15-MAY-1998;
PR 15-MAY-1998;
PR 15-MAY-1998;
PR 18-MAY-1998;
PR 22-MAY-1998;
PR 22-MAY-1998;
PR 28-MAY-1998;
PR 28-MAY-1998;
PR 02-JUN-1998;
PR 02-JUN-1998;
PR 02-JUN-1998;
PR 03-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 04-JUN-1998;
PR 05-JUN-1998;
PR 05-JUN-1998;
PR 05-JUN-1998;
PR 05-JUN-1998;
PR 09-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;
PR 10-JUN-1998;
PR 11-JUN-1998;
PR 11-JUN-1998;
PR 11-JUN-1998;
PR 12-JUN-1998;
PR 12-JUN-1998;
PR 16-JUN-1998;
PR 16-JUN-1998;
PR 17-JUN-1998;
PR 17-JUN-1998;
PR 17-JUN-1998;
PR 18-JUN-1998;
PR 19-JUN-1998;
```


XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM14597-ABM14901) and nucleic acids encoding them (ACF38085-ACF38389).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF38085-ACF38389 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTGTCTTACCACCTCTTCTCTTTATCTTATTATAAATAATGTGGTCTCCACCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCTTCCCATCTCTTGTACACATTTTAATAAATAAGGTTGGCTTCTGAACATA 2712
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2181 NCTCCCAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAIAA 2772
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2241 AA 2242
||
Db 2773 AA 2774

RESULT 609
ACF25105
ID ACF25105 standard; cDNA; 2846 BP.
XX ACF25105;
AC ACF25105;
XX
DT 01-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulneryary; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003068712-A1.
PN 10-APR-2003.
PD 17-JUL-2002; 2002US-00197693.
XX 24-NOV-1997; 97US-0066466P.
PR 16-SEP-1998; 98WO-US019330.
PR 25-AUG-1999; 99US-00380139.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
PI WPI; 2003-615882/58.
DR P-PSDB; ABM04562.
DR
XX New secreted and transmembrane PRO nucleic acids, useful for the
PT manufacture of a medicament for diagnosing or treating tumors or for
PT tissue typing.
XX Claim 2; Fig 169; 700pp; English.
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM04478-ABM04782) and nucleic acids encoding them (ACF25021-ACF25325).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF25021-ACF25325 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ

XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 28-APR-1998; 98US-0082797P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088302P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.

PR	10-SEP-1998;	98US-0099812P;
PR	15-SEP-1998;	98US-0100388P;
PR	16-SEP-1998;	98US-0100662P;
PR	16-SEP-1998;	98US-0100664P;
PR	16-SEP-1998;	98US-0101751P;
PR	16-SEP-1998;	98WO-US019330;
PR	17-SEP-1998;	98US-0100683P;
PR	17-SEP-1998;	98US-0100684P;
PR	17-SEP-1998;	98US-0100919P;
PR	17-SEP-1998;	98US-0100930P;
PR	18-SEP-1998;	98US-0100849P;
PR	18-SEP-1998;	98US-0101014P;
PR	18-SEP-1998;	98US-0101068P;
PR	23-SEP-1998;	98US-0101471P;
PR	23-SEP-1998;	98US-0101472P;
PR	23-SEP-1998;	98US-0101475P;
PR	23-SEP-1998;	98US-0101477P;
PR	24-SEP-1998;	98US-0101738P;
PR	24-SEP-1998;	98US-0101739P;
PR	24-SEP-1998;	98US-0101743P;
PR	24-SEP-1998;	98US-0101922P;
PR	25-SEP-1998;	98US-0101786P;
PR	29-SEP-1998;	98US-0102207P;
PR	29-SEP-1998;	98US-0102240P;
PR	29-SEP-1998;	98US-0102330P;
PR	29-SEP-1998;	98US-0102331P;
PR	30-SEP-1998;	98US-0102487P;
PR	30-SEP-1998;	98US-0102570P;
PR	30-SEP-1998;	98US-0102571P;
PR	01-OCT-1998;	98US-0102684P;
PR	01-OCT-1998;	98US-0102687P;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

[illegible]

RESULT 612

ACD87695

ACD87695;

DT 06-OCT-2003 (first entry)

DE Human secreted/transmembrane protein (PRO) cDNA #85.

Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha; tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy; tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour; cervical tumour; liver tumour.

OS Homo sapiens.

PN US2003068775-A1.

PD 10-APR-2003.

29-JUL-2002: 2002US-00208029.

PR 23-MAR-1999: 99US-0125775P

02-MAR-2000; 2000WO-US005841.
28-FEB-2001; 2001WO-US006520.
15-JAN-2002; 2002US-00052586.

(GETH) GENENTECH INC.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-625481/59.
P-PSDB; ABO39231.

Novel isolated PRO polypeptides e.g. PRO1079, PRO827 and PRO791, useful for stimulating the release of TNF alpha from human blood and for stimulating the proliferation or differentiation of chondrocyte cells.

Claim 2; Fig 169; 700pp; English.

The invention discloses human nucleic acids encoding secreted and transmembrane (PRO) polypeptides, with or without their associated signal peptide. Also disclosed is an antibody that specifically binds to the PRO polypeptide, a method for stimulating the release of tumour necrosis factor alpha (TNF-alpha) from human blood by contacting the blood with a PRO polypeptide, a method for stimulating the proliferation or differentiation of chondrocyte cells by contacting the cells with a PRO polypeptide, a method for detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the PRO nucleotide sequences. The nucleotide sequences are useful as probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant techniques and in gene therapy (e.g. for replacement of defective gene). The PRO polypeptides are useful as molecular weight markers for protein electrophoresis purposes, for chromosome identification, as chromosome markers, as therapeutic agents, for stimulating the release of TNF-alpha from human blood, for stimulating the proliferation or differentiation of chondrocytes and detecting the presence, prevention and/or treatment of a tumour, such as adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour. The PRO polypeptides and nucleic acids may also be used diagnostically for tissue typing. The sequence presented is a cDNA encoding one of the PRO polypeptides of the invention. Note: The sequence data for this patent can also be obtained in electronic format directly from USPTO at seqdata.uspto.gov/sequence.html

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match	3.0%	Score 66.6	DB 9	Length 2846
-------------	------	------------	------	-------------

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGCTTACCACTCTTTCCCTTTATCTTATTAATAAAAAAGTTGGTCTCCACCACTG 2180

[illegible]

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 613

ACF76156

ID ACF76156 standard; cDNA; 2846 BP.

AC
ACF76156;

DT 06-NOV-2003 (first entry)

Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

Human: PRO: secreted protein: transmembrane protein:

PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.

PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.

```
PR 01-OCT-1998; 98US-0102687P.
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCTCCTTTATCTTATTAATAAATGTTGGTCTCCACCACTG 2180
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 615
ACF43905
ID ACF43905 standard; cDNA; 2846 BP.
XX
AC ACF43905;
XX
DT 03-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003104554-A1.
XX
PD 05-JUN-2003.
XX
PF 24-JUL-2002; 2002US-00205508.
XX
PR 10-JUN-1998; 98US-0088826P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-670250/63.
DR P-PSDB; ABM19930.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
PT colon, breast, prostate, rectal, cervical or liver tumors.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM19846-ABM20150) and nucleic acids encoding them (ACF43821-ACF44125).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
```

```
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF43821-ACF44125 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCTCCTTTATCTTATTAATAAATGTTGGTCTCCACCACTG 2180
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAATAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 616
ACH06250
ID ACH06250 standard; cDNA; 2846 BP.
XX
AC ACH06250;
XX
DT 08-OCT-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #85.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW chromosome mapping; gene mapping; tumour necrosis factor-alpha;
KW TNF-alpha; proliferation; differentiation; chondrocyte cell; cytostatic;
KW gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003049762-A1.
XX
PD 13-MAR-2003.
XX
PF 19-JUL-2002; 2002US-00199314.
```

XX 23-SEP-1998; 98US-0101472P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-669841/63.
DR P-PSDB; ABO46836.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful in
PT gene therapy, or for preparing a medicament for treating a condition that
PT is responsive to the PRO polypeptide or anti-PRO antibody.
XX Claim 2; Fig 169; 700pp; English.
XX The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polynucleotide sequences are useful in molecular biology as hybridisation
CC probes, in chromosome and gene mapping, in generating antisense RNA and
CC DNA, and in gene therapy. The PRO polypeptides are useful as
CC pharmaceuticals, diagnostics, biosensors or bioreactors for the detection
CC of tumours. They are also useful for stimulating the release of tumour
CC necrosis factor (TNF)-alpha from human blood, or for stimulating the
CC proliferation or differentiation of chondrocyte cells. The anti-PRO
CC antibodies may be used in diagnostic assays for PRO polypeptides, or for
CC the affinity purification of PRO polypeptides from recombinant cell
CC culture or natural sources. ACH06166-ACH06470 represent cDNA sequences
CC encoding the human PRO polypeptides of the invention. Note: The sequence
CC data for this patent was obtained in electronic format directly from the
CC USPTO web site at seqdata.uspto.gov/psipsdIDEntry.html
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGTCTTACCACCTCTTCTCTTTATCTTTATTAATAAAATGTTGGTCTCCACCACGTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATTAATAAAGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAA 2240
Db 2713 CAAAAAATAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 617
ACH06557
ID ACH06557 standard; cDNA; 2846 BP.
XX ACH06557;
AC ACH06557;
XX 08-OCT-2003 (first entry)
XX cDNA encoding human PRO polypeptide #85.
DE Human; PRO polypeptide; secreted protein; transmembrane protein;
XX chromosome mapping; gene mapping; molecular weight marker;
KW protein electrophoresis; affinity purification; tumour; adrenal; lung;
KW colon; breast; prostate; rectal; cervical; liver; cancer; cytostatic;
KW gene therapy; gene; ss.
XX

OS Homo sapiens.
XX US2003049765-A1.
PN 13-MAR-2003.
PD 18-JUL-2002; 2002US-00199666.
PF 05-JUN-1998; 98US-0088217P.
XX 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX (GETH) GENENTECH INC.
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
PI WPI; 2003-669842/63.
DR P-PSDB; ABO47141.
XX Three hundred and five nucleic acids encoding PRO polypeptides, useful in
PT gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX Claim 2; Fig 169; 700pp; English.
XX The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polynucleotide sequences are useful in molecular biology as hybridisation
CC probes, in chromosome and gene mapping, in generating antisense RNA and
CC DNA, and in gene therapy. The PRO polypeptides are useful for the
CC diagnosis, prevention and/or treatment of tumours. They are also useful
CC as molecular weight markers for protein electrophoresis purposes. The
CC anti-PRO antibodies may be used in diagnostic assays for PRO
CC polypeptides, or for the affinity purification of PRO polypeptides from
CC recombinant cell culture or natural sources. ACH06473-ACH06777 represent
CC cDNA sequences encoding the human PRO polypeptides of the invention.
CC Note: The sequence data for this patent was obtained in electronic format
CC directly from the USPTO web site at seqdata.uspto.gov/psipsdIDEntry.html
XX SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGTCTTACCACCTCTTCTCTTTATCTTTATTAATAAAATGTTGGTCTCCACCACGTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTATTAATAAAGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAA 2240
Db 2713 CAAAAAATAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 618
ADA83238
ID ADA83238 standard; cDNA; 2846 BP.
XX ADA83238;
AC ADA83238;
XX 20-NOV-2003 (first entry)
DT Human secreted/transmembrane protein (PRO) cDNA #85.
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW

PR 29-APR-1998; 98US-00835559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.

PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCTTTGCTTTACCACCTCTTCCCTTTTATCTTATTATAAAAAATGTTGGTCTCCACCACCTG 2180

Db 22653 CCTTTTCCTTCCCATCTCTTGTAACACATTTTATAAAATAAGGGTTGGCTTCTGAACTA 2712

Qy 2181 NCTCCCAAA 2240

Db 2713 CAAA 2772

Qy 2241 AA 2242

Db ||
 2773 AA 2774

RESULT 620
ACC93227
ID ACC93227 standard; cDNA; 2846 BP.
XX
AC ACC93227;
XX
DT 22-AUG-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003032136-A1.
XX
PD 13-FEB-2003.
XX
PF 02-JUL-2002; 2002US-00187596.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.

PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.

Qy	2241 AA 2242	
Db	2773 AA 2774	
RESULT 622		
ACD12963		
ID	ACD12963 standard; cDNA; 2846 BP.	
XX		
AC	ACD12963;	
XX	17-AUG-2003 (first entry)	
DT		
XX	Human secreted/transmembrane protein (PRO) cDNA #85.	
DE		
XX	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;	
KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;	
KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;	
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.	
XX		
OS	Homo sapiens.	
XX		
PN	US2003040053-A1.	
XX		
PD	27-FEB-2003.	
XX		
PF	17-JUN-2002; 2002US-00173708.	
XX		
PR	18-SEP-1997;	97US-0059263P.
PR	18-SEP-1997;	97US-0059266P.
PR	17-OCT-1997;	97US-0062250P.
PR	21-OCT-1997;	97US-0063486P.
PR	24-OCT-1997;	97US-0063120P.
PR	24-OCT-1997;	97US-0063121P.
PR	28-OCT-1997;	97US-0063540P.
PR	28-OCT-1997;	97US-0063541P.
PR	28-OCT-1997;	97US-0063544P.
PR	28-OCT-1997;	97US-0063564P.
PR	29-OCT-1997;	97US-0063734P.
PR	31-OCT-1997;	97US-0063870P.
PR	31-OCT-1997;	97US-0064103P.
PR	13-NOV-1997;	97US-0065311P.
PR	21-NOV-1997;	97US-0066120P.
PR	24-NOV-1997;	97US-0066466P.
PR	24-NOV-1997;	97US-0066772P.
PR	11-DEC-1997;	97US-0069335P.
PR	12-DEC-1997;	97US-0069425P.
PR	17-DEC-1997;	97US-0069870P.
PR	18-DEC-1997;	97US-0068017P.
PR	10-MAR-1998;	98US-0077450P.
PR	11-MAR-1998;	98US-0077632P.
PR	11-MAR-1998;	98US-0077649P.
PR	20-MAR-1998;	98US-0078886P.
PR	20-MAR-1998;	98US-0078939P.
PR	27-MAR-1998;	98US-0079664P.
PR	27-MAR-1998;	98US-0079786P.
PR	31-MAR-1998;	98US-0080107P.
PR	31-MAR-1998;	98US-0080194P.
PR	01-APR-1998;	98US-0080327P.
PR	01-APR-1998;	98US-0080333P.
PR	08-APR-1998;	98US-0081049P.
PR	08-APR-1998;	98US-0081070P.
PR	09-APR-1998;	98US-0081195P.
PR	15-APR-1998;	98US-0081838P.
PR	21-APR-1998;	98US-0082568P.
PR	21-APR-1998;	98US-0082569P.
PR	22-APR-1998;	98US-0082704P.
PR	22-APR-1998;	98US-0082797P.
PR	28-APR-1998;	98US-0083322P.
PR	29-APR-1998;	98US-0083495P.
PR	29-APR-1998;	98US-0083496P.
PR	29-APR-1998;	98US-0083499P.

PR	29-APR-1998;	98US-0083559P.
PR	05-MAY-1998;	98US-0084366P.
PR	06-MAY-1998;	98US-0084414P.
PR	07-MAY-1998;	98US-0084639P.
PR	07-MAY-1998;	98US-0084640P.
PR	07-MAY-1998;	98US-0084643P.
PR	15-MAY-1998;	98US-0085579P.
PR	15-MAY-1998;	98US-0085580P.
PR	15-MAY-1998;	98US-0085582P.
PR	15-MAY-1998;	98US-0085700P.
PR	18-MAY-1998;	98US-0086023P.
PR	22-MAY-1998;	98US-0086392P.
PR	22-MAY-1998;	98US-0086486P.
PR	28-MAY-1998;	98US-0087098P.
PR	28-MAY-1998;	98US-0087208P.
PR	02-JUN-1998;	98US-0087609P.
PR	02-JUN-1998;	98US-0087759P.
PR	03-JUN-1998;	98US-0087827P.
PR	04-JUN-1998;	98US-0088025P.
PR	04-JUN-1998;	98US-0088028P.
PR	04-JUN-1998;	98US-0088029P.
PR	04-JUN-1998;	98US-0088033P.
PR	04-JUN-1998;	98US-0088326P.
PR	05-JUN-1998;	98US-0088167P.
PR	05-JUN-1998;	98US-0088202P.
PR	05-JUN-1998;	98US-0088212P.
PR	05-JUN-1998;	98US-0088217P.
PR	09-JUN-1998;	98US-0088655P.
PR	10-JUN-1998;	98US-0088722P.
PR	10-JUN-1998;	98US-0088738P.
PR	10-JUN-1998;	98US-0088740P.
PR	10-JUN-1998;	98US-0088811P.
PR	10-JUN-1998;	98US-0088824P.
PR	10-JUN-1998;	98US-0088825P.
PR	10-JUN-1998;	98US-0088826P.
PR	11-JUN-1998;	98US-0088861P.
PR	11-JUN-1998;	98US-0088863P.
PR	11-JUN-1998;	98US-0088876P.
PR	12-JUN-1998;	98US-0089090P.
PR	12-JUN-1998;	98US-0089105P.
PR	16-JUN-1998;	98US-0089512P.
PR	16-JUN-1998;	98US-0089514P.
PR	17-JUN-1998;	98US-0089538P.
PR	17-JUN-1998;	98US-0089598P.
PR	17-JUN-1998;	98US-0089653P.
PR	18-JUN-1998;	98US-0089908P.
PR	19-JUN-1998;	98US-0089952P.
PR	22-JUN-1998;	98US-0090246P.
PR	22-JUN-1998;	98US-0090252P.
PR	22-JUN-1998;	98US-0090254P.
PR	24-JUN-1998;	98US-0090429P.
PR	24-JUN-1998;	98US-0090435P.
PR	24-JUN-1998;	98US-0090444P.
PR	24-JUN-1998;	98US-0090461P.
PR	24-JUN-1998;	98US-0090535P.
PR	24-JUN-1998;	98US-0090540P.
PR	25-JUN-1998;	98US-0090676P.
PR	25-JUN-1998;	98US-0090678P.
PR	25-JUN-1998;	98US-0090688P.
PR	25-JUN-1998;	98US-0090694P.
PR	25-JUN-1998;	98US-0090695P.
PR	25-JUN-1998;	98US-0090696P.
PR	26-JUN-1998;	98US-00105413.
PR	26-JUN-1998;	98US-0090862P.
PR	26-JUN-1998;	98US-0090863P.
PR	26-JUN-1998;	98US-0091010P.
PR	01-JUL-1998;	98US-0091359P.
PR	01-JUL-1998;	98US-0091544P.
PR	02-JUL-1998;	98US-0091478P.
PR	02-JUL-1998;	98US-0091486P.
PR	02-JUL-1998;	98US-0091626P.
PR	02-JUL-1998;	98US-0091628P.


```
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 30-SEP-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 01-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
```

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

```
Qy 2121 CCTTTGCTTTACCACCTCTTTCCTTTTATCTTATTAATAAAAAATGTTGCTCTCCACCACGTG 2180
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTCCCATCTCTTGACACATTTTAATAAAATAAGGGTTGGCTTCTGAACATA 2712
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
```

```
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
Qy 2241 AA 2242
      ||
Db 2773 AA 2774

RESULT 623
ACF06421
ID ACF06421 standard; cDNA; 2846 BP.
XX
AC ACF06421;
XX
DT 13-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003040057-A1.
XX
PD 27-FEB-2003.
XX
PF 24-JUN-2002; 2002US-00179507.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
```


Db 2713 CAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 624
ACC94455
ID ACC94455 standard; cDNA; 2846 BP.
XX ACC94455;
AC ACC94455;
DT 29-AUG-2003 (first entry)
XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
DE Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX US2003054467-A1.
XX 20-MAR-2003.
XX 18-JUL-2002; 2002US-00199458.
XX 25-JUN-1998; 98US-0090694P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-479873/45.
DR P-PSDB; ABR73402.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
PT colon, breast, prostate, rectal, cervical or liver tumors.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABR73318-ABR73622) and nucleic acids encoding them (ACC94371-ACC94675).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may

be used in a method for detecting the presence of a tumour (e.g., an
adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
method involves comparing the level of expression of the PRO polypeptide,
in test and control samples, where a higher level of expression of PRO
polypeptide in the test sample as compared to the control sample is
indicative of the presence of a tumour. The PRO polypeptides are
additionally useful for in drug screening to identify agonists and
antagonists of PRO polypeptides. PRO nucleic acids are useful as
hybridisation probes (for isolation of cDNA molecules), in chromosome and
gene mapping, in the generation of antisense RNA and DNA and in gene
therapy. The nucleic acids can also be used for mapping genes encoding
PRO polypeptides, for genetic analysis of individuals with genetic
disorders, and for generating either transgenic animals or knock-out
animals which are useful in the development and screening of
therapeutically useful compounds. Sequences ACC94371-ACC94675 represent
cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
invention. Note: The sequence data for this patent is also available in
electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTGTCTTACCACCTCTTTCTTTATCTTATTATAATAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCCTTCCCCATCTCTGTACACATTTTAAATAAATAGGTTGGCTTCTGAACCTA 2712
QY 2181 NCTCCCAA 2240
Db 2713 CAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774
RESULT 625
ACC97883
ID ACC97883 standard; cDNA; 2846 BP.
XX
AC ACC97883;
XX
DT 19-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX Homo sapiens.
XX US2003044932-A1.
PN 06-MAR-2003.
XX
PD 09-JUL-2002; 2002US-00192010.
PF 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-00633544P.
PR 28-OCT-1997; 97US-00633564P.
PR 29-OCT-1997; 97US-00637344P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.

PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.

Query Match	3.0%;	Score 66.6;	DB 9;	Length 2846;
Best Local Similarity	71.3%;	Pred. No. 0.00023;		
Matches 87;	Conservative 0;	Mismatches 35;	Indels 0;	Gaps 0;
QY	2121	CCTTTGCTTTACCACTCTTTCTCTTTTATCTTATTAATAAATGTTGGTCTCCACCACCTG	2180	
DB	2653	CCTTTTCTTCCCATCTCTTGTACACATTTTAATAAATAAGGTTGGCTTCTGAACCTA	2712	
QY	2181	NCTCCCAA	2240	
DB	2713	CAA	2772	
QY	2241	AA 2242		
DB	2773	AA 2774		
RESULT 626				
ACC94148				
ID	ACC94148	standard; cDNA; 2846 BP.		
XX				
AC	ACC94148;			
XX				
DT	22-AUG-2003	(first entry)		
XX				
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.			
XX				
KW	Human; PRO; secreted protein; transmembrane protein;			
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;			
KW	chondrocyte; proliferation; differentiation; cartilage disorder;			
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;			
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;			
KW	liver; drug screening; transgenic animal; genetic analysis;			
KW	antiarthritic; vulnary; gene therapy; gene; ss.			
XX				
OS	Homo sapiens.			
XX				
PN	US2003027270-A1.			
XX				
PD	06-FEB-2003.			
XX				
PF	19-JUN-2002; 2002US-00175746.			
XX				
PR	18-SEP-1997; 97US-0059263P.			
PR	18-SEP-1997; 97US-0059266P.			
PR	17-OCT-1997; 97US-0062250P.			
PR	21-OCT-1997; 97US-0063486P.			
PR	24-OCT-1997; 97US-0063120P.			
PR	28-OCT-1997; 97US-0063121P.			
PR	28-OCT-1997; 97US-0063540P.			
PR	17-SEP-1998; 98US-0100930P.			
PR	18-SEP-1998; 98US-0100849P.			
PR	18-SEP-1998; 98US-0101014P.			
PR	18-SEP-1998; 98US-0101068P.			
PR	23-SEP-1998; 98US-0101471P.			
PR	23-SEP-1998; 98US-0101472P.			
PR	23-SEP-1998; 98US-0101475P.			
PR	23-SEP-1998; 98US-0101477P.			
PR	24-SEP-1998; 98US-0101738P.			
PR	24-SEP-1998; 98US-0101739P.			
PR	24-SEP-1998; 98US-0101743P.			
PR	24-SEP-1998; 98US-0101922P.			
PR	25-SEP-1998; 98US-0101786P.			
PR	29-SEP-1998; 98US-0102207P.			
PR	29-SEP-1998; 98US-0102240P.			
PR	29-SEP-1998; 98US-0102330P.			
PR	30-SEP-1998; 98US-0102331P.			
PR	30-SEP-1998; 98US-0102487P.			
PR	30-SEP-1998; 98US-0102570P.			
PR	30-SEP-1998; 98US-0102571P.			
PR	01-OCT-1998; 98US-0102684P.			
PR	01-OCT-1998; 98US-0102687P.			
PR	28-OCT-1997; 97US-0063541P.			
PR	28-OCT-1997; 97US-0063544P.			
PR	28-OCT-1997; 97US-0063564P.			
PR	29-OCT-1997; 97US-0063734P.			
PR	31-OCT-1997; 97US-0063870P.			
PR	31-OCT-1997; 97US-0064103P.			
PR	13-NOV-1997; 97US-0065311P.			
PR	21-NOV-1997; 97US-0066120P.			
PR	24-NOV-1997; 97US-0066466P.			
PR	24-NOV-1997; 97US-0066772P.			
PR	11-DEC-1997; 97US-0069335P.			
PR	12-DEC-1997; 97US-0069425P.			
PR	17-DEC-1997; 97US-0069870P.			

PR	15-MAY-1998;	98US-00851998;	98US-0085700P;
PR	18-MAY-1998;	98US-0086023P;	98US-0086023P;
PR	22-MAY-1998;	98US-0086392P;	98US-0086392P;
PR	22-MAY-1998;	98US-0086486P;	98US-0086486P;
PR	28-MAY-1998;	98US-0087098P;	98US-0087098P;
PR	28-MAY-1998;	98US-0087208P;	98US-0087208P;
PR	02-JUN-1998;	98US-0087609P;	98US-0087609P;
PR	02-JUN-1998;	98US-0087759P;	98US-0087759P;
PR	03-JUN-1998;	98US-0087827P;	98US-0087827P;
PR	04-JUN-1998;	98US-0088025P;	98US-0088025P;
PR	04-JUN-1998;	98US-0088028P;	98US-0088028P;
PR	04-JUN-1998;	98US-0088029P;	98US-0088029P;
PR	04-JUN-1998;	98US-0088326P;	98US-0088326P;
PR	05-JUN-1998;	98US-0088167P;	98US-0088167P;
PR	05-JUN-1998;	98US-0088202P;	98US-0088202P;
PR	05-JUN-1998;	98US-0088212P;	98US-0088212P;
PR	05-JUN-1998;	98US-0088217P;	98US-0088217P;
PR	09-JUN-1998;	98US-0088655P;	98US-0088655P;
PR	10-JUN-1998;	98US-0088722P;	98US-0088722P;
PR	10-JUN-1998;	98US-0088738P;	98US-0088738P;
PR	10-JUN-1998;	98US-0088740P;	98US-0088740P;
PR	10-JUN-1998;	98US-0088811P;	98US-0088811P;
PR	10-JUN-1998;	98US-0088824P;	98US-0088824P;
PR	10-JUN-1998;	98US-0088825P;	98US-0088825P;
PR	10-JUN-1998;	98US-0088826P;	98US-0088826P;
PR	11-JUN-1998;	98US-0088861P;	98US-0088861P;
PR	11-JUN-1998;	98US-0088863P;	98US-0088863P;
PR	11-JUN-1998;	98US-0088876P;	98US-0088876P;
PR	12-JUN-1998;	98US-0089090P;	98US-0089090P;
PR	12-JUN-1998;	98US-0089105P;	98US-0089105P;
PR	16-JUN-1998;	98US-0089512P;	98US-0089512P;
PR	16-JUN-1998;	98US-0089514P;	98US-0089514P;
PR	17-JUN-1998;	98US-0089538P;	98US-0089538P;
PR	17-JUN-1998;	98US-0089598P;	98US-0089598P;
PR	17-JUN-1998;	98US-0089653P;	98US-0089653P;
PR	18-JUN-1998;	98US-0089908P;	98US-0089908P;
PR	19-JUN-1998;	98US-0089952P;	98US-0089952P;
PR	22-JUN-1998;	98US-0090246P;	98US-0090246P;
PR	22-JUN-1998;	98US-0090252P;	98US-0090252P;
PR	22-JUN-1998;	98US-0090254P;	98US-0090254P;
PR	24-JUN-1998;	98US-0090429P;	98US-0090429P;
PR	24-JUN-1998;	98US-0090435P;	98US-0090435P;
PR	24-JUN-1998;	98US-0090444P;	98US-0090444P;
PR	24-JUN-1998;	98US-0090461P;	98US-0090461P;
PR	24-JUN-1998;	98US-0090535P;	98US-0090535P;
PR	24-JUN-1998;	98US-0090540P;	98US-0090540P;
PR	25-JUN-1998;	98US-0090676P;	98US-0090676P;
PR	25-JUN-1998;	98US-0090678P;	98US-0090678P;
PR	25-JUN-1998;	98US-0090688P;	98US-0090688P;
PR	25-JUN-1998;	98US-0090690P;	98US-0090690P;
PR	25-JUN-1998;	98US-0090694P;	98US-0090694P;
PR	25-JUN-1998;	98US-0090695P;	98US-0090695P;
PR	25-JUN-1998;	98US-0090696P;	98US-0090696P;
PR	26-JUN-1998;	98US-00105413;	98US-00105413;
PR	26-JUN-1998;	98US-0090862P;	98US-0090862P;
PR	26-JUN-1998;	98US-0090863P;	98US-0090863P;
PR	26-JUN-1998;	98US-0091010P;	98US-0091010P;
PR	01-JUL-1998;	98US-0091359P;	98US-0091359P;
PR	01-JUL-1998;	98US-0091544P;	98US-0091544P;
PR	02-JUL-1998;	98US-0091478P;	98US-0091478P;
PR	02-JUL-1998;	98US-0091486P;	98US-0091486P;
PR	02-JUL-1998;	98US-0091626P;	98US-0091626P;
PR	02-JUL-1998;	98US-0091628P;	98US-0091628P;
PR	02-JUL-1998;	98US-0091632P;	98US-0091632P;
PR	24-JUL-1998;	98US-0094006P;	98US-0094006P;
PR	04-AUG-1998;	98US-0095282P;	98US-0095282P;
PR	10-AUG-1998;	98US-0095998P;	98US-0095998P;
PR	10-AUG-1998;	98US-0096012P;	98US-0096012P;
PR	17-AUG-1998;	98US-0096757P;	98US-0096757P;
PR	17-AUG-1998;	98US-0096766P;	98US-0096766P;
PR	17-AUG-1998;	98US-009686	

PR	17-AUG-1998;	98US-0096897P;
PR	18-AUG-1998;	98US-0096949P;
PR	18-AUG-1998;	98US-0096959P;
PR	18-AUG-1998;	98US-0097022P;
PR	26-AUG-1998;	98US-0097952P;
PR	26-AUG-1998;	98US-0097954P;
PR	26-AUG-1998;	98US-0097955P;
PR	26-AUG-1998;	98US-0097971P;
PR	26-AUG-1998;	98US-0097974P;
PR	26-AUG-1998;	98US-0098014P;
PR	01-SEP-1998;	98US-0098716P;
PR	01-SEP-1998;	98US-0098723P;
PR	02-SEP-1998;	98US-0098803P;
PR	02-SEP-1998;	98US-0098821P;
PR	02-SEP-1998;	98US-0098843P;
PR	09-SEP-1998;	98US-0099602P;
PR	10-SEP-1998;	98US-0099741P;
PR	10-SEP-1998;	98US-0099754P;
PR	10-SEP-1998;	98US-0099763P;
PR	15-SEP-1998;	98US-0099812P;
PR	15-SEP-1998;	98US-0100388P;
PR	16-SEP-1998;	98US-0100662P;
PR	16-SEP-1998;	98US-0100664P;
PR	16-SEP-1998;	98US-0101751P;
PR	16-SEP-1998;	98WO-US019330;
PR	17-SEP-1998;	98US-0100683P;
PR	17-SEP-1998;	98US-0100684P;
PR	17-SEP-1998;	98US-0100919P;
PR	17-SEP-1998;	98US-0100930P;
PR	18-SEP-1998;	98US-0100849P;
PR	18-SEP-1998;	98US-0101014P;
PR	18-SEP-1998;	98US-0101068P;
PR	23-SEP-1998;	98US-0101471P;
PR	23-SEP-1998;	98US-0101472P;
PR	23-SEP-1998;	98US-0101475P;
PR	23-SEP-1998;	98US-0101477P;
PR	24-SEP-1998;	98US-0101738P;
PR	24-SEP-1998;	98US-0101739P;
PR	24-SEP-1998;	98US-0101743P;
PR	24-SEP-1998;	98US-0101922P;
PR	25-SEP-1998;	98US-0101786P;
PR	29-SEP-1998;	98US-0102207P;
PR	29-SEP-1998;	98US-0102240P;
PR	29-SEP-1998;	98US-0102330P;
PR	29-SEP-1998;	98US-0102331P;
PR	30-SEP-1998;	98US-0102487P;
PR	30-SEP-1998;	98US-0102570P;
PR	30-SEP-1998;	98US-0102571P;
PR	01-OCT-1998;	98US-0102684P;
PR	01-OCT-1998;	98US-0102687P;
PR	02-OCT-1998;	98US-0102965P;
PR	06-OCT-1998;	98US-0103258P;
PR	06-OCT-1998;	98US-0103449P;

Query Match

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Qy	2121	CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAAATAAAATGTTGGTCTCCACCAC	2180
Db	2653	CCTTTTCCTTCCCATCTCTTGTCACATTTTAATAAAATAAGGTTGGCTTCTGAAC	2712
Qy	2181	NCTCCCAA	2240
Db	2713	CAA	2772
Qy	2241	AA	2242
Db	2773	AA	2774

RESULT 629
ACD43037

Db 2653 CCTTTCTCCCATCTCTGTACACATTTTAATAAAATAAGGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCAAAAAATAA 2240
Db 2713 CAAAAAATAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 631
ACF14874
ID ACF14874 standard; cDNA; 2846 BP.
XX
XX ACF14874;
XX
DT 02-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.

OS Homo sapiens.
XX
XX US2003059879-A1.
PN
XX
PD 27-MAR-2003.
XX
PF 12-JUL-2002; 2002US-00194456.
XX
XX 15-SEP-2000; 2000US-0232887P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-540681/51.
XX P-PSDB; ABR94079.

PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for diagnosing, preventing and/or treating tumors, such as
PT adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
XX
PS Claim 2; Fig 169; 700pp; English.

XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABR93995-ABR94299) and nucleic acids encoding them (ACF14790-ACF15094).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as

CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF14790-ACF15094 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
SQ
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2653 CCTTTTCTTCCCATCTCTTGTACACATTTTAATAAAATAGGGTTGCTTCTGAACTA 2712
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2181 NCTCCAAAAAATAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 632

ADA92792
ID ADA92792 standard; cDNA; 2846 BP.
XX
AC ADA92792;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein PRO1344.
XX
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; ss; gene; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX
PN US2003060407-A1.
XX
PD 27-MAR-2003.
XX
PF 14-NOV-2001; 2001US-00990440.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 25-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.

PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.

PR	08-OCT-1999;	99US-0158663P.
PR	30-NOV-1999;	99WO-US028313.
PR	01-DEC-1999;	99WO-US028301.
PR	01-DEC-1999;	99WO-US028634.
PR	16-DEC-1999;	99WO-US030095.
PR	20-DEC-1999;	99WO-US030911.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004914.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006319.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	30-MAR-2000;	2000WO-US008439.
PR	15-MAY-2000;	2000WO-US013358.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	23-JUN-2000;	2000US-0213637P.

	Query Match	3.0%;	Score 66.6;	DB 9;	Length 2846;
	Best Local Similarity	71.3%;	Pred. No. 0.00023;		
	Matches	87;	Conservative	0;	Mismatches 35; Indels 0; Gaps 0;
Qy	2121	CCTTTGGTTTACCACACTCTTTTCCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG	2180		
Db	2653	CCTTTTCCTTCCCCCATCTCTTGTCACACATTTTAATAAAATAAGGTTGGCTTCTGAACTA	2712		
Qy	2181	NCTCCCAA	2240		
Db	2713	CAA	2772		
Qy	2241	AA	2242		
Db	2773	AA	2774		

RESULT 633	
ACF01606	
ID	ACF01606 standard; cDNA; 2846 BP.
XX	
AC	ACF01606;
XX	
DT	05-SEP-2003. (first entry)
XX	
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX	
KW	Human; PRO; secreted protein; transmembrane protein;
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW	chondrocyte; proliferation; differentiation; cartilage disorder;
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW	liver; drug screening; transgenic animal; genetic analysis;
KW	antiarthritic; vulnerary; gene therapy; gene; ss.
XX	
OS	Homo sapiens.
XX	
PN	US2003049738-A1.
XX	
PD	13-MAR-2003.
XX	
PF	27-JUN-2002; 2002US-00184619.
XX	
PR	18-SEP-1997; 97US-0059263P.
PR	18-SEP-1997; 97US-0059266P.
PR	17-OCT-1997; 97US-0062250P.
PR	21-OCT-1997; 97US-0063486P.
PR	24-OCT-1997; 97US-0063120P.

PR	24-OCT-1997;	97US-0063121P.
PR	28-OCT-1997;	97US-0063540P.
PR	28-OCT-1997;	97US-0063541P.
PR	28-OCT-1997;	97US-0063544P.
PR	28-OCT-1997;	97US-0063564P.
PR	29-OCT-1997;	97US-0063734P.
PR	31-OCT-1997;	97US-0063870P.
PR	31-OCT-1997;	97US-0064103P.
PR	13-NOV-1997;	97US-0065311P.
PR	21-NOV-1997;	97US-0066120P.
PR	24-NOV-1997;	97US-0066466P.
PR	24-NOV-1997;	97US-0066772P.
PR	11-DEC-1997;	97US-0069335P.
PR	12-DEC-1997;	97US-0069425P.
PR	17-DEC-1997;	97US-0069870P.
PR	18-DEC-1997;	97US-0068017P.
PR	10-MAR-1998;	98US-0077450P.
PR	11-MAR-1998;	98US-0077632P.
PR	11-MAR-1998;	98US-0077649P.
PR	20-MAR-1998;	98US-0078886P.
PR	20-MAR-1998;	98US-0078939P.
PR	27-MAR-1998;	98US-0079664P.
PR	27-MAR-1998;	98US-0079786P.
PR	31-MAR-1998;	98US-0080107P.
PR	31-MAR-1998;	98US-0080194P.
PR	01-APR-1998;	98US-0080327P.
PR	01-APR-1998;	98US-0080333P.
PR	08-APR-1998;	98US-0081049P.
PR	08-APR-1998;	98US-0081070P.
PR	09-APR-1998;	98US-0081195P.
PR	15-APR-1998;	98US-0081838P.
PR	21-APR-1998;	98US-0082568P.
PR	21-APR-1998;	98US-0082569P.
PR	22-APR-1998;	98US-0082704P.
PR	22-APR-1998;	98US-0082797P.
PR	28-APR-1998;	98US-0083222P.
PR	29-APR-1998;	98US-0083495P.
PR	29-APR-1998;	98US-0083496P.
PR	29-APR-1998;	98US-0083499P.
PR	29-APR-1998;	98US-0083559P.
PR	05-MAY-1998;	98US-0084366P.
PR	06-MAY-1998;	98US-0084414P.
PR	07-MAY-1998;	98US-0084639P.
PR	07-MAY-1998;	98US-0084640P.
PR	07-MAY-1998;	98US-0084643P.
PR	15-MAY-1998;	98US-0085579P.
PR	15-MAY-1998;	98US-0085580P.
PR	15-MAY-1998;	98US-0085582P.
PR	15-MAY-1998;	98US-0085700P.
PR	18-MAY-1998;	98US-0086023P.
PR	22-MAY-1998;	98US-0086392P.
PR	22-MAY-1998;	98US-0086486P.
PR	28-MAY-1998;	98US-0087098P.
PR	28-MAY-1998;	98US-0087208P.
PR	02-JUN-1998;	98US-0087609P.
PR	02-JUN-1998;	98US-0087759P.
PR	03-JUN-1998;	98US-0087827P.
PR	04-JUN-1998;	98US-0088025P.
PR	04-JUN-1998;	98US-0088028P.
PR	04-JUN-1998;	98US-0088029P.
PR	04-JUN-1998;	98US-0088033P.
PR	04-JUN-1998;	98US-0088326P.
PR	05-JUN-1998;	98US-0088167P.
PR	05-JUN-1998;	98US-0088202P.
PR	05-JUN-1998;	98US-0088212P.
PR	05-JUN-1998;	98US-0088217P.
PR	09-JUN-1998;	98US-0088655P.
PR	10-JUN-1998;	98US-0088722P.
PR	10-JUN-1998;	98US-0088738P.
PR	10-JUN-1998;	98US-0088740P.
PR	10-JUN-1998;	98US-0088811P.
PR	10-JUN-1998;	98US-0088824P.
PR	10-JUN-1998;	98US-0088825P.

10-JUN-1998; 98US-0088826P.
 11-JUN-1998; 98US-0088861P.
 11-JUN-1998; 98US-0088863P.
 11-JUN-1998; 98US-0088876P.
 12-JUN-1998; 98US-0089090P.
 12-JUN-1998; 98US-0089105P.
 16-JUN-1998; 98US-0089512P.
 16-JUN-1998; 98US-0089514P.
 17-JUN-1998; 98US-0089538P.
 17-JUN-1998; 98US-0089598P.
 17-JUN-1998; 98US-0089653P.
 18-JUN-1998; 98US-0089908P.
 19-JUN-1998; 98US-0089952P.
 22-JUN-1998; 98US-0090246P.
 22-JUN-1998; 98US-0090252P.
 22-JUN-1998; 98US-0090254P.
 24-JUN-1998; 98US-0090429P.
 24-JUN-1998; 98US-0090435P.
 24-JUN-1998; 98US-0090444P.
 24-JUN-1998; 98US-0090461P.
 24-JUN-1998; 98US-0090535P.
 24-JUN-1998; 98US-0090540P.
 25-JUN-1998; 98US-0090567P.
 25-JUN-1998; 98US-0090678P.
 25-JUN-1998; 98US-0090688P.
 25-JUN-1998; 98US-0090690P.
 25-JUN-1998; 98US-0090694P.
 25-JUN-1998; 98US-0090695P.
 25-JUN-1998; 98US-0090696P.
 26-JUN-1998; 98US-00105413.
 26-JUN-1998; 98US-0090862P.
 26-JUN-1998; 98US-0090863P.
 26-JUN-1998; 98US-0091010P.
 01-JUL-1998; 98US-0091359P.
 01-JUL-1998; 98US-0091544P.
 02-JUL-1998; 98US-0091478P.
 02-JUL-1998; 98US-0091486P.
 02-JUL-1998; 98US-0091626P.
 02-JUL-1998; 98US-0091628P.
 02-JUL-1998; 98US-0091632P.
 24-JUL-1998; 98US-0094006P.
 04-AUG-1998; 98US-0095282P.
 10-AUG-1998; 98US-0095998P.
 10-AUG-1998; 98US-0096012P.
 17-AUG-1998; 98US-0096757P.
 17-AUG-1998; 98US-0096766P.
 17-AUG-1998; 98US-0096867P.
 17-AUG-1998; 98US-0096891P.
 17-AUG-1998; 98US-0096897P.
 18-AUG-1998; 98US-0096949P.
 18-AUG-1998; 98US-0096959P.
 18-AUG-1998; 98US-0097022P.
 26-AUG-1998; 98US-0097952P.
 26-AUG-1998; 98US-0097954P.
 26-AUG-1998; 98US-0097955P.
 26-AUG-1998; 98US-0097971P.
 26-AUG-1998; 98US-0097974P.
 26-AUG-1998; 98US-0098014P.
 01-SEP-1998; 98US-0098716P.
 01-SEP-1998; 98US-0098723P.
 02-SEP-1998; 98US-0098803P.
 02-SEP-1998; 98US-0098821P.
 02-SEP-1998; 98US-0098843P.
 09-SEP-1998; 98US-0099602P.
 10-SEP-1998; 98US-0099741P.
 10-SEP-1998; 98US-0099754P.
 10-SEP-1998; 98US-0099763P.
 10-SEP-1998; 98US-0099812P.
 15-SEP-1998; 98US-0100388P.
 16-SEP-1998; 98US-0100662P.
 16-SEP-1998; 98US-0100664P.
 16-SEP-1998; 98US-0101751P.
 16-SEP-1998; 98WO-US019330.

17-SEP-1998; 98US-0100683P.
 17-SEP-1998; 98US-0100684P.
 17-SEP-1998; 98US-0100919P.
 17-SEP-1998; 98US-0100930P.
 18-SEP-1998; 98US-0100849P.
 18-SEP-1998; 98US-0101014P.
 18-SEP-1998; 98US-0101068P.
 23-SEP-1998; 98US-0101471P.
 23-SEP-1998; 98US-0101472P.
 23-SEP-1998; 98US-0101475P.
 23-SEP-1998; 98US-0101477P.
 24-SEP-1998; 98US-0101738P.
 24-SEP-1998; 98US-0101739P.
 24-SEP-1998; 98US-0101743P.
 24-SEP-1998; 98US-0101922P.
 25-SEP-1998; 98US-0101786P.
 29-SEP-1998; 98US-0102207P.
 29-SEP-1998; 98US-0102240P.
 29-SEP-1998; 98US-0102331P.
 29-SEP-1998; 98US-0102487P.
 30-SEP-1998; 98US-0102570P.
 30-SEP-1998; 98US-0102571P.
 01-OCT-1998; 98US-0102684P.
 01-OCT-1998; 98US-0102687P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
 Best Local Similarity 71.3%; Pred. No. 0.00023;
 Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY	2121	CCTTTGCTTTACCACTCTTTTCCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCAC	2180
Db	2653	CCTTTTCCTTCCCATCTCTTGACACATTTTATAAAAAATAAGGTTGGCTTCTGAACTA	2712
QY	2181	NCTCCCAAAAAA	2240
Db	2713	CAAAAAA	2772
QY	2241	AA 2242	
Db	2773	AA 2774	

RESULT 634
 ACF31678
 ID ACF31678 standard; cDNA; 2846 BP.
 XX
 AC ACF31678;
 XX
 DT 24-SEP-2003 (first entry)
 XX
 DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
 XX
 KW Human; PRO; secreted protein; transmembrane protein;
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; proliferation; differentiation; cartilage disorder;
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
 KW liver; drug screening; transgenic animal; genetic analysis;
 KW antiarthritic; vulnerary; gene therapy; gene; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003064469-A1.
 XX
 PD 03-APR-2003.
 XX
 PF 29-JUL-2002; 2002US-00208027.
 XX
 PR 11-APR-2000; 2000US-0196000P.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 15-JAN-2002; 2002US-00052586.
 XX

Db2713 CAAA2772

Qy2241 AA 2242

Db2773 AA 2774

RESULT 636

ACD48545

ID ACD48545 standard; cDNA; 2846 BP.

XX

AC ACD48545;

XX

DT 05-OCT-2003 (first entry)

XX

DE Human secreted/transmembrane protein (PRO) cDNA #85.

XX

KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;

KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;

KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;

KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX

OS Homo sapiens.

XX

PN US2003064466-A1.

XX

PD 03-APR-2003.

XX

PF 29-JUL-2002; 2002US-00207914.

XX

PR 30-OCT-1998; 98US-0106464P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 18-FEB-2000; 2000WO-US004342.

PR 24-AUG-2000; 2000WO-US023328.

PR 01-DEC-2000; 2000WO-US032678.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX

PA (GETH) GENENTECH INC.

XX

PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-605865/57.

DR P-PSDB; ABO30639.

XX

XX New secreted and transmembrane PRO polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy, chromosome identification, tissue typing, or as hybridization probes in chromosome and gene mapping.

XX

PS Claim 2; Fig 169; 700pp; English.

XX

CC The invention discloses human nucleic acids encoding secreted and transmembrane (PRO) polypeptides, with or without their associated signal peptide. Also disclosed is an antibody that specifically binds to the PRO polypeptide, a method for stimulating the release of tumour necrosis factor alpha (TNF-alpha) from human blood by contacting the blood with a PRO polypeptide, a method for stimulating the proliferation or differentiation of chondrocyte cells by contacting the cells with a PRO polypeptide, a method for detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the PRO nucleotide sequences. The nucleotide sequences are useful as probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant techniques and in gene therapy (e.g. for replacement of defective gene). The PRO polypeptides are useful as molecular weight markers for protein electrophoresis purposes, for chromosome identification, as chromosome markers, as therapeutic agents, for stimulating the release of TNF-alpha from human blood, for stimulating the proliferation or differentiation of chondrocytes and detecting the presence, prevention and/or treatment of a tumour, such as

CCadrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.

CCThe PRO polypeptides and nucleic acids may also be used diagnostically for tissue typing. The sequence presented is a cDNA encoding one of the PRO polypeptides of the invention. Note: The sequence data for this patent can also be obtained in electronic format directly from USPTO at seqdata.uspto.gov/sequence.html

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity71.3%; Pred. No. 0.00023;

Matches87; Conservative0; Mismatches35; Indels0; Gaps0;

Qy2121 CCTTTGCTTTACCACTCTTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG2180

Db2653 CCTTTTCCTTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA2712

Qy2181 NCTCCCAA2240

Db2713 CAAA2772

Qy2241 AA 2242

Db2773 AA 2774

RESULT 637

ACD48852

ID ACD48852 standard; cDNA; 2846 BP.

XX

AC ACD48852;

XX

DT 05-OCT-2003 (first entry)

XX

DE Human secreted/transmembrane protein (PRO) cDNA #85.

XX

KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;

KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;

KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;

KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX

OS Homo sapiens.

XX

XX US2003064468-A1.

XX

PD 03-APR-2003.

XX

PF 29-JUL-2002; 2002US-00207922.

XX

PR 11-APR-2000; 2000US-0195975P.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX

PA (GETH) GENENTECH INC.

XX

PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-605866/57.

DR P-PSDB; ABO30944.

XX

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for diagnosing, preventing and/or treating tumors, such as adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.

XX

PS Claim 2; Fig 169; 700pp; English.

XX

CC The invention discloses human nucleic acids encoding secreted and transmembrane (PRO) polypeptides, with or without their associated signal peptide. Also disclosed is an antibody that specifically binds to the PRO polypeptide, a method for stimulating the release of tumour necrosis factor alpha (TNF-alpha) from human blood by contacting the blood with a PRO polypeptide, a method for stimulating the proliferation or

CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCCTTCCCATCTCTGTACACATTTTAATAAAATAGGGTTGGCTTCTGAACCTA 2712

QY 2181 NCTCCCAAAAAA AA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 638
ACF51290
ID ACF51290 standard; cDNA; 2846 BP.
XX
AC ACF51290;
XX
07-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.

XX Homo sapiens.
OS
PN US2003068760-A1.
XX
PD 10-APR-2003.
XX
PF 26-JUL-2002; 2002US-00206921.
XX
XX 15-SEP-2000; 2000US-0232887P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX

PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX

DR WPI; 2003-605929/57.
DR P-PSDB; ABM27250.
XX
PT New isolated nucleic acid encoding a secreted and transmembrane PRO
PT polypeptide, e.g. PRO1079 or PRO827, useful in molecular biology,
PT chromosome and gene mapping, in generating antisense RNA and DNA, and in
PT gene therapy for cancers.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM27166-ABM27470) and nucleic acids encoding them (ACF51206-ACF51510).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF51206-ACF51510 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCCTTCCCATCTCTGTACACATTTTAATAAAATAGGGTTGGCTTCTGAACCTA 2712

QY 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 639
ACF54053
ID ACF54053 standard; cDNA; 2846 BP.
XX
AC ACF54053;

10-OCT-2003 (first entry)

Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

Human; PRO; secreted protein; transmembrane protein; extracellular domain; tumour necrosis factor-alpha; TNF-alpha; chondrocyte; proliferation; differentiation; cartilage disorder; bone disorder; arthritis; sports injury; cancer; tumour; diagnosis; adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix; liver; drug screening; transgenic animal; genetic analysis; antiarthritic; vulnery; gene therapy; gene; ss.

Homo sapiens.

US2003068769-A1.

10-APR-2003.

29-JUL-2002; 2002US-00207920.

18-APR-2000; 2000US-0198121P.

28-FEB-2001; 2001WO-US006520.

15-JAN-2002; 2002US-00052586.

(GETH) GENENTECH INC.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL; Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-605930/57.

P-PSDB; ABM29995.

New PRO polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy, chromosome identification, tissue typing, or as hybridization probes in chromosome and gene mapping.

Claim 2; Fig 169; 700pp; English.

The invention relates to human PRO secreted/transmembrane polypeptides (ABM29911-ABM30215) and nucleic acids encoding them (ACF53969-ACF54273). The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of

CC	therapeutically useful compounds. Sequences ACF53969-ACF54273 represent
CC	cdnas encoding the human PRO secreted/transmembrane polypeptides of the
CC	invention. Note: The sequence data for this patent is also available in
CC	electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX	
QQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
	Query Match 3.0%; Score 66.6; DB 9; Length 2846;
	Best Local Similarity 71.3%; Pred. No. 0.00023;
	Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY	2121 CCTTTGCTTACCACCTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG 2180
DB	2653 CCTTTTCCTCCCATCTCTTGTCACACATTTTAATAAAATAAGGTTGGCTTCTGAACTA 2712
QY	2181 NCTCCCAAA 2240
DB	2713 CAAA 2772
QY	2241 AA 2242
DB	2773 AA 2774
RESULT 640	
ACF25777	
ID	ACF25777 standard; cDNA; 2846 BP.
XX	
AC	ACF25777;
XX	
DT	22-SEP-2003 (first entry)
XX	
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX	
KW	Human; PRO; secreted protein; transmembrane protein;
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW	chondrocyte; proliferation; differentiation; cartilage disorder;
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW	liver; drug screening; transgenic animal; genetic analysis;
KW	antiarthritic; vulnery; gene therapy; gene; ss.
XX	
OS	Homo sapiens.
XX	
PN	US2003045700-A1.
XX	
PD	06-MAR-2003.
XX	
PF	25-JUL-2002; 2002US-00205908.
XX	
PR	03-MAR-2000; 2000US-0187202P.
PR	28-FEB-2001; 2001WO-US006520.
PR	15-JAN-2002; 2002US-00052586.
XX	
PA	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX	
DR	WPI; 2003-615781/58.
DR	P-PSDB; ABM05531.
XX	
PT	New genes encoding secreted and transmembrane PRO polypeptides, useful
PT	for stimulating Tumor Necrosis Factor alpha or chondrocyte proliferation,
PT	particularly for treating e.g. lung or breast tumors, or arthritis in a
PT	mammal.
XX	
PS	Claim 2; Fig 169; 567pp; English.
XX	
CC	The invention relates to human PRO secreted/transmembrane polypeptides
CC	(ABM05447-ABM05751) and nucleic acids encoding them (ACF25593-ACF25997).
CC	The invention also relates to sequences at least 80% identical to the PRO
CC	nucleic acid and polypeptide sequences of the invention, recombinant

vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF25693-ACF2597 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPRO at seqdata.uspto.gov/sequence.html

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

```
Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
```

Qy	2121	CCTTTGCTTTACCACTTTTCCTTTTATCTATTATAAAAAAGTTGGTCTCCACCAC	2180
Db	2653	CCTTTTCCTTCCCACACTCTTGTAACAATTTAAFAAAAATAAGGGTTGGCTTCTGAAC	2712

Db 2653 CCTTTTCCCTTCCCCATCTCTTGTAACACATTTTAATAAAATAAGGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCAAAAA 2240

Db 2713 CAAA 2772

Ov 2241 AA 2242

D_b 2773 AA 2774

RESULT 641

ACF39090

ID ACF39090 standard; cDNA; 2846 BP.

AC ACF39090;

DT 08-OCT-2003 (first entry)

DE Human secreted polypeptide PR01344-encoding cDNA SEQ ID NO:169

Human: pp0: secreted protein: transmembrane protein.

KW extracellular domain; tumour necrosis factor- α lpha: TNF- α lpha;
Human; PKO; secreted protein; transmembrane protein;

KW
chondrocyte: proliferation: cartilage disorder:
extracellular domain; tumour necrosis factor- α pna; TNF- α pna;

KW
chronocycle; proliferation; differentiation; carcinoma; carcinoma
bone disorder: arthritis: sports injury: cancer: tumour: diagnosis:

bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
adrenal tumour: lung: colon: breast: prostate: kidney: rectum: cervix:

liver: drug screening: transgenic animal: genetic analysis: adenoma: cancer: lung, colon, breast, prostate, kidney; fecal

antiarthritic: vulnervary: gene therapy: gene: 88.

OS Homo sapiens.

US2003068698-A1.

10-APR-2003.

12-JUL-2002: 2002US-00194362.

05-JUN-2000: 2000US-0209832P.

03-JUN-2000; 2000US-VZ0383ZF;
28-FEB-2001; 2001WO-US006520;

20 FEB 2001; 2001WG-03000320
15-JAN-2002; 2002US-00052586;

(GETH) GENENTECH INC.

Baker KP, Chen J, Desnoyers I, Goddard A, Godowski PT, Gurnev AI.

Baker KF, Chen U, Desnoyers U, Goudara A, Goudara A, Smith V, Watanabe CK, Wood WT, Zhang Z, Pan J.

WPT: 2003-615874/58

WFI: 2003-615874/
P-PSDB: ABM15596

New secreted and transmembrane PRO nucleic acid, useful for the manufacture of a medicament for diagnosing or treating tumor or for tissue typing.

Claim 2: Fig 169: 700pp: English

The invention relates to human PRO secreted/transmembrane polypeptides (ABM15512-ABM15816) and nucleic acids encoding them (ACF39006-ACF39310). The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially

Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match	3.0%	Score 66.6	DB 9	Length 2846
-------------	------	------------	------	-------------

Best Local Similarity 71.38; Pred. No. 0.00023;

Mismatches	0;	Mismatches	35;	Indels	0;	Gaps	0;
Conservative	87;	Conservative	0;	Indels	0;	Gaps	0;

Qy 2121 CCTTGGCTTTACCACTCTTTTCCTTTATCTATTAAATAAAAATGTTGGTCTCCACCACTG 2180

Db 2653 CCCCCCCCCTCTCTCTGTACACATTTTAAATAAGGGTTGGCTTCGAACCTA 2712

Qy	2181	NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2240
-	2712	CAAA	2772

QY	2241	AA	2242
D _b	2773	AA	2774

RESULT 642
ACF28847
ID ACF28847 standard; cDNA; 2846 BP.
XX
XX
AC ACF28847;
XX
DT 20-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

Human; PRO; secreted protein; transmembrane protein; extracellular domain; tumour necrosis factor- α ; TNF- α ; chondrocyte; proliferation; differentiation; cartilage disorder; bone disorder; arthritis; sports injury; cancer; tumour; diagnosis; adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix; liver; drug screening; transgenic animal; genetic analysis; antiarthritic; vulnerability; gene therapy; gene; ss.

OS Homo sapiens.
XX
PN US2003068759-A1.
XX
PD 10-APR-2003.

26-JUL-2002; 2002US-00206920.
XX
15-SEP-2000; 2000US-0232887P.
PR
28-FEB-2001; 2001WO-US006520.
PR
15-JAN-2002; 2002US-00052586.
PR

(GETH) GENENTECH INC.
 Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 WPI; 2003-615902/58.
 P-PSDB; ABM08581.

xx New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or
pt PRO827, useful in molecular biology, chromosome and gene mapping, in
pt generating antisense RNA and DNA, and in gene therapy.
xx
xx Claim 2: Fig 169: 700pp: English.
ps

The invention relates to human PRO secreted/transmembrane polypeptides (ABM08497-ABM08801) and nucleic acids encoding them (ACF28763-ACF29067). The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may

be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF28763-ACF29067 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at sendata.uspto.gov/sequence.html

XX
SO
sequence 2846 BP: 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match	3.0%;	Score 66.6;	DB 9;	Length 2846;
Best Local Similarity	71.3%;	Pred. No. 0.00023;		
Matches 87;	Conservative	0;	Mismatches 35;	Indels 0;
				Gaps 0;

QY	2121	CC	TT	GC	TT	TA	CA	CT	TT	CC	TT	TT	AT	CT	TA	TA	TA	AA	AA	AT	GT	TG	GT	CT	CC	CA	CT	GT	2180	
QY	2121																													
nb	2653	CC	TT	TT	CC	CT	CT	CT	CG	CA	CT	CT	TT	GT	GA	CA	CA	CT	TT	TA	TA	AA	AA	TA	AA	AA	CT	GA	CT	2712

[illegible]

Qy 2241 AA 2242
2773 AA 2774
Db

RESULT 643	
ACD90764	
ID	ACD90764 standard; cDNA; 2846 BP.
XX	
AC	ACD90764;
XX	
DT	09-OCT-2003 (first entry)
XX	
XX	Human secreted/transmembrane protein (PRO) cDNA #85.

XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW metastatic tumour; rectal tumour; cervical tumour; liver tumour.

OS	Homo sapiens.
XX	
PN	US2003049748-A1.
XX	
PD	13-MAR-2003.
XX	
PF	16-JUL-2002; 2002US-00196748.
XX	
PR	11-APR-2000; 2000US-0196000P.
PR	28-FEB-2001; 2001WO-US006520.
PR	15-JAN-2002; 2002US-00052586.

XX PA (GETH) GENENTECH INC.
 XX PA
 XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 PI
 XX WPI; 2003-625418/59.
 DR P-PSDB: ABO42281.
 DR

KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW chromosome mapping; gene mapping; molecular weight marker;
KW protein electrophoresis; affinity purification; tumour; adrenal; lung;
KW colon; breast; prostate; rectal; cervical; liver; cancer; cytostatic;
KW gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003049754-A1.
PN
XX
XX 13-MAR-2003.
PD
XX
XX 18-JUL-2002; 2002US-00198764.
PF
XX
XX 08-APR-1998; 98US-0081049P.
PR
XX 08-MAR-1999; 99WO-US005028.
PR
XX 25-AUG-1999; 99US-00380138.
PR
XX 22-MAY-2000; 2000WO-US014042.
PR
XX 28-FEB-2001; 2001WO-US006520.
PR
XX 15-JAN-2002; 2002US-00052586.
PF
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
PI
XX WPI; 2003-657406/62.
DR P-PSDB; ABO45921.
DR
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for diagnosing, preventing and/or treating tumors, such as
PT adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
PT
XX Claim 2; Fig 169; 700pp; English.
PS
XX The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polynucleotide sequences are useful in molecular biology as hybridisation
CC probes, in chromosome and gene mapping, in generating antisense RNA and
CC DNA, and in gene therapy. The PRO polypeptides are useful for the
CC diagnosis, prevention and/or treatment of tumours such as those found in
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver
CC cancers. The PRO polypeptides are also useful as molecular weight markers
CC for protein electrophoresis purposes. ACH05245-ACH05549 represent cDNA
CC sequences encoding the human PRO polypeptides of the invention. Note: The
CC sequence data for this patent was obtained in electronic format directly
CC from the USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACCTCTTCTCTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTG 2180
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2653 CCTTTCTCTCCCATCTCTGTGTACACATTTTAAATAAAATAGGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAA 2240
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2713 CAA 2772

QY 2241 AA 2242
Db ||
2773 AA 2774

RESULT 646
ACF65125
ID ACF65125 standard; cDNA; 2846 BP.
XX
AC ACF65125;

XX 14-OCT-2003 (first entry)
DT Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
DE
XX
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003068688-A1.
PN
XX
XX 10-APR-2003.
PD
XX
XX 02-JUL-2002; 2002US-00188766.
PF
XX
XX 26-JUN-1998; 98US-00105413.
PR
XX 16-SEP-1998; 98WO-US019330.
PR
XX 07-OCT-1998; 98US-00168978.
PR
XX 07-OCT-1998; 98WO-US021141.
PR
XX 06-NOV-1998; 98US-00187368.
PR
XX 01-DEC-1998; 98WO-US025108.
PR
XX 07-DEC-1998; 98US-00202054.
PR
XX 03-MAR-1999; 99US-00254311.
PR
XX 08-MAR-1999; 99WO-US005028.
PR
XX 14-MAY-1999; 99US-00311832.
PR
XX 14-MAY-1999; 99WO-US010733.
PR
XX 02-JUN-1999; 99WO-US012252.
PR
XX 25-AUG-1999; 99US-00380137.
PR
XX 25-AUG-1999; 99US-00380138.
PR
XX 25-AUG-1999; 99US-00380139.
PR
XX 25-AUG-1999; 99US-00380142.
PR
XX 01-SEP-1999; 99WO-US020111.
PR
XX 15-SEP-1999; 99WO-US021090.
PR
XX 18-OCT-1999; 99US-00403297.
PR
XX 12-NOV-1999; 99US-00423844.
PR
XX 01-DEC-1999; 99WO-US028301.
PR
XX 02-DEC-1999; 99WO-US028551.
PR
XX 30-DEC-1999; 99WO-US031274.
PR
XX 05-JAN-2000; 2000WO-US000219.
PR
XX 18-FEB-2000; 2000WO-US004341.
PR
XX 18-FEB-2000; 2000WO-US004342.
PR
XX 22-FEB-2000; 2000WO-US004414.
PR
XX 24-FEB-2000; 2000WO-US005004.
PR
XX 01-MAR-2000; 2000WO-US005601.
PR
XX 02-MAR-2000; 2000WO-US005841.
PR
XX 15-MAR-2000; 2000WO-US006884.
PR
XX 30-MAR-2000; 2000WO-US008439.
PR
XX 17-MAY-2000; 2000WO-US013705.
PR
XX 22-MAY-2000; 2000WO-US014042.
PR
XX 30-MAY-2000; 2000WO-US014941.
PR
XX 02-JUN-2000; 2000WO-US015264.
PR
XX 28-JUL-2000; 2000WO-US020710.
PR
XX 22-AUG-2000; 2000US-00644848.
PR
XX 24-AUG-2000; 2000WO-US023328.
PR
XX 18-SEP-2000; 2000US-00664610.
PR
XX 18-SEP-2000; 2000US-00665350.
PR
XX 08-NOV-2000; 2000US-00709238.
PR
XX 08-NOV-2000; 2000WO-US030952.
PR
XX 01-DEC-2000; 2000WO-US032678.
PR
XX 20-DEC-2000; 2000US-00747259.
PR
XX 20-DEC-2000; 2000WO-US034956.
PR
XX 28-FEB-2001; 2001WO-US006520.
PR
XX 22-MAR-2001; 2001US-00816744.
PR
XX 10-MAY-2001; 2001US-00854208.
PR
XX 10-MAY-2001; 2001US-00854280.
PR
XX 25-MAY-2001; 2001US-00866028.
PR
XX 01-JUN-2001; 2001WO-US017800.
PR

PR	22-APR-1998;	98US-0082797P.	PR	01-JUL-1998;	98US-0091544P.
PR	28-APR-1998;	98US-0083322P.	PR	02-JUL-1998;	98US-0091478P.
PR	29-APR-1998;	98US-0083495P.	PR	02-JUL-1998;	98US-0091486P.
PR	29-APR-1998;	98US-0083496P.	PR	02-JUL-1998;	98US-0091626P.
PR	29-APR-1998;	98US-0083499P.	PR	02-JUL-1998;	98US-0091628P.
PR	29-APR-1998;	98US-0083559P.	PR	02-JUL-1998;	98US-0091632P.
PR	05-MAY-1998;	98US-0084366P.	PR	24-JUL-1998;	98US-0094006P.
PR	06-MAY-1998;	98US-0084414P.	PR	04-AUG-1998;	98US-0095282P.
PR	07-MAY-1998;	98US-0084639P.	PR	10-AUG-1998;	98US-0095998P.
PR	07-MAY-1998;	98US-0084640P.	PR	10-AUG-1998;	98US-0096012P.
PR	07-MAY-1998;	98US-0084643P.	PR	17-AUG-1998;	98US-0096757P.
PR	15-MAY-1998;	98US-0085579P.	PR	17-AUG-1998;	98US-0096766P.
PR	15-MAY-1998;	98US-0085580P.	PR	17-AUG-1998;	98US-0096867P.
PR	15-MAY-1998;	98US-0085582P.	PR	17-AUG-1998;	98US-0096891P.
PR	15-MAY-1998;	98US-0085700P.	PR	17-AUG-1998;	98US-0096897P.
PR	18-MAY-1998;	98US-0086023P.	PR	18-AUG-1998;	98US-0096949P.
PR	22-MAY-1998;	98US-0086392P.	PR	18-AUG-1998;	98US-0096959P.
PR	22-MAY-1998;	98US-0086486P.	PR	18-AUG-1998;	98US-0097022P.
PR	22-MAY-1998;	98US-0087098P.	PR	26-AUG-1998;	98US-0097952P.
PR	28-MAY-1998;	98US-0087208P.	PR	26-AUG-1998;	98US-0097954P.
PR	28-MAY-1998;	98US-0087609P.	PR	26-AUG-1998;	98US-0097955P.
PR	02-JUN-1998;	98US-0087759P.	PR	26-AUG-1998;	98US-0097971P.
PR	02-JUN-1998;	98US-0087759P.	PR	26-AUG-1998;	98US-0097974P.
PR	03-JUN-1998;	98US-0087827P.	PR	26-AUG-1998;	98US-0098014P.
PR	04-JUN-1998;	98US-0088025P.	PR	01-SEP-1998;	98US-0098716P.
PR	04-JUN-1998;	98US-0088028P.	PR	01-SEP-1998;	98US-0098723P.
PR	04-JUN-1998;	98US-0088029P.	PR	01-SEP-1998;	98US-0098803P.
PR	04-JUN-1998;	98US-0088033P.	PR	02-SEP-1998;	98US-0098821P.
PR	04-JUN-1998;	98US-0088326P.	PR	02-SEP-1998;	98US-0098843P.
PR	04-JUN-1998;	98US-0088167P.	PR	02-SEP-1998;	98US-0098843P.
PR	05-JUN-1998;	98US-0088202P.	PR	09-SEP-1998;	98US-0099602P.
PR	05-JUN-1998;	98US-0088212P.	PR	10-SEP-1998;	98US-0099741P.
PR	05-JUN-1998;	98US-0088217P.	PR	10-SEP-1998;	98US-0099754P.
PR	09-JUN-1998;	98US-0088655P.	PR	10-SEP-1998;	98US-0099763P.
PR	10-JUN-1998;	98US-0088722P.	PR	10-SEP-1998;	98US-0099812P.
PR	10-JUN-1998;	98US-0088738P.	PR	10-SEP-1998;	98US-0099812P.
PR	10-JUN-1998;	98US-0088740P.	PR	15-SEP-1998;	98US-0100388P.
PR	10-JUN-1998;	98US-0088811P.	PR	16-SEP-1998;	98US-0100662P.
PR	10-JUN-1998;	98US-0088824P.	PR	16-SEP-1998;	98US-0100664P.
PR	10-JUN-1998;	98US-0088825P.	PR	16-SEP-1998;	98US-0101751P.
PR	10-JUN-1998;	98US-0088826P.	PR	16-SEP-1998;	98WO-US019330.
PR	11-JUN-1998;	98US-0088861P.	PR	17-SEP-1998;	98US-0100683P.
PR	11-JUN-1998;	98US-0088863P.	PR	17-SEP-1998;	98US-0100684P.
PR	11-JUN-1998;	98US-0088876P.	PR	17-SEP-1998;	98US-0100919P.
PR	12-JUN-1998;	98US-0089090P.	PR	17-SEP-1998;	98US-0100930P.
PR	12-JUN-1998;	98US-0089105P.	PR	18-SEP-1998;	98US-0100849P.
PR	16-JUN-1998;	98US-0089512P.	PR	18-SEP-1998;	98US-0101014P.
PR	16-JUN-1998;	98US-0089514P.	PR	23-SEP-1998;	98US-0101068P.
PR	17-JUN-1998;	98US-0089538P.	PR	23-SEP-1998;	98US-0101471P.
PR	17-JUN-1998;	98US-0089598P.	PR	23-SEP-1998;	98US-0101472P.
PR	17-JUN-1998;	98US-0089598P.	PR	23-SEP-1998;	98US-0101475P.
PR	17-JUN-1998;	98US-0089653P.	PR	23-SEP-1998;	98US-0101477P.
PR	18-JUN-1998;	98US-0089908P.	PR	24-SEP-1998;	98US-0101738P.
PR	19-JUN-1998;	98US-0089952P.	PR	24-SEP-1998;	98US-0101739P.
PR	22-JUN-1998;	98US-0090246P.	PR	24-SEP-1998;	98US-0101743P.
PR	22-JUN-1998;	98US-0090252P.	PR	24-SEP-1998;	98US-0101922P.
PR	22-JUN-1998;	98US-0090254P.	PR	25-SEP-1998;	98US-0101786P.
PR	24-JUN-1998;	98US-0090429P.	PR	29-SEP-1998;	98US-0102207P.
PR	24-JUN-1998;	98US-0090435P.	PR	29-SEP-1998;	98US-0102240P.
PR	24-JUN-1998;	98US-0090444P.	PR	29-SEP-1998;	98US-0102330P.
PR	24-JUN-1998;	98US-0090461P.	PR	29-SEP-1998;	98US-0102331P.
PR	24-JUN-1998;	98US-0090535P.	PR	30-SEP-1998;	98US-0102487P.
PR	24-JUN-1998;	98US-0090540P.	PR	30-SEP-1998;	98US-0102570P.
PR	25-JUN-1998;	98US-0090676P.	PR	30-SEP-1998;	98US-0102571P.
PR	25-JUN-1998;	98US-0090678P.	PR	01-OCT-1998;	98US-0102684P.
PR	25-JUN-1998;	98US-0090688P.	PR	01-OCT-1998;	98US-0102687P.
PR	25-JUN-1998;	98US-0090690P.	PR	02-OCT-1998;	98US-0102965P.
PR	25-JUN-1998;	98US-0090694P.	PR	06-OCT-1998;	98US-0102965P.
PR	25-JUN-1998;	98US-0090695P.	PR	06-OCT-1998;	98US-0103258P.
PR	25-JUN-1998;	98US-0090696P.	PR	06-OCT-1998;	98US-0103449P.
PR	26-JUN-1998;	98US-00105413.			
PR	26-JUN-1998;	98US-0090862P.			
PR	26-JUN-1998;	98US-0090863P.			
PR	26-JUN-1998;	98US-0091010P.			
PR	01-JUL-1998;	98US-00913359P.			

Query Match

Best Local Similarity

Matches

3.0%;

87;

Conservative

Score 66.6;

DB 9;

Length 2846;

Pred. No. 0.00023;

0;

Mismatches 35;

Indels 0;

Gaps 0;

QY

2121

CCTTTGCTTTACCAC

TCTTTCC

TTTATCTTATTAATAAAATGTTGGTCTCCACCAC

TG 2180

Db 2653 CCTTTCCTCCCACTCTCTGTACACATTTTAATAAATAAGGTTGGCTTCGAACTA 2712
QY 2181 NCTCCAAAAAATAA 2240
Db 2713 CAAAAAATAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 648
ACF43598
ID ACF43598 standard; cDNA; 2846 BP.
XX
AC ACF43598;
XX
DT 03-OCT-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX

OS Homo sapiens.

XX US2003104552-A1.
PN
XX 05-JUN-2003.
PD
XX 24-JUL-2002; 2002US-00202940.
PF
XX 29-APR-1998; 98US-0083496P.
PR 08-MAR-1999; 99WO-US005028.
PR 25-AUG-1999; 99US-00380138.
PR 18-FEB-2000; 2000WO-US004341.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX

PA (GETH) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-670249/63.
DR P-PSDB; ABM19625.

PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
PT colon, breast, prostate, rectal, cervical or liver tumors.

PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM19541-ABM19845) and nucleic acids encoding them (ACF43514-ACF43818).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from

CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF43514-ACF43818 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTCTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180
Db 2653 CCTTTCTCTCCCATCTCTGTACACATTTTAATAAAATAGGTTGGCTTCGAACTA 2712
QY 2181 NCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 649

ACH09068

ID ACH09068 standard; cDNA; 2846 BP.

XX

AC ACH09068;

XX

DT 10-OCT-2003 (first entry)

XX

DE Human secreted/transmembrane protein (PRO) cDNA #85.

XX

KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX Homo sapiens.

XX US2003049774-A1.

PN

XX 13-MAR-2003.

PD

XX 24-JUL-2002; 2002US-00202934.

PF

XX 06-MAY-1998; 98US-0084414P.

PR 08-MAR-1999; 99WO-US005028.

PR 25-AUG-1999; 99US-00380138.

PR 18-FEB-2000; 2000WO-US004341.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX	PA	(GETH) GENENTECH INC.	XX	OS	Homo sapiens.
XX	PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;	XX	PN	US2003049775-A1.
XX	PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;	XX	PD	13-MAR-2003.
XX	DR	WPI; 2003-669848/63.	XX	XX	24-JUL-2002; 2002US-00202935.
DR	DR	P-PSDB; ABO49337.	PF	XX	03-JUN-1998; 98US-0087827P.
XX	XX	Three hundred and five nucleic acids encoding PRO polypeptides, useful	PR	XX	02-JUN-1999; 99WO-US012252.
PT	PT	for the manufacture of a medicament for diagnosing or treating tumor or	PR	PR	28-JUL-1999; 99US-0146222P.
PT	PT	for tissue typing.	PR	PR	25-AUG-1999; 99US-00380137.
XX	XX	Claim 2; Fig 169; 699pp; English.	PR	PR	30-MAR-2000; 2000WO-US008439.
PS	PS	The invention discloses human nucleic acids encoding secreted and	PR	PR	28-FEB-2001; 2001WO-US006520.
XX	XX	transmembrane (PRO) polypeptides, with or without their associated signal	PR	PR	15-JAN-2002; 2002US-00052586.
CC	CC	peptide. Also disclosed is an antibody that specifically binds to the PRO	XX	PA	(GETH) GENENTECH INC.
CC	CC	polypeptide, a method for stimulating the release of tumour necrosis	XX	PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
CC	CC	factor alpha (TNF-alpha) from human blood by contacting the blood with a	PI	PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
CC	CC	PRO polypeptide, a method for stimulating the proliferation or	XX	DR	WPI; 2003-669849/63.
CC	CC	differentiation of chondrocyte cells by contacting the cells with a PRO	DR	DR	P-PSDB; ABO49642.
CC	CC	polypeptide, a method for detecting the presence of a tumour in a mammal	XX	XX	Three hundred and five nucleic acids encoding PRO polypeptides, useful
CC	CC	and an oligonucleotide probe derived from any of the PRO nucleotide	PT	PT	for the manufacture of a medicament for diagnosing or treating tumor or
CC	CC	sequences. The nucleotide sequences are useful as probes, in chromosome	PT	PT	for tissue typing.
CC	CC	and gene mapping, in generating antisense RNA and DNA, in preparing PRO	XX	XX	Claim 2; Fig 169; 699pp; English.
CC	CC	polypeptides by recombinant techniques and in gene therapy (e.g. for	XX	XX	The invention discloses human nucleic acids encoding secreted and
CC	CC	replacement of defective gene). The PRO polypeptides are useful as	CC	CC	transmembrane (PRO) polypeptides, with or without their associated signal
CC	CC	molecular weight markers for protein electrophoresis purposes, for	CC	CC	peptide. Also disclosed is an antibody that specifically binds to the PRO
CC	CC	chromosome identification, as chromosome markers, as therapeutic agents,	CC	CC	polypeptide, a method for stimulating the release of tumour necrosis
CC	CC	for stimulating the release of TNF-alpha from human blood, for	CC	CC	factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC	CC	stimulating the proliferation or differentiation of chondrocytes and	CC	CC	PRO polypeptide, a method for stimulating the proliferation or
CC	CC	detecting the presence, prevention and/or treatment of a tumour, such as	CC	CC	differentiation of chondrocyte cells by contacting the cells with a PRO
CC	CC	adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.	CC	CC	polypeptide, a method for detecting the presence of a tumour in a mammal
CC	CC	The PRO polypeptides and nucleic acids may also be used diagnostically	CC	CC	and an oligonucleotide probe derived from any of the PRO nucleotide
CC	CC	for tissue typing. The sequence presented is a cDNA encoding one of the	CC	CC	sequences. The nucleotide sequences are useful as probes, in chromosome
CC	CC	PRO polypeptides of the invention. Note: The sequence data for this	CC	CC	and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC	CC	patent can also be obtained in electronic format directly from USPTO at	CC	CC	polypeptides by recombinant techniques and in gene therapy (e.g. for
CC	CC	seqdata.uspto.gov/sequence.html	CC	CC	replacement of defective gene). The PRO polypeptides are useful as
XX	XX	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;	CC	CC	molecular weight markers for protein electrophoresis purposes, for
SQ	SQ	Query Match 3.0%; Score 66.6; DB 9; Length 2846;	CC	CC	chromosome identification, as chromosome markers, as therapeutic agents,
		Best Local Similarity 71.3%; Pred. No. 0.00023;	CC	CC	for stimulating the release of TNF-alpha from human blood, for
		Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;	CC	CC	stimulating the proliferation or differentiation of chondrocytes and
			CC	CC	detecting the presence, prevention and/or treatment of a tumour, such as
QY	2121	CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCCTG 2180	CC	CC	adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
Db	2653	CCTTTTCTTCCCATCTCTTGTACACATTTAATAAAATAGGGTTGGCTTCTGAACTA 2712	CC	CC	The PRO polypeptides and nucleic acids may also be used diagnostically
QY	2181	NCTCCCAA 2240	CC	CC	for tissue typing. The sequence presented is a cDNA encoding one of the
Db	2713	CAA 2772	CC	CC	PRO polypeptides of the invention. Note: The sequence data for this
QY	2241	AA 2242	CC	CC	patent can also be obtained in electronic format directly from USPTO at
Db	2773	AA 2774	CC	CC	seqdata.uspto.gov/sequence.html
		Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;	XX	XX	Query Match 3.0%; Score 66.6; DB 9; Length 2846;
		Query Match 3.0%; Score 66.6; DB 9; Length 2846;	XX	XX	Best Local Similarity 71.3%; Pred. No. 0.00023;
		Best Local Similarity 71.3%; Pred. No. 0.00023;	XX	XX	Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
		Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;	QY	2121	CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCCTG 2180
RESULT 650			Db	2653	CCTTTTCTTCCCATCTCTTGTACACATTTAATAAAATAGGGTTGGCTTCTGAACTA 2712
ACH09375			QY	2181	NCTCCCAA 2240
ID	ACH09375	standard; cDNA; 2846 BP.	Db	2713	CAA 2772
XX	AC	ACH09375;	QY	2241	AA 2242
XX	XX	10-OCT-2003 (first entry)	Db	2773	AA 2774
DT	DE	Human secreted/transmembrane protein (PRO) cDNA #85.			Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
XX	XX	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;			Query Match 3.0%; Score 66.6; DB 9; Length 2846;
KW	KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;			Best Local Similarity 71.3%; Pred. No. 0.00023;
KW	KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;			Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
KW	KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.			

RESULT 651
ADA78533
ID ADA78533 standard; cDNA; 2846 BP.
XX
AC
XX ADA78533;
DT 20-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour; tumour.
XX
OS Homo sapiens.
XX
PN US2003073181-A1.
XX
PD 17-APR-2003.
XX
PF 24-JUL-2002; 2002US-00205510.
XX
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-743812/70.
DR P-PSDB; ADA78534.
XX
PT New secreted and transmembrane PRO nucleic acids, useful for the
PT manufacture of a medicament for diagnosing or treating tumor or for
PT measuring or detecting expression of an associated gene.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one the PRO
CC polypeptides of the invention. Note: The sequence data for this patent
CC can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTACCACTCTTCTCTTTTATCTTATTAATAAAAAATGTTGGTCTCCACCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCTTCCCATCTCTTGTACACATTTTAATAAAAAAAGGGTTGGCTTCTGAACTA 2712
QY 2181 NCTCCCAAAAAA AA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAA AA 2772
QY 2241 AA 2242
||
Db 2773 AA 2774
RESULT 652
ACF09798
ID ACF09798 standard; cDNA; 2846 BP.
XX
AC ACF09798;
XX
DT 06-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003068720-A1.
XX
PD 10-APR-2003.
XX
PF 18-JUL-2002; 2002US-00198763.
XX
PR 07-MAY-1998; 98US-0084639P.
PR 08-MAR-1999; 99WO-US005028.
PR 25-AUG-1999; 99US-00380138.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-576427/54.
DR P-PSDB; ABR88199.
XX
PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for the manufacture of a medicament for diagnosing or treating tumor or
PT for tissue typing.
XX
PS Claim 2; Fig 169; 699pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABR88115-ABR88419) and nucleic acids encoding them (ACF09714-ACF10018).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA

Db 2713 CAAA 2772

QY 2241 AA 2242
||

Db 2773 AA 2774

RESULT 654

ACF23877

ID ACF23877 standard; cDNA; 2846 BP.

XX AC

AC ACF23877;

DT 26-SEP-2003 (first entry)

XX Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

KW Human; PRO; secreted protein; transmembrane protein;

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; proliferation; differentiation; cartilage disorder;

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; drug screening; transgenic animal; genetic analysis;

KW antiarthritic; vulnery; gene therapy; gene; ss.

OS Homo sapiens.

XX US2003068763-A1.

PN 10-APR-2003.

XX 25-JUL-2002; 2002US-00206926.

XX 20-JUL-1999; 99US-0145070P.

PR 22-MAY-2000; 2000WO-US014042.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-615905/58.

DR P-PSDB; ABM03342.

XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1079 or

PT PRO827, useful in molecular biology, chromosome and gene mapping, in

PT generating antisense RNA and DNA, and in gene therapy for cancers.

XX Claim 2; Fig 169; 700pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides

CC (ABM03258-ABM03562) and nucleic acids encoding them (ACF23793-ACF24097).

CC The invention also relates to sequences at least 80% identical to the PRO

CC nucleic acid and polypeptide sequences of the invention, recombinant

CC vectors and host cells comprising a PRO nucleic acid, a method for the

CC recombinant production of a PRO polypeptide, antibodies against a PRO

CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic

CC acids encoding PRO polypeptides of the invention were initially

CC identified via homology screening using consensus sequences based on the

CC extracellular domain sequences from known secreted proteins. Human cDNA

CC libraries containing sequences of interest were identified using

CC oligonucleotides based on the consensus sequences, and cDNA clones were

CC isolated and characterised. The PRO polypeptides are useful for

CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from

CC human blood and may thus be used in the treatment of conditions in which

CC enhanced TNF-alpha release would be beneficial. They are also useful for

CC stimulating the proliferation or differentiation of chondrocytes and as

CC such may be used in the treatment of various bone and/or cartilage

CC disorders such as arthritis and sports injuries. The PRO polypeptides may

CC be used in a method for detecting the presence of a tumour (e.g., an

CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate

CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This

CC method involves comparing the level of expression of the PRO polypeptide

CC in test and control samples, where a higher level of expression of PRO

CC polypeptide in the test sample as compared to the control sample is

CC indicative of the presence of a tumour. The PRO polypeptides are

CC additionally useful for in drug screening to identify agonists and

CC antagonists of PRO polypeptides. PRO nucleic acids are useful as

CC hybridisation probes (for isolation of cDNA molecules), in chromosome and

CC gene mapping, in the generation of antisense RNA and DNA and in gene

CC therapy. The nucleic acids can also be used for mapping genes encoding

CC PRO polypeptides, for genetic analysis of individuals with genetic

CC disorders, and for generating either transgenic animals or knock-out

CC animals which are useful in the development and screening of

CC therapeutically useful compounds. Sequences ACF23793-ACF24097 represent

CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the

CC invention. Note: The sequence data for this patent is also available in

CC electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTCTTTTATCTTATTAATAAAATGTTGGTCTCCCACTG 2180

Db 2653 CCTTTCTCTCCCACTCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAATA 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 655

ACD88309

ID ACD88309 standard; cDNA; 2846 BP.

XX AC

AC ACD88309;

XX 06-OCT-2003 (first entry)

XX Human secreted/transmembrane protein (PRO) cDNA #85.

DE Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;

XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;

KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;

KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX Homo sapiens.

OS US2003068689-A1.

PN 10-APR-2003.

XX 02-JUL-2002; 2002US-00188771.

XX 05-JUN-2000; 2000US-0209832P.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-625461/59.

DR P-PSDB; ABO39841.

XX New PRO nucleic acid, useful for the manufacture of a medicament for

KW prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX Homo sapiens.

PN US2003049780-A1.

XX 13-MAR-2003.

XX 25-JUL-2002; 2002US-00205895.

XX 23-MAR-1999; 99US-0125778P.

PR 01-MAR-2000; 2000WO-US005601.

PR 22-MAY-2000; 2000WO-US014042.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-669853/63.

DR P-PSDB; ABO50862.

XX Three hundred and five nucleic acids encoding PRO polypeptides, useful for the manufacture of a medicament for diagnosing or treating tumor or for tissue typing.

PS Claim 2; Fig 169; 700pp; English.

XX The invention discloses human nucleic acids encoding secreted and transmembrane (PRO) polypeptides, with or without their associated signal peptide. Also disclosed is an antibody that specifically binds to the PRO polypeptide, a method for stimulating the release of tumour necrosis factor alpha (TNF-alpha) from human blood by contacting the blood with a PRO polypeptide, a method for stimulating the proliferation or differentiation of chondrocyte cells by contacting the cells with a PRO polypeptide, a method for detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the PRO nucleotide sequences. The nucleotide sequences are useful as probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant techniques and in gene therapy (e.g. for replacement of defective gene). The PRO polypeptides are useful as molecular weight markers for protein electrophoresis purposes, for chromosome identification, as chromosome markers, as therapeutic agents, for stimulating the release of TNF-alpha from human blood, for stimulating the proliferation or differentiation of chondrocytes and detecting the presence, prevention and/or treatment of a tumour, such as adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour. The PRO polypeptides and nucleic acids may also be used diagnostically for tissue typing. The sequence presented is a cDNA encoding one of the PRO polypeptides of the invention. Note: The sequence data for this patent can also be obtained in electronic format directly from USPTO at seqdata.uspto.gov/sequence.html

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTCTCTTTTATCTTTAATAAAAAATGTTGGTCTCCCACTG 2180

Db 2653 CCTTTCTCTCCCATCTCTTGTAACACATTTTATAAAAAAAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 658

ACD11410

ID ACD11410 standard; cDNA; 2846 BP.

XX

AC ACD11410;

XX

DT 13-AUG-2003 (first entry)

XX

DE Human secreted/transmembrane protein (PRO) cDNA #85.

XX

KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha; tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy; tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour; cervical tumour; liver tumour.

XX

OS Homo sapiens.

XX

PN US2003036126-A1.

XX

PD 20-FEB-2003.

XX

PF 26-JUN-2002; 2002US-00183013.

XX

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 17-OCT-1997; 97US-0062250P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 28-OCT-1997; 97US-0063540P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063734P.

PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066120P.

PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066772P.

PR 11-DEC-1997; 97US-0069335P.

PR 12-DEC-1997; 97US-0069425P.

PR 17-DEC-1997; 97US-0069870P.

PR 18-DEC-1997; 97US-0068017P.

PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077649P.

PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078939P.

PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079786P.

PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080194P.

PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080333P.

PR 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.

PR 09-APR-1998; 98US-0081195P.

PR 15-APR-1998; 98US-0081838P.

PR 21-APR-1998; 98US-0082568P.

PR 21-APR-1998; 98US-0082569P.

PR 22-APR-1998; 98US-0082704P.

PR 22-APR-1998; 98US-0082797P.

PR 28-APR-1998; 98US-0083322P.

PR 29-APR-1998; 98US-0083495P.

PR 29-APR-1998; 98US-0083496P.

PR 29-APR-1998; 98US-0083499P.

PR 29-APR-1998; 98US-0083559P.

PR 05-MAY-1998; 98US-0084366P.

PR 06-MAY-1998; 98US-0084414P.

PR 07-MAY-1998; 98US-0084639P.

PR 07-MAY-1998; 98US-0084640P.

PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR -05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.

PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 2121 CCITTGCTTTACCACCTCTTTCCTTTTATCTTATTATAATAAATGTTGGTCTCCACCAC TG 2180

Db 2653 CCITTTCCTTCCCCATCTCTGTACACATTTTAAATAAAGGTTGGCTTCTGAACTA 2712

Qy 2181 NCTCCCAAA 2240

Db 2713 CAA 2772

Qy 2241 AA 2242

Db 2773 AA 2774

RESULT 659		
ACC96460		
ID	ACC96460 standard; cDNA; 2846 BP.	
XX		
AC	ACC96460;	
XX		
DT	05-SEP-2003 (first entry)	
XX		
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.	
XX		
KW	Human; PRO; secreted protein; transmembrane protein;	
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;	
KW	chondrocyte; proliferation; differentiation; cartilage disorder;	
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;	
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;	
KW	liver; drug screening; transgenic animal; genetic analysis;	
KW	antiarthritic; vulnery; gene therapy; gene; ss.	
XX		
OS	Homo sapiens.	
XX		
PN	US2003044924-A1.	
XX		
PD	06-MAR-2003.	
XX		
PF	25-JUN-2002; 2002US-00180556.	
XX		
PR	18-SEP-1997; 97US-0059263P.	98US-0084366P.
PR	18-SEP-1997; 97US-0059266P.	98US-0084414P.
PR	17-OCT-1997; 97US-0062250P.	98US-0084639P.
PR	21-OCT-1997; 97US-0063486P.	98US-0084640P.
PR	24-OCT-1997; 97US-0063120P.	98US-0084643P.
PR	24-OCT-1997; 97US-0063121P.	98US-0085579P.
PR	28-OCT-1997; 97US-0063540P.	98US-0085580P.
PR	28-OCT-1997; 97US-0063541P.	98US-0085582P.
PR	28-OCT-1997; 97US-0063544P.	98US-0085700P.
PR	28-OCT-1997; 97US-0063564P.	98US-0086023P.
PR	29-OCT-1997; 97US-0063734P.	98US-0086392P.
PR	31-OCT-1997; 97US-0063870P.	98US-0086486P.
PR	31-OCT-1997; 97US-0064103P.	98US-0087098P.
PR	13-NOV-1997; 97US-0065311P.	98US-0087208P.
PR	21-NOV-1997; 97US-0066120P.	98US-0087609P.
PR	24-NOV-1997; 97US-0066466P.	98US-0087759P.
PR	24-NOV-1997; 97US-0066772P.	98US-0087827P.
PR	11-DEC-1997; 97US-0069335P.	98US-0088025P.
PR	12-DEC-1997; 97US-0069425P.	98US-0088028P.
PR	17-DEC-1997; 97US-0069870P.	98US-0088029P.
PR	18-DEC-1997; 97US-0068017P.	98US-0088033P.
PR	10-MAR-1998; 98US-0077450P.	98US-0088326P.
PR	11-MAR-1998; 98US-0077632P.	98US-0088167P.
PR	11-MAR-1998; 98US-0077649P.	98US-0088202P.
PR	20-MAR-1998; 98US-0078886P.	98US-0088212P.
PR	20-MAR-1998; 98US-0078939P.	98US-0088217P.
PR	27-MAR-1998; 98US-0079664P.	98US-0088555P.
PR	27-MAR-1998; 98US-0079786P.	98US-0088722P.
PR	31-MAR-1998; 98US-0080107P.	98US-0088738P.
PR	31-MAR-1998; 98US-0080194P.	98US-0088740P.
PR	01-APR-1998; 98US-0080327P.	98US-0088811P.
PR	01-APR-1998; 98US-0080333P.	98US-0088824P.
PR	08-APR-1998; 98US-0081049P.	98US-0088825P.
PR	08-APR-1998; 98US-0081070P.	98US-0088826P.
PR	09-APR-1998; 98US-0081195P.	98US-0088861P.
PR	15-APR-1998; 98US-0081838P.	98US-0088863P.
PR	21-APR-1998; 98US-0082568P.	98US-0088876P.
PR	21-APR-1998; 98US-0082569P.	98US-0089090P.
PR	22-APR-1998; 98US-0082704P.	98US-0089105P.
PR	22-APR-1998; 98US-0082797P.	98US-0089512P.
PR	28-APR-1998; 98US-0083322P.	98US-0089514P.
PR	29-APR-1998; 98US-0083495P.	98US-0089588P.
PR	29-APR-1998; 98US-0083496P.	98US-0089598P.
PR	29-APR-1998; 98US-0083499P.	98US-0089653P.
PR	29-APR-1998; 98US-0083559P.	98US-0089908P.
		98US-0090246P.
		98US-0090252P.
		98US-0090254P.
		98US-0090429P.
		98US-0090435P.
		98US-0090444P.
		98US-0090461P.
		98US-0090535P.
		98US-0090540P.
		98US-0090676P.
		98US-0090678P.
		98US-0090688P.
		98US-0090690P.
		98US-0090694P.
		98US-0090695P.
		98US-0090696P.
		98US-00105413.
		98US-0090862P.
		98US-0090863P.
		98US-0091010P.
		98US-0091359P.
		98US-0091544P.
		98US-0091478P.
		98US-0091486P.
		98US-0091626P.
		98US-0091628P.
		98US-0091632P.

[illegible]

```
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
```

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

```
QY 2121 CCTTTGCTTTACCACCTCTTCTCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACCTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCTTCCCATCTCTTGTAACACATTTTATAATAAATAAGGGTTGGCTTCTGAACCTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772
```

```
QY 2241 AA 2242
Db |||
    2773 AA 2774

RESULT 662
ACF16716
ID ACF16716 standard; cDNA; 2846 BP.
XX
AC ACF16716;
XX
DT 13-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003040073-A1.
XX
PD 27-FEB-2003.
XX
PF 28-JUN-2002; 2002US-00184655.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
```


QY 2241 AA 2242
Db 2773 AA 2774

RESULT 663
ACD32236
ID ACD32236 standard; cDNA; 2846 BP.
XX
AC ACD32236;
XX
DT 31-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
OS Homo sapiens.
XX
PN US2003054475-A1.
XX
PD 20-MAR-2003.
XX
PF 23-JUL-2002; 2002US-00202408.
XX
PR 18-SEP-1998; 98US-0100849P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
DR WPI; 2003-521851/49.
DR P-PSDB; ABO21842.
XX
PS New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention discloses human nucleic acids encoding secreted and
CC transmembrane (PRO) polypeptides, with or without their associated signal
CC peptide. Also disclosed is an antibody that specifically binds to the PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC PRO polypeptide, a method for stimulating the proliferation or
CC differentiation of chondrocyte cells by contacting the cells with a PRO
CC polypeptide, a method for detecting the presence of a tumour in a mammal
CC and an oligonucleotide probe derived from any of the PRO nucleotide
CC sequences. The nucleotide sequences are useful as probes, in chromosome
CC and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC polypeptides by recombinant techniques and in gene therapy (e.g. for
CC replacement of defective gene). The PRO polypeptides are useful as
CC molecular weight markers for protein electrophoresis purposes, for
CC chromosome identification, as chromosome markers, as therapeutic agents,
CC for stimulating the release of TNF-alpha from human blood, for
CC stimulating the proliferation or differentiation of chondrocytes and
CC detecting the presence, prevention and/or treatment of a tumour, such as
CC adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC The PRO polypeptides and nucleic acids may also be used diagnostically
CC for tissue typing. The sequence presented is a cDNA encoding one of the
CC PRO polypeptides of the invention. Note: The sequence data for this
CC patent can also be obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html

XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 2121 CCTTTGCTTTTACCACCTCTTTCTCTTTTATCTTATTATAATAATGTTGGTCTCCACCCTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCTCTCCCATCTCTGTGTACACATTTTAAATAAATAAGGGTTGGCTTCTGAAC 2712
QY 2181 NCTCCCAAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAA 2772
QY 2241 AA 2242
Db 2773 AA 2774

RESULT 664
ACD30394
ID ACD30394 standard; cDNA; 2846 BP.
XX
AC ACD30394;
XX
DT 30-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003032124-A1.
XX
PD 13-FEB-2003.
XX
PF 25-JUN-2002; 2002US-00180559.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.

PR	01-APR-1998;	98US-0080327P.
PR	01-APR-1998;	98US-0080333P.
PR	08-APR-1998;	98US-0081049P.
PR	08-APR-1998;	98US-0081070P.
PR	09-APR-1998;	98US-0081195P.
PR	15-APR-1998;	98US-0081838P.
PR	21-APR-1998;	98US-0082568P.
PR	21-APR-1998;	98US-0082569P.
PR	22-APR-1998;	98US-0082704P.
PR	22-APR-1998;	98US-0082797P.
PR	28-APR-1998;	98US-0083322P.
PR	29-APR-1998;	98US-0083495P.
PR	29-APR-1998;	98US-0083496P.
PR	29-APR-1998;	98US-0083499P.
PR	29-APR-1998;	98US-0083559P.
PR	05-MAY-1998;	98US-0084366P.
PR	06-MAY-1998;	98US-0084414P.
PR	07-MAY-1998;	98US-0084639P.
PR	07-MAY-1998;	98US-0084640P.
PR	07-MAY-1998;	98US-0084643P.
PR	15-MAY-1998;	98US-0085579P.
PR	15-MAY-1998;	98US-0085580P.
PR	15-MAY-1998;	98US-0085700P.
PR	18-MAY-1998;	98US-0086023P.
PR	22-MAY-1998;	98US-0086392P.
PR	22-MAY-1998;	98US-0086486P.
PR	28-MAY-1998;	98US-0087098P.
PR	28-MAY-1998;	98US-0087208P.
PR	02-JUN-1998;	98US-0087609P.
PR	02-JUN-1998;	98US-0087759P.
PR	03-JUN-1998;	98US-0087827P.
PR	04-JUN-1998;	98US-0088025P.
PR	04-JUN-1998;	98US-0088028P.
PR	04-JUN-1998;	98US-0088029P.
PR	04-JUN-1998;	98US-0088033P.
PR	04-JUN-1998;	98US-0088326P.
PR	05-JUN-1998;	98US-0088167P.
PR	05-JUN-1998;	98US-0088202P.
PR	05-JUN-1998;	98US-0088212P.
PR	05-JUN-1998;	98US-0088217P.
PR	09-JUN-1998;	98US-0088655P.
PR	10-JUN-1998;	98US-0088722P.
PR	10-JUN-1998;	98US-0088738P.
PR	10-JUN-1998;	98US-0088740P.
PR	10-JUN-1998;	98US-0088811P.
PR	10-JUN-1998;	98US-0088824P.
PR	10-JUN-1998;	98US-0088825P.
PR	10-JUN-1998;	98US-0088826P.
PR	11-JUN-1998;	98US-0088861P.
PR	11-JUN-1998;	98US-0088863P.
PR	11-JUN-1998;	98US-0088876P.
PR	12-JUN-1998;	98US-0089090P.
PR	12-JUN-1998;	98US-0089105P.
PR	16-JUN-1998;	98US-0089512P.
PR	16-JUN-1998;	98US-0089514P.
PR	17-JUN-1998;	98US-0089538P.
PR	17-JUN-1998;	98US-0089598P.
PR	17-JUN-1998;	98US-0089653P.
PR	19-JUN-1998;	98US-0089952P.
PR	22-JUN-1998;	98US-0090246P.
PR	22-JUN-1998;	98US-0090252P.
PR	22-JUN-1998;	98US-0090254P.
PR	24-JUN-1998;	98US-0090429P.
PR	24-JUN-1998;	98US-0090435P.
PR	24-JUN-1998;	98US-0090444P.
PR	24-JUN-1998;	98US-0090461P.
PR	24-JUN-1998;	98US-0090535P.
PR	24-JUN-1998;	98US-0090540P.
PR	25-JUN-1998;	98US-0090676P.
PR	25-JUN-1998;	98US-0090678P.
PR	25-JUN-1998;	98US-0090688P.
PR	25-JUN-1998;	98US-0090690P.
PR	25-JUN-1998;	98US-0090694P.
PR	25-JUN-1998;	98US-0090695P.
PR	25-JUN-1998;	98US-0090696P.
PR	26-JUN-1998;	98US-00105413.
PR	26-JUN-1998;	98US-0090862P.
PR	26-JUN-1998;	98US-0090863P.
PR	26-JUN-1998;	98US-0091010P.
PR	01-JUL-1998;	98US-0091359P.
PR	01-JUL-1998;	98US-0091544P.
PR	02-JUL-1998;	98US-0091478P.
PR	02-JUL-1998;	98US-0091486P.
PR	02-JUL-1998;	98US-0091626P.
PR	02-JUL-1998;	98US-0091628P.
PR	02-JUL-1998;	98US-0091632P.
PR	24-JUL-1998;	98US-0094006P.
PR	04-AUG-1998;	98US-0095282P.
PR	10-AUG-1998;	98US-0095998P.
PR	10-AUG-1998;	98US-0096012P.
PR	17-AUG-1998;	98US-0096757P.
PR	17-AUG-1998;	98US-0096766P.
PR	17-AUG-1998;	98US-0096867P.
PR	17-AUG-1998;	98US-0096891P.
PR	17-AUG-1998;	98US-0096897P.
PR	18-AUG-1998;	98US-0096949P.
PR	18-AUG-1998;	98US-0096959P.
PR	18-AUG-1998;	98US-0097022P.
PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100683P.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101475P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.

PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

[illegible]

Qy 2241 AA 2242
2773 AA 2774
Db

RESULT 665
ACD41265
ID ACD41265 standard; cDNA; 2846 BP.

AC ACD41265;

DT 11-SEP-2003 (first entry)

DE Human secreted/transmembrane protein (PRO) cDNA #85.

Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha; tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy; tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour; cervical tumour; liver tumour.

OS Homo sapiens.

PN US2003064467-A1.

PD 03-APR-2003.

PF 29-JUL-2002; 2002US-00207921.

PR 21-MAR-2000; 2000US-0191048P.

PR 15-JAN-2002; 2002US-00052586.

PA (GETH) GENENTECH INC.

PI Baker KP, Chen J, De

10. **Ergebnisse**

DR WPI; 2003-531722/50.

XX

PT gene therapy, chr

XX

11

CC transmembrane (PRO) polypeptides,

CC polypeptide, a method for stimulating

PRO polypeptide, a method for stimulating the proliferation or differentiation of chondrocyte cells by contacting the cells with a PRO polypeptide, a method for detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the PRO nucleotide sequences. The nucleotide sequences are useful as probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO

PT Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT for stimulating tumor necrosis factor alpha or chondrocyte proliferation,
PT particularly for treating e.g. lung or breast tumors, or arthritis in a
XX mammal.
XX
XX Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABR85980-ABR86284) and nucleic acids encoding them (ACF07565-ACF07869).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumor necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adenoma, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF07565-ACF07869 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCTCTTTTATCTTTATTAATAAAATGTTGGTCTCCCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCTTCCCATCTCTTGACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 667
ACF31064
ID ACF31064 standard; cDNA; 2846 BP.
XX
AC ACF31064;
XX
DT 24-SEP-2003 (first entry)
XX

DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003064455-A1.
XX
PD 03-APR-2003.
XX
XX 18-JUL-2002; 2002US-00198766.
XX
XX 28-MAY-1998; 98US-0087098P.
PR 08-MAR-1999; 99WO-US005028.
PR 25-AUG-1999; 99US-00380138.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-567184/53.
DR P-PSDB; ABM10716.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy and for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody.
XX
PS Claim 2; Fig 169; 699pp; English.
XX
XX The invention relates to human PRO secreted/transmembrane polypeptides
CC (ABM10632-ABM10936) and nucleic acids encoding them (ACF30980-ACF31284).
CC The invention also relates to sequences at least 80% identical to the PRO
CC nucleic acid and polypeptide sequences of the invention, recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACF30980-ACF31284 represent

XX 17-APR-2003.
XX 18-JUN-2002; 2002US-00174578.
PF 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.

```
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match      3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGTCTTACCACCTCTTCCCTTTATCTTTATTAATAAAAAATGTTGGTCTCCACCACCTG 2180
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAAATAAAATGAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 670
ACF32906
ID ACF32906 standard; cDNA; 2846 BP.
XX
AC ACF32906;
XX
DT 22-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
```

```
PN US2003073176-A1.
XX
PD 17-APR-2003.
XX
PF 12-JUL-2002; 2002US-00194360.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-585299/55.
XX P-PSDB; ABM12546.
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
PT in tissue typing, and in identifying chromosomes.
XX
PS Claim 2; Fig 169; 700pp; English.
XX
CC The invention relates to human PRO secreted/transmembrane polypeptides
CC and nucleic acids encoding them, the invention also provides recombinant
CC vectors and host cells comprising a PRO nucleic acid, a method for the
CC recombinant production of a PRO polypeptide, antibodies against a PRO
CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC acids encoding PRO polypeptides of the invention were initially
CC identified via homology screening using consensus sequences based on the
CC extracellular domain sequences from known secreted proteins. Human cDNA
CC libraries containing sequences of interest were identified using
CC oligonucleotides based on the consensus sequences, and cDNA clones were
CC isolated and characterised. The PRO polypeptides are useful for
CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
CC human blood and may thus be used in the treatment of conditions in which
CC enhanced TNF-alpha release would be beneficial. They are also useful for
CC stimulating the proliferation or differentiation of chondrocytes and as
CC such may be used in the treatment of various bone and/or cartilage
CC disorders such as arthritis and sports injuries. The PRO polypeptides may
CC be used in a method for detecting the presence of a tumour (e.g., an
CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. The present sequence appears in the
CC exemplification of the specification. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
```

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACCTCTTTCCTTTTATCTTTATTAATAAAAAATGTTGGTCTCCACCACCTG 2180
Db 2653 CCTTTCTCTCCCATCTCTTGACACATTTTAAATAAAATGAGGTTGGCTTCTGAACTA 2712

QY 2181 NCTCCCAA 2240
Db 2713 CAAA 2772

QY 2241 AA 2242
Db 2773 AA 2774

RESULT 670
ACF32906
ID ACF32906 standard; cDNA; 2846 BP.
XX
AC ACF32906;
XX
DT 22-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerary; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX

Db 2773 AA 2774

RESULT 674

ACF42984

ID ACF42984 standard; cDNA; 2846 BP.

XX

AC ACF42984;

XX

DT 03-OCT-2003 (first entry)

XX

DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX

KW Human; PRO; secreted protein; transmembrane protein; TNF-alpha; extracellular domain; tumour necrosis factor-alpha; TNF-alpha; chondrocyte; proliferation; differentiation; cancer; tumour; diagnosis; bone disorder; arthritis; sports injury; cancer; tumour; rectum; cervix; adrenal tumour; lung; colon; breast; prostate; kidney; genetic analysis; liver; drug screening; transgenic animal; genetic analysis; antiarthritic; vulnery; gene therapy; gene; ss.

XX

OS Homo sapiens.

XX

PN US2003104550-A1.

XX

PD 05-JUN-2003.

XX

PF 23-JUL-2002; 2002US-00202413.

XX

PR 30-SEP-1998; 98US-0102571P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX

PA (GETH) GENENTECH INC.

XX

PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-670247/63.

DR P-PSDB; ABM19015.

XX

PT Three hundred and five nucleic acids encoding PRO polypeptides, useful for diagnosing, preventing and/or treating tumors, such as adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.

XX

PS Claim 2; Fig 169; 700pp; English.

XX

CC The invention relates to human PRO secreted/transmembrane polypeptides (ABM18931-ABM19235) and nucleic acids encoding them (ACF42900-ACF43204).

CC

CC The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide

CC in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF42900-ACF43204 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX

SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCCTTCCTTTACCACTCTTCTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180

Db 2653 CCCTTTCCTTCCCATCTCTGTACACATTTTAATAAATAGGGTTGGTCTCTGAACCTA 2712

QY 2181 NCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240

Db 2713 CAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 675

ACF43291

ID ACF43291 standard; cDNA; 2846 BP.

XX

AC ACF43291;

XX

DT 03-OCT-2003 (first entry)

XX

DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX

KW Human; PRO; secreted protein; transmembrane protein; extracellular domain; tumour necrosis factor-alpha; TNF-alpha; chondrocyte; proliferation; differentiation; cartilage disorder; bone disorder; arthritis; sports injury; cancer; tumour; diagnosis; adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix; liver; drug screening; transgenic animal; genetic analysis; antiarthritic; vulnery; gene therapy; gene; ss.

XX

OS Homo sapiens.

XX

PN US2003104551-A1.

XX

PD 05-JUN-2003.

XX

PF 24-JUL-2002; 2002US-00202938.

XX

PR 31-OCT-1997; 97US-0064103P.

PR 16-SEP-1998; 98WO-US019330.

PR 25-AUG-1999; 99US-00380139.

PR 22-FEB-2000; 2000WO-US004414.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX

PA (GETH) GENENTECH INC.

XX

PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX

RESULT 677	
ACH08761	
ID	ACH08761 standard; cDNA; 2846 BP.
XX	
AC	ACH08761;
XX	
DT	10-OCT-2003 (first entry)
XX	
DE	Human secreted/transmembrane protein (PRO) cDNA #85.
XX	
KW	Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW	tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW	tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX	
OS	Homo sapiens.
XX	
PN	US2003049757-A1.
XX	
PD	13-MAR-2003.
XX	
PF	18-JUL-2002; 2002US-00198769.
XX	
PR	15-MAY-1998; 98US-0085700P.
PR	08-MAR-1999; 99WO-US005028.
PR	25-AUG-1999; 99US-00380138.
PR	28-FEB-2001; 2001WO-US006520.
PR	15-JAN-2002; 2002US-00052586.
XX	
PA	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX	
DR	WPI: 2003-677931/64.
DR	P-PSDE; ABO49032.
XX	
PT	Three hundred and five nucleic acids encoding PRO polypeptides, useful
PT	for diagnosing, preventing and/or treating tumors, such as adrenal, lung,
PT	colon, breast, prostate, rectal, cervical or liver tumors.
XX	
PS	Claim 2; Fig 169; 700pp; English.
XX	
CC	The invention discloses human nucleic acids encoding secreted and
CC	transmembrane (PRO) polypeptides, with or without their associated signal
CC	peptide. Also disclosed is an antibody that specifically binds to the PRO
CC	polypeptide, a method for stimulating the release of tumour necrosis
CC	factor alpha (TNF-alpha) from human blood by contacting the blood with a
CC	PRO polypeptide, a method for stimulating the proliferation or
CC	differentiation of chondrocyte cells by contacting the cells with a PRO
CC	polypeptide, a method for detecting the presence of a tumour in a mammal
CC	and an oligonucleotide probe derived from any of the PRO nucleotide
CC	sequences. The nucleotide sequences are useful as probes, in chromosome
CC	and gene mapping, in generating antisense RNA and DNA, in preparing PRO
CC	polypeptides by recombinant techniques and in gene therapy (e.g. for
CC	replacement of defective gene). The PRO polypeptides are useful as
CC	molecular weight markers for protein electrophoresis purposes, for
CC	chromosome identification, as chromosome markers, as therapeutic agents,
CC	for stimulating the release of TNF-alpha from human blood, for
CC	stimulating the proliferation or differentiation of chondrocytes and
CC	detecting the presence, prevention and/or treatment of a tumour, such as
CC	adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumour.
CC	The PRO polypeptides and nucleic acids may also be used diagnostically
CC	for tissue typing. The sequence presented is a cDNA encoding one of the
CC	PRO polypeptides of the invention. Note: The sequence data for this
CC	patent can also be obtained in electronic format directly from USPTO at
CC	segdata.uspto.gov/sequence.html
XX	
SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match	3.0%;	Score 66.6;	DB 9;	Length 2846;
Best Local Similarity	71.3%;	Pred. No. 0.00023;		
Matches	87;	Conservative	0;	Mismatches 35;
		Indels	0;	Gaps 0;

Qy	2121	CCTTTGGCTTTACCACTCTTCCCTTTTATCTTATTAATAAATGTTGGTCTCCCACTG	2180
Db	2653	CCTTTTCCCTTCCCCATCTCTTGACACATTTTAAATAAATAAGGTTGGCTTCTGAACTA	2712
Qy	2181	NCTCCCAA	2240
Db	2713	CAA	2772
Qy	2241	AA 2242	
Db	2773	AA 2774	
RESULT 678			
ACC90355			
ID	ACC90355	standard; cDNA; 2846 BP.	
XX			
AC	ACC90355;		
XX			
DT	11-AUG-2003	(first entry)	
XX			
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.		
XX			
KW	Human; PRO; secreted protein; transmembrane protein;		
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;		
KW	chondrocyte; proliferation; differentiation; cartilage disorder;		
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;		
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;		
KW	liver; drug screening; transgenic animal; genetic analysis;		
KW	antiarthritic; vulneryary; gene therapy; gene; ss.		
XX			
OS	Homo sapiens.		
XX			
PN	US2003027273-A1.		
XX			
PD	06-FEB-2003.		
XX			
PF	20-JUN-2002; 2002US-00176747.		
XX			
PR	18-SEP-1997;	97US-0059263P.	
PR	18-SEP-1997;	97US-0059266P.	
PR	17-OCT-1997;	97US-0062250P.	
PR	21-OCT-1997;	97US-0063486P.	
PR	24-OCT-1997;	97US-0063120P.	
PR	24-OCT-1997;	97US-0063121P.	
PR	28-OCT-1997;	97US-0063540P.	
PR	28-OCT-1997;	97US-0063541P.	
PR	28-OCT-1997;	97US-0063544P.	
PR	28-OCT-1997;	97US-0063564P.	
PR	29-OCT-1997;	97US-0063734P.	
PR	31-OCT-1997;	97US-0063870P.	
PR	31-OCT-1997;	97US-0064103P.	
PR	13-NOV-1997;	97US-0065311P.	
PR	21-NOV-1997;	97US-0066120P.	
PR	24-NOV-1997;	97US-0066466P.	
PR	24-NOV-1997;	97US-0066772P.	
PR	11-DEC-1997;	97US-0069335P.	
PR	12-DEC-1997;	97US-0069425P.	
PR	17-DEC-1997;	97US-0069870P.	
PR	18-DEC-1997;	97US-0068017P.	
PR	10-MAR-1998;	98US-0077450P.	
PR	11-MAR-1998;	98US-0077632P.	
PR	11-MAR-1998;	98US-0077649P.	
PR	20-MAR-1998;	98US-0078886P.	
PR	20-MAR-1998;	98US-0078939P.	
PR	27-MAR-1998;	98US-0079664P.	
PR	27-MAR-1998;	98US-0079786P.	
PR	31-MAR-1998;	98US-0080107P.	
PR	31-MAR-1998;	98US-0080194P.	
PR	01-APR-1998;	98US-0080327P.	
PR	01-APR-1998;	98US-0080333P.	
PR	08-APR-1998;	98US-0081049P.	

PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.

PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Matches	87;	Conservative	0;	Mismatches	35;	Indels	0;	Gaps	0;
QY	2121	CCTTTGCTTTACCACTCTTTCC	TTTTATCTTATTATAATAAATGTTGGTCTCCACCACTG	2180					
Db	2653	CCTTTTCCTCCCATCTCTTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACTA	2712						
QY	2181	NCTCCCAA	2240						
Db	2713	CAA	2772						
QY	2241	AA	2242						
Db	2773	AA	2774						
RESULT 679									
ACF10719									
ID	ACF10719 standard; cDNA; 2846 BP.								
XX									
AC									
XX									
DT	06-SEP-2003 (first entry)								
XX									
DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.								
XX									
KW	Human; PRO; secreted protein; transmembrane protein;								
KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;								
KW	chondrocyte; proliferation; differentiation; cartilage disorder;								
KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;								
KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;								
KW	liver; drug screening; transgenic animal; genetic analysis;								
KW	antiarthritic; vulnery; gene therapy; gene; ss.								
XX									
OS	Homo sapiens.								
XX									
PN	US2003036119-A1.								
XX									
PD	20-FEB-2003.								
XX									
PF	20-JUN-2002; 2002US-00176990.								
XX									
PR	18-SEP-1997;	97US-0059263P.							
PR	18-SEP-1997;	97US-0059266P.							
PR	17-OCT-1997;	97US-0062250P.							
PR	21-OCT-1997;	97US-0063486P.							
PR	24-OCT-1997;	97US-0063120P.							
PR	24-OCT-1997;	97US-0063121P.							
PR	28-OCT-1997;	97US-0063540P.							
PR	28-OCT-1997;	97US-0063541P.							
PR	28-OCT-1997;	97US-0063544P.							
PR	28-OCT-1997;	97US-0063564P.							
PR	29-OCT-1997;	97US-0063734P.							
PR	31-OCT-1997;	97US-0063870P.							
PR	31-OCT-1997;	97US-0064103P.							
PR	13-NOV-1997;	97US-0065311P.							
PR	21-NOV-1997;	97US-0066120P.							
PR	24-NOV-1997;	97US-0066466P.							
PR	24-NOV-1997;	97US-0066772P.							
PR	11-DEC-1997;	97US-0069335P.							
PR	12-DEC-1997;	97US-0069425P.							
PR	17-DEC-1997;	97US-0069870P.							
PR	18-DEC-1997;	97US-0068017P.							
PR	10-MAR-1998;	98US-0077632P.							
PR	11-MAR-1998;	98US-0077649P.							
PR	20-MAR-1998;	98US-0078886P.							
PR	20-MAR-1998;	98US-0078939P.							
PR	27-MAR-1998;	98US-0079664P.							
PR	27-MAR-1998;	98US-0079786P.							
PR	31-MAR-1998;	98US-0080107P.							
PR	31-MAR-1998;	98US-0080194P.							
PR	01-APR-1998;	98US-0080327P.							
PR	01-APR-1998;	98US-0080333P.							

PR	08-APR-1998;	98US-0081049P.
PR	08-APR-1998;	98US-0081070P.
PR	09-APR-1998;	98US-0081195P.
PR	15-APR-1998;	98US-0081838P.
PR	21-APR-1998;	98US-0082568P.
PR	21-APR-1998;	98US-0082569P.
PR	22-APR-1998;	98US-0082704P.
PR	22-APR-1998;	98US-0082797P.
PR	28-APR-1998;	98US-0083322P.
PR	29-APR-1998;	98US-0083495P.
PR	29-APR-1998;	98US-0083496P.
PR	29-APR-1998;	98US-0083499P.
PR	29-APR-1998;	98US-0083559P.
PR	05-MAY-1998;	98US-0084366P.
PR	06-MAY-1998;	98US-0084414P.
PR	07-MAY-1998;	98US-0084639P.
PR	07-MAY-1998;	98US-0084640P.
PR	07-MAY-1998;	98US-0084643P.
PR	15-MAY-1998;	98US-0085579P.
PR	15-MAY-1998;	98US-0085580P.
PR	15-MAY-1998;	98US-0085582P.
PR	15-MAY-1998;	98US-0085700P.
PR	18-MAY-1998;	98US-0086023P.
PR	22-MAY-1998;	98US-0086392P.
PR	22-MAY-1998;	98US-0086486P.
PR	28-MAY-1998;	98US-0087098P.
PR	28-MAY-1998;	98US-0087208P.
PR	02-JUN-1998;	98US-0087609P.
PR	02-JUN-1998;	98US-0087759P.
PR	03-JUN-1998;	98US-0087827P.
PR	04-JUN-1998;	98US-0088025P.
PR	04-JUN-1998;	98US-0088028P.
PR	04-JUN-1998;	98US-0088029P.
PR	04-JUN-1998;	98US-0088033P.
PR	04-JUN-1998;	98US-0088326P.
PR	05-JUN-1998;	98US-0088167P.
PR	05-JUN-1998;	98US-0088202P.
PR	05-JUN-1998;	98US-0088212P.
PR	05-JUN-1998;	98US-0088217P.
PR	09-JUN-1998;	98US-0088655P.
PR	10-JUN-1998;	98US-0088722P.
PR	10-JUN-1998;	98US-0088738P.
PR	10-JUN-1998;	98US-0088740P.
PR	10-JUN-1998;	98US-0088811P.
PR	10-JUN-1998;	98US-0088824P.
PR	10-JUN-1998;	98US-0088825P.
PR	10-JUN-1998;	98US-0088826P.
PR	11-JUN-1998;	98US-0088861P.
PR	11-JUN-1998;	98US-0088863P.
PR	11-JUN-1998;	98US-0088876P.
PR	12-JUN-1998;	98US-0089090P.
PR	12-JUN-1998;	98US-0089105P.
PR	16-JUN-1998;	98US-0089512P.
PR	16-JUN-1998;	98US-0089514P.
PR	17-JUN-1998;	98US-0089538P.
PR	17-JUN-1998;	98US-0089598P.
PR	17-JUN-1998;	98US-0089653P.
PR	18-JUN-1998;	98US-0089908P.
PR	19-JUN-1998;	98US-0089952P.
PR	22-JUN-1998;	98US-0090246P.
PR	22-JUN-1998;	98US-0090252P.
PR	22-JUN-1998;	98US-0090254P.
PR	24-JUN-1998;	98US-0090429P.
PR	24-JUN-1998;	98US-0090435P.
PR	24-JUN-1998;	98US-0090444P.
PR	24-JUN-1998;	98US-0090461P.
PR	24-JUN-1998;	98US-0090535P.
PR	24-JUN-1998;	98US-0090540P.
PR	25-JUN-1998;	98US-0090676P.
PR	25-JUN-1998;	98US-0090678P.
PR	25-JUN-1998;	98US-0090688P.
PR	25-JUN-1998;	98US-0090690P.
PR	25-JUN-1998;	98US-0090694P.

Best Local Similarity

71.3%; Pred.No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy

2121

CCTTTGCTTTTACCACACTCTTTTCCTTTTATCTTTATTATAAAAAATGTGGTCTCCACCACTG

2180

Dd

2653

CCTTTTCCTTCCCCTCTCTTGACACATTTTAATAAAATAAGGGTTGGCTTCTGAACA

2712

Qy

2181

NCTCCCCAAA

2240

Dd

2713

CAA

2772

Qy

2241

AA 2242

Dd

2773

AA 2774

RESULT 680

ACC93534

ID ACC93534 standard; cDNA; 2846 BP.

XX

AC ACC93534;

XX

DT 22-AUG-2003 (first entry)

DE Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

XX

KW Human; PRO; secreted protein; transmembrane protein;
extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; proliferation; differentiation; cartilage disorder;
bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
liver; drug screening; transgenic animal; genetic analysis;
antiarthritic; vulnery; gene therapy; gene; ss.

OS Homo sapiens.

XX

PN US2003036120-A1.

XX

PD 20-FEB-2003.

XX

PF 25-JUN-2002; 2002US-00180541.

XX

PR 18-SEP-1997; 97US-0059263P.
18-SEP-1997; 97US-0059266P.
17-OCT-1997; 97US-0062250P.
21-OCT-1997; 97US-0063486P.
24-OCT-1997; 97US-0063120P.
24-OCT-1997; 97US-0063121P.
28-OCT-1997; 97US-0063540P.
28-OCT-1997; 97US-0063541P.
28-OCT-1997; 97US-0063544P.
29-OCT-1997; 97US-0063734P.
31-OCT-1997; 97US-0063870P.
31-OCT-1997; 97US-0064103P.
13-NOV-1997; 97US-0065311P.
21-NOV-1997; 97US-0066120P.
24-NOV-1997; 97US-0066466P.
24-NOV-1997; 97US-0066772P.
11-DEC-1997; 97US-0069335P.
12-DEC-1997; 97US-0069425P.
17-DEC-1997; 97US-0069870P.
18-DEC-1997; 97US-0068017P.
10-MAR-1998; 98US-0077450P.
11-MAR-1998; 98US-0077632P.
11-MAR-1998; 98US-0077649P.
20-MAR-1998; 98US-0078886P.
20-MAR-1998; 98US-0078939P.
27-MAR-1998; 98US-0079664P.
27-MAR-1998; 98US-0079786P.
31-MAR-1998; 98US-0080107P.
31-MAR-1998; 98US-0080194P.
01-APR-1998; 98US-0080327P.

Query Match

3.0%; Score 66.6; DB 9; Length 2846;

PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.

PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.


```
CC method involves comparing the level of expression of the PRO polypeptide
CC in test and control samples, where a higher level of expression of PRO
CC polypeptide in the test sample as compared to the control sample is
CC indicative of the presence of a tumour. The PRO polypeptides are
CC additionally useful for in drug screening to identify agonists and
CC antagonists of PRO polypeptides. PRO nucleic acids are useful as
CC hybridisation probes (for isolation of cDNA molecules), in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA and in gene
CC therapy. The nucleic acids can also be used for mapping genes encoding
CC PRO polypeptides, for genetic analysis of individuals with genetic
CC disorders, and for generating either transgenic animals or knock-out
CC animals which are useful in the development and screening of
CC therapeutically useful compounds. Sequences ACC96069-ACC96373 represent
CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

  Query Match      3.0%; Score 66.6; DB 9; Length 2846;
  Best Local Similarity 71.3%; Pred. No. 0.00023;
  Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTATAAAAAATGTTGGTCTCCACCACTG 2180
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTTCCTTCCCATCTCTTGTACACATTTTAATAAAATAAGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2240
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2772

QY 2241 AA 2242
    ||
Db 2773 AA 2774

RESULT 682
ACD24828
ID ACD24828 standard; cDNA; 2846 BP.
XX
AC ACD24828;
XX
DT 29-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
FN US2003044921-A1.
XX
PD 06-MAR-2003.
XX
PF 24-JUN-2002; 2002US-00179513.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
```

```
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 18-MAY-1998; 98US-0085700P.
PR 22-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
```


DR	P-PSDB; ABR80291.	DE	Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.
XX		XX	
PT	Three hundred and five nucleic acids encoding PRO polypeptides, useful	KW	Human; PRO; secreted protein; transmembrane protein;
PT	for stimulating tumor necrosis factor alpha or chondrocyte proliferation.	KW	extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX		KW	chondrocyte; proliferation; differentiation; cartilage disorder;
PS	Claim 2; Fig 169; 700pp; English.	KW	bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX		KW	adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
CC	The invention relates to human PRO secreted/transmembrane polypeptides	KW	liver; drug screening; transgenic animal; genetic analysis;
CC	(ABR80207-ABR80511) and nucleic acids encoding them (ACF01829-ACF02133).	XX	antiarthritic; vulnerary; gene therapy; gene; ss.
CC	The invention also relates to sequences at least 80% identical to the PRO	OS	Homo sapiens.
CC	nucleic acid and polypeptide sequences of the invention, recombinant	XX	
CC	vectors and host cells comprising a PRO nucleic acid, a method for the	PN	US2003059882-A1.
CC	recombinant production of a PRO polypeptide, antibodies against a PRO	XX	
CC	polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic	PD	27-MAR-2003.
CC	acids encoding PRO polypeptides of the invention were initially	XX	
CC	identified via homology screening using consensus sequences based on the	XX	19-JUL-2002; 2002US-00198770.
CC	extracellular domain sequences from known secreted proteins. Human cDNA	XX	
CC	libraries containing sequences of interest were identified using	PR	15-MAY-1998; 98US-0085573P.
CC	oligonucleotides based on the consensus sequences, and cDNA clones were	PR	08-MAR-1999; 99WO-US005028.
CC	isolated and characterised. The PRO polypeptides are useful for	PR	25-AUG-1999; 99US-00380138.
CC	stimulating release of tumour necrosis factor-alpha (TNF-alpha) from	PR	28-FEB-2001; 2001WO-US006520.
CC	human blood and may thus be used in the treatment of conditions in which	PR	15-JAN-2002; 2002US-00052586.
CC	enhanced TNF-alpha release would be beneficial. They are also useful for	XX	
CC	stimulating the proliferation or differentiation of chondrocytes and as	PA	(GETH) GENENTECH INC.
CC	such may be used in the treatment of various bone and/or cartilage	XX	
CC	disorders such as arthritis and sports injuries. The PRO polypeptides may	XX	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
CC	be used in a method for detecting the presence of a tumour (e.g., an	PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
CC	adrenal tumour, lung tumour, colon tumour, breast tumour, prostate	XX	
CC	tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This	DR	WPI; 2003-555481/52.
CC	method involves comparing the level of expression of the PRO polypeptide	DR	P-PSDB; ABM01512.
CC	in test and control samples, where a higher level of expression of PRO	XX	
CC	polypeptide in the test sample as compared to the control sample is	XX	New secreted and transmembrane PRO polypeptides and nucleic acids, useful
CC	indicative of the presence of a tumour. The PRO polypeptides are	PT	in gene therapy, or for preparing a medicament for treating a condition
CC	additionally useful for in drug screening to identify agonists and	PT	that is responsive to the PRO polypeptide or anti-PRO antibody.
CC	antagonists of PRO polypeptides. PRO nucleic acids are useful as	XX	
CC	hybridisation probes (for isolation of cDNA molecules), in chromosome and	PS	Claim 2; Fig 169; 700pp; English.
CC	gene mapping, in the generation of antisense RNA and DNA and in gene	XX	
CC	therapy. The nucleic acids can also be used for mapping genes encoding	CC	The invention relates to human PRO secreted/transmembrane polypeptides
CC	PRO polypeptides, for genetic analysis of individuals with genetic	CC	(ABM01428-ABM01732) and nucleic acids encoding them (ACF21951-ACF22255).
CC	disorders, and for generating either transgenic animals or knock-out	CC	The invention also relates to sequences at least 80% identical to the PRO
CC	animals which are useful in the development and screening of	CC	nucleic acid and polypeptide sequences of the invention, recombinant
CC	therapeutically useful compounds. Sequences ACF01829-ACF02133 represent	CC	vectors and host cells comprising a PRO nucleic acid, a method for the
CC	cDNAs encoding the human PRO secreted/transmembrane polypeptides of the	CC	recombinant production of a PRO polypeptide, antibodies against a PRO
CC	invention. Note: The sequence data for this patent is also available in	CC	polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic
CC	electronic format from USPTO at seqdata.uspto.gov/sequence.html	CC	acids encoding PRO polypeptides of the invention were initially
XX		CC	identified via homology screening using consensus sequences based on the
SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;	CC	extracellular domain sequences from known secreted proteins. Human cDNA
		CC	libraries containing sequences of interest were identified using
		CC	oligonucleotides based on the consensus sequences, and cDNA clones were
		CC	isolated and characterised. The PRO polypeptides are useful for
		CC	stimulating release of tumour necrosis factor-alpha (TNF-alpha) from
		CC	human blood and may thus be used in the treatment of conditions in which
		CC	enhanced TNF-alpha release would be beneficial. They are also useful for
		CC	stimulating the proliferation or differentiation of chondrocytes and as
		CC	such may be used in the treatment of various bone and/or cartilage
		CC	disorders such as arthritis and sports injuries. The PRO polypeptides may
		CC	be used in a method for detecting the presence of a tumour (e.g., an
		CC	adrenal tumour, lung tumour, colon tumour, breast tumour, prostate
		CC	tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This
		CC	method involves comparing the level of expression of the PRO polypeptide
		CC	in test and control samples, where a higher level of expression of PRO
		CC	polypeptide in the test sample as compared to the control sample is
		CC	indicative of the presence of a tumour. The PRO polypeptides are
		CC	additionally useful for in drug screening to identify agonists and
		CC	antagonists of PRO polypeptides. PRO nucleic acids are useful as
		CC	hybridisation probes (for isolation of cDNA molecules), in chromosome and
		CC	gene mapping, in the generation of antisense RNA and DNA and in gene
		CC	therapy. The nucleic acids can also be used for mapping genes encoding
		CC	PRO polypeptides, for genetic analysis of individuals with genetic
		CC	disorders, and for generating either transgenic animals or knock-out
		CC	animals which are useful in the development and screening of
		CC	therapeutically useful compounds. Sequences ACF01829-ACF02133 represent
		CC	cDNAs encoding the human PRO secreted/transmembrane polypeptides of the
		CC	invention. Note: The sequence data for this patent is also available in
		CC	electronic format from USPTO at seqdata.uspto.gov/sequence.html
		XX	
		SQ	Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;
	Query Match 3.0%; Score 66.6; DB 9; Length 2846;		
	Best Local Similarity 71.3%; Pred. No. 0.00023;		
	Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;		
QY	2121 CCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTG 2180		
Db	2653 CCTTTCTCTCCCACTCTCTGTGACACATTTTAATAAAATAAGGGTTGGCTTCTGAACTA 2712		
QY	2181 NCTCCCAA 2240		
Db	2713 CAAA 2772		
QY	2241 AA 2242		
Db	2773 AA 2774		
	RESULT 684		
	ACF22035		
ID	ACF22035 standard; cDNA; 2846 BP.		
XX			
AC	ACF22035;		
XX			
DT	19-SEP-2003 (first entry)		
XX			

ACF48527;

07-OCT-2003 (first entry)

Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

Human; PRO; secreted protein; transmembrane protein; extracellular domain; tumour necrosis factor-alpha; TNF-alpha; chondrocyte; proliferation; differentiation; cartilage disorder; bone disorder; arthritis; sports injury; cancer; tumour; diagnosis; adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix; liver; drug screening; transgenic animal; genetic analysis; antiarthritic; vulnery; gene therapy; gene; ss.

Homo sapiens.

US2003064444-A1.

03-APR-2003.

02-JUL-2002; 2002US-00187883.

01-OCT-1998; 98US-0102687P.

01-SEP-1999; 99WO-US020111.

18-OCT-1999; 99US-00403297.

18-FEB-2000; 2000WO-US004342.

28-FEB-2001; 2001WO-US006520.

15-JAN-2002; 2002US-00052586.

(GETH) GENENTECH INC.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL; Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-605857/57.

P-PSDB; ABM24505.

New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for diagnosing, preventing and/or treating tumors, such as adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.

Claim 2; Fig 169; 700pp; English.

The invention relates to human PRO secreted/transmembrane polypeptides (ABM24421-ABM24725) and nucleic acids encoding them (ACF48443-ACF48747). The invention also relates to sequences at least 80% identical to the PRO nucleic acid and polypeptide sequences of the invention, recombinant vectors and host cells comprising a PRO nucleic acid, a method for the recombinant production of a PRO polypeptide, antibodies against a PRO polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic acids encoding PRO polypeptides of the invention were initially identified via homology screening using consensus sequences based on the extracellular domain sequences from known secreted proteins. Human cDNA libraries containing sequences of interest were identified using oligonucleotides based on the consensus sequences, and cDNA clones were isolated and characterised. The PRO polypeptides are useful for stimulating release of tumour necrosis factor-alpha (TNF-alpha) from human blood and may thus be used in the treatment of conditions in which enhanced TNF-alpha release would be beneficial. They are also useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as arthritis and sports injuries. The PRO polypeptides may be used in a method for detecting the presence of a tumour (e.g., an adrenal tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This method involves comparing the level of expression of the PRO polypeptide in test and control samples, where a higher level of expression of PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumour. The PRO polypeptides are additionally useful for in drug screening to identify agonists and antagonists of PRO polypeptides. PRO nucleic acids are useful as hybridisation probes (for isolation of cDNA molecules), in chromosome and

gene mapping, in the generation of antisense RNA and DNA and in gene therapy. The nucleic acids can also be used for mapping genes encoding PRO polypeptides, for genetic analysis of individuals with genetic disorders, and for generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful compounds. Sequences ACF48443-ACF48747 represent cDNAs encoding the human PRO secreted/transmembrane polypeptides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX
SQ Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

Query Match 3.0%; Score 66.6; DB 9; Length 2846;
Best Local Similarity 71.3%; Pred. No. 0.00023;
Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTGGTTTACCCTCTTCCTTTATCTATTATAAAATGTTGGTCTCCCACTG 2180
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2653 CCTTTCCTTCCCCATCTCTTGACACATTTAATAAAATAAGGTTGGCTTCTGAATA 2712

QY 2181 NCTCCCAA 2240
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2713 CAAAAAIAAA 2772

QY 2241 AA 2242
||
Db 2773 AA 2774

RESULT 690
ACD47317
ID ACD47317 standard; cDNA; 2846 BP.
XX
AC ACD47317;
XX
DT 13-SEP-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #85.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003068697-A1.
XX
PD 10-APR-2003.
XX
PF 09-JUL-2002; 2002US-00192016.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 28-FEB-2001; 2001WO-US006520.
PR 15-JAN-2002; 2002US-00052586.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-605913/57.
DR P-PSDB; ABO29419.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for diagnosing, preventing and/or treating tumors, e.g.
PT adrenal, lung, colon, breast, prostate, rectal, cervical or liver tumors.
XX
PS Claim 2; Fig 169; 700pp; English.

The invention discloses human nucleic acids encoding secreted and transmembrane (PRO) polypeptides, with or without their associated signal peptide. Also disclosed is an antibody that specifically binds to the PRO

XX 10-APR-2003.

XX 02-JUL-2002; 2002US-00187742.

XX 02-JUL-1998; 98US-0091486P.

PR 02-JUN-1999; 99WO-US012252.

PR 25-AUG-1999; 99US-00380137.

PR 30-MAR-2000; 2000WO-US008439.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586.

XX (GETH) GENENTECH INC.

XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-615871/58.

DR P-PSDB; ABM14376.

XX New PRO nucleic acid, useful for the manufacture of a medicament for

PT diagnosing or treating tumor or for tissue typing.

XX Claim 2; Fig 169; 700pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides

CC (ABM14292-ABM14596) and nucleic acids encoding them (ACF37778-ACF38082).

CC The invention also relates to sequences at least 80% identical to the PRO

CC nucleic acid and polypeptide sequences of the invention, recombinant

CC vectors and host cells comprising a PRO nucleic acid, a method for the

CC recombinant production of a PRO polypeptide, antibodies against a PRO

CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic

CC acids encoding PRO polypeptides of the invention were initially

CC identified via homology screening using consensus sequences based on the

CC extracellular domain sequences from known secreted proteins. Human cDNA

CC libraries containing sequences of interest were identified using

CC oligonucleotides based on the consensus sequences, and cDNA clones were

CC isolated and characterised. The PRO polypeptides are useful for

CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from

CC human blood and may thus be used in the treatment of conditions in which

CC enhanced TNF-alpha release would be beneficial. They are also useful for

CC stimulating the proliferation or differentiation of chondrocytes and as

CC such may be used in the treatment of various bone and/or cartilage

CC disorders such as arthritis and sports injuries. The PRO polypeptides may

CC be used in a method for detecting the presence of a tumour (e.g., an

CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate

CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This

CC method involves comparing the level of expression of the PRO polypeptide

CC in test and control samples, where a higher level of expression of PRO

CC polypeptide in the test sample as compared to the control sample is

CC indicative of the presence of a tumour. The PRO polypeptides are

CC additionally useful for in drug screening to identify agonists and

CC antagonists of PRO polypeptides. PRO nucleic acids are useful as

CC hybridisation probes (for isolation of cDNA molecules), in chromosome and

CC gene mapping, in the generation of antisense RNA and DNA and in gene

CC therapy. The nucleic acids can also be used for mapping genes encoding

CC PRO polypeptides, for genetic analysis of individuals with genetic

CC disorders, and for generating either transgenic animals or knock-out

CC animals which are useful in the development and screening of

CC therapeutically useful compounds. Sequences ACF37778-ACF38082 represent

CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the

CC invention. Note: The sequence data for this patent is also available in

CC electronic format from USPTO at seqdata.uspto.gov/sequence.html

XX Sequence 2846 BP; 768 A; 696 C; 745 G; 637 T; 0 U; 0 Other;

SQ

Query Match 3.0%; Score 66.6; DB 9; Length 2846;

Best Local Similarity 71.3%; Pred. No. 0.00023;

Matches 87; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2121 CCTTTGCTTTACCACTCTTTCCTTTTATCTTTATTAATAAAATGTTGGTCTCCACCACGTG 2180

||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

DB 2653 CCTTTTCCTTCCCCATCTCTGTACACATTTTAATAAAATAGGGTTGGCTTCTGAACATA 2712

QY 2181 NCTCCCAA 2240

Db 2713 CAAA 2772

QY 2241 AA 2242

Db 2773 AA 2774

RESULT 693

ACF30075

ID ACF30075 standard; cDNA; 2846 BP.

XX ACF30075;

AC ACF30075;

XX 20-SEP-2003 (first entry)

DT Human secreted polypeptide PRO1344-encoding cDNA, SEQ ID NO:169.

DE Human; PRO; secreted protein; transmembrane protein;

XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; proliferation; differentiation; cartilage disorder;

KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;

KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;

KW liver; drug screening; transgenic animal; genetic analysis;

KW antiarthritic; vulneryary; gene therapy; gene; ss.

XX Homo sapiens.

OS US2003073178-A1.

PN 17-APR-2003.

XX 15-JUL-2002; 2002US-00195895.

PF 11-APR-2000; 2000US-0196187P.

PR 28-FEB-2001; 2001WO-US006520.

PR 15-JAN-2002; 2002US-00052586;

XX (GETH) GENENTECH INC.

PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;

XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

PI WPI; 2003-615956/58.

XX P-PSDB; ABM09801.

DR Three hundred and five nucleic acids encoding PRO polypeptides, useful

DR for the manufacture of a medicament for diagnosing or treating tumor or

XX for measuring or detecting expression of an associated gene.

PT Claim 2; Fig 169; 700pp; English.

XX The invention relates to human PRO secreted/transmembrane polypeptides

XX (ABM09717-ABM10021) and nucleic acids encoding them (ACF29991-ACF30295).

CC The invention also relates to sequences at least 80% identical to the PRO

CC nucleic acid and polypeptide sequences of the invention, recombinant

CC vectors and host cells comprising a PRO nucleic acid, a method for the

CC recombinant production of a PRO polypeptide, antibodies against a PRO

CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic

CC acids encoding PRO polypeptides of the invention were initially

CC identified via homology screening using consensus sequences based on the

CC extracellular domain sequences from known secreted proteins. Human cDNA

CC libraries containing sequences of interest were identified using

CC oligonucleotides based on the consensus sequences, and cDNA clones were

CC isolated and characterised. The PRO polypeptides are useful for

CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from

CC human blood and may thus be used in the treatment of conditions in which

CC enhanced TNF-alpha release would be beneficial. They are also useful for

CC stimulating the proliferation or differentiation of chondrocytes and as

CC such may be used in the treatment of various bone and/or cartilage

CC disorders such as arthritis and sports injuries. The PRO polypeptides may

XX US2003104538-A1.
PN
XX
PD 05-JUN-2003.
XX
PF 17-JUN-2002; 2002US-00173701.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.

DT 10-AUG-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #85.
DE Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX Homo sapiens.
OS US2003036158-A1.
XX 20-FEB-2003.
PN 02-JUL-2002; 2002US-00188770.
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.